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Abstract 
 
 
 
Synthesis and evaluation of fluorinated sialic acid 
derivatives as novel ‘mechanism-based’ neuraminidase 
inhibitors 
 
Doctor of Philosophy 
 
by Stefan Hader 
 
 
Increasing drug resistance towards 
the front line influenza 
neuraminidase inhibitor Oseltamivir 
(Tamiflu, Roche) has recently 
been reported, emphasising the 
need to perform further studies to 
gain insight into receptor ligand 
interactions.
 
 
 
 
 
 
 
 
Recently, influenza neuraminidase activity has been tackled using a novel 
class of mechanism-based inactivator, which incorporates fluorine atoms at 
positions C-2 and C-3 of sialic acid. These inactivators are anticipated to be 
less susceptible to drug induced resistance as they target essential catalytic 
amino acids. However, individual hydrogen-bonding interactions formed 
between these inactivators and the neuraminidase in both the Michaelis 
complex and at the transition-state remain unclear. 
Abstract 
 
II 
The aim of this project is to synthesise a series of monodeoxygenated 
2,3-difluoro-N-acetyl-neuraminic acid derivatives, designed to probe the 
importance of individual hydrogen-bonding interactions towards transition-
state stabilisation. 
The syntheses of the four novel monodeoxygenated 2,3-difluorosialic acid 
inactivators at position C-4,C-7, C-8 and C-9 deploying a Barton-McCombie 
protocol were accomplished. The time-dependant inactivation of wild type 
influenza neuraminidase N9 G70C by these monodeoxygenated 
2,3-difluorosialic acid inactivators was tested in a fluorescent kinetic assay. 
Further biochemical evaluation (performed by our collaborators) in IC50 
measurements against a panel of influenza viruses including wild types (wt.) 
and Oseltamivir resistant mutants showed potent inhibition of influenza B and 
H1N1 strains. 
We also wished to develop a further understanding of the effects of the 
monodeoxygenated 2,3-difluorosialic acid inactivators upon inactivation on a 
physical basis. Hence, we will discuss X-ray crystallographic structures, 
(obtained by our collaborators) of influenza neuraminidase N9 in complex with 
the monodeoxygenated 2,3-difluoro-sialic acid inactivators. 
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Their specific effect on the glycosides might thus be explained 
by assuming that the intimate contact between the molecules 
necessary for the release of the chemical reaction is possible 
only with similar geometrical configurations. To give an 
illustration I will say that enzyme and glycoside must fit together 
like lock and key in order to be able to exercise a chemical 
action on each other. 
This concept has undoubtedly gained in probability and value 
for stereochemical research, after the phenomenon itself was 
transferred from the biological to the purely chemical field. It is 
an extension of the theory of asymmetry without being a direct 
consequence of it: for the conviction that the geometrical 
structure of the molecule even for optical isomers exercises 
such a great influence on the chemical affinities, in my opinion 
could only be gained by new actual observations. 
 
— Emil Fischer 
 
'Einfluss der Configuration auf die Wirkung der Enzyme', Berichte der deutschen 
Chemischen Gesellschaft, 1894, 27, 2985-93. Trans. B. Holmstedt and G. Liljestrand 
(eds.) Readings in Pharmacology (1963), 251 
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 Preface 1.1
 
Infection caused by the influenza virus is a persistent problem in the human 
population and the recent H1N1 pandemic influenza outbreak in 2009 
demonstrated the on-going global need for specific influenza anti-virals. The 
current production time of vaccines is too slow to have an impact on the first 
wave of an influenza pandemic and recently reported increases in resistance 
towards the existing front-line neuraminidase inhibitor Oseltamivir emphasises 
the urgent need for novel anti-influenza therapeutics.3-5 
Neuraminidase is a feasible target for antiviral therapy but, in order to be able 
to develop novel anti-influenza therapeutics, more detailed kinetic and 
X-ray crystallographic studies are needed to gain insight into receptor-ligand 
interactions. 
The first study performed to embrace the systematic removal of side chains 
involved in hydrogen-bonding interactions with the substrate through site-
specific mutagenesis and measurement of the affinity of the ligand for each 
mutant generated was accomplished by Fersht et al. on tyrosyl tRNA 
synthetase.6 The study quantified tyrosyl tRNA synthetase mutants generated 
in terms of Michaelis-Menten parameters compared to the wild type enzyme. 
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In a complementary approach by Street et al., substrate/protein interactions 
have also been investigated through specific modifications of the substrate 
rather than the protein, creating carefully selected analogues that differ in their 
electronic properties and hydrogen-bonding capability but retain the ability to 
be accepted and/or processed by the enzyme.7,8 
Detailed studies of modified substrates performed by Street et al. on glycogen 
phosphorylase demonstrated the usefulness of fluorinated and deoxygenated 
substrates to gain insight into both the electronic structure of the enzymatic 
ground-state Michaelis complex and transition-state of the reaction.7,8 The 
experiments of Street et al. initiated the development of 2-deoxy-2-fluoro 
glycosides, which were amongst the first derivatives of representing a specific 
class of mechanism-based inactivators for glycoside hydrolase activity.9,10 
Targeting influenza neuraminidase, the auspicious class of novel mechanism-
based neuraminidase inactivators reported by Watts et al.11,12 and 
Amaya et al.13 are based upon the incorporation of fluorine atoms at positions 
C-2 and C-3 of sialic acid. These modifications result in formation of a covalent 
linkage within the neuraminidase active site and subsequent inactivation of the 
enzyme. 
The aim of the present work is to translate the approach of Street et al. to the 
generation of deoxygenated and fluorinated sialic acid derivatives towards 
gaining a more detailed understanding of individual hydroxyl group 
contribution to transition-state stabilisation by influenza neuraminidases.7,8 
This is achievable by investigating the kinetic behaviour of the deoxygenated 
and fluorinated sialic acid derivatives towards neuraminidase, as well as 
gaining structural information by X-ray crystallographic studies of these 
derivatives in complex with neuraminidase. 
 Sialic acids 1.2
 
The generic term sialic acid is the name given to a group of more than 
40 different variations of the two parent monosaccharides 3-deoxy-2-keto-D-
glycero-D-galactononulosonic acid (KDN) (1) and 5-N-acetyl-3,5-dideoxy-2-
keto-D-glycero-D-galactononulosonic acid (Neu5Ac) (2) originally isolated from 
salivary mucins (Figure 1).14 
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Figure 1 General structures of 3-deoxy-2-keto-D-glycero-D-galactononulosonic acid (KDN) 
(1), 5-N-acetyl-3,5-dideoxy-2-keto-D-glycero-D-galactononulosonic acid (Neu5Ac) (2), 5-N-
amino-3,5-dideoxy-2-keto-D-glycero-D-galactononulosonic acid (Neu) (3), and 
5-N-glycolylamido-3,5-dideoxy-2-keto-D-glycero-D-galacto-nonulosonic acid (Neu5Gc) (4). 
 
All sialic acids are thought to be metabolically derived from the two parent 
monosaccharides KDN (1) and Neu5Ac (2) including modifications such as 
oxidation, single and multiple acetylations, sulfation and methylation.1 
 1.2.1 Nomenclature 
 
The structural features common to all sialic acids are a 9-carbon backbone 
and a carboxylic acid at C-1 (pKa ~ 2.2) making them negatively charged 
under physiological conditions.15 The systematic names for sialic acids are too 
complicated for use in practice, so a uniform and simple nomenclature system 
is available. The root abbreviation KDN (1) and 5-N-amino-3,5-dideoxy-2-keto-
D-glycero-D-galactononulosonic acid (Neu) (3) are then designated by letter 
codes (Ac = acetyl, Gc = glycolyl, Me = methyl, Lt = lactyl, S = sulfate), which 
are listed along with numbers indicating the location of the modification relative 
to the carbon backbone position (Figure 1). Thus, for example, the sialic acid 
5-N-gycolylacetyl-3,5-dideoxy-2-keto-D-glycero-D-galacto-nonulosonic acid is 
named Neu5Gc (4). 
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 1.2.2 Roles of sialic acids in vertebrate cells 
 
Sialic acids are typically found at the outermost ends of N-linked glycans, 
O-linked glycans and glycosphingolipids, which easily interact with 
components of other cell surfaces, extracellular substances and effector 
molecules. In human biology, sialic acids play the dual role of either masking 
recognition sites or representing a biological target that allows recognition by a 
receptor protein, a lectin, thus being a ligand or counter-receptor.16 
In vertebrate cells, KDN (1) and Neu5Ac (2) are biosynthetically derived 
through condensation of mannose-6-phosphate (Man-6-P) for KDN (1) or 
N-acetyl-D-mannosamine-6-phosphate (ManNAc-6-P) for Neu5Ac (2) with 
activated forms of pyruvate (e.g. phosphoenolpyruvate, PEP) and are believed 
to be the metabolic precursors of all other sialic acids (Figure 2).1 Following 
dephosphorylation, the free Neu5Ac is activated by conversion to the 
nucleotide donor cytidine monophosphate sialic acid (CMP-Neu5Ac) and is 
pumped from the cytosol into the lumen of Golgi compartments by the action 
of a specific CMP Neu5Ac antiporter. 
The transfer of sialic acids from CMP donors to newly synthesised 
glycoconjugates in the Golgi is catalysed by a family of linkage-specific 
sialyltransferases. Once these newly formed glycoconjugates are released in 
the cytosol, they can either be secreted from the cell via exocytosis, or are 
transported to the lysosomes via endosomes. Extracellular glycoconjugates 
are also transferred to the lysosomes by endosomes, where Neu5Ac is 
cleaved by the action of lysosomal sialidase. Once Neu5Ac is released into 
the lysosome, it is transported back into the cytosol by a specific exporter, 
which allows Neu5Ac to be either reutilized or degraded by pyruvate lyases 
into ManNAc and pyruvate. 
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Figure 2 General pathways for biosynthesis, activation, transfer and eventual recycling of the 
common sialic acid Neu5Ac including CMP-Sia antiporter (1), sialyltransferases (2), exocytosis 
(3), endosomes (4), endocytosis (5), lysosomal sialidase (6) and sialic acid exporter (7) in 
vertebrate cells. (Adopted from Varki, A.)1 
 
Many pathogens, for example viruses, bacteria and parasites have evolved 
two major strategies to rely on sialic acids in order to evade the host immune 
response, target and infect cells. Firstly, the pathogens cover through 
sialylation of external glycoconjugates, making it more likely for them to pass 
undetected through the host immune system, as the macrophages cannot 
detect the penultimate sugars and phagocytise the pathogens.14 Secondly, 
some pathogens target specific sialic acid motifs on the host cell to aid the 
infection process.17 
As a consequence of the important roles played by sialic acid and the 
enzymes responsible for hydrolysing these monosaccharides, the sialidases 
are of key interest as potential therapeutic interventions. 
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 Sialidases 1.3
 
Sialidases are a superfamily of sialic acid-degrading enzymes (EC 3.2.1.18) 
widely found in higher eukaryotes and in a vast number of microbial 
pathogens.18 In the glycoside hydrolase clan E (GH-E) of the Carbohydrate 
Active Enzymes Database (CAZy, http://www.cazy.org/), members of the 
sialidase superfamily have been classified according to their amino acid 
sequence similarities into the three distinct families of glycoside hydrolases 
comprising family 33 (GH 33) which includes most bacterial, simple eukaryotic 
and trans-sialidases, family GH 34 this includes viral sialidases and family 
GH 83 which contains the haemagglutinin-neuraminidases.19 
Studies on viral20, bacterial21 and eukaryotic homologues22 have shown that all 
sialidases share a six-bladed β-propeller topology and a highly conserved 
catalytic domain (Figure 3). 
 
 
Figure 3 Six-bladed β-propeller topology of influenza neuraminidase N2 in complex with sialic 
acid (2). Generated with PyMOL23 (PDB 2BAT).24 
 
The fourth member of the GH-E clan is an exo-arabinanase that shares the 
six-bladed β propeller topology.25 However, the catalytic mechanism is very 
different from that of sialidases. 
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 1.3.1 Retaining glycoside hydrolases 
 
The glycosidic bond is generally considered to be a very stable linkage within 
naturally occurring biopolymers, with the most prominent half-lives for 
spontaneous hydrolysis of cellulose and starch being in the range of 5 million 
years.26 As such, enzymes hydrolysing these acetals have earned the 
reputation as some of the most proficient catalysts known. 
Glycoside hydrolases hydrolyse the glycosidic bond with two possible 
stereochemical outcomes: inversion or retention of anomeric 
configuration.2,27-29 Sialidases belonging to glycoside hydrolase families 
GH 33, GH 34 and GH 83 are known to operate with retention of anomeric 
configuration, hence for the purpose of this work we shall only focus on 
retaining glycoside hydrolases. 
There are two proposed mechanisms for retaining glycoside hydrolases; both 
proceed through a double displacement mechanism. In the first mechanism, 
proposed by Koshland in 1953, one of the carboxylic groups acts as a general 
acid catalyst and protonates the glycosidic oxygen to promote glycosidic bond 
cleavage (Scheme 1).2,30 
 
Scheme 1 Covalent glycosyl-enzyme intermediate mechanism for retaining glycoside 
hydrolases. (Taken from Zechel, D.L. et al.)2 
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The other carboxylic group functions as a nucleophile, forming a covalent 
glycosyl-enzyme intermediate at the anomeric position. 
In the second step, the carboxylic side-chain group deprotonates an incoming 
water molecule, which then attacks at the anomeric centre and displaces the 
glycosyl-moiety. This mechanism claims the acid/base amino acid residue 
acting first as an acid catalyst (glycosylation) and second as a base catalyst 
(deglycosylation) with both steps involving transition-states with substantial 
oxocarbenium-ion character. 
In contrast, the second mechanism for retaining glycoside hydrolases, 
proposed by Phillips in 1967, proceeds through a long-lived oxocarbenium-ion-
pair intermediate rather than formation of a formal covalent glycosyl-enzyme 
linkage (Scheme 2).31 
 
Scheme 2 Ion-pair intermediate mechanism for retaining glycoside hydrolases. (Taken from 
Zechel, D.L. et al.)2 
 
The disclosure of the mechanisms for retaining glycoside hydrolases and the 
identification of the catalytic amino acid residues responsible has provided a 
rationale to intervene with their enzymatic function and led to the development 
of a number of potent and highly selective inhibitors.32 
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 1.3.2 Inhibition of retaining glycoside hydrolases 
 
In due consideration of the importance of glycoside hydrolases in many 
biological processes, the ability to moderate their enzymatic function is 
associated with numerous medical applications, ranging from treatment of type 
II diabetes33 to antiviral34-36 and cancer therapeutics.37 Inhibitors of glycoside 
hydrolases can be classified as either reversible inhibitors or irreversible 
inactivators according to their mode of interaction with the enzyme.38 
 Reversible inhibitors 1.3.2.1
 
The majority of enzyme inhibitors operate through simple, reversible binding 
mechanisms with their target enzyme in a highly selective manner.39 The 
formation of enzyme-inhibitor binary complexes can be quantified in familiar 
thermodynamic terms, such as an equilibrium dissociation constant for 
inhibition (Ki) and the Gibbs free energy of binding (∆GS).
40 
A general enzyme catalysed reaction starts with the reversible binding of 
substrate (S) to the free enzyme (E) to form the E•S complex, also commonly 
referred to as Michaelis complex, quantified by the dissociation constant KS 
associated with the energetically favourable Gibbs free energy ∆GS of 
realisation of the binding energy (Scheme 3). 
 
 
 
 
 
 
 
 
Scheme 3 Equilibrium scheme for enzyme turnover and the potential interactions of reversible 
inhibitors with enzyme. - Enzyme (E), substrate (S), inhibitor (I), substrate dissociation 
constant (KS), Michaelis complexes (E•S) and (E•I), catalytic rate constant (kcat), inhibitor (I), 
dissociation constant for inhibition/inactivation (Ki), ternary Michaelis complex (E•S•I) and 
product (P). (Taken from Copeland, R.A.)40 
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The E•S complex thus formed reacts through a series of chemical steps to the 
reaction product(s) (P), which are collectively defined by the first-order 
catalytic rate constant kcat associated with the energetically unfavourable 
Gibbs free energy (∆G‡) of the chemical steps of bond making and breaking 
The first mode of reversible inhibitor interaction is in which the inhibitor (I) 
binds to the free enzyme in direct competition with the substrate (competitive 
inhibitor) to form the E•I complex, defined by the dissociation constant Ki. The 
E•I complex could then react with substrate (S) to form the ternary E•S•I 
complex. However, the affinity of the E•I complex for substrate (S) may differ 
from the free enzyme (E), hence KS must be modified by the constant α to 
describe the degree to which inhibitor binding effects the affinity of the enzyme 
(E) for substrate (S). Alternatively, the E•S•I complex can be formed by 
binding of inhibitor to the preformed E•S complex, defined by the modified 
dissociation constant αKi. It is possible for the E•S•I complex formed to 
generate product(s), albeit at a reduced rate relative to the uninhibited 
reaction, which is referred to as partial inhibition. An inhibitor that binds 
exclusively to the free enzyme, for which α = ∞, is said to be competitive 
because these inhibitors compete with the substrate for the pool of free 
enzyme molecules. 
A reaction coordinate diagram for a chemical reaction to turn over the 
substrate (S) and the same reaction catalysed by an enzyme shows the 
Michaelis complex (E•S) at an energetically favourable Gibbs free energy. 
Together with the Gibbs energetically unfavourable high energy transition-
state (ES‡) the dependence of the Gibbs free energy for kcat/KM (∆G
‡
T) on ∆G
‡ 
and ∆GS is illustrated (Figure 4).
41 
 
 
 
 
 
 
 
 
Introduction                                                                                           Chapter 1 
 
- 11 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Reaction coordinate diagram for the reaction pathway of a chemical reaction and the 
same reaction catalysed by an enzyme. - Enzyme (E), substrate (S), Michaelis complex (E•S) 
and (E•P), transition-state (ES‡), transition-state for the substrate (S‡), Gibbs free energy of 
binding (∆GS), Gibbs free energy for kcat/KM (∆G
‡
T), Gibbs free energy of bond breaking and 
making (∆G‡), and product (P). (Adopted from Copeland, R.A)40 
 Transition-state theory 1.3.2.2
 
The transition-state (ES‡) represents the species with the highest energy 
formed during the enzyme catalysed cycle at which chemical bonds are in the 
process of being made and broken. This is in contrast to intermediates, whose 
bonds are fully formed and occupy troughs in a reaction coordinate diagram. 
Enzymes have evolved to form strong binding interactions with transition-
states, which can be described by the apparent second-order rate constant 
kcat/KM and the proportional Gibbs free energy (∆G
‡
T) (Scheme 4).
42 
 
 
 
 
Scheme 4 Equilibrium scheme for transition-state formation. – Enzyme (E), substrate (S), 
apparent rate constant kcat/KM, and transition-state (ES
‡). (Adopted from Copeland, R.A)40 
 
ES
‡
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The transition-state (ES‡) is an unstable structure which is poised between the 
chemical structures of the substrates and products.43 The idea of the 
enzymatic transition-state was largely developed from the chemical rate theory 
by Eyring which allowed mathematical treatment using the thermodynamic and 
activated state concepts of the time.44 
Transition-state theory relates the rate of a reaction to the difference in Gibbs 
free energy (∆G) between the transition-state and the ground-state.45 In terms 
of time, the smallest fraction of the catalytic cycle is spent in the transition-
state with proposed lifetimes of 10-13 sec, equivalent to the time for a single 
bond vibration. A useful tool in the application of transition-state theory or in 
the analysis of structure-reactivity data is the Hammond postulate, which 
states that if there is an unstable intermediate on the reaction pathway, the 
transition-state for this reaction will resemble the structure of this 
intermediate.42 This is a useful way of predicting the structure of the transition-
state and for predicting the types of stabilisation it requires.46 
Once a substrate (S) progresses from the Michaelis complex (E•S) to product 
(P), enzymes alter the electronic structure of the substrate by protonation, 
proton abstraction, electron transfer or interactions with Lewis acids and bases 
through sequential protein and substrate conformational changes resulting in a 
different Michaelis complex (E•S)’.47 The summation of individually weak 
forces are brought to bear on the substrate and, combined, result in large 
forces capable of relocating bonding electrons to cause the breaking or 
formation of bonds, geometric distortion or hydrophobic partitioning. 
Hydrogen bonds are the most common chemistry-promoting force between 
enzymes and substrates with an average bond distance from 2.6 to 3.1 Å.48 
At 3.1 Å, the hydrogen bond energy is weak, typically <1 Kcal/mol; however, 
short hydrogen bonds can contribute 4 – 6 Kcal/mol toward catalysis.49 The 
strong dependence of hydrogen and ionic binding energy on bond distance, 
angle, solvent environment and relative pKa values can be used to explain the 
increases in binding forces of the transition-state complex (ES‡) relative to the 
Michaelis complex (E•S). 
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The catalytic site of an enzyme remains closed during the lifetime of the 
transition-state, preventing reactants from diffusing from the catalytic site, a 
definition of tight-binding at the transition-state.50 A major energetic obstacle 
an enzyme has to overcome is to bind tightly only to the unstable transition-
state structure, while avoiding comparative tight-binding to the substrate or 
products. The energetics of catalysis and binding a transition-state analogue 
with optimum binding energy are shown in the following reaction coordinate 
diagram (Figure 5).47 
 
Figure 5 Reaction coordinate diagram of a catalysis and binding for an energetically perfect 
transition-state inhibitor (I). - Enzyme (E), substrate (S), Michaelis complexes (E•S) (E•S)’ 
(E•P) (E•I) (E•I)’, transition-states (S‡) (ES‡) (EI‡), difference in Gibbs free energy of binding 
(∆∆G‡), difference in Gibbs free energy for binding of the transition-state inhibitor and 
substrate (∆∆G – IS), rate of onset for tight-binding inhibitors (k1
‡), rate of escape for tight-
binding inhibitors (k-1
‡), and product (P). (Adopted from Schramm, V.L)47 
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The difference in Gibbs free energy of binding (∆∆G‡) is the enzymatic 
efficiency compared to the uncatalysed reaction which equals kenzyme/kchemical in 
terms of Gibbs free energy. The term ∆∆G – IS describes the difference in 
Gibbs free energy of binding for a perfect transition-state inhibitor (I) and 
substrate (S). 
The slow-onset inhibition common with transition-state inhibitors occurs after 
formation of a readily reversible (E•I) complex with the rate of onset for tight-
binding inhibitors k1
‡. It is noteworthy that the rate of escape k-1
‡ has an 
unfavourable energetic barrier to escape from the stable (E•I)’ complex. 
A common mechanism in enzymatic catalysis is to generate a differential 
charge on the substrate between ground-state and transition-state, permitting 
electrostatic interactions to specifically stabilise the transition-state (ES‡).51 
However, an imperfect match between the enzyme (E) and the transition-state 
inhibitor is inevitable, mainly because it is impossible for stable compounds to 
mimic perfectly the non-equilibrium bond lengths of the transition-state. For the 
necessarily imperfect transition-state inhibitors, the k1
‡ barrier corresponds to 
the time to fit the imperfect inhibitor into the lowest-energy structure.52 
A common strategy, used in structure based drug design, is to mimic the 
assumed charge or the assumed geometry of the transition-state that is 
formed during the catalytic cycle of the enzyme. An example of a competitive 
inhibitor mimicking the transition-state charge would be Miglitol (5), which is 
prescribed towards type II diabetes.53 This α-glycoside hydrolase inhibitor with 
the protonated endocyclic nitrogen at physiological pH imitates the 
oxocarbenium-ion present at the transition state in glycoside hydrolases. An 
inhibitor focusing on transition-state geometry is the anti-influenza therapeutic 
Oseltamivir (6). This influenza neuraminidase inhibitor mimics the half-chair 
conformation, which is commonly accepted to be the conformation adopted by 
the transition-state (ES‡).54 
 
 
 
    5   6 
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 Irreversible inactivators 1.3.2.3
 
Compounds that interact with an enzyme molecule in such a way as to abolish 
enzyme function permanently are referred to as irreversible inactivators.55 
Enzyme inactivation generally occurs as a result of enzyme-based 
nucleophiles undergoing reaction with an electrophilic portion of the 
inactivator, leading to formation of a covalent bond between the enzyme and 
the inactivator. This covalent linkage either physically blocks substrate from 
entering the active or modifies an active site residue that is critical for 
catalysis, hence the activity of the enzyme is reduced irreversibly. 
Two general mechanisms for irreversible enzyme inactivation are based on 
covalent modification of the enzyme, or of a critical cofactor or substrate of the 
enzyme reaction and are referred to as affinity labelling and mechanism-based 
inactivation.56 
Affinity labels commonly incorporate an inherently reactive functional group 
that can covalently modify appropriate nucleophiles at any location within the 
enzyme. This lack of specificity in general makes affinity label therapeutics, 
also referred to as non-specific affinity label therapeutics, less acceptable as 
therapeutics. However, there are a number of examples of DNA-alkylating 
agents such as methanesulfonates and nitrosoureas that act as non-specific 
affinity labels, yet are still used clinically for the treatment of some forms of 
cancer.40 In the case of non-specific affinity labelling, the rate constant kinact for 
the single-step inactivation has units of a second-order rate constant (M-1s-1) to 
form the covalent enzyme inactivator complex (E-I) (Scheme 5a).40 
As a result, quiescent affinity labels have been utilised containing a weak 
electrophile, which reversibly binds in the active site of the enzyme with some 
reasonable affinity (Scheme 5b). The electrophile in sensible concentration in 
solution does not react readily with nucleophiles but, in the case of already 
being bound within the solvent-shielded environment of the active site, the 
electrophile and the corresponding nucleophile is enough to form a covalent 
linkage. A clinical example of this class includes the β-lactam-containing 
antibiotics, which selectively modify the serine hydroxyl group of bacterial 
peptidoglycan transpeptidases to elicit their antibiotic activity.40 
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Scheme 5 Mechanisms of irreversible enzyme inactivation for enzyme (E), inactivator (I) and 
affinity label (A) in the case of a) Non-specific affinity labelling, b) quiescent affinity labelling 
and c) mechanism-based inactivation. (Taken from Copeland, R.A.)40 
 
For quiescent affinity labels, the inactivation follows a two-step mechanism, 
involving binding of the inactivator to the enzyme (E•I), often under 
rapid equilibrium conditions, and subsequent covalent bond formation 
(Scheme 5b).40 
In general, mechanism-based inactivators are chemically inert and require 
specific activation by the catalytic machinery of the enzyme into a species that 
can then act as an affinity label a transition-state analogue or a very tight-
binding reversible inhibitor, prior to release from the active site.57 
The inactivator is recognized by the enzyme as an alternative substrate that is 
acted upon by groups within the active site to catalytically generate an 
inhibitor, hence mechanism-based inactivators are competitive with the natural 
substrate of the enzyme and also commonly referred to as suicide substrates. 
Owing to their reliance on enzyme catalysis, mechanism-based inactivators 
generally display very high target specifity and inactivation can proceed either 
in a single step, or through a two-step mechanism (Scheme 5c).40 
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Whereas with quiescent affinity labels the second step involves the chemistry 
of covalent bond formation, the situation for mechanism-based inactivators is 
significantly more complicated. 
Mechanism-based inactivators can bind in a reversible fashion to the enzyme 
to form an initial encounter complex (E•I), analogous to formation of E•S in the 
normal catalytic reaction of the enzyme. The bound complex is then 
chemically transformed by the catalytic machinery of the enzyme to form the 
affinity label A, defined by the forward equilibrium rate constant k4. Hence, 
there is also the possibility of a reverse reaction going from (E•A) to (E•I), 
governed by the rate constant k5. 
Once the binary complex (E•A) has been formed, the affinity label can either 
react irreversibly with an enzyme nucleophile to a covalent species (E-A), or 
dissociate through a reversible process from the enzyme to form free enzyme 
(E) and the free affinity label (A). 
 Mechanism-based inactivators: Fluorinated glycosides 1.3.2.4
 
Mechanism-based inactivators target the catalytic nucleophile residue, which 
was shown to be of paramount importance to the activity of the enzyme and 
has been utilized in the development of new inactivators. Fluorinated 
glycosides have found much use a class of mechanism-based inactivators, 
owing to their mode of action specific to retaining glycoside hydrolases. 
The activated 2-deoxy-2-fluoro glucoses (7) and (8), 5-fluoro glucose (9) and 
2-deoxy-2,2-difluoro glycosides (10) belong to a specific class of mechanism-
based inactivators of glucoside hydrolase activity.9,10 
 
 
 
    7     8 
 
 
 
9    10 
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The 2-deoxy-2-fluoro substitution allows differentiation of glycosylation and 
deglycosylation rates involved in the catalytic mechanism in retaining 
glucoside hydrolases (Scheme 1). 
The introduction of an electronegative fluorine atom in glucose causes an 
inductive effect on neighbouring charges and, if present at C-2 adjacent to the 
anomeric centre, leads to a destabilisation of the formation of positive charges 
at the anomeric centre in both glycosylation and deglycosylation transition-
states. The destabilisation of the positive charge in the transition-state slows 
down the formation of the glycosyl-enzyme intermediate and its hydrolysis. 
The addition of an activated leaving group (LG) at position C-1 such as 
fluorine, 2,4-dinitrophenyl (DNP), or 2,4,6-trinitrophenyl (TNP) accelerates the 
glycosylation step, leading to the accumulation of the covalent glycosyl-
enzyme intermediate whereby the enzyme is inactivated with observed 
lifetimes ranging from seconds to months (Scheme 6).55 
 
 
Scheme 6 General proposed mechanism of inactivation of retaining glycoside hydrolases by 
fluorinated-β-glycoside. - Leaving group (LG) and protonated leaving group (HLG). (Taken 
from Rempel, P.B. et al.)55 
 
The enzyme is capable of reactivation through either hydrolysis of the covalent 
glycosyl-enzyme intermediate, or through trans-glycosylation onto a suitable 
acceptor substrate. As a consequence of the ability to recover enzyme activity, 
this class of inactivators is often referred to as very slow enzymatic substrates 
rather than true inactivators. However, for all practical purposes, the life-time 
of the trapped covalent glycosyl-enzyme intermediate are usually sufficiently 
long lived for enzyme inactivation. 
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Mechanism-based fluorinated glycoside inactivators were used by Withers and 
Aebersold to identify and label the catalytic nucleophile in retaining glycoside 
hydrolases through inactivation of the glycoside hydrolase.56 Subsequent 
proteolysis, peptide localisation and sequencing by HPLC/MS using 
collision-induced fragmentation led to identify the label residue. 
An example of identification of the catalytic nucleophile residue was performed 
by Watts et al. on Trypanosoma cruzi trans-sialidase leading to the 
identification of tyrosine as the catalytic nucleophile residue being responsible 
for the cleavage of anionic sialic acid residues.11 The identification of the 
alternative tyrosine catalytic nucleophile residue instead of a carboxylic group, 
common in glycoside hydrolases, led to the development of novel mechanism-
based fluorinated sialoside inactivators for neuraminidases. These novel 
inactivators have the promise of being a tool in drug discovery to tackle the 
pathogenic enzymes like influenza neuraminidase.11 
 Influenza virus 1.4
 
The influenza virus belongs to the Orthomyxoviridae family including six 
genera, Influenza virus A, Influenza virus B, Influenza virus C, Isa virus, 
Thogota virus and Quarja virus with a genome consisting of six to eight 
segments of single-strand RNA.58 Due to the genetic capacity of the 
Orthomyxoviridae family to undergo reassortment within a specific genus, new 
virus strains can emerge that continue to elude the immune response and 
infect humans, poultry and livestock.59 In terms of infection and mortality to 
humans, by far the most important virus from this family is influenza virus A. 
The nomenclature of the different subtypes (HxNy) of influenza virus A relates 
to immunological specifications of the haemagglutinin (H) and neuraminidase 
(N) surface proteins. To date, sixteen different hemagglutinin subtypes (H1-
H16) and nine neuraminidase subtypes (N1-N9) have been identified in a 
variety of hosts with wild water fowls as the native host and the ability to cross 
species barriers (Figure 6).60,61 
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Figure 6 Range of hosts of influenza viruses (Taken from Suzuki,Y.)61 
 
In 1980 the World Health Organisation introduced a new nomenclature system 
which is still in use to follow up on the diversity of influenza virus strains.62 So, 
for example A/Wisconsin/67/2005/(H3N2) describes the type of influenza, the 
geographic origin, the isolate number, the year of isolation and the distinct 
haemagglutinin and neuraminidase subtype of the isolate. The large diversity 
of haemagglutinin and neuraminidase subtypes is the result of the two 
processes known as antigenic drift and antigenic shift.63 Antigenic drift occurs 
during replication of the virus in the infected host cell by errors of 
polymerisation of the viral RNA with a rate of mutation of about 1 in 104 bases 
per replication, resulting in the formation of new serotypes which no longer can 
be targeted by antibodies.64 
Antigenic shift is defined as the simultaneous infection of a host cell by at least 
two different strains of influenza virus, resulting in mixing and recombination of 
the genes of each strain during replication, forming a new strain of virus 
particles with new genetic material. 
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The continuous formation of virus particles with new genetic material enables 
the influenza virus continually to generate new subtypes, all with the potential 
to initiate a new pandemic. 
Historically, the first well documented account of an influenza pandemic was 
what became known as the ‘Spanish Flu’ from 1918 till 1920, with an 
estimated death toll between 50 and 100 million people.65 The next major 
outbreak of influenza virus A occurred in 1997, where a new strain, H5N1 
commonly referred to as ‘Bird Flu’ emerged in the human population, never 
reaching pandemic status but still circulating with another outbreak in 2005.66 
However, the first pandemic of the 21st century was caused by an H1N1 strain 
originating from pigs, hence named ‘Swine Flu’ which had been endemic in 
pigs since 1918, when the virus crossed the species barrier to infect pigs and 
had remained there until recently crossing the species barrier back to humans 
again.67 
 1.4.1 Structure and life cycle of the influenza virus A 
 
The influenza virus A particle is roughly spherical with a diameter of 80 – 120 
nanometres, enveloped with a lipid bilayer and functions in combination with 
the two major surface glycoproteins haemagglutinin (H) and 
neuraminidase (N) (Figure 7).68 The inner side of the lipid bilayer is lined by 
the non-structural proteins (NS1 and NS2) and the matrix protein (M1 and M2) 
of which M2 is forming ion channels. The RNA segments are packed with the 
3 polymerase polypeptides PA, PB1 and PB2 in a helical form in the core of 
the viral particle (RNPs = RNA + nucleoprotein).69 
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Figure 7 Cartoon illustration of an influenza virus particle. (Taken from Jordan, D.)68 
 
In order to replicate in a host cell, the life cycle of the virus starts with binding 
of the viral particle surface glycoprotein haemagglutinin (H) to terminal sialic 
acid residues present on glycoproteins, glycolipids, or receptors located on the 
target cell surface (Figure 8).70 
Figure 8 Schematic representation of the replication cycle of influenza virus A and targets for 
therapeutic intervention. (Taken from von Itzstein, M. with permission from the author)70 
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Once the new viral particle is formed, it first remains attached to the host cell 
membrane through binding of viral haemagglutinin protein to the terminal sialic 
acid residues present on cell surface glycoconjugates. If the new viral particle 
would remain on the cell surface, the host immune system would come into 
action and phagocytise the particle. The crucial role of viral neuraminidase at 
this late stage of viral replication is to hydrolyse the terminal sialic acid 
residues on the host cell surface in order to liberate the new viral particle, 
ready to infect other cells. 
 1.4.2 Therapeutic targets of influenza virus 
 
The life cycle of influenza virus replication reveals key stages that have 
potential to act as therapeutic targets for inhibition of virus replication, such as 
the M2 ion-channels, RNA polymerase and sialidase (Figure 8).70 The 
M2 ion-channels play a crucial role in the process of uncoating for the effective 
release of viral RNA into the host cytoplasm.71 The RNA polymerase replicates 
viral RNA in the host cell and influenza neuraminidase facilitates the release of 
the new viral particles. Over the past decades all these key stages have been 
tackled in drug discovery efforts, resulting in several small-molecule approved 
therapeutics on the market.70 
 M2 ion-channel 1.4.2.1
 
The first synthetic compound to inhibit influenza virus replication was 
amantadine (Symmetrel®, Mantadix®) (11), which was postulated to block the 
interior channel within the tetrameric M2 helix bundle. Hence, amantadine 
stops the migration of H+ ions from the cytosol into the inner virus particle, an 
important process for the viral uncoating to occur.72 
The adamantamine derivatives amantadine (11)73-75 and rimantadine 
(Flumadin®) (12)76 have long been available for specific influenza virus A 
infection prophylaxis and therapy. 
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However, due to the rapid emergence of drug resistance, the ready 
transmissibility of drug-resistant viruses and particularly for amantadine, the 
occurrence of central nervous system side effects, they are no longer used as 
stand-alone therapeutics but still find use as a component of combination 
therapy.77 
 RNA transcription 1.4.2.2
 
Ribavirin (Virazole®) (13) was recognised as a broad-spectrum antiviral agent 
against the Orthomyxoviridae family and targets inosine 5`-monophosphate 
(IMP) dehydrogenase, a key enzyme involved in guanosine 3’-triposphate 
(GTP) and viral RNA synthesis. Ribavirin (13) is notable for not generating 
drug resistance and is active against both avian and human H5N1 influenza 
viruses.78  
 
 
 
 
 
    13     14 
However, the use of ribavirin (13) is limited due to possible side effects in 
pregnant women and the dose-limiting toxicity of haemolytic anaemia.79 
Another RNA transcription inhibitor showing promising results is the pyrazine 
derivative T-705 (Favipiravir) (14) which is currently in phase II clinical trials 
and has been postulated to be converted intracellularly to the triphosphate 
ribonucleotide and then inhibit influenza virus polymerase in a GTP 
competitive manner.80 
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Nevertheless, a small number of side effects in humans and no significant 
effects as commonly stand-alone therapy do not make it an auspicious 
candidate in drug discovery efforts towards the influenza virus, leaving 
influenza neuraminidase as the most viable target.81. 
 Neuraminidase 1.4.2.3
 
Over the past few decades, vital structural and functional information on 
influenza neuraminidase has been gathered in order to elucidate the enzymes 
mode of action. Subsequently this information was used in the design of novel 
potent inhibitors with Zanamivir (15) and Oseltamivir (6) being the most 
prominent examples.20,82 A more detailed structural and functional study of 
influenza neuraminidase will be the focus of this thesis. 
 
 
 
 
    15         6 
 Influenza neuraminidase 1.5
 
Influenza neuraminidase (EC 3.2.1.18) is a glycoside hydrolase, cleaving 
terminal sialic acids from glycoconjugates. This cleavage facilitates infection 
by the virus in the upper respiratory tract and allows the liberation of the 
progeny viral particles from the host cell surface.70 
X-ray crystallographic studies have identified key residues within the active 
site, which are conserved in neuraminidases across all influenza A and 
influenza B viruses and provide exciting opportunities for structure-based drug 
design. 
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The active site of influenza neuraminidase N2 consists of a tri-arginyl cluster of 
Arg118, Arg 292 and Arg371 which forms a salt bridge with the carboxylic 
group at C-1 on sialic acid (2), the Tyr406 which has been reported to act as 
the catalytic nucleophile, hydrogen bond interactions between Glu227 and 
Glu277 with the N-acetyl group as well as a catalytic water molecule (Figure 
9). 
 
Figure 9 Interactions of sialic acid (2) with the residues present within the active site of 
influenza neuraminidase N2. Generated with LigPlot+ (PDB 2BAT).83 
 
The description of the active site residues in conjunction with mechanistic 
considerations of general retaining glycoside hydrolases has previously been 
mentioned (Chapter 1.3.1) and led to two proposals for the catalytic 
mechanisms of influenza neuraminidases. 
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 1.5.1 Proposed catalytic mechanisms 
 
In analogy to general retaining glycoside hydrolases (see Chapter 1.3.1), there 
are two proposed mechanisms for neuraminidases, both proceeding by a 
double displacement mechanism involving three catalytic amino acids, namely 
aspartic acid, glutamic acid and tyrosine. The first proposed mechanism by 
Horenstein et al. proceeds through an initial distortion from a solution-
dominant α-sialoside 2C5 conformer into an α boat conformer upon binding, in 
order to form a salt bridge between the negatively charged carboxyl group of 
sialic acid and the highly conserved tri-arginyl cluster within the active site of 
neuraminidases (Scheme 7).70,84 
 
Scheme 7 Ion-pair intermediate mechanism for neuraminidases. R = glycoside. (Taken from 
von Itzstein, M.)70 
 
The resulting conformational strain facilitates leaving of the protonated 
glycosidic oxygen and the formation of an oxocarbenium-ion intermediate, 
which has been identified by kinetic isotope effect measurements and 
modelling studies.85,86  
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Deprotonating a water molecule by an aspartic acid residue is activating a 
water molecule towards nucleophilic attack of the oxocarbenium-ion 
intermediate, forming an α sialic acid anomer, which then mutarotates to the 
thermodynamically favourable β anomer. 
The identification of a tyrosine residue as the catalytic nucleophile in 
Trypanosoma cruzi trans-sialidase, as previously mentioned (Chapter 1.3.2.4) 
led to the proposal of a different catalytic mechanism for neuraminidases by 
Watts and Withers.87 Following deprotonation of the hydroxyl group of the 
catalytic tyrosine residue by glutamic acid, the tyrosine can then act as a 
nucleophile, attacking the anomeric position C-2 of the sialic acid residue 
(Scheme 8).70 
 
 
Scheme 8 Covalent glycosyl-enzyme intermediate mechanism for neuraminidases. 
R = glycoside. (Taken from von Itzstein, M.)70,87 
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Parallel to this action, the glycosidic oxygen is protonated by an aspartic acid 
residue activating it towards leaving and resulting in an oxocarbenium-ion 
transition-state, which with the tyrosine residue is leading to a covalent 
sialosyl-enzyme intermediate. This glycosylation step involves the cleavage of 
the sialic acid from the host cell membrane glycoconjugate. 
However, in order to complete the catalytic cycle and to regain enzymatic 
activity, the deglycosylation step proceeds through deprotonating a water 
molecule by an aspartic acid residue, activating it towards nucleophilic attack 
on the sialosyl-enzyme intermediate. This nucleophilic attack leads to a 
second oxocarbenium-ion transition-state and results in bond cleavage 
between the sialic acid and the tyrosine residue under overall retention of 
configuration at the anomeric centre of the sialic acid. 
The structural information and the proposed mechanisms proved valuable in 
the discovery and development of novel competitive inhibitors of influenza 
neuraminidase. 
 1.5.2 Competitive neuraminidase inhibitors as therapeutics 
 
The first generation of competitive influenza neuraminidase inhibitors were 
targeted to mimic the oxocarbenium-ion species and its flattened 
conformation, which led to the idea of using 2-deoxy-2,3-didehydro-N-
acetylneuraminic acid (DANA) (16) as a parent scaffold. 
 
 
 
          16 
DANA (16) served as a starting point for structural based drug design as it 
gave potent inhibition of bacterial and mammalian neuraminidases88 both 
in vitro and in vivo with a promising Ki of 4 µM against influenza 
neuraminidase N2 compared to a Ki of 1 mM with sialic acid (2), but DANA 
(16) lacked in specificity.89 
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 Zanamivir 1.5.2.1
 
X-ray diffraction studies performed on DANA (16) in complex with influenza 
neuraminidase suggested that a cavity around the hydroxyl group at C-4 only 
present in viral neuraminidase, but absent in mammalian neuraminidase, 
could be used to achieve specificity.90,91 Hence, introducing a large basic 
functionality at this position would benefit from interactions with neighbouring 
amino acid residues and could result in better inhibition.90,91 The targeted 
molecule was identified as 4-N-amino-4-deoxy DANA (17) and was tested 
against influenza neuraminidase N2 showing a 100-fold improvement in the Ki 
compared to DANA (16).70 The alternative introduction of a guanidino 
functional group to yield 4-guanidino DANA, better known as Zanamivir (15), 
gave a 10.000-fold improvement compared to the parent compound DANA 
(16) and a Ki of 0.2 nM.
70 
 
 
 
 
 
    17        15 
As predicted, X-ray crystal structures of Zanamivir (15) in complex with 
influenza neuraminidase N2 showed that the guanidino group at C-4 position 
occupies the cavity and forms hydrogen bonds with glutamic acid and several 
hydrophobic interactions with asparagine, methionine, isoleucine, and tyrosine 
amino acid residues (Figure 10).86,92 
Due to the highly polar nature of Zanamivir (15) and therefore its low 
bioavailability (< 5%), it was developed as an inhaled formulation, delivering 
the drug directly to the lung, the main site of infection. 
In 1999, following the success in clinical trials, Zanamivir (15) was approved 
by the US Food and Drug Administration (FDA) as the first neuraminidase 
targeting influenza inhibitor with the trade name Relenza®.24,70 
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Figure 10 Interactions of Zanamivir (15) with the residues present within the active site of 
influenza neuraminidase N2. Generated with LigPlot+ (PDB 2F0Z). 
 
Zanamivir (15) is very effective in the treatment of influenza viruses A and B 
and has shown low incidence of drug-induced resistance with only one case of 
resistance in an immunocompromised child reported in literature.93-95 
The side effects of Zanamivir (15) treatment are very mild and largely confined 
to the airways (e.g. cough, nasal symptoms) but unfortunately the method of 
inhaled formulation cannot be employed to people with impaired lung 
capacity.96 
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 Oseltamivir 1.5.2.2
 
The development of Zanamivir (15) provided a platform for further influenza 
neuraminidase inhibitors, with one aim being to increase hydrophobicity and 
potentially increase bioavailability without compromising inhibitory activity. The 
removal of the ring oxygen was considered to help increase hydrophobicity of 
the molecule and allow the development of cyclohexene analogues that mimic 
more closely the geometry of the oxocarbenium-ion species by changing the 
position of the alkene bond like compound (18). 
 
 
 
           18     19 
Compound (18) showed promising results against influenza neuraminidase N2 
with an IC50 of 20 µM compared to a Ki of 4 µM with DANA (16).
97 In order to 
increase inhibitory activity further, the introduction of a hydroxyl group at C-6 
instead of the glycerol side chain could pose an inductive electron-withdrawing 
effect on the double bond, similar to the highly polarised oxocarbenium-ion 
species, and could become a parent compound for the synthesis of ether 
analogues at the C-6 position. In addition, analogous to the introduction of an 
amino group during the development of Zanamivir (15), the introduction of an 
amino group at C-4 lead to compound (19) with an IC50 of 6.3 µM against 
influenza neuraminidase N2.98 Extensive structure-activity studies with a range 
of alkyl group modifications at C-6 position were performed and the 3-pentyl 
side chain containing compound GS4071 (20) was found to be the most potent 
inhibitor against H1N1 with an IC50 of 1 nM.
99 
 
 
 
         20        6 
The oral bioavailability of the free acid was still found to be poor, hence the 
ethyl ester prodrug of GS4071 was formed to give the final compound 
Oseltamivir (6). 
CO2HO
AcHN
H2N
CO2EtO
AcHN
H2N
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Oseltamivir (6) is readily converted to the active form in vivo by the action of 
endogenous liver esterase and was marketed as the second neuraminidase 
targeting influenza inhibitor with the trade name Tamiflu®.100 
X-ray crystallographic studies of influenza neuraminidase N1 in complex with 
Oseltamivir (6) showed that the alkoxy side chain is involved in several 
hydrophobic contacts with Glu276, Glu277, Arg224, Arg292 and Asn294 in the 
space which was previously occupied by the glycerol side chain of sialic acid 
(Figure 11).101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 Interactions of Oseltamivir (6) with the residues present within the active site of 
influenza neuraminidase N1. Generated with LigPlot+ (PDB 2HU0).101 
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Oseltamivir (6) was found to exhibit high bioavailability when administered 
orally, produces very mild side effects and is currently stockpiled by countries 
around the world as the drug of choice against the influenza virus dominating 
over 90% of the world market.102 
However, quite alarming is the number of mutant influenza viruses which have 
developed resistances towards Oseltamivir (6) and already circulate in the 
human population. One particular mutation was seen to pass from 0.4% 
resistance in the 2007-2008 flu season to virtually 100% in the following 
year.4,103-107 
 1.5.3 Point mutations conferring resistance towards current 
therapeutics 
 
Reversible influenza neuraminidase inhibitors are strikingly similar in structure 
to their natural substrates and have been designed to target amino acid 
residues that are not essential for enzymatic activity. These non-essential 
amino acid residues are more likely to suffer point mutations, as these 
mutations do not compromise the ability of the enzyme to turnover the natural 
substrate. The number of mutant influenza viruses circulating in the human 
population is already alarming, affecting the inhibitor efficacy of Oseltamivir (6) 
and to a lesser extent Zanamivir (15) through five specific point mutations at 
positions Glu119, Arg152, Asp198, His274 or Arg292 (Figure 12).77,108-113 
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Figure 12 Point mutations of influenza neuraminidase known to induce drug resistance to 
Oseltamivir (6) shown on influenza neuraminidase N1 in complex with Oseltamivir (6). Amino 
acid residues are shown in stick representation. Generated with PyMOL (PDB 2HU0).101 
 
Four different point mutations at residue Glu119 have been identified in 
several different strains of both influenza A and B viruses in vivo, these include 
the mutations Glu119Gly, Glu119Ala, Glu119Asp and Glu119Val. The 
mutation Glu119Val represents a clinically relevant mutant leading to 
Oseltamivir (6) resistance in the human strain 
A/Wuhan/359/1995/(H3N2). 114-117 The residue Glu119 interacts strongly with 
the basic nitrogen group at C-4 of Oseltamivir (6) and structural information 
suggests that diminished binding may be a consequence of an additional 
water molecule occupying the position previously occupied by the carboxylate 
of Glu119.118 
The residue Arg152 is conserved in all influenza A and B viruses and forms a 
hydrogen bond to the N-acetyl group present at C-5 of the natural substrate 
sialic acid (2), Oseltamivir (6) and Zanamivir (15). The Arg152Lys mutant, first 
isolated from an immunocompromised child infected with influenza B virus and 
treated with Zanamivir (15) showed a very low enzyme activity (3 – 5% 
compared to the wild type enzyme) and was 1000-fold less sensitive to 
Zanamivir (15).114 
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The residue Asp198 interacts with Arg152, so altered interactions between 
Asp198 and Arg152 affect interactions of Arg152 with the N-acetyl group. The 
Asp198Glu mutant of B/Perth/211/2001 is known to confer cross resistance to 
Oseltamivir (6), Zanamivir (15) and Peramivir (21) and, as such, has proven to 
be useful for testing interactions around the N-acetyl group in novel influenza 
neuraminidase inhibitors being developed.119 
Residue His274 interacts with Glu276 and the mutation His274Tyr affects the 
reorientation of Glu276 in order to form a salt link with Arg224.4,120 This salt 
bridge is necessary to enable creation of the hydrophobic pocket necessary to 
accommodate the bulky hydrophobic pentenyl ether side chain in Oseltamivir 
(6) and Peramivir (21) (Figure 11).121 
The residue Arg292 is one of the three highly conserved arginines that form 
part of the catalytic triad of influenza neuraminidase (Figure 9), hence 
enzymes mutated at this position all exhibit decreased catalytic activity relative 
to the wild type enzyme.114 Detailed structural analysis of the Arg292Lys 
mutant revealed altered binding of the carboxylate group and the glycerol side-
chain on the ligand, which would correlate with reduced enzyme activity as 
well as altered drug sensitivity. Further, this lysine residue is seen tor restrict 
Glu276 from moving, again required to accommodate the bulkier pentenyl 
ether group at Oseltamivir (6).122,123 
Based on these results, it has been postulated that in terms of substrate 
architecture, inhibitors of a greater structural difference between inhibitor and 
natural substrate sialic acid (2), are more likely to induce the virus to mutate in 
order for it to maintain substrate binding, but decrease inhibitor binding. 
Hence, minimalist approach to drug design and mechanism-based inactivators 
would be less likely to generate viable mutants.114 
 1.5.4 Novel clinical candidates 
 
Additional drug discovery efforts against the influenza virus are exceptionally 
well-motivated by the US Food and Drug Administration (FDA) which now 
provides a fast-track programme for the approval of potential future influenza 
neuraminidase inhibitors. Peramivir (21) and the dimeric derivatives of 
Zanamivir (22) are currently being evaluated in such fast-tracked clinical 
trials.124 
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Peramivir (21) was designed to exploit the hydrophobic pocket observed with 
Oseltamivir (6) in complex with neuraminidase N1 (Figure 11) and has shown 
to be highly specific towards viral neuraminidase over bacterial and 
mammalian neuraminidases with in vitro and in vivo activities comparable to 
the activity of Zanamivir (15) and Oseltamivir (6).124 In addition, the injectable 
formulation of Peramivir (21) might be of great value to patients who cannot 
readily take tablets and/or have a compromised lung capacity. However, quite 
alarming recent reports indicate that viruses resistant to Oseltamivir (6) may 
also be cross-resistant to Peramivir (21).125-130 
The dimeric Zanamivir derivatives (22) with a carbamate linkage and a variety 
of hydrocarbon chains or benzylic spacers, have shown to be 100-fold more 
potent inhibitors than the parent compound Zanamivir (15) against influenza 
viruses H1N1 and H3N2, possibly due to aggregation of several viral particles 
and a subsequently more efficient auto immune response.131 Furthermore, the 
dimeric Zanamivir derivatives (22) have proven to be long-lasting 
neuraminidase inhibitors with the potential to reduce the number of treatments 
required.132,133 However, due to the highly polar nature and therefore low bio-
availability, dimeric Zanamivir derivatives (22) are not considered to be a 
viable alternative in influenza treatment. 
 1.5.5 Mechanism-based inactivators as potential therapeutics 
 
Mechanism-based inactivators of influenza neuraminidase are designed to 
target the covalently linked sialosyl-enzyme intermediate (Scheme 8), unlike 
the current influenza neuraminidase inhibitors Zanamivir (15) and Oseltamivir 
(6) which target the oxocarbenium-ion species (Scheme 7). It is anticipated 
that mechanism-based inactivators have the potential to be less susceptible to 
drug induced resistance in influenza neuraminidase as they target essential 
amino acid residues. 
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These essential amino acid residues are less likely to mutate as the influenza 
neuraminidase mutant is unable to turn over sialic acid, the natural 
substrate.134-136 
The novel class of neuraminidase inhibitors based on 2,3-difluoro-sialic acid 
(23) were developed to attenuate glycosylation and deglycosylation rates in 
the catalytic cycle of neuraminidases and have previously been demonstrated 
in a number of studies on bacterial and trypanosomal neuraminidiases.12 
 
 
 
            23 
The introduction of a fluorine atom at C-3, adjacent to the anomeric position 
serves to destabilise the formation of a positive charge during the transition-
state due to its electronegativity and is reducing the rate of glycosylation (k1) 
and deglycosylation (k2) (Scheme 9). A ‘good leaving group’ at the anomeric 
position C-2, such as fluorine, increases the rate of glycosylation, whereas 
deglycosylation remains unaffected, allowing the covalently linked sialosyl-
enzyme intermediate to be kinetically accessible and accumulate to a high 
steady-state concentration, whereby the enzyme is inactivated. 
 
Scheme 9 The glycosylation (k1) and deglycosylation (k2) rate constants are attenuated by 
fluorine-containing mechanism-based inactivators. (Adopted from Watts, A. G. et al.)12 
 
Recent unpublished work by the research groups of Dr. Andrew Watts and 
Prof. Stephen Withers has shown that influenza neuraminidase operates 
through a similar mechanism to bacterial and trypanosomal neuraminidase 
utilising a covalent sialosyl-enzyme intermediate and oxocarbenium-ion 
transition-states (Scheme 8), making 2,3-difluoro-sialic acid (23) viable as a 
parent compound to inhibit the action of influenza neuraminidase. 
Introduction                                                                                           Chapter 1 
 
- 39 - 
 Aims and objectives 1.6
 
The binding of a ligand and its protein receptor based on intermolecular 
forces, such as ionic bonds, hydrogen bonds and Van der Waals forces, is 
fairly well documented but the relative contribution of each to both the overall 
binding interaction and to the specificity thereof are poorly understood.7 Fersht 
et al. suggested that hydrophobic interactions contribute as the major driving 
force to association and that hydrogen-bonding interactions and salt-bridge 
formation primarily can be held responsible for specificity.6 
In due consideration of the important role of carbohydrate/protein interactions 
(such as cell-cell recognition events), the large number of hydroxyl groups on 
carbohydrates may suggest that hydrogen-bonding interactions would be more 
important, particularly for monosaccharides that are completely buried in the 
active site of the protein.6 In aqueous solution, water competes for hydrogen-
bonding sites on both the carbohydrate and the protein making the binding 
energy a complex result of partially enthalpic differences, due to different 
hydrogen-bond geometry but largely a consequence of an increase in entropy 
associated with water release from the active site and the ligand into bulk 
water.7 
X-ray crystallographic studies have proven to be a tremendously useful 
technique to derive information on carbohydrate/protein interactions, but 
provide little help to evaluate the contribution that individual hydrogen-bonding 
interactions towards transition-state stabilisation. Conservative modifications 
of the substrate such as deoxy and fluorodeoxy analogues that differ in their 
electronic properties and hydrogen-bonding capacity but may still be accepted 
by the enzyme, have proven to be a useful tool in the studies of individual 
hydroxyl group contribution to transition-state stabilisation, as has previously 
been demonstrated by Street et al. on glycogen phosphorylase.8 
The proposed mechanism involving formation of a covalent sialosyl-enzyme 
intermediate (Scheme 8) applied to 2,3-difluoro-sialic acid (23) gives an 
energy profile with two high-energy transition-states and the covalent 
intermediate as a local energy minimum (Graph 1). 
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Graph 1 Reaction coordinate diagram representing the reaction pathway of 2,3-difluoro-sialic 
acid (23) and neuraminidase. Enzyme (E), inhibitor (I), product (P), Michaelis complexes (E•I) 
(E•P), transition-states (EI‡) (EP‡) and covalent intermediate (E-I). 
 
Although the covalent sialosyl-enzyme intermediate is at a local energy 
minimum, this is not sufficient for complete inactivation and turnover of the 
intermediate at a greatly reduced rate is still observed. 
The objective of this project is to translate the approach of Street et al. to the 
novel class of mechanism-based inactivators, based on 2,3-difluoro-sialic acid 
(23), in order to gain further information on the active site of influenza 
neuraminidase during the inactivation mechanism, both on the ground-state 
Michaelis complex (E•I) and at the transition-state(EI‡).8 
We propose to achieve this through the synthesis of the novel 
monodeoxygenated 2,3-difluoro-sialic acid analogues (24) - (27), which are 
designed to function as mechanism-based inactivators of influenza 
neuraminidases. 
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23 R1, R2, R3, R4 = OH 
24 R1 = H, R2, R3, R4 = OH 
    25 R2 = H, R1, R3, R4 = OH 
    26 R3 = H, R1, R2, R4 = OH 
    27 R4 = H, R1, R2, R3 = OH 
 
The systematic removal of each individual hydroxyl group allows dissection of 
individual hydroxyl group contribution towards transition-state stabilisation. It is 
anticipated that the monodeoxygenated 2,3-difluoro-sialic acid derivatives 
(24) - (27) will be useful to gain further information on the inactivation 
mechanism through X-ray protein crystal structures. Furthermore, biochemical 
evaluation of the kinetic behaviour of the monodeoxygenated 2,3-difluoro-sialic 
acid inactivators (24) - (27) towards influenza neuraminidase N9 will also give 
access to Michaelis-Menten kinetic parameters. We plan to determine key 
parameters for each monodeoxygenated 2,3-difluoro-sialic acid compound 
(24) to (27) such as the inactivation rate constant (kinact) and the dissociation 
constant for the inactivator (Ki) through time-dependent inactivation of 
influenza neuraminidase N9 over a range of inactivator concentrations. 
Based on these findings future projects are set up to utilise pharmacophores in 
order to optimise the 2,3-difluoro-sialic acid (23) parent compound as a 
potential therapeutic for the treatment of the influenza virus. 
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Synthesis of 4-deoxy-2,3-difluoro-sialic Chapter 2 - 
acid (24) 
 
 
We began the synthesis of the putative mechanism-based influenza 
neuraminidase inactivator 4-deoxy-2,3-difluoro-sialic acid (24) by first studying 
known approaches towards the synthesis of 4-deoxy-sialic acid (28). 
2       24    28 
The synthesis of 4-deoxy-sialic acid (28) has been reported by Hagedorn and 
Brossmer which was accomplished via dehalogen hydrogenation of a C-4 iodo 
intermediate (Chapter 8.1.1).137 However, this method was low yielding and as 
such was not considered appropriate for translation towards the synthesis of 
4-deoxy-2,3-difluoro-sialic acid (24).137 In a similar manner, the synthesis of 
4-deoxy-sialic acid (28) was also accomplished by Baumberger and Vasella138 
who employed a 12-step sequence, which commenced with D-glucose. In an 
improved synthesis of 4-deoxy-sialic acid (28), performed by Estenne et al.139 
sialic acid (2) was used in an eight-step sequence. However, it was anticipated 
that applying either of these reported syntheses to the synthesis of 4-deoxy-
2,3-difluoro-sialic acid (24) would require numerous synthetic steps with an 
anticipated low overall yield and, as such, neither approach was pursued any 
further. 
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A more encouraging synthesis has been reported by Ooi et al., utilising the 
per-O-acetyl derivative (29) to generate the oxazoline (30), which following 
hydrogenation with palladium on charcoal yielded the per-O-acetyl-4-deoxy 
DANA (31) (Scheme 10).140  
 
 
      2         29     30 
 
 
 
 
          31 
 
Scheme 10 Literature procedure for the synthesis of the 4-deoxy DANA derivative (31). 
a) (i) TFA, MeOH; (ii) Ac2O, pyridine; b) TMSOTf, MeCN; (c) H2/Pd.
140 
 
We envisaged that the per-O-acetyl-4-deoxy DANA derivative (31) could be a 
useful intermediate in the synthesis of 4-deoxy-2,3-difluoro-sialic acid (24) as a 
number of methods for the difluorination of glycals are reported in the 
literature.141,142 
 Attempted synthesis of 4-deoxy-2,3-difluoro-sialic 2.1
acid (24) via the oxazoline (30) 
 
 2.1.1 Retrosynthetic analysis 
 
The synthesis of 4-deoxy-2,3-difluoro-sialic acid (24) could be performed by 
difluorination of the 4-deoxy DANA derivative (31), based on a number of 
methods reported for the difluorination of unsaturated sialic acids deploying 
either a single step difluorination utilising F2 or XeF2 or deploying sequential 
introduction of fluorine at C-3 and then C-2 in two-steps (Scheme 11).141,142 
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30      2 
 
Scheme 11 Retrosynthetic strategy for the synthesis of 4-deoxy-2,3-difluoro-sialic acid (24) 
via the oxazoline (30). 
 
However, as seen in the work previously performed by Nakajima et al. 
difluorination utilising F2 afforded a mixture of isomers which were difficult to 
purify and gave a low overall yield.141 As a result, we were prompted to 
consider a sequential two-step fluorination strategy. 
Fluorination could be achieved utilising Selectfluor® (33) and previously 
performed mechanistic studies by Vincent et al. have shown that Selectfluor® 
(33) is reacting regioselective with glycals in a syn addition two-electron 
mechanism. In the case of sialic acid specific fluorination at the C-3 position 
and subsequent hydrolysis as previously shown by Burkart et al. then 
hydrolyses the trietylenediammonium moiety to give hemiketal (34) in 80% 
yield with a ratio of axial to equatorial fluorine of 3:1.143 (Scheme 12).144 
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            34 
 
Scheme 12 Mechanism for the fluorination of DANA (32) with Selectfluor® (33). (DMF/H2O, 
50 ºC, 80%).144 
 
In the case of the 4-deoxy DANA derivative (31) the resulting axial fluorine 
hemiketal could then be treated with (diethylamino)sulfur trifluoride (DAST) 
(35) in a nucleophilic fluorination step in accordance with the procedure 
reported by Watts and Withers to give the desired 4-deoxy-2,3-difluoro-sialic 
acid (24).87 
 
 
 
         35 
It then was intended to form 4-deoxy DANA derivative (31) according to the 
procedure previously accomplished by Ooi et al. in a reduction reaction of 
oxazoline (30) using hydrogen and palladium on charcoal (Scheme 11).140 
The desired oxazoline (30) could be yielded following the procedure which has 
previously been described by Schreiner et al. by treatment of per-O-acetyl-
sialic acid (29) with trifluoromethanesulfonate (TMSOTf).145 
 
 
 
 
 
S
N
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F
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 2.1.2 Formation of oxazoline (30) 
 
The formation of oxazoline (30) was accomplished according to 
Schreiner et al. starting with the esterification of sialic acid (2), using 
trifluoroacetic acid (TFA) in MeOH at room temperature and subsequent 
acetylation of the sialic acid methyl ester with acetic anhydride (Ac2O) in 
pyridine gave the per-O-acetyl derivative (29) (Scheme 13).145 
        2           29         32 
 
 
 
 
 
              30 
 
Scheme 13 Synthesis of oxazoline (30). a) (i) TFA, MeOH, r.t., O/N; (ii) Ac2O, pyridine, r.t., 
3 days; b) TMSOTf, MeCN, 50 ºC, O/N, 76% (over 3 steps). 
 
Analysis of the crude reaction mixture from this step showed an inseparable 
mixture of the desired per-O-acetyl compound (29), as well as the per-O-acetyl 
DANA compound (32) and oxazoline (30) in a ratio of 5:1:2. 
The proposed mechanism for the formation of oxazoline (30) proceeds by 
activation of the anomeric acetyl group with trifluoromethanesulfonate 
(TMSOTf), which triggers a trans-diaxial elimination, forming the per-O-acetyl 
DANA (32) (Scheme 14). The proposed mechanism for the formation of 
oxazoline (30) commences by activation of the C-4 acetyl group of 
per-O-acetyl DANA (32) by TMSOTf, which then can be displaced by 
nucleophilic attack of the oxygen present at the N-acetyl group in position C-5 
to give oxazoline (30). 
 
 
 
O CO2MeN
OAc
AcO OAc O
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        30 
 
Scheme 14 Mechanism for the formation of oxazoline (30). TMSOTf, MeCN, 50 ºC, O/N. 
 
The per-O-acetyl DANA (32) intermediate has already been identified to be 
part of the mixture from the acetylation step, hence it was proposed that the 
crude mixture could be used for conversion to the desired product (30). 
Therefore, following the acetylation, the crude mixture was purified by filtration 
through a silica plug and treated with TMSOTf and acetonitrile (MeCN) to give 
the oxazoline (30) in 76% yield starting from sialic acid (2). 
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 2.1.3 Attempted synthesis of per-O-acetyl-4-deoxy DANA (31) 
 
The formation of the 4-deoxy DANA derivative (31) was then attempted 
according to the literature procedure by Ooi et al. utilising 10% Pd/C in 
1,4-dioxane for 4 hours at room temperature.140 However, reaction of 
oxazoline (30) under these conditions only gave unreacted starting material 
(Table 1, entry 1). 
 
Table 1 Different conditions used for the synthesis of 4-deoxy DANA derivative (31). 
Condition A: H2, 10% Pd/C (0.2 eq.), 1,4-dioxane; Condition B: H2, 5% Pd/C (0.2 eq.), 
1,4-dioxane; Condition C: H2, 10% Pd/C (0.2 eq.), THF; Condition D: H2, 10% Pd/C 
(0.2 eq.), MeOH. 
 
 
 
 
   30     31 
 
 
n.d. = not determined 
 
 
 
Subsequently increasing the reaction time to 14 hours in 1,4-dioxane at room 
temperature also failed to yield the desired product and again only starting 
material (30) was recovered (Table 1, entry 2). Finally, extending the reaction 
time to 19 hours (Table 1, entry 3) resulted in mixture of starting material (30) 
and over-reduced compound (36) in a ratio of 3:1 being formed. 
 
Entry Condition Time T [°C] Product Yield (%), Ratio
1 A 4 h r.t. 30 67
2 A 14 h r.t. 30 n.d.
3 A 19 h r.t. 30 + 36 3:1
4 B 17 h r.t. 30 + 36 5:1
5 C 15 h 4 30 n.d.
6 C 15 h r.t. 36 n.d.
7 D 5 h r.t. 36 n.d.
8 D 3 h 4 30 + 36 9:1
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               36 
The formation of the over-reduced derivative (36) then prompted us to 
investigate the use of alternative catalysts as well as reducing the loading of 
palladium on charcoal. Unfortunately, reduction with 5% Pd/C for 17 hours 
(Table 1, entry 4) was also found to give a mixture of starting material (30) 
and fully reduced compound (36) in a ratio of 5:1. Furthermore, changing the 
solvent to THF (Table 1, entry 5 and 6) or methanol (Table 1, entry 7 and 8) 
and employing a variety of reaction temperatures and reaction times also 
failed to improve the reaction, with only over reduced derivative (36) or starting 
material (30) ever being observed. 
Given the problem of over-reduction of oxazoline (30), it was considered that 
by performing the introduction of fluorine at position C-3 prior to the reduction 
step at position C-4 these difficulties could be overcome. 
 Attempted synthesis of 4-deoxy-2,3-difluoro-sialic 2.2
acid (24) via the 3-fluoro-oxazoline (37) 
 
We then set out to synthesise was the novel 3-fluoro-oxazoline derivative (37). 
This molecule, to our knowledge, has never been synthesised before and we 
envisaged that it could be a useful intermediate towards the synthesis of 
4-deoxy-2,3-difluoro-sialic acid (24). 
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 2.2.1 Retrosynthetic analysis 
 
We considered that the 4-deoxy-2,3-difluoro-sialic acid (24) could be produced 
by fluorination of the 4-deoxy-3-fluoro-sialic acid hemiketal (38) employing the 
method previously described by Watts and Withers utilising 
(diethylamino)sulfur trifluoride (DAST) (Scheme 15).87 
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Scheme 15 Retrosynthetic strategy for the synthesis of 4-deoxy-2,3-difluoro-sialic acid (24) 
via the 3-fluoro-oxazoline (37). 
 
We anticipated that the synthesis of the 4-deoxy-3-fluoro-sialic acid hemiketal 
(38) could be achieved through reduction of 3-fluoro-oxazoline derivative (37) 
using hydrogen and palladium on charcoal, based on the methods previously 
deployed (Chapter 2.1.3) but avoiding over-reduction. The 3-fluoro-oxazoline 
derivative (37) could be yielded following the procedure described by 
Schreiner et al. utilising 3-fluoro-sialic acid (39).145 
The formation of 3-fluorosialic acid (39) has previously been demonstrated by 
Watts and Withers performing an enzymatic aldolase reaction of 2-N-acetyl-D-
mannosamine (40) and β-fluoropyruvic acid (41).87 It was intended to obtain 
the desired axial 3-fluoro-sialic acid (39) exclusively in highest possible yield 
by the enzymatic aldolase approach of Watts and Withers.87 
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 2.2.2 Synthesis of 3-fluoro-sialic acid (39) 
 
The first step in the synthesis of 4-deoxy-2,3-difluoro-sialic acid (24) involved 
the formation of 3-fluoro-sialic acid (39), which has previously been described 
by Watts and Withers using an enzymatic aldolase reaction (Scheme 16).87 
According to this procedure, 2-N-acetyl-D-mannosamine (40) and 
β-fluoropyruvic acid (41) were subjected to Neu5Ac aldolase in aqueous 
solution at room temperature for five days. 
 
 
 
          40       41          39 
 
Scheme 16 Formation of 3-fluoro-sialic acid (39). Neu5Ac aldolase, H2O, r.t., 5 days. 
 
The Neu5Ac aldolase catalysed aldol reaction can be performed at a pH range 
of 6 to 9 and at an optimum temperature of 37 ºC. Neu5Ac aldolase is tolerant 
towards slight modifications to the pyruvate donor such as the presence of a 
fluorine atom at the β carbon, although a large reduction in the rate of 
enzymatic turnover is observed. 
During the synthesis of 3-fluoro-sialic acid (39) the reaction was monitored by 
the disappearing 19F NMR signal corresponding to β-fluoropyruvic acid (41) at 
δ -229.1 ppm and the appearing signals corresponding to formation of 
β-3-axial-fluoro-sialic acid (42) at δ -208.1 ppm and the β-3-equatorial-fluoro-
sialic acid (43) at -199.2 ppm (Figure 13). 
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Figure 13 19F NMR of the aldolase reaction, showing the consumption of β-fluoropyruvic acid 
(41) and the formation of three different 3-fluoro-sialic acid isomers (42), (43) and (44). 
 
At δ -217.7 ppm the formation of the epimer of the desired product (42) the 
α-3-axial-fluoro-sialic acid (44) could be observed. The reaction mixture was 
purified by ion-exchange column chromatography (formate form) from 
unreacted 2-N-acetyl-D-mannosamine (40) to afford the 3-fluoro-sialic acid 
isomers (42), (43) and (44). 
The aldolase-catalysed reaction of 2-N-acetyl-D-mannosamine (40) and β-
fluoropyruvic acid (41) is known to result in mixtures of isomers as non-natural 
substrates are used for the enzymatic conversion. A possible explanation 
might be given in consideration of the enzyme-catalysed mechanism proposed 
by Lin et al. (Scheme 17).146 This mechanism proceeds via formation of an 
enamine between a lysine (Lys) residue in the active site of the aldolase and 
β-fluoropyruvic acid (41).146-148 At this stage cis/trans isomerisation of the 
enamine adduct can occur with its ratio directing the formation of axial or 
equatorial fluorine at position C-3. 
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Scheme 17 Mechanism for the Neu5Ac aldolase-catalysed aldol reaction between 2-N-acetyl-
D-mannosamine (40) and β-fluoropyruvic acid (41). The numbering of the carbon backbone is 
indicated corresponding to the final 3-fluoro-sialic acid isomers (42) and (43).147 
 
Subsequently the aldehyde group of the acyclic form of 2-N-acetyl-
D-mannosamine (40) is activated by a histidine (His) residue in the active site 
of the aldolase. A new carbon-carbon bond between the activated aldehyde 
and the preformed β-fluoropyruvic acid enamine is then formed. 
The resulting iminium cation is hydrolysed to release the catalytic lysine 
residue of the aldolase and also generates the carbohydrate moiety in an 
acyclic form. The hydrolysed acyclic aldehyde is then cyclised to form the 
3-fluoro-sialic acid isomers (42) and (43). 
The ratio of the fluorine atom at C-3 in axial (42) or equatorial orientation (43) 
has been reported to be dependent on the stoichiometric ratio between 
β-fluoropyruvic acid (41) and 2-N-acetyl-D-mannosamine (40).149 
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The reason for this correlation is still not fully understood, however an 
experimental study by Beliczey et al. together with experimental data has 
determined that a ratio of 1:2 of (41) to (40) results in the isomer with an axial 
fluorine atom at C-3 (42) being the predominant isomer in 90%.149 
As well as accepting alterations on the pyruvic acid moiety, aldolase also 
accepts a number of modifications on the hexose moiety at C-7, C-8 and 
C-9 (numbered according to the carbon backbone of the final product 
(Scheme 17). We considered that this might be of interest for the synthesis of 
some subsequent monodeoxygenated 2,3-difluorosialic acid derivatives (25), 
(26) and (27). 
 2.2.3 Attempted synthesis of 3-fluoro-oxazoline (37) 
 
Following the enzyme-catalysed aldolase reaction, the crude residue was 
esterified using trifluoroacetic acid (TFA) in methanol to give 3-fluoro-sialic 
acid methyl ester (44) (Scheme 18). 
     39    44    45 
 
Scheme 18 Synthesis of per-O-acetyl-3-fluoro-sialic acid (45). a) TFA, MeOH, r.t., O/N; 
b) Ac2O, pyridine, DMAP, r.t., 17 h, 72% (starting from β-fluoropyruvic acid (41)). 
 
Due to its highly polar nature, the 3-fluoro-sialic acid methyl ester (44) was not 
purified and isolated at this stage. However, subsequent acetylation with 
acetic anhydride in pyridine gave the per-O-acetyl-3-fluoro-sialic acid (45) after 
silica column chromatography in 72% yield. 
Following the procedure of Schreiner et al. the formation of 3-fluoro-oxazoline 
(37) was attempted by treatment of per-O-acetyl-3-fluorosialic acid (45) with 
trimethylsilyl trifluoromethanesulfonate (TMSOTf) in acetonitrile (MeCN) at 
50 °C overnight (Scheme 19).145 
 
 
 
Chapter 2                                 Synthesis of 4-deoxy-2,3-difluoro-sialic acid (24) 
 
- 56 - 
 
 
 
   45     37 
 
Scheme 19 Attempted synthesis of 3-fluoro-oxazoline (37). TMSOTf, MeCN, 50 ºC, O/N. 
 
However, the reaction failed under the conditions applied and only starting 
material was isolated. In consideration of the mechanism to form the 
oxazoline, which has previously been shown (Scheme 14), the formation of a 
DANA-like intermediate seems to be crucial for oxazoline formation as it 
results in allylic activation of the acetyl group at position C-4. In addition, the 
introduction of a fluorine atom at position C-3 with its electron-withdrawing 
effect prevents activation and subsequent nucleophilic substitution of the 
acetyl group at position C-4. Hence, the introduction of a fluorine atom at 
position C-3, as intended prevents the formation of a DANA-like intermediate 
but undesirably also averts oxazoline formation. 
As a result, the synthetic strategy was re-assessed and it was decided to 
investigate an alternative class of reactions for the formation of 4-deoxy-2,3-
difluoro-sialic acid (24) with the Barton-McCombie deoxygenation being 
amongst the most common methods for the removal of hydroxyl groups in 
synthetic chemistry.150,151 
 Synthesis of 4-deoxy-2,3-difluoro-sialic acid (24) 2.3
via the C-4 Barton-McCombie deoxygenation 
 
It was anticipated that, the previously synthesised 3-fluoro-sialic acid methyl 
ester (44) via a selective protection protocol to form a C-4 xanthate (46) and 
subsequent C-4 Barton-McCombie deoxygenation, could provide a feasible 
route to form 4-deoxy-2,3-difluoro-sialic acid (24). 
 
 
 
 
 
   46 
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 2.3.1 Retrosynthetic analysis 
 
The formation of 4-deoxy-2,3-difluoro-sialic acid (24) could proceed via a 
fluorination step with (diethylamino)sulfur trifluoride (DAST) following the 
procedure reported by Watts and Withers but utilising the 4-deoxy-3-fluoro-
sialic acid hemiketal (38) (Scheme 20).87 
 
 
 
24     38 
47      48 
 
  
  
  
  
  44 
 
Scheme 20 Retrosynthetic strategy for the synthesis of 4-deoxy-2,3-difluoro-sialic acid (24) 
via the C-4 xanthate (47). 
 
As such, formation of 4-deoxy-3-fluoro-sialic acid hemiketal (38) could be 
accomplished by Barton-McCombie deoxygenation with Bu3SnH on a C-4 
xanthate (47).150,152 It was predicted that formation of the C-4 xanthate (47) 
could be attempted on 3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester 
(48) without further protection steps. 
This strategy is based upon the assumption that following activation, the most 
nucleophilic hydroxyl group in 3-fluoro-8,9-O-isopropylidene-sialic acid methyl 
ester (48) would be at C-4 position. 
Isopropylidene
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O
OH
CO2Me
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The 3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (48) could be 
yielded according to the procedure of Ogura et al. utilising TFA in methanol 
and 2,2’-dimethoxypropane on 3-fluoro-sialic acid (39).153 The formation of 
3-fluoro-sialic acid (39) could be performed employing an enzymatic aldolase 
reaction of 2-N-acetyl-D-mannosamine (40) and β-fluoropyruvic acid (41) as 
previously accomplished (Chapter 2.2.2).87 
 2.3.2 Formation of 4-deoxy-3-fluoro-8,9-O-isopropylidene-sialic 
acid methyl ester (50) 
 
The 3-fluorosialic acid methyl ester (44) was treated with 
2,2’-dimethoxypropane and catalytic amounts of p-toluenesulfonic acid 
(p-TSA) in acetone according to the procedure of Ogura et al. to give the 
3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (48) in 71% yield from 
β-fluoropyruvic acid (41) (Scheme 21).153 
     44        48       46 
 
 
 
 
Scheme 21 Synthesis of the C-4 xanthate (46). a) 2,2’-Dimethoxypropane, p-TSA, acetone, 
r.t., O/N, 71% (starting from β-fluoropyruvic acid (41)); b) CS2, CH3I; c) Phenyl 
chlorothionoformate; d) 1,1’-Thiocarbonyldiimidazole. 
 
Although acceptable, it was considered that the yield of 71% could potentially 
be improved upon. As such, an alternative method to introduce the 
isopropylidene protecting group utilising 2-methoxypropene was attempted. 
However, this reaction failed to improve the yield of the desired product (48) 
and so was not investigated further. 
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The Barton-McCombie protocol consists of first transforming an alcohol into a 
xanthate, thionocarbonate or O-thiocarbamate followed by treatment with 
tributyltin hydride under radical conditions to yield the deoxygenated product. 
The driving force for the Barton-McCombie deoxygenation is the formation of 
the energetically favoured sulfur-tin bond. A possible mechanism 
for the Barton-McCombie deoxygenation involves the steps of initiation 
(Scheme 22a) with azobisisobutyronitrile (AIBN) as a radical carrier, which 
then is attacked (Scheme 22b) by sulfur of xanthates, thionocarbonates or 
O-thiocarbamates. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 22 A mechanism for the Barton-McCombie deoxygention.151 
 
Subsequent β – cleavage (Scheme 22c) and finally hydrogen radical transfer 
from tributyltin hydride (Scheme 22d) gives the deoxygenated product and the 
radical carrier tributyl tin. 
The commonly used radical initiator azobisisobutyronitrile (AIBN) is no longer 
commercially accessible, due to its explosive property, but there are 
alternatives such as azobiscyanocyclohexane or the peroxides 2,2-bis(tert-
butylperoxy)-butane and (2,5-bis(tert-butylperoxy)-2,5-dimethylhexane), also 
known as Luperox® 101, which are available. 
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According to the procedure of Barton et al. methyl xanthates can be 
introduced under basic conditions through the addition of carbon disulfide and 
iodomethane.154 For the synthesis of the C-4 xanthate (46), the risk of 
elimination of methyl xanthates under basic conditions and the lack of 
selectivity to introduce methyl xanthates at position C-4 with other hydroxyl 
groups present prompted us to consider thionocarbonates and 
O-thiocarbamates. 
As alternatives to methyl xanthates, thionocarbonates and O-thiocarbamates 
can be introduced under essentially neutral conditions from O-phenyl 
chlorothionoformate and 1,1’-thiocarbonyldiimidazole respectively. As well, 
thionocarbonates and O-thiocarbamates can react at lower temperatures for 
the radical deoxygenation and have been used successfully to deoxygenate 
sialic acid derivatives.155 
As such, 3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (48) was 
treated with phenyl chlorothionoformate in pyridine and dichloromethane to 
give 3-fluoro-8,9-O-isopropylidene-4-O-(phenoxy)thiocarbonyl-sialic acid 
methyl ester (49) in 76% yield (Scheme 23). 
 48    49         50 
 
Scheme 23 Synthesis of 4-deoxy-3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (50). 
a) Phenyl chlorothionoformate, CH2Cl2/pyridine, - 40 ºC → r.t., 4 h, 76% (49); b) 2,2-Bis(tert-
butylperoxy)-butane, Bu3SnH, 1,4-dioxane, 100 ºC, 4 h, 81% (50). 
 
In order to probe the optimal conditions for the Barton-McCombie 
deoxygenation, the thionocarbonate (49) was used as the model substrate, 
while radical initiator, radical carriers, solvents and temperatures were varied 
in an effort to generate 4-deoxy-3-fluoro-8,9-O-isopropylidene-sialic acid 
methyl ester (50) in the highest possible yield. 
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In the first set of reactions (Table 2, entry 1 - 3) according to 
Lopez et al. bis(tributyltin) oxide was used to generate tributyltin hydride in situ 
(Scheme 24).151  
 
 
 
Scheme 24 In situ formation of Bu3SnH. Toluene, 80 °C, 4 h, without n-BuOH n = 1, with 
n-BuOH n = 2. 
 
This has the advantage of low costs and longer storage stability over tributyltin 
hydride. In this procedure poly(methylhydrosiloxane) (PMHS) and n-butanol in 
toluene are used in order to generate two equivalents of tributyltin hydride. 
The 4-O-(phenoxy)thiocarbonyl derivative (49) was subjected to bis(tributyltin) 
oxide, n-BuOH and azobiscyanocyclohexane in toluene at 80 °C overnight as 
previously described by Lopez et al. (Table 2, entry 1).151 However, under 
these conditions only starting material (49) was recovered largely owing to the 
low solubility of the compound. To overcome the problem of solubility the 
reaction was repeated using DMF as a co-solvent (Table 2, entry 2), but no 
reaction was observed. In an attempt to generate desired product (50), the 
solution of 3-fluoro-8,9-O-isopropylidene-4-O-(phenoxy)thiocarbonyl-sialic acid 
methyl ester (49) was degassed and molecular sieves was added (Table 2, 
entry 3). Nevertheless, decomposition of the starting material (49) could be 
observed through formation of a highly polar side product. As a consequence, 
a different strategy not involving toxic tributyltin derivatives was pursued. 
Tributyltin hydride is a versatile reagent for organic synthesis, however the 
undesirable toxicity140 stimulated the development of alternatives for tributyltin 
hydride such as silanes,156 dialkyl phosphate,151 hydrophosphorous acid 
together with its salts146 and recent developments also involve 
tetrabutylammonium peroxydisulfate and formate ion.157 
 
 
 
 
 
(Bu3SnO)2 + Bu3SnH
(1 eq.) (excess) (n eq.)
PMHS
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Table 2 Overview of the different conditions used for the synthesis of 4-deoxy-3-fluoro-
8,9-O-isopropylidene-sialic acid methyl ester (50). Condition A: (Bu3Sn)2O (0.037 eq.), PMHS 
(5 eq.), n-BuOH (5.5 eq.), azobiscyanocyclohexane (0.15 eq.), toluene; Condition B: 
(Bu3Sn)2O (0.037 eq.), PMHS (5 eq.), n-BuOH (5.5 eq.), azobiscyanocyclohexane (0.15 eq.), 
toluene/DMF; Condition C: (Bu3Sn)2O (0.037 eq.), PMHS (5 eq.), n-BuOH (5.5 eq.), 
azobiscyanocyclohexane (0.15 eq.), toluene/DMF, solution was degassed and molecular 
sieves added; Condition D: (Bu4N)2S2O8 (3 eq.), NaHCO3 (6 eq.), DMF; Condition E: 
(Bu4N)2S2O8 (3 eq.), NaHCO3 (6 eq.), DMF, solution was degassed and molecular sieves 
added; Condition F: Bu3SnH (2 eq.), azobiscyanocyclohexane (0.3 eq.), toluene; Condition 
G: Bu3SnH (2 eq.), azobiscyanocyclohexane (0.3 eq.), toluene, the solution was heated under 
reflux with Dean Stark apparatus for 2 hours prior to radical reaction; Condition H: Bu3SnH 
(3.7 eq.), 50% 2,2-bis(tert-butylperoxy)-butane solution (0.45 eq.), 1,4-dioxane. 
 
 
 
 
 
      50    51 
 
 
    49 
 
 
             48 
 
a Isolated yields after silica chromatography, dec. = decomposition, n.d. = not determined. 
 
 
 
 
 
Entry Condition Time T [°C] Product Yield (%)a
1 A O/N 80 49 n.d.
2 B O/N 80 49 n.d.
3 C 3.5 h 90 dec. n.d.
4 D 2.5 h 60 dec. n.d.
5 E 1 d 60 50 17
6 E 5 h 70 50 24
7 F 23 h 80 dec. n.d.
8 G 1 d 120 50 24
9 H 4 h 100 50 81
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It has been reported by Park et al. (Table 2, entry 4 - 6) that 
tetrabutylammonium peroxydisulfate and sodium formate can be used in a 
facile Barton-McCombie deoxygenation.157 A reported mechanism utilising 
tetrabutylammonium peroxydisulfate and sodium formate suggests that a 
carbon dioxide radical anion (CO2
•¯) is initially formed (Scheme 25a).157 
Subsequent sulfur attack on the carbon dioxide radical anion (Scheme 25b), 
β – cleavage (Scheme 25c), and hydrogen radical transfer from DMF or 
HCO2¯ (Scheme 25d) gives the deoxygenated product.
157 
 
 
Scheme 25 Reported mechanism for the deoxygenation of alcohols with (Bu4N)2S2O8 and 
HCO2Na.
157 
 
The 4-O-(phenoxy)thiocarbonyl derivative (49) was subjected to 
tetrabutylammonium peroxydisulfate and sodium formate in DMF at 60 °C for 
two and a half hours as previously described by Park et al. (Table 2, 
entry 4).157 An aqueous work up in order to remove the polar reagents was 
then performed. However, an undesired side reaction gave a highly polar 
product that under these conditions could not be isolated. 
 
a) S2O8
2 2SO4
SO4 HCO2+ HSO4 CO2+
b)
RO
S
R'
RO
S
R'
CO2
O
O
RO
S
R'
R + O
S
R'c)
O
O
O
O
d) R
H source: HCO2, DMF
RH
R' CO2+ COS+
R = alkyl chain, carbohydrate
R' = SMe (xanthate),
= OPh (thionocarbonate),
NN (O-thiocarbamate)
=
Chapter 2                                 Synthesis of 4-deoxy-2,3-difluoro-sialic acid (24) 
 
- 64 - 
To overcome the formation of side products, the solution was degassed and 
molecular sieves were added. After silica column chromatography 
(EtOAc:MeOH, 85:15) the desired product (50) was obtained in 17% yield 
(Table 2, entry 5).157 In addition to desired product (50), starting material (49) 
as well as the hydrolysed compound (48) could be isolated and polar 
decomposed material in the aqueous phase could be observed.158,159 Several 
attempts to improve the yield under the same conditions could only be 
optimised to give a yield of 24% (Table 2, entry 6). 
In an attempt to improve the yield for the deoxygenation reaction, the 
4-O-(phenoxy)thiocarbonyl derivative (49) was subjected to the general 
Barton-McCombie protocol utilising tributyltin hydride in toluene under reflux 
conditions (Table 2, entry 7 - 9). However, (Table 2, entry 7) only formation 
of a highly polar product could be seen. Hence, in order to eliminate side 
reactions correlating with water, it was concluded to perform an azeotropic 
Dean-Stark distillation prior to the Barton-McCombie reaction, which gave 
desired product (50) in 24% yield (Table 2, entry 8). The major side product 
under these conditions could be identified as the sulphur-oxygen exchanged 
carbonate (51). This rearrangement reaction of thionocarbonates under 
Barton-McCombie conditions to give O-thiocarbonyl (51) has previously been 
described by Powers and Tarbell.160 Hence, in an effort to optimise the yield, 
shorter reaction times were chosen and moreover, to resolve solubility issues 
the solvent was changed from toluene to 1,4-dioxane. 
The 3-fluoro-8,9-O-isopropylidene-4-O-(phenoxy)thiocarbonyl-sialic acid 
methyl ester (49) was next subjected to radical Barton-McCombie conditions 
using 2,2-bis(tert-butylperoxy)-butane as a radical initiator and the radical 
carrier tributyltin hydride under reflux conditions in 1,4-dioxane to give the 
4-deoxy-3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (50) in 81% 
yield (Table 2, entry 9).150 
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 2.3.3 Synthesis of 4-deoxy-3-fluoro hemiketal (53) 
 
We next set out to perform a selective deacetylation at the anomeric position 
of the 4-deoxy-3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (50). As a 
consequence, the 4-deoxy-3-fluoro-8,9-O-isopropylidene-sialic acid methyl 
ester (50) was subjected to 80% acetic acid according to the procedure of 
Anazawa et al. to remove the isopropylidene protection group. Subsequent 
global acetylation with acetic anhydride in pyridine gave the per-O-acetyl-
4-deoxy-3-fluoro-sialic acid methyl ester (52) in 76% yield (Scheme 26).161 
 50    52         53 
 
Scheme 26 Synthesis of 7,8,9-tri-O-acetyl-4-deoxy-3-fluoro-sialic acid methyl ester (53). a) (i) 
80% AcOH/H2O, 60 °C, 2 h; (ii) Ac2O, DMAP, pyridine, r.t., O/N, 76% (over 2 steps) (52); b) 
Hydrazine acetate, CH2Cl2/MeOH, 4 °C, O/N, 51% (53). 
 
The per-O-acetyl-4-deoxy-3-fluoro-sialic acid methyl ester (52) was then 
selectively deprotected at position C-2 utilizing hydrazine acetate in 
dichloromethane and MeOH, affording the hemiketal (53) in 51% yield. The 
higher reactivity of the anomeric acetal relative to the other hydroxyl groups in 
conjunction with hydrazine acetate, as a weak nucleophile, makes the 
deacetylation reaction selective for the anomeric position.162 However, 
hydrazine acetate is highly hygroscopic and additional water molecules can 
act as alternative nucleophiles to hydrazine in the reaction, leading to further 
deacetylation. Despite numerous attempts, like re-crystallisation or pre-drying 
of hydrazine acetate, the moderate yield could not be improved. 
 2.3.4 Formation of 4-deoxy-2,3-difluoro-sialic acid (24)con 
 
The fluorination of position C-2 of sialic acid hemiketal (54) utilising DAST to 
give 2,3-difluoro-sialic acid (55) has previously been performed by Watts and 
Withers (Scheme 27).87 
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     54         55 
 
Scheme 27 Mechanism for the fluorination of hemiketal (54) using DAST. CH2Cl2 - 30 ºC, 
30 min., 45%.87 
 
The fluorination of hemiketal (54) was reported to proceed through a 
nucleophilic attack on the sulfonium ion by the anomeric hydroxyl of the 
hemiketal (54). Subsequently, this activation increases the leaving group 
ability of the anomeric hydroxyl group, which then undergoes SN2 
displacement by a fluoride with inversion of configuration at C-2 and affords 
the fluorinated product (55).163 
Following the procedure of Watts and Withers the hemiketal (53) was then 
fluorinated by treatment with DAST in dichloromethane at - 40 °C → - 10 °C 
(Scheme 28).87 
 
 53            56        57 
 
Scheme 28 Formation of 4-deoxy-2,3-difluoro-sialic acid methyl ester (56) and (57). DAST, 
CH2Cl2, - 40 ºC → - 10 ºC, 1 hr, 45% (56) and 30% (57). 
 
However, after silica column chromatography, two compounds, characterised 
by different Rf, different chemical shift and multiplicity in 
19F NMR but identical 
molecular mass, were obtained. 
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Identification of the two compounds by analysis of 19F NMR coupling constants 
was not possible as the coupling constants between F-2 and F-3 were 
ambiguous for the identification of the anomers. As such, we utilised X-ray 
crystallographic analysis of the less polar compound to confirm the axial 
fluorine atom at position C-2 labelled F1 in the X-ray structure (Figure 14). 
Figure 14 X-ray crystallographic structure of C-2 axial fluorine per-O-acetyl-4-deoxy-2,3-
difluoro-sialic acid methyl ester (57). 
 
Concluding from the X-ray crystallographic structure the desired α-anomer 
(56) was isolated in 45% and the β-anomer (57) in 30%. 
An explanation for the formation of the two isomers might be given in 
consideration of a proposed mechanism for the fluorination of hemiketal (53), 
which proceeds by a nucleophilic attack of the anomeric hydroxyl of the 
hemiketal (53) on the sulfonium ion (Scheme 29). 
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Scheme 29 Proposed mechanism for the formation of the two 2,3-difluoro-sialic acid methyl 
ester anomers (56) and (57). 
 
This increase in the leaving group ability of the anomeric hydroxyl group then 
results in the formation of an oxocarbenium-ion (58). Once the oxocarbenium-
ion is formed, the fluoride ion can then attack either the re-face to form the 
β-anomer (57) (path A), or the si-face to form the desired α-anomer (56) 
(path B). 
In addition, the stereochemical outcome of the fluorination reaction of 
hemiketal (53) might be due to a competing nucleophilic substitution SN1 
character, forming a stable oxocarbenium-ion (58) (Scheme 29) over a SN2 
nucleophilic substitution reaction (Scheme 27). 
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In addition, the flat geometric predisposition of the oxocarbenium-ion (58) and 
steric hindrance of the glycerol side chain might preferentially enhance path 
B over path A but not enough to make it completely stereoselective.164 
Subsequently, the per-O-acetyl-α-4-deoxy-2,3-difluoro-sialic acid methyl ester 
(56) was globally deacetylated following Zemplén conditions using sodium in 
methanol at room temperature.165 Finally, saponification of the crude with 0.5M 
sodium hydroxide solution in water and subsequent silica column 
chromatography gave the target compound 4-deoxy-2,3-difluoro-sialic acid 
(24) in 52% yield (Scheme 30).  
 
 
 
          56        24 
 
Scheme 30 Formation of 4-deoxy-2,3-difluoro-sialic acid (24). (i) NaOMe, MeOH, r.t., 3 h; (ii) 
0.5M NaOH, H2O, r.t, 30 min., 52% (over 2 steps). 
 
The total synthesis from β-fluoropyruvic acid (41) to 4-deoxy-2,3-difluoro-sialic 
acid (24) was achieved in 11 steps, with an overall yield of 4%. 
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Synthesis of 7-deoxy-2,3-difluoro-sialic Chapter 3 - 
acid (25) 
 
 
For the synthesis of the putative mechanism-based influenza neuraminidase 
inactivator 7-deoxy-2,3-difluoro-sialic acid (25) we intended to utilise the 
synthesis of 4-deoxy-2,3-difluoro-sialic acid (24) (Chapter 2.3).  
       25         48          59 
We also considered known approaches towards the synthesis of 7-deoxy 
derivative (59), including a study performed by Miyazaki et al. utilising sialic 
acid (2) in a Barton-McCombie protocol via a C-7 O-thiocarbamate 
derivative.155 Hence, it was concluded that the previously successfully 
synthesised 3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (48) could 
be used as a common intermediate towards the synthesis of the C-7 xanthate 
(60). This intermediate could be part of a viable route towards the synthesis of 
7-deoxy-2,3-difluoro-sialic acid (25). 
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 Retrosynthetic analysis 3.1
 
We considered it likely that the 7-deoxy-2,3-difluoro-sialic acid (25) could be 
produced from hemiketal (61) by fluorination with DAST in a similar manner to 
that used for the synthesis of 4-deoxy-2,3-difluoro-sialic acid (24) 
(Chapter 2.3.4) (Scheme 31). 
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Scheme 31 Retrosynthetic strategy for the synthesis of 7-deoxy-2,3-difluoro-sialic acid (25) 
via the C-7 xanthate (62). 
 
The formation of 7-deoxy-3-fluoro-sialic acid hemiketal (61) could be 
accomplished by performing a Barton-McCombie deoxygenation on the C-7 
xanthate (62) with tributyltin hydride.150 
It was predicted that formation of the C-7 xanthate (62) could be attempted on 
3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (48) deploying a 
selective protection protocol. This selective protection protocol is based upon 
differential nucleophilicity of hydroxyl groups present at 3-fluoro-
8,9-O-isopropylidene-sialic acid methyl ester (48) after activation. 
As such, it was concluded that the hydroxyl group present at C-7 position 
based on nucleophilicity differences along with steric hindrances could be the 
least reactive hydroxyl group. A benzoyl protecting group seemed to be most 
applicable for the selective protection protocol to protect the hydroxyl groups 
at position C-2 and C-4. 
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Furthermore, it was intended that after the Barton-McCombie deoxygenation 
the benzoyl protecting group would enable selective deprotection at position 
C-2 using hydrazine acetate to form the hemiketal (61). 
The formation of 3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (48) 
could be yielded utilising TFA in methanol and 2,2’-dimethoxypropane on 
3-fluoro-sialic acid (39) as previously accomplished (Chapter 2.3.2). 
 Synthesis of 2,4-di-O-benzoyl-7-deoxy-3-fluoro-3.2
8,9-O-isopropylidene-sialic acid methyl ester (68) 
 
The 3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (48) was treated 
with benzoyl chloride in a mixture of dichloromethane/pyridine, which after 
standard work up and silica column chromatography afforded a mixture of 
2,4-di-O-benzoyl-3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (63) in 
54% and 2,4,7-tri-O-benzoyl-3-fluoro-8,9-O-isopropylidene-sialic acid methyl 
ester (64) in 18% yield respectively (Scheme 32). 
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Scheme 32 Formation of 2,4-di-O-benzoyl-3-fluoro-8,9-O-isopropylidene-sialic acid methyl 
ester (63) and 2,4,7-tri-O-benzoyl-3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (64). 
Benzoyl chloride, CH2Cl2/pyridine, - 40 °C → -20 °C, 1.5 h, 54% (63) and 18% (64). 
 
The synthesis of O-thionocarbonate at C-7 position utilising phenyl 
chlorothionoformate under conditions previously deployed on the synthesis of 
4-O-(phenoxy)thiocarbonyl-sialic acid methyl ester (49) (Chapter 2.3.2) gave 
an inseparable mixture of starting material (63), desired product (65) and the 
previously observed sulphur-oxygen exchanged rearrangement (66) according 
to Powers et al. in a ratio of 1:2:2 (Scheme 33).160 
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Scheme 33 Attempted synthesis of 2,4-di-O-benzoyl-3-fluoro-8,9-O-isopropylidene-
7-O-(phenoxy)thiocarbonyl-sialic acid methyl ester (65). Phenyl chlorothionoformate, 
CH2Cl2/pyridine, r.t., O/N. 
 
Furthermore, changing the solvent to pyridine and employing a variety of 
reaction temperatures (such as - 40 °C and 0 °C), together with attempts to 
degas the solution failed to improve the reaction and gave the known mixture 
in comparable ratios. 
Given the problem of forming an inseparable mixture, it was considered that 
utilising a thiocarbamate following the protocol of Miyazaki et al. these 
difficulties could be overcome. The thiocarbamate was anticipated to give 
better yields in the following Barton-McCombie deoxygenation, as the 
deoxygenation reaction itself requires lower temperatures and the risk of side 
reactions with forming the sulphur-oxygen exchanged side product is 
considerable lower.154 
The 2,4-di-O-benzoyl-3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester 
(65) was treated with 1,1’-thiocarbonyldiimidazole in anhydrous 
dichloromethane to give after silica column chromatography the 3-fluoro-
8,9-O-isopropylidene-7-O-thiocarbamate-sialic acid derivative (67) in 95% 
yield (Scheme 34).155 
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Scheme 34 Synthesis of 7-deoxy-3-fluoro-8,9-O-isopropylidene-sialic derivative (68). 
a) 1,1’-Thiocarbonyldiimidazole, CH2Cl2, 40 °C, 20 h, 95% (67) b) Luperox® 101, Bu3SnH, 1,4-
dioxane, 100 °C, 4 h, 89% (68). 
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The 3-fluoro-8,9-O-isopropylidene-7-O-thiocarbamate-sialic acid 
derivative (67) was then subjected to Barton-McCombie deoxygenation 
conditions using Luperox® 101 as a radical initiator and the radical carrier 
tributyltin hydride under reflux conditions in 1,4-dioxane to give 7-deoxy-
3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (68) in 89% yield 
(Scheme 34). The radical initiator Luperox® 101 was used as the previous 
deployed 2,2-bis(tert-butylperoxy)-butane radical initiator was no longer 
commercially available and Luperox® 101, as an alternative, gave advantages 
in terms of cost and longer stability over other radical initiators available. 
 Formation of 7-deoxy-3-fluoro hemiketal (71) 3.3
 
The anomeric deprotection of 2,4-di-O-benzoyl-7-deoxy-3-fluoro-
8,9-O-isopropylidene-sialic acid methyl ester (68) with hydrazine acetate 
in a solvent mixture of dichloromethane and methanol was attempted 
(Scheme 35). 
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Scheme 35 Attempted formation of 4-O-benzoyl-7-deoxy-3-fluoro-8,9-O-isopropylidene-sialic 
acid methyl ester (69). Hydrazine acetate, CH2Cl2/MeOH, 4 °C, O/N. 
 
However, numerous reaction conditions were tried including increasing the 
temperature from 4 °C to 40 °C and the use of more equivalents of hydrazine 
acetate failed to give desired product but resulted in decomposition of starting 
material (68). In addition, the use of a stronger nucleophile hydrazine hydrate 
and different work up methods to remove excess of hydrazine were performed 
with acidic or copper sulfate washes. Nevertheless, the reaction conditions 
applied were found to give starting material (68) and polar side product 
formation. 
 
 
 
Chapter 3                                 Synthesis of 7-deoxy-2,3-difluoro-sialic acid (25) 
 
- 76 - 
The unsuccessful selective anomeric deprotection of 2,4-di-O-benzoyl-
7-deoxy-3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (68) prompted 
us to investigate an alternative synthetic strategy involving global deprotection 
and subsequent acetylation to finally perform anomeric deprotection on an 
anomeric acetate, as previously performed on the per-O-acetyl-4-deoxy-3-
fluoro-sialic acid methyl ester (52) (Chapter 2.3.3). 
The 2,4-di-O-benzoyl-7-deoxy-3-fluoro-8,9-O-isopropylidene-sialic acid 
methyl ester (68) was subjected to sodium in methanol according to the 
previously deployed method (Chapter 2.3.3) following Zemplén conditions 
(Scheme 36).165 The crude mixture was then treated with 80% acetic acid 
following the procedure of Anazawa et al.161 (Chapter 2.3.3) and finally, 
globally acetylated with acetic anhydride in pyridine to give the per-O-acetyl-
7-deoxy-3-fluoro-sialic acid methyl ester (70) in 83% yield over 3 steps 
(Scheme 36). 
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Scheme 36 Synthesis of 4,8,9-tri-O-acetyl-7-deoxy-3-fluoro-sialic acid methyl ester (71). a) (i) 
NaOMe, MeOH, 40 °C, 36 h; (ii) 80% AcOH/H2O, 60 °C, 2 h; (iii) Ac2O, DMAP, pyridine, r.t., 
O/N, 83% (over 3 steps) (70); b) Hydrazine acetate, CH2Cl2/MeOH, 4 °C, O/N, 84% (71). 
 
The per-O-acetyl-7-deoxy-3-fluoro-sialic acid methyl ester (70) was then 
deprotected at position C-2 using hydrazine acetate in a solvent mixture of 
dichloromethane and methanol at 4 °C following the method previously 
deployed on per-O-acetyl-4-deoxy-3-fluoro-sialic acid methyl ester (52) 
(Chapter 2.3.3) to afford the hemiketal (71) in 84% yield (Scheme 36). 
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 Synthesis of 7-deoxy-2,3-difluoro-sialic acid (25) 3.4
 
The hemiketal (71) was then treated with DAST in dichloromethane at - 40 °C 
→ - 10 °C according to the methodology previously deployed on hemiketal 
(53) (Chapter 2.3.4) to afford a mixture of α- and β-fluoride anomers (72) 
(Scheme 37). 
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Scheme 37 Synthesis of 7-deoxy-2,3-difluoro-sialic acid methyl ester anomers (73) and (74). 
a) DAST, CH2Cl2, - 40 ºC → - 10 ºC, 1 hr; b) NaOMe, MeOH, r.t., 3 h, 41% (over 2 steps) (73), 
20% (over 2 steps) (74). 
 
The formation of a mixture of anomers is in compliance with results previously 
observed on hemiketal (53) (Chapter 2.3.4). The correct molecular weight was 
confirmed by mass spectrometry but, despite exhaustive solvent combinations 
in silica column chromatography the α- and β-anomers (72) could not be 
purified by at this stage, as the two anomers coeluted. 
It was considered, that separation might be possible following deacetylation of 
the anomeric mixture. As such, the α-/β-mixture (72) was deacetylated using 
sodium in methanol at room temperature following Zemplén conditions.165 
Subsequent purification by silica column chromatography gave the desired α 
isomer (73) pure in 41% yield and the β isomer (74) in 20%, over the 2 steps. 
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Finally, ester saponification of the 7-deoxy-2,3-difluoro-sialic acid methyl ester 
(73) with 0.5M sodium hydroxide solution in water at room temperature gave 
then the desired 7-deoxy-2,3-difluoro-sialic acid (25) in 49% yield (Scheme 
38). 
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Scheme 38 Formation of 7-deoxy-2,3-difluoro-sialic (25). 0.5M NaOH, H2O, r.t, 45 min., 49%. 
 
The total synthesis from β-fluoropyruvic acid (41) to 7-deoxy-2,3-difluoro-sialic 
acid (25) was achieved in 13 steps, with an overall yield of about 5%. 
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Synthesis of 8-deoxy-2,3-difluoro-sialic Chapter 4 - 
acid (26) 
 
 
The synthesis of the putative mechanism-based influenza neuraminidase 
inactivator 8-deoxy-2,3-difluoro-sialic acid (26) was deployed in consideration 
of the previously accomplished syntheses of 4-deoxy-2,3-difluoro-sialic acid 
(24) (Chapter 2.3) and 7-deoxy-2,3-difluoro-sialic acid (25) (Chapter 3). 
       26        48          75 
We also considered known approaches towards the synthesis of the 8-deoxy 
derivative (75), which was achieved following Barton-McCombie 
deoxygenation of a C-8 O-thionocarbonate by Miyazaki et al.155 This approach 
could be used as a proof of principle for the Barton-McCombie deoxygenation 
strategy. It was intended again to utilise the 3-fluoro-8,9-O-isopropylidene-
sialic acid methyl ester (48), the common intermediate of the succeeding 
syntheses of C-7 and C-4 xanthate to develop a feasible approach via the C-8 
xanthate (76) towards the synthesis of 8-deoxy-2,3-difluoro-sialic acid (26). 
 
 
 
 
       76 
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 Retrosynthetic analysis 4.1
 
Given the successful hemiketal fluorination with DAST in the synthesis of 
4-deoxy-2,3-difluoro-sialic acid (24) and 7-deoxy-2,3-difluoro-sialic acid (25), 
we considered a similar approach to perform the synthesis of 8-deoxy-
2,3-difluoro-sialic acid (26) from the hemiketal (78) (Scheme 39). 
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Scheme 39 Retrosynthetic strategy for the synthesis of 8-deoxy-2,3-difluoro-sialic acid (26) 
via the C-8 xanthate (78). 
 
It was concluded that the 8-deoxy-3-fluoro-sialic acid hemiketal (77) could be 
achieved through Barton-McCombie deoxygenation of the xanthate (78). The 
xanthate (78) could be accessible from the previously formed 3-fluoro-
8,9-O-isopropylidene-sialic acid methyl ester (48) through a series of standard 
protecting group manipulations. 
It was anticipated that acetylation at position C-2, C-4 and C-7 of the common 
intermediate 3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (48) 
following isopropylidene deprotection according to the procedure of Anazawa 
et al. would permit subsequent selective protection of the hydroxyl group at 
position C-9 over the hydroxyl group at position C-8, using for example a 
benzoate protecting group.161 
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 Synthesis of C-8 xanthate (84) 4.2
 
The common intermediate 3-fluoro-8,9-O-isopropylidene-sialic acid methyl 
ester (48) was achieved as mentioned previously (Chapter 2.3.2). Subsequent 
acetylation by treatment with acetic anhydride in pyridine gave 2,4,7-tri-
O-acetyl-3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester (79) in 91% 
yield from the 8,9-O-isopropylidene-sialic acid derivative (48) (Scheme 40). 
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Scheme 40 Formation of 2,4,7-tri-O-acetyl-3-fluoro-8,9-O-isopropylidene-sialic acid methyl 
ester (79). Ac2O, pyridine, r.t., 7 days, 91%. 
 
In an attempt to shorten reaction times, catalytic amounts of DMAP were 
added to the reaction mixture but the reaction failed as formation of 
isopropylidene-deprotected side product was observed. 
Next, the 2,4,7-tri-O-acetyl-3-fluoro-8,9-O-isopropylidene-sialic acid methyl 
ester (79), was treated with 80% acetic acid according to the procedure of 
Anazawa et al. (Scheme 41).161  
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Scheme 41 Synthesis of 2,4,7-tri-O-acetyl-9-O-benzoyl-3-fluoro-sialic acid methyl ester (81). 
a) 80% AcOH/H2O, 60 °C, 2 h; b) Benzoyl chloride, pyridine, r.t., O/N, 70% (over 2 steps). 
 
An aqueous work up following the acidic hydrolysis failed as the desired 
product 2,4,7-tri-O-acetyl-3-fluoro-sialic acid methyl ester (80) did decompose 
and was found to accumulate in the aqueous phase. 
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Acetyl group migration under acidic conditions was known to occur and 
together with further deacetylation might be an explanation for the difficulties 
envisaged in the purification of 2,4,7-tri-O-acetyl-3-fluoro-sialic acid methyl 
ester (80).161,166,167 
Hence, following isopropylidene deprotection, the crude mixture was treated 
with benzoyl chloride in pyridine at room temperature to give the selective C-9 
benzoyl-protected derivative (81) in 70% over the two steps (Scheme 41). 
Considering our previous success of introducing the C-7 O-thiocarbamate in 
the synthesis of 7-deoxy-2,3-difluoro-sialic acid (25) (Chapter 3.2), we applied 
the use of this group in the synthesis of 8-deoxy-2,3-difluoro-sialic acid (26). 
Consequently, the 2,4,7-tri-O-acetyl-9-O-benzoyl-3-fluoro-sialic acid methyl 
ester (81) was subjected to 1,1’-thiocarbonyldiimidazole in anhydrous 
dichloromethane (Scheme 42). 
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Scheme 42 Attempted formation of 2,4,7-tri-O-acetyl-9-O-benzoyl-3-fluoro-
8-O-thiocarbamate-sialic acid methyl ester (82). 1,1’-Thiocarbonyldiimidazole, CH2Cl2, 40 °C, 
24 h. 
 
Following aqueous work up and silica column chromatography, analysis by 
mass spectrometry confirmed the formation of a species with the correct 
molecular weight. However, analysis of the 1H NMR spectrum indicated the 
product was a mixture of C-8 (82) and C-7 O-thiocarbamate (83) in a ratio of 
1:1. Despite exhaustive solvent combinations in silica column chromatography 
the mixture of C-8 (82) and C-7 O-thiocarbamate (83) could not be purified. It 
was concluded that formation of the mixture of thiocarbamates at C-7 and C-8 
might be due to acetyl migration under the conditions applied. 
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In an attempt to overcome the problem of acetyl migration we anticipated that 
formation of the C-8 thionocarbonate could be less susceptible to acetyl 
migration, as shorter reaction times and lower temperatures are required. 
Hence, the 2,4,7-tri-O-acetyl-9-O-benzoyl-3-fluoro-sialic acid methyl ester (81) 
was treated with phenyl chlorothionoformate in pyridine at 0 °C affording, after 
silica column chromatography, the 2,4,7-tri-O-acetyl-9-O-benzoyl-
3-fluoro-8-O-(phenoxy)thiocarbonyl-sialic acid methyl ester (84) in 84% yield 
(Scheme 43). 
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Scheme 43 Formation of 2,4,7-tri-O-acetyl-9-O-benzoyl-3-fluoro-8-O-(phenoxy)thiocarbonyl-
sialic acid methyl ester (84). Phenyl chlorothionoformate, pyridine, 0 ºC → r.t., 15 h, 84%. 
 
 Formation of 8-deoxy-3-fluoro hemiketal (86) 4.3
 
The 2,4,7-tri-O-acetyl-9-O-benzoyl-3-fluoro-8-O-(phenoxy)thiocarbonylsialic 
acid methyl ester (84) was then subjected to Barton-McCombie conditions 
using Luperox® 101 as a radical initiator and the radical carrier tributyltin 
hydride under reflux conditions in 1,4-dioxane to give according to the 
methodology previously deployed on 7-O-thiocarbamate-sialic acid methyl 
ester (67) (Chapter 3.2) the 8-deoxy-3-fluoro-sialic acid derivative (85) in 80% 
yield (Scheme 44). 
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Scheme 44 Synthesis of 8-deoxy-3-fluoro-sialic acid derivative (85). Luperox® 101, Bu3SnH, 
1,4-dioxane, 100 ºC, 4 h, 80%. 
Chapter 4                                 Synthesis of 8-deoxy-2,3-difluoro-sialic acid (26) 
 
- 84 - 
Subsequent anomeric deprotection of the 2,4,7-tri-O-acetyl-9-O-benzoyl-
8-deoxy-3-fluoro-sialic acid methyl ester (85) employing the method using 
hydrazine acetate in dichloromethane and methanol at 4 °C as previously 
described on per-O-acetyl-4-deoxy-3-fluoro-sialic acid methyl ester (52) 
(Chapter 2.3.3) to give the hemiketal (86) in 83% yield (Scheme 45). 
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Scheme 45 Formation of 4,7-di-O-acetyl-9-O-benzoyl-8-deoxy-3-fluoro-sialic acid methyl ester 
(86). Hydrazine acetate, CH2Cl2/MeOH, 4 °C, O/N, 83%. 
 
 Synthesis of 8-deoxy-2,3-difluoro-sialic acid (26) 4.4
 
The hemiketal (86) was then treated with DAST in dichloromethane 
at - 40 °C → - 10 °C according to the methodology previously deployed on 
hemiketal (53) (Chapter 2.3.4) to afford a mixture of α- and β-fluoride anomers 
(87) (Scheme 46). 
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Scheme 46 Synthesis of 8-deoxy-2,3-difluoro-sialic acid methyl ester anomers (88) and (89). 
a) DAST, CH2Cl2, - 40 ºC → - 10 ºC, 1 hr; b) (i) NaOMe, MeOH, r.t., O/N; (ii) TFA, MeOH, r.t., 
O/N, 25% (over 3 steps) (88), 11% (over 3 steps) (89). 
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The formation of a mixture of anomers is in compliance with results observed 
on hemiketal (53) (Chapter 2.3.4). The correct molecular weight was 
confirmed by mass spectrometry but, despite exhaustive solvent combinations 
in silica column chromatography the α-/β-mixture (87) could not be purified by 
at this stage, as the two anomers coeluted. 
It was considered, that separation might be possible following deacetylation of 
the anomeric mixture as previously demonstrated on the α-/β-mixture (72) 
(Chapter 3.4). As such, the α-/β-mixture (87) was deacetylated using sodium 
in methanol at room temperature following Zemplén conditions.165 
However, applying Zemplén conditions resulted in formation of a polar side 
product.165 The suspected de-esterification generated a highly polar mixture α- 
and β-fluoride anomers, impossible to purify by C18 reverse phase column 
chromatography. Hence, subsequent esterification using trifluoroacetic acid in 
methanol was attempted, followed by silica column chromatography to give 
the desired α anomer (88) in 25% and the β anomer (89) in 11% yield 
respectively over the 3 steps. 
Finally, ester saponification of the desired anomer 8-deoxy-2,3-difluoro-sialic 
acid methyl ester (88) with 0.5M sodium hydroxide solution in water and 
subsequent silica column chromatography gave the desired 8-deoxy-2,3-
difluoro-sialic acid (26) in 22% yield (Scheme 47). 
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Scheme 47 Formation of 8-deoxy-2,3-difluoro-sialic (26). 0.5M NaOH, H2O, r.t, 45 min., 22%. 
 
The total synthesis from β-fluoropyruvic acid (41) to 8-deoxy-2,3-difluoro-sialic 
acid (26) was achieved in 12 steps, with an overall yield of 2%. 
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Synthesis of 9-deoxy-2,3-difluoro-sialic Chapter 5 - 
acid (27) 
 
 
In order to synthesise the putative mechanism-based influenza neuraminidase 
inactivator 9-deoxy-2,3-difluoro-sialic acid (27), we considered known 
approaches towards the synthesis of 9-deoxy-sialic acid (90). 
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A study performed by Miyazaki et al. proceeded via a C-9 O-thionocarbonate 
derivative, which after Barton-McCombie deoxygenation gave the 9-deoxy-
sialic acid derivative in 39% yield. The Barton-McCombie deoxygenation is 
known to give low yields at position C-9 of sialic acid.154 Therefore, it was 
anticipated to achieve better results utilising 2-N-acetyl-6-deoxy-
D-mannosamine (91) in an enzymatic aldolase reaction, which has previously 
been pointed out (Chapter 2.2.2) to give 9-deoxy-3-difluoro-sialic acid (92) 
(Scheme 48). 
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Scheme 48 Proposed formation of 9-deoxy-3-fluoro-sialic acid (92). Neu5Ac aldolase, H2O, 
r.t.. 
Chapter 5                                 Synthesis of 9-deoxy-2,3-difluoro-sialic acid (27) 
 
- 88 - 
As such, the synthesis of 2-N-acetyl-6-deoxy-D-mannosamine (91) has 
previously been accomplished by Bucchini et al. starting from 2-N-acetyl-
D-mannosamine (40).168 2-N-acetyl-D-mannosamine (40) itself is a cheap 
starting material and the formation of 2-N-acetyl-6-deoxy-D-mannosamine (91) 
in highest possible yields could be a vigorous route towards the synthesis of 
9-deoxy-2,3-difluorosialic acid (27). 
 Attempted synthesis of 9-deoxy-2,3-difluoro-sialic 5.1
acid (27) via the 2-N-acetyl-6-deoxy-
D-mannosamine (91) 
 
 5.1.1 Retrosynthetic analysis 
 
We considered it likely that the 9-deoxy-2,3-difluorosialic acid (27) could be 
produced from hemiketal (93) by fluorination with DAST in a similar manner to 
that used for the synthesis of 4-deoxy-2,3-difluoro-sialic acid (24) 
(Chapter 2.3.4) (Scheme 49). 
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Scheme 49 Retrosynthetic strategy for the synthesis of 9-deoxy-2,3-difluoro-sialic acid (27) 
via the 2-N-acetyl-6-deoxy-D-mannosamine (91). 
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The 9-deoxy-3-fluoro-sialic acid hemiketal (93) could be achieved in an 
enzymatic aldolase reaction of 2-N-acetyl-6-deoxy-D-mannosamine (91) and 
β-fluoropyruvic acid (41), according to the method employed by Watts and 
Withers.87 The 2-N-acetyl-6-deoxy-D-mannosamine (91) could be yielded 
utilising the C-6 iodo derivative (94) in a dehalogen hydrogenation reaction 
following the previously accomplished synthesis of Bucchini et al.168 
The formation of the C-6 iodo derivative (94) could be achieved, after 
activation of the C-6 position in 2-N-acetyl-D-mannosamine with sodium iodide 
(40). 
 5.1.2 Synthesis of per-O-acetyl-2-N-acetyl-6-iodo-
D-mannosamine (96) 
 
The 2-N-acetyl-D-mannosamine (40) was treated with p-toluenesulfonyl 
chloride in pyridine at 0 °C and subsequently acetylated with acetic anhydride 
in pyridine overnight to give the per-O-acetyl-N-acetyl-6-tosyl-D-mannosamine 
(95) following the procedure of Saxon et al.169 and Buchini et al.168 in 48% over 
the 2 steps (Scheme 50). 
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Scheme 50 Synthesis of per-O-acetyl-2-N-acetyl-6-tosyl-D-mannosamine (95). 
(i) 4-Toluenesulfonyl chloride, pyridine, 0 °C, 7 h; (ii) Ac2O, pyridine, r.t., O/N, 48% (over 
2 steps). 
 
The low yield might be due to impure starting material 2-N-acetyl-
D-mannosamine (40), which had been recovered from previously performed 
enzymatic aldolase reactions of 2-N-acetyl-D-mannosamine (40) with 
β-fluoropyruvic acid (41) (Chapter 2.2.2). 
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The per-O-acetyl-2-N-acetyl-6-tosyl-D-mannosamine (95) was then subjected 
to potassium iodide in butanone to give per-O-acetyl-2-N-acetyl-6-iodo-
D-mannosamine (96) according to the procedure by Horita et al. after silica 
column chromatography in 50% yield (Scheme 51).170 
 
 
 
    95        96 
 
Scheme 51 Formation of per-O-acetyl-2-N-acetyl-6-iodo-D-mannosamine (96). KI, butanone, 
90 °C, 18 h, O/N, 50%. 
 
Although acceptable, it was considered that the yield of 50% could potentially 
be improved upon. As such, alternative methods to introduce the iodine by 
testing a number of iodide sources and employing a number of solvents and 
temperatures were attempted (Table 3). 
 
Table 3 Different conditions used for the formation of per-O-acetyl-2-N-acetyl-6-iodo-
D-mannosamine (96). Condition A: NaI (2 eq.), DMF; Condition B: KI (2 eq.), DMF; 
Condition C: KI (2 eq.), butanone; Condition D: CsI (2 eq.), butanone. 
 
 
 
 
           95         96 
 
 
a Isolated yields after silica chromatography. n.d. = not determined. 
 
 
 
Entry Condition Time T [°C] Product Yield (%)a
1 A 18 h 80 96 30
2 B 24 h 70 96 44
3 C 24 h r.t. 95 n.d.
4 C 17 h 70 96 44
5 C 36 h 90 96 40
6 C 18 h 90 96 50
7 D 23 h 70 96 39
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The per-O-acetyl-2-N-acetyl-6-tosyl-D-mannosamine (95) was treated with 
sodium iodide in dimethylformamide at 80 °C (Table 3, entry 1) and gave 
desired product (96) in 30% yield, but also resulted in formation of a highly 
polar side product that could not be isolated under the conditions applied. 
Therefore, the alternative iodide source potassium iodide was investigated 
under similar conditions but at 70 °C (Table 3, entry 2) and gave more 
encouraging yield of 44%. Difficulties in removing the solvent DMF and 
subsequent purification were tried to be resolved by changing the solvent to 
butanone instead (Table 3, entry 3 to 7). The best yield for the transformation 
of per-O-acetyl-2-N-acetyl-6-tosyl-D-mannosamine (95) to the 6-iodo 
derivative (96) was achieved utilising potassium iodide in butanone at 90 °C in 
50% yield respectively (Table 3, entry 6). Despite, numerous alternative 
reaction conditions, such as using caesium iodide (Table 3, entry 7) no better 
yields could be achieved. 
In all reactions performed starting material per-O-acetyl-2-N-acetyl-6-tosyl-
D-mannosamine (95) was recovered. However, longer reaction times in order 
to push the reaction to completion resulted in decomposition of the product 
and afforded lower yields. The expected elimination product (97), which also 
could have been used for the synthesis of 2-N-acetyl-6-deoxy-
D-mannosamine (91), was not observed. 
 
 
 
           97 
 5.1.3 Attempted synthesis of 2-N-acetyl-6-deoxy-
D-mannosamine (91) 
 
The per-O-acetyl-2-N-acetyl-6-iodo-D-mannosamine (96) was then subjected 
to Barton-McCombie conditions using Luperox® 101 as a radical initiator and 
the radical carrier tributyltin hydride under reflux conditions in 1,4 dioxane as 
previously employed (Chapter 3.2) to give the per-O-acetyl-2-N-acetyl-
6-deoxy-D-mannosamine (98) in 70% yield (Scheme 52). 
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Scheme 52 Synthesis of per-O-acetyl-2-N-acetyl-6-deoxy-D-mannosamine (98). 
Luperox® 101, Bu3SnH, 1,4-dioxane, 100 ºC, 4 h, 70%. 
 
The per-O-acetyl-2-N-acetyl-6-deoxy-D-mannosamine (98) was 
then deacetylated using sodium in methanol following Zemplén conditions 
(Table 4).165 The conditions applied generated, due to epimerisation of the 2-
N-acetyl group at basic conditions, an inseparable mixture of 2-N-acetyl-D-
mannosamine and 2-N-acetyl-D-glucosamine (99) together with their 
corresponding mixture of anomers (Table 4, entry 1). 
 
Table 4 Different conditions used for the synthesis of 2-N-acetyl-6-deoxy-D-mannosamine 
(91). Condition A: NaOMe (0.3 eq.), MeOH;165 Condition B: AcCl (0.1 eq.), MeOH;171 
Condition C: Molecular sieves 4 Å, MeOH.172 
 
 
 
 
          98     99        100 
 
 
n.d. = not determined 
 
 
 
The deacetylation following Zemplén165 conditions has previously been 
performed by Buchini et al.168 on per-O-acetyl-2-N-acetyl-6-azido-
D-mannosamine (101), but translation towards the synthesis of 2-N-acetyl-
6-deoxy-D-mannosamine (91) could not be accomplished.168 
Entry Condition Time T [°C] Product Yield (%)
1 A 5 h 0 99 n.d.
2 B 21 h 4 100 n.d.
3 C 72 h r.t. 98 n.d.
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We investigated known approaches for the deprotection of acetyl groups such 
as acidic conditions utilising acetyl chloride in methanol (Table 4, entry 2), but 
these acidic conditions enhanced the formation of the methyl glycoside 
2-N-acetyl-6-deoxy-D-mannosamine (100).171 
We also examined milder basic conditions deploying the use of molecular 
sieves 4 Å in methanol (Table 4, entry 3), but only starting material (98) 
together with similar side reactions as previously reported using Zemplén 
conditions (Table 4, entry 1) were observed.165,172 
Given the difficulties using acetyl protecting groups at the anomeric position of 
2-N-acetyl-D-mannosamine, we were prompted to use alternative anomeric 
protecting groups. 
A synthesis performed by Liu et al. afforded allyl 2-N-acetyl-3,4-di-O-acetyl-2-
deoxy-6-O-tolylsulfonyl-α-D-mannopyranoside (103) using an allyl anomeric 
protecting group. This known approach could be useful to accomplish the 
synthesis of 2-N-acetyl-6-deoxy-D-mannosamine (91) (Scheme 53).173 
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Scheme 53 Literature protocol for the synthesis of allyl 2-N-acetyl-3,4-di-O-acetyl-2-deoxy-
6-O-tolylsulfonyl-α-mannopyranoside (103). a) (i) Ac2O, pyridine, r.t., O/N; (ii) Allyl alcohol, 
BF3•OEt2, CH3NO2, 40 °C, 3 h, 36% (over 2 steps) (102); b) (i) NaOMe, MeOH, r.t., 3 h; 
(ii) TosCl, pyridine, 0 °C, 7 h; (iii) Ac2O, pyridine, r.t., O/N, 36% (over 3 steps) (103).
173 
 
The 2-N-acetyl-D-mannosamine (40) was acetylated using acetic anhydride in 
pyridine at room temperature overnight and subsequently treated with 
borontrifluoride dietherate in nitromethane at 40 °C for 3 hours to give allyl per-
O-acetyl-2-N-acetyl-D-mannosamine (102) in 36% over the 2 steps. 
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The allyl per-O-acetyl-2-N-acetyl-D-mannosamine (102) was deprotected 
using sodium in methanol following Zemplén conditions and then subjected to 
p-toluenesulfonyl chloride in pyridine at 0 °C. Subsequent acetylation with 
acetic anhydride in pyridine overnight gave the allyl per-O-acetyl-2-N-acetyl-
6-tosyl-D-mannosamine (103) in 36% yield over the 3 steps.165 Reassessing 
the number of steps and taking into account the moderate yields obtained, the 
formation of 2-N-acetyl-6-deoxy-D-mannosamine (91) following this approach 
seemed not viable. 
Therefore, a different approach by Liu et al. was pursued to form benzyl 
2-N-acetyl-α-D-mannopyranoside (104). 
 
 
 
 
    40      104 
 
Scheme 54 Literature protocol for the synthesis of benzyl 2-N-acetyl-α-D-mannopyranoside 
(102). (i) Ac2O, pyridine, r.t., O/N; (ii) BnOH, BF3•OEt2, CH3NO2, 80 °C, 3 h; (iii) NaOMe, 
MeOH, r.t., 1.5 h, 48% (over 3 steps).173 
 
The 2-N-acetyl-D-mannosamine (40) was acetylated using acetic anhydride in 
pyridine at room temperature overnight (Scheme 54). The crude residue was 
then benzyl protected at the anomeric position using borontrifluoride 
dietherate, followed by acetyl deprotection using  Zemplén conditions to give 
benzyl 2-N-acetyl-α-D-mannopyranoside (104) in 48% over the 3 steps 
(Scheme 54).165 
The benzyl 2-N-acetyl-α-D-mannopyranoside (104) was subjected to iodine, 
triphenylphosphine and imidazole following an encouraging method developed 
by Garegg and Samuelsson to convert primary hydroxyl groups into an iodo 
group in the presence of secondary hydroxyl groups on carbohydrates 
(Scheme 55).174-176 
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The proposed mechanism of Garegg and Samuelsson’s method proceeds via 
a phosphor-imidazolium cation a), which subsequently activates the primary 
hydroxyl group b) as a phosphonium oxide (Scheme 55). This activated 
hydroxyl group is then replaced by iodine in a nucleophilic substitution c). 
 
 
 
 
 
 
 
Scheme 55 Proposed mechanism for the conversion of primary hydroxyl groups into iodo 
groups in carbohydrates.176 
 
Due to limited solubility of benzyl 2-N-acetyl-α-D-mannopyranoside (104) in 
toluene, nitromethane as a co-solvent was added. However, the reaction 
resulted in the formation of a highly polar side product (Scheme 56). 
 
 
 
    104   105 
 
Scheme 56 Protocol of Garegg and Samuelsson to form benzyl 2-N-acetyl-6-iodo-α-D-
mannopyranoside (105).176 I2, Ph3P, imidazole, toluene/MeCN, 90 °C, 2 h. 
 
In order to resolve the difficulties in the one step Garegg and Samuelsson 
process, the primary hydroxyl group at position C-6 was first converted into a 
tosyl group, using p-toluenesulfonyl chloride in pyridine at 0 °C to give benzyl 
6-O-tolylsulfonyl-α-D-mannopyranoside derivative (Scheme 57). 
Subsequently, the tosyl group at position C-6 was treated with sodium iodide 
in acetone to give benzyl 2-N-acetyl-6-iodo-α-D-mannopyranoside (103) in 
52% yield over the 2 steps (Scheme 57). 
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Scheme 57 Formation of benzyl 2-N-acetyl-6-iodo-α-D-mannopyranoside (105). (i) TosCl, 
pyridine, 0 ºC → r.t., 6 h; (ii) NaI, acetone, 50 ºC, 32 h, 52% (over 2 steps). 
 
It was anticipated that hydrogenation of benzyl 2-acetyl-6-iodo-
α-D-mannopyranoside (105) would remove the iodine at position C-6 as well 
as the benzyl protection group at the anomeric C-1 position to generate 
2-N-acetyl-6-deoxy-D-mannosamine (91) and a number of hydrogenation 
conditions were examined (Table 5). 
 
Table 5 Different conditions used for the synthesis of 2-N-acetyl-6-deoxy-
D-mannosamine (91). Condition A: Pd(OH)2/C, MeOH/H2O; Condition B: Pd/C, THF/AcOH. 
 
 
 
 
    105    106 
 
 
 
 
 
 
a Condition A but hydrogenation was performed at 6 bar. 
 
 
 
A number of hydrogenation protocols including alternative palladium catalysts, 
such as Pd(OH)2 and solvent systems such as methanol/water and 
tetrahydrofuran/acetic acid together with raising the reaction temperature and 
hydrogen gas pressure only resulted in the isolation of benzyl 2-N-acetyl-
6-deoxy-α-D-mannopyranoside (106) (Table 5, entry 1 to 4). 
Entry Condition Time T [°C] Product
1 A 4 d r.t. 106
2 Aa 17 h r.t. 106
3 A 17 h 40 106
4 B 17 h 40 106
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Hence, the removal of the benzyl protecting group at the anomeric position 
could not be accomplished. 
Given the difficulties we encountered towards the synthesis of 2-N-acetyl-
6-deoxy-D-mannosamine (91) we re-evaluated our synthetic strategy and 
concluded to focus our studies on methods to form 9-iodo-3-fluoro-sialic acid 
(107). 
 
 
 
         107 
 
 Synthesis of 9-deoxy-2,3-difluoro-sialic acid (27) 5.2
via the 3-fluoro-9-iodo-sialic acid methyl ester 
(107) 
 
 5.2.1 Retrosynthetic analysis 
 
Given the successful hemiketal fluorination with DAST in the synthesis of 
4-deoxy-2,3-difluoro-sialic acid (24), 7-deoxy-2,3-difluoro-sialic acid (25) and 
8-deoxy-2,3-difluoro-sialic acid (26), we considered a similar approach to 
perform the synthesis of 9-deoxy-2,3-difluoro-sialic acid (27) from the 
hemiketal (108) (Scheme 58).  
 
 
 
         27              108 
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Scheme 58 Retrosynthetic strategy for the synthesis of 9-deoxy-2,3-difluoro-sialic acid (27) 
via the C-9 iodo-sialic acid (107). 
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The 9-deoxy-3-fluoro-sialic acid hemiketal (108) itself could be formed in a 
reduction reaction deploying dehalogen hydrogenation from 3-fluoro-9-iodo-
sialic acid (107). It was anticipated that formation of 3-fluoro-9-iodo-sialic acid 
(107) could be achieved through a series of standard protecting group 
manipulations based upon the differential nucleophilicity of primary over 
secondary hydroxyl groups present in 3-fluoro-sialic acid methyl ester (44). 
The synthesis of 3-fluoro-sialic acid methyl ester (44) using an enzymatic 
aldolase reaction of 2-N-acetyl-D-mannosamine (40) and β-fluoropyruvic acid 
(41) has previously been accomplished (Chapter 2.2.3). 
 5.2.2 Synthesis of 9-iodo-3-fluoro-sialic acid methyl ester (107) 
 
The 3-fluoro-sialic acid methyl ester (44) was subjected to the previously 
employed method using iodine, triphenylphosphine and imidazole according to 
the method of Garegg and Samuelsson (Chapter 5.1.3) to form 3-fluoro-
9-iodo-sialic acid (107) (Scheme 59).176 
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Scheme 59 Attempted formation of 3-fluoro-9-iodo-sialic acid methyl ester (107). I2, Ph3P, 
imidazole, toluene/MeCN, 90 °C, 2 h. 
 
However, solubility issues of the starting material (44) and purification 
difficulties of triphenylphosphine oxide, which have previously been 
encountered on benzyl 2-N-acetyl-α-D-mannopyranoside (104) (Chapter 5.1.3) 
failed to give desired product (107). 
To overcome the problems of the one-step Garegg and Samuelsson method, 
stepwise series of standard protecting group manipulations of the hydroxyl 
group at position C-9 with mesyl, tosyl or trityl followed by acetylation of 
position C-2, C-4, C-7 and C-8 with a subsequent nucleophilic substitution at 
position C-9 with iodine was attempted (Scheme 60). 
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Scheme 60 Proposed synthesis of per-O-acetyl-3-fluoro-9-iodo-sialic acid methyl ester (110). 
a) (i) MesCl, pyridine, - 20 °C; (ii) Ac2O, pyridine, r.t.; b) (i) TosCl, pyridine, 0 °C; (ii) Ac2O, 
pyridine, r.t.; c) (i) Trityl chloride, pyridine, - 20 °C; (ii) Ac2O, pyridine, r.t.; d) KI, butanone, 
90 °C; 
 
However, the conditions applied resulted in elimination of the protection group 
present at position C-9. A strategy based on a series of standard protecting 
group manipulations of the primary hydroxyl group at position C-9 such as silyl 
groups, followed by acetylation of position C-2, C-4, C-7 and C-8 with 
subsequent deprotection of position C-9 was considered to involve too many 
steps and was not attempted. 
A known method deployed by Schreiner et al. subjected sialic acid methyl 
ester methyl glycoside (111) to thiophosgene and p-cresol to form a cyclic 
8,9-O-carbonothioate derivative (112), which was then opened with 
iodomethane to give the C-9 iodo compound (113). Subsequently, the C-9 
iodo compound (113) was treated with tributyltin hydride to give a 4,7,9-
trideoxy derivative. It was anticipated that this approach could provide a 
vigorous method and could be used for the synthesis of 9-deoxy-2,3-difluoro-
sialic acid (27) (Scheme 61).177 
   111         112           113 
 
 
 
 
Scheme 61 Literature protocol for the synthesis 9-iodo-8-O-methylthiocarbonyl-sialic acid 
methyl ester (113). a) (i) CSCl2, DMAP, CH2Cl2, - 45 °C; (ii) p-Cresol, 68% (112); b) CH3I, 
56 °C, O/N, 57% (113).177 
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The 2,4,7-tri-O-benzoyl-3-fluoro-8,9-O-isopropylidene-sialic acid methyl ester 
(64), a side product formed in the synthesis of 7-deoxy-2,3-difluoro-sialic acid 
(25) (Chapter 3.2), following isopropylidene deprotection could be used to 
generate a cyclic carbonothioate. Therefore, the 2,4,7-tri-O-benzoyl-3-fluoro-
8,9-O-isopropylidene-sialic acid methyl ester (64) was subjected to acetic acid 
as previously deployed (Chapter 2.3.3) (Scheme 62).161 
64     114       115 
 
Scheme 62 Synthesis of 2,4,7-tri-O-benzoyl-3-fluoro-9-iodo-8-O-methylthiocarbonyl-sialic acid 
methyl ester (115). a) (i) 80% AcOH/H2O, 60 °C, 2 h; (ii) 1,1’-Thiocarbonyldiimidazole, CH2Cl2, 
40 °C, 2 d, 81% (over 2 steps) (114); b) CH3I, 56 °C, 20 h, 95% (115). 
 
Next, the crude mixture was treated with thiophosgene according to the 
procedure of Schreiner et al. to form the cyclic 8,9-O-carbonothioate (114) but 
no desired product could be isolated.177 
However, reaction of the crude mixture with 1,1’-thiocarbonyldiimidazole in 
anhydrous dichloromethane gave the desired 2,4,7-tri-O-benzoyl-
8,9-O-carbonothioate-3-fluoro-sialic acid methyl ester (114) in 81% yield over 
the 2 steps (Scheme 62). 
The 2,4,7-tri-O-benzoyl-8,9-O-carbonothioate-3-fluoro-sialic acid methyl ester 
(114) was then subjected to freshly distilled iodomethane at 56 °C overnight as 
previously deployed by Schreiner et al. to give the 9-iodo-
8-O-methylthiocarbonyl-sialic acid derivative (115) in 95% yield. 
 5.2.3 Formation of 9-deoxy-3-fluoro hemiketal (118) 
 
The 9-iodo-8-O-methylthiocarbonyl-sialic acid derivative (115) was then 
subjected to Barton-McCombie deoxygenation conditions using Luperox® 101 
as a radical initiator and the radical carrier tributyltin hydride under reflux 
conditions in 1,4-dioxane as previously deployed on 7-O-thiocarbamate-sialic 
acid methyl ester (68) (Chapter3.2) to give the 9-deoxy-3-fluoro-
8-O-methylthiocarbonyl-sialic acid derivative (114) in 98% yield (Scheme 63). 
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Scheme 63 Synthesis of 2,4,7-tri-O-benzoyl-9-deoxy-3-fluoro-8-O-methylthiocarbonyl-sialic 
acid methyl ester (116). Luperox® 101, Bu3SnH, 1,4-dioxane, 100 °C, 4 h, 98%. 
 
The 9-deoxy-3-fluoro-8-O-methylthiocarbonyl-sialic acid derivative (114) was 
then globally deprotected using sodium in methanol according to Zemplén 
conditions and subsequently acetylated utilising acetic anhydride in pyridine 
to give the per-O-acetyl-9-deoxy-3-fluoro-sialic acid methyl ester (117) 
(Scheme 64) in 77% yield over the 2 steps.165 
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Scheme 64 Formation of 4,7,8-tri-O-acetyl-9-deoxy-3-fluoro-sialic acid methyl ester (118). a) 
(i) NaOMe, MeOH, r.t., O/N; (ii) Ac2O, DMAP, pyridine, r.t., O/N, 77% (over 2 steps) (117); b) 
Hydrazine acetate, CH2Cl2/MeOH, 4 °C, O/N, 68% (118). 
 
Finally, the per-O-acetyl-9-deoxy-3-fluoro-sialic acid methyl ester (117) was 
deprotected at position C-2 with hydrazine acetate in dichloromethane and 
methanol at 4 °C as previously described on per-O-acetyl-4-deoxy-3-fluoro-
sialic acid methyl ester (52) (Chapter 2.3.3) to afford hemiketal (118). 
 5.2.4 Synthesis of 9-deoxy-2,3-difluoro-sialic acid (27) 
 
The hemiketal (118) was then treated with DAST in dichloromethane 
at - 40 °C → - 10 °C according to the methodology previously deployed on 
hemiketal (53) (Chapter 2.3.4) to afford a mixture of α- and β-fluoride anomers 
(Scheme 65). 
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Scheme 65 Synthesis of 9-deoxy-2,3-difluoro-sialic acid methyl ester anomers (119) and 
(120). DAST, CH2Cl2, - 40 ºC → - 10 ºC, 1 hr, 38% (119), 38% (120). 
 
The formation of a mixture of anomers is in agreement with results previously 
observed on hemiketal (Chapter 2.3.4). The mixture of anomers was purified 
by silica column chromatography and gave the anomers in a ratio of 1:1 in 
38% yields respectively. 
The per-O-acetyl-9-deoxy-α-2,3-difluoro-sialic acid methyl ester (119) was 
then globally deacetylated using sodium in methanol at room temperature 
following Zemplén conditions. Finally, ester saponification of the crude residue 
with 0.5M sodium hydroxide solution in water gave the desired 9-deoxy-2,3-
difluoro-sialic acid (27) after column chromatography in 99% over the 2 steps 
(Scheme 66).165 
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Scheme 66 Formation of 9-deoxy-2,3-difluoro-sialic acid (27). (i) NaOMe, MeOH, r.t., 3 h; 
(ii) 0.5M NaOH, H2O, r.t, 30 min., 99% (over 2 steps). 
 
The total synthesis from β-fluoropyruvic acid (41) to 9-deoxy-2,3-difluoro-sialic 
acid (27) was achieved in 14 steps, with an overall yield of 9%. 
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Kinetic analysis of inactivation of influenza Chapter 6 - 
neuraminidase by monodeoxygenated 
2,3-difluoro-sialic acids 
 
 
 Preface 6.1
 
A general mechanism for inactivation of influenza neuraminidase by 
mechanism-based inactivators can be expressed by the following scheme 
with Ki being the dissociation constant of inhibition/inactivation and (E-I) 
being the covalent sialosyl-enzyme intermediate (Scheme 67). 
 
Scheme 67 Equilibrium scheme for mechanism-based inactivators with enzyme. - Enzyme 
(E), inactivator (I), Michaelis complex (E•I) and (E•P), rate of glycosylation (k1), rate of 
deglycosylation (k2), dissociation constant for inhibition/inactivation (Ki) and product (P). 
 
Recent unpublished work by the research groups of Dr. Andrew Watts and 
Prof. Stephen Withers has shown that 2,3-difluoro-sialic acid (23) attenuates 
the rate of glycosylation (k1) and deglycosylation (k2) of influenza 
neuraminidase, allowing the covalently linked sialosyl-enzyme intermediate 
(E-I) to be kinetically accessible and accumulate to a high steady-state 
concentration, whereby the enzyme is inactivated. We proposed that on 
influenza neuraminidase the putative mechanism-based inactivators 
(24) - (27) operate through a similar mechanism. 
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23 R1, R2, R3, R4 = OH 
24 R1 = H, R2, R3, R4 = OH 
    25 R2 = H, R1, R3, R4 = OH 
    26 R3 = H, R1, R2, R4 = OH 
    27 R4 = H, R1, R2, R3 = OH 
 
This chapter will first discuss inactivation kinetics of influenza 
G70C/H1N9/wt. by the monodeoxygenated 2,3-difluoro-sialic acid putative 
inactivators (24) - (27). The time-dependent inactivation study of influenza 
neuraminidase N9 G70C was based on a previous inactivation study 
performed on Trypanosoma rangeli with 2,3-difluoro-sialic acid (23) by Watts 
and Withers.12 
Furthermore, the monodeoxygenated 2,3-difluoro-sialic acid putative 
inactivators (24) - (27) have been evaluated in IC50 measurements against a 
panel of influenza viruses including wild types (wt.) and Oseltamivir (6) 
resistant mutants by our collaborators and the results will be discussed.178 
Finally, plaque reduction assays as the first stage of in vivo assays were 
performed on the 4-deoxy-2,3-difluoro-sialic acid (24) and the 8-deoxy-
2,3-difluoro-sialic acid (26) by our collaborators and the results will be 
analysed in this chapter. 
 Time-dependent inactivation of wild type influenza 6.2
neuraminidase N9 G70C by monodeoxygenated 
2,3-difluoro-sialic acids 
 
Influenza neuraminidase G70C/H1N9/wt. was chosen for inactivation kinetics 
as this strain has previously been utilised in enzyme inhibition kinetics by 
Blick et al.,118 which in conjunction with extensive X-ray crystal structures on 
G70C/H1N9/wt. allows interpretation of inactivation kinetics on a physical 
basis.128 
Kinetic analysis of inactivation of influenza neuraminidase               Chapter 6 
by monodeoxygenated 2,3-difluoro-sialic acids
 
- 105 - 
 
An assay measuring the time-dependent fluorescent intensity of the 
hydrolysed 4-methylumbelliferone from the substrate 
2′-(4-methylumbelliferyl) α-D-N-acetylneuraminic acid (121) by influenza 
neuraminidase G70C/H1N9/wt. at different monodeoxygenated 2,3-difluoro-
sialic acid inactivator (24) - (27) concentrations has to be developed. 
 
 
 
 
 
           121 
A reduction in the fluorescence intensity correlates with the association of the 
inactivator to the enzyme, which results in a slower rate of the enzyme 
processing the substrate and less 4-methylumbelliferone being released. 
A time-dependent inactivation assay investigating the inactivation of 
Trypanosoma cruzi trans-sialidase by 2,3-difluoro-sialic acid (23) based on 
the reduction of the fluorescent intensity has previously been performed by 
Buchini et al.168 
In general, the time-dependent inactivation assay of influenza neuraminidase 
70C/H1N9/wt., which was kindly provided by Dr. Jennifer McKimm-Breschkin 
(Materials Science and Engineering, CSIRO, Australia), was performed at 
37 °C in 1 mM NaOAc buffer pH 5.5, 0.1 mM CaCl2 and 0.2 mM 
2′-(4-methylumbelliferyl) α-D-N-acetylneuraminic acid (121) in duplicate on a 
96 well plate. The fluorescence intensity of the hydrolysed 
4-methylumbelliferone was monitored over 30 minutes following addition of 
the substrate 2′-(4-methylumbelliferyl) α-D-N-acetylneuraminic acid (121), 
using an excitation wavelength of 355 nm and an emission wavelength of 
460 nm for 6 different incubation time-points at 5 different concentrations of 
inactivator. The measured activity with no inactivator gave the maximum 
activity, and was set to 100%. The activities obtained for the different 
concentrations of inactivator were correlated to this maximum activity to give 
the residual activities. 
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 6.2.1 Time-dependent inactivation of wild type influenza 
neuraminidase N9 G70C by 4-deoxy-2,3-difluoro-sialic 
acid (24) 
 
Time-dependent inactivation studies of influenza neuraminidase 
G70C/H1N9/wt. were performed utilising the general inactivation assay in 
5 different concentrations of the putative mechanism-based inactivator 
4-deoxy-2,3-difluoro-sialic acid (24). 
 
 
 
           24 
As such, concentrations of 200, 100, 50, 25 and 10 nM of inactivator (24) 
and incubation times of 5, 10, 15, 25, 35 and 50 minutes were deployed and 
the residual activities were plotted versus time (Graph 2). 
 
Graph 2 Residual activity of wild type neuraminidase N9 G70C with inactivator 4-deoxy-
2,3-difluoro-sialic acid (24) versus time (unpublished results). 
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It can clearly be seen from (Graph 2) that increasing the concentration of 
4-deoxy-2,3-difluoro-sialic acid (24) inactivator results in a decrease of 
residual activity. However, it can also be seen that the residual activity 
remains constant at incubation time-points from 5 to 35 minutes, indicating 
no time-dependent inactivation. A similar result has been observed for 
inactivation kinetics on α-glycosidases and 5-fluoro-α-glycosyl fluorides 
performed by Howard et al, which gave fast glycosylation on a time scale 
shorter than the assay time.179 Based on inactivation kinetics of 
Trypanosoma rangeli neuraminidase with 2,3-difluoro-sialic acid (23), which 
also showed fast turnover and have previously been performed by Watts et 
al.,12 it was concluded that the rate of 4-deoxy-2,3-difluoro-sialic acid (24) 
inactivator glycosylation (k1) by influenza neuraminidase G70C/H1N9/wt. to 
form the sialosyl-enzyme intermediate takes place faster than the assay 
time. 
A number of methods have been reported to reduce the rate of intermediate 
formation. These include using lower inhibitor concentrations (which could 
also result in increased ratio of reactivation), reducing the temperature of the 
assay, use of a competitive inhibitor during inactivation (in case of influenza 
neuraminidase with a competitive inhibitor like DANA), or stopped-flow 
kinetic experiments.12 
It can also be seen, that after incubation of 50 minutes increasing residual 
activities were observed, indicating reactivation (Graph 2). This reactivation 
might represent fast deglycosylation (k2) of the 4-deoxy-2,3-difluoro-sialic 
acid (24) inactivator. 
Since the 4-deoxy-2,3-difluoro-sialic acid (24) inactivator did not display time-
dependent inactivation characteristics, but steady-state characteristics we 
investigated the properties of the inactivator as a competitive inhibitor 
obeying Michaelis-Menten parameters to calculate IC50 values.
179 Hence, the 
mean residual activities at incubation time-points from 5 to 35 minutes 
including their standard errors were re-plotted against the inactivator 
concentration, [24], using GraFit 5.0.13 (Graph 3).180  
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Graph 3 Residual activity of wild type neuraminidase N9 G70C versus concentration of 
inactivator 4-deoxy-2,3-difluoro-sialic acid (24) (unpublished results). 
 
The inhibition data was then fitted to the non-linear 4 parameter equation 
(Equation 1) to give the parameters for y range, slope factor, background 
and for the inhibition of influenza neuraminidase G70C/H1N9/wt. by 
4-deoxy-2,3-difluoro-sialic acid (24) an encouraging IC50 value of 92 + 71 nM 
(Table 6). 
 
 
 
Equation 1 Four parameter equation for the calculation of IC50 values. The range is the 
fitted uninhibited value minus the background, and S is a slope factor. Equation fulfilled if y 
falls with increasing x. 
 
Table 6 Non-linear fit of the inhibition data of 4-deoxy-2,3-difluoro-sialic acid (24) on 
G70C/H1N9/wt. to four parameter equation (Equation 1). 
 
 
 
 
 
 
 
Value Std. error
y range 93.6650 53.9331
IC50 91.9577 71.2254
Slope factor 0.7583 0.6975
Background 13.4222 38.7926
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 6.2.2 Time-dependent inactivation of wild type influenza 
neuraminidase N9 G70C by 7-deoxy-2,3-difluoro-sialic 
acid (25) 
 
Time-dependent inactivation studies of influenza neuraminidase 
G70C/H1N9/wt. were performed utilising the general inactivation assay in 
5 different concentrations of the putative mechanism-based inactivator 
7-deoxy-2,3-difluoro-sialic acid (25). 
 
 
 
           25 
As such, concentrations of 50, 25, 10, 5 and 1 µM of inactivator (25) and 
incubation times of 5, 10, 15, 25, 35 and 50 minutes were deployed and the 
residual activities were plotted versus time (Graph 4). 
 
Graph 4 Residual activity of wild type neuraminidase N9 G70C with inactivator 7-deoxy-
2,3-difluoro-sialic acid (25) versus time (unpublished results). 
 
It can clearly be seen from (Graph 4) that increasing the concentration of 
7-deoxy-2,3-difluoro-sialic acid (25) inactivator results in a decrease of 
residual activity. 
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It also can be seen that the residual activity remains constant for the 
incubation time points from 5 to 50 minutes (Graph 4). This lack of time-
dependent inactivation is similar to the inactivation behaviour of 4-deoxy-
2,3-difluoro-sialic acid (24) (Chapter 6.2.1) and as previously proposed can 
be due to the fast rate of glycosylation (k1), on a time scale shorter than the 
assay time.179 
In contrast to inactivation kinetics of 4-deoxy-2,3-difluoro-sialic acid (24), the 
7-deoxy-2,3-difluoro-sialic acid (25) showed no reactivation after 50 minutes, 
which might indicate a slow deglycosylation (k2) and an accumulation of high 
steady-state concentration of the covalent intermediate, whereby the enzyme 
is inactivated (Graph 4). 
Unfortunately, the inactivation assay for the range of concentrations of 
inactivator 7-deoxy-2,3-difluoro-sialic acid (25) gave residual activities lower 
than 30%. Hence, it was not possible to determine an IC50 value for the 
inactivation of 7-deoxy-2,3-difluoro-sialic acid (25) on influenza 
neuraminidase G70C H1N9. 
 6.2.3 Time-dependent inactivation of wild type influenza 
neuraminidase N9 G70C by 8-deoxy-2,3-difluoro-sialic 
acid (26) 
 
Time-dependent inactivation studies of influenza neuraminidase 
G70C/H1N9/wt. were performed utilising the general inactivation assay in 
4 different concentrations of the putative mechanism-based inactivator 
8-deoxy-2,3-difluoro-sialic acid (26). 
 
 
 
           26 
As such, concentrations of 50, 25, 10 and 1 µM of inactivator (26) and 
incubation times of 5, 10, 15, 25 and 35 were deployed and the residual 
activities were plotted versus time (Graph 5). 
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Graph 5 Residual activity of wild type neuraminidase N9 G70C with inactivator 8-deoxy-
2,3-difluoro-sialic acid (26) versus time (unpublished results). 
 
A clear time-dependent inactivation of wild type influenza neuraminidase N9 
G70C by 8-deoxy-2,3-difluoro-sialic acid (26) was seen (Graph 5), which 
could be consistent with a kinetic model whereby the rate of deglycosylation 
(k2) is significantly slower than the rate of glycosylation (k1) for high 
inactivator concentrations.168 However, particularly at lower inactivator 
concentrations, the inactivation was not complete and steady-state 
characteristics can be observed (Graph 5), which could be due more rapid 
rates of deglycosylation (k2). 
This steady-state allows determination of an apparent dissociation constant 
for inhibition/inactivation Ki’ (Equation 2) which takes the form of the 
Michaelis-Menten expression for KM. 
 
 
 
Equation 2 Equation for the apparent dissociation constant for inhibition/inactivation Ki’ in 
steady-state conditions with dissociation constant of inhibition/inactivation Ki, the rate of 
glycosylation k1 and the rate of deglycosylation k2. 
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The residual activity plotted versus time (Graph 5) was used to calculate first 
order rate constants for each concentration of inactivator 8-deoxy-
2,3-difluorosialic acid (26) by fitting a single exponential decay with offset 
(Equation 3) to the measured residual activities (Table 7) using GraFit 
5.0.13.180 The single exponential decay with offset was chosen as the 
experimental data retained a steady-state with a discrete residual activity. 
 
 
 
Equation 3 Single exponential decay that decays to a non-zero value. 
 
The rate constants calculated (Table 7) were then used to generate the 
Lineweaver-Burk plot with the inverse of rate constants versus the inverse of 
the inactivator (26) concentrations (Graph 6).181 
 
Table 7 Results of single exponential curve fitting with offset to residual activities over time 
for each concentration of 8-deoxy-2,3-difluorosialic acid (26). 
 
 
 
 
 
           26 
 
 
 
 
 
 
 
 
 
y = A0e
- kt+ offset
Value Std. error Value Std. error Value Std. error
Initial value 88.1126 1.2659 79.5657 1.9659 64.2365 3.9324
Rate constant 0.6828 0.0837 0.4405 0.0443 0.2239 0.0354
Offset 11.8862 0.5745 20.4026 0.9287 35.2395 2.1834
50 µM (X1) 25 µM (X2) 10 µM (X3)
Value Std. error
Initial value 27.4192 7.1426
Rate constant 0.0698 0.0438
Offset 72.1606 7.1943
1 µM (X5)
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Equation 4 Lineweaver-Burk equation for Michaelis-Menten kinetics with reaction rate V, 
dissociation constant of inhibition/inactivation Ki, maximum reaction rate Vm and inhibitor 
concentration [inhibitor]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 6 Lineweaver-Burk plot of wild type influenza neuraminidase N9 G70C with 
inactivator 8-deoxy-2,3-difluoro-sialic acid (26). The intercept at the x axis gives the inverse 
of Ki, the intercept at the y axis the inverse of Vm and a gradient of Ki/Vm. 
 
The apparent dissociation constant for inhibition/inactivation Ki’ was then 
readily determined through linear regression of the Lineweaver-Burk plot 
(Graph 6) with the intercept at the x axis giving the inverse of Ki’ (Table 8). 
The Ki’ of 8-deoxy-2,3-difluoro-sialic acid (26) on influenza neuraminidase 
G70C/H1N9/wt. was determined as 6.1 + 1.99 µM. 
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Table 8 Linear regression of the Lineweaver-Burk plot (Graph 6). 
 
 
 
 
 
 
 
 6.2.4 Time-dependent inactivation of wild type influenza 
neuraminidase N9 G70C by 9-deoxy-2,3-difluoro-sialic 
acid (27) 
 
Time-dependent inactivation studies of influenza neuraminidase 
G70C/H1N9/wt. were performed utilising the general inactivation assay in 
5 different concentrations of the putative mechanism-based inactivator 
9-deoxy-2,3-difluoro-sialic acid (27). 
 
 
 
           27 
As such, concentrations of 25, 10, 5, 2 and 1 µM of inactivator (27) and 
incubation times of 5, 10, 15, 25 and 35 were deployed and the residual 
activities were plotted versus time (Graph 7). 
 
 
 
 
 
 
 
 
 
 
 
Value Std. error
a (intercept) 2.0432 0.6372
b (gradient) 12.3747 1.2668
Correlation coefficient 0.9897
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Graph 7 Residual activity of wild type neuraminidase N9 G70C with inactivator 9-deoxy-
2,3-difluoro-sialic acid (27) versus time (unpublished results). 
 
A clear time-dependent inactivation of wild type influenza neuraminidase N9 
G70C by 9-deoxy-2,3-difluoro-sialic acid (27) was seen and an increase in 
the concentration of inactivator (27) resulted in a decrease of residual activity 
(Graph 7). It also can be seen that the inactivation did not reach a discrete 
residual activity after 35 minutes, indicating a slower rate of glycosylation 
(k1). However, it was proposed that the residual activities might level off to a 
discrete standard to give steady-state characteristics. This steady-state 
allows determination of an apparent dissociation constant for 
inhibition/inactivation Ki’ (Equation 2) which takes the form of the Michaelis-
Menten expression for KM. 
The residual activity plotted versus time (Graph 7) was used to calculate first 
order rate constants for each concentration of inactivator 9-deoxy-
2,3-difluoro-sialic acid (27) by fitting a single exponential decay without offset 
(Equation 5) to the measured residual activities (Table 9) using GraFit 
5.0.13.180 The single exponential decay without offset was chosen as the 
inactivator expressed slow-binding kinetics with proposed steady-state 
characteristics, but experimental conditions applied did not allow 
determination of the discrete residual activity offset. 
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Equation 5 Single exponential decay without offset. 
 
The rate constants calculated (Table 9) were then used to generate the 
Lineweaver-Burk plot with the inverse of rate constants versus the inverse of 
the [27] (Graph 8).181 
 
Table 9 Results of single exponential curve fitting without offset to residual activities over 
time for each concentration of 9-deoxy-2,3-difluorosialic acid (27). 
 
 
 
 
 
           27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
y = A0e
- kt
Value Std. error Value Std. error
Initial value 27.4192 7.1426 27.4192 7.1426
Rate constant 0.0698 0.0438 0.0698 0.0438
2 µM (X4) 1 µM (X5)
Value Std. error Value Std. error Value Std. error
Initial value 88.8962 11.5054 89.3275 7.1433 93.5438 4.0750
Rate constant 0.0720 0.0187 0.0286 0.0064 0.0170 0.0029
25 µM (X1) 10 µM (X2) 5 µM (X3)
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Graph 8 Lineweaver-Burk plot of wild type neuraminidase N9 G70C with 9-deoxy-
2,3-difluoro-sialic acid (27). The intercept at the x axis gives the inverse of Ki, the intercept at 
the y axis the inverse of Vm and a gradient of Ki/Vm. 
 
The apparent dissociation constant for inhibition/inactivation Ki’ was then 
readily determined through linear regression of the Lineweaver-Burk plot 
(Graph 8) with the intercept at the x axis giving the inverse of Ki’ (Table 10). 
The Ki’ of 9-deoxy-2,3-difluoro-sialic acid (27) on influenza neuraminidase 
G70C/H1N9/wt. was determined as 12.1 + 1.96 µM. 
 
Table 10 Linear regression of the Lineweaver-Burk plot (Graph 8). 
 
 
 
 
 
 
 
The preliminary inactivation results of wild type influenza neuraminidase N9 
G70C gave Ki’ values in the low µM range for 8-deoxy-2,3-difluoro-sialic acid 
(26) and 9-deoxy-2,3-difluoro-sialic acid (27) and an encouraging IC50 value 
in the low nM range for 4-deoxy-2,3-difluoro-sialic acid (24). 
Value Std. error
a (intercept) 15.1856 4.4157
b (gradient) 183.5423 8.6537
Correlation coefficient 0.9967
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However, the ambiguous properties for the rate of glycosylation (k1) and 
deglycosylation (k2) of wild type influenza neuraminidase N9 G70C by the 
monodeoxygenated 2,3-difluoro-sialic acid inactivators (24) - (27) prompted 
us to further investigate the time-dependent inactivation and reactivation. In 
addition to time-dependant inactivation of influenza neuraminidase N9 G70C, 
a panel of influenza viruses also will be explored. 
 Inhibitory studies of monodeoxygenated 6.3
2,3-difluoro-sialic acids against a panel of 
influenza viruses 
 
In addition to time-dependant inactivation of influenza neuraminidase N9 
G70C, the inactivation of a panel of influenza viruses also will be explored to 
begin to examine whether neuraminidase inhibition is consistent across a 
range of serotypes. This set of experiments was performed by our 
collaborator Sue Barrett, Molecular and Health Technologies, CSIRO, 
Australia. A description of the influenza strains and mutants tested will be 
given in the summary. Since the efficacy of the mechanism-based 
2,3-difluoro-sialic acid inactivators (24) - (27) is dependent on the 
combination of rate of glycosylation (k1) and deglycosylation (k2) the IC50 
measurements were executed in two different experimental modes.54 
Experiments with no pre-incubation and experiments with pre-incubation of 
inactivator and influenza neuraminidase for 30 minutes prior to addition of 
the substrate 2′-(4-methylumbelliferyl) α-D-N-acetylneuraminic acid (121) 
were performed.182 
 
 
 
 
 
           121 
The experiment with no pre-incubation is used to follow the rate of 
glycosylation (k1) of the inactivator with the influenza neuraminidase over a 
60 minutes period. 
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On the other hand, the experiment with pre-incubation prior to the addition of 
substrate (121), allows the examination of further association processes, 
such as conformational changes of the enzyme and gives qualitative 
information concerning the rate of deglycosylation (k2) of the inactivator-
influenza neuraminidase complex. 
 
To clarify: The inactivator IC50 kinetic assay was performed by our 
collaborators (Molecular and Health Technologies, CSIRO, Australia), 
while the analysis and interpretation of the results obtained was 
performed by the author. 
 
 6.3.1 IC50 analysis of monodeoxygenated 2,3-difluoro-sialic 
acids against a panel of influenza viruses 
 
The 2,3-difluoro-sialic acid derivative (23) has previously been identified by 
Watts et al. (unpublished results) to be a time-dependent mechanism-based 
inactivator of influenza neuraminidases (unpublished results), also referred to 
as slow binding inactivator. 
 
 
     23 
The loss of the slow-binding characteristics often correlates with resistances 
towards influenza neuraminidases.183-186 However, as as we previously 
described only the 8-deoxy-2,3-difluoro-sialic acid (26) and 9-deoxy-
2,3-difluoro-sialic acid (27) inactivator gave time-dependent inactivation 
characteristics whereas time-dependent inactivation could not be observed 
for the 4-deoxy-2,3-difluoro-sialic acid (24) and the 7-deoxy-2,3-difluoro-sialic 
acid (25) (Chapter 6.2). To further investigate this behaviour on an extensive 
panel of influenza neuraminidase a novel influenza neuraminidase inactivator 
IC50 kinetic assay was developed.
54 
In general, the inactivator IC50 kinetic assay without pre-incubation was 
performed on a variety of influenza neuraminidases with a series of dilutions 
of inactivator and the fluorescence intensity was monitored in 10 minute 
intervals for 60 minutes after addition of substrate (121). 
O
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The inactivator IC50 kinetic assay with pre-incubation was performed with 
30 minutes pre-incubation of influenza neuraminidase with inactivator prior to 
the addition of substrate (121). Subsequently, the fluorescence intensity was 
monitored in 10 minute intervals for 60 minutes. 
The inactivator IC50 kinetic assay without pre-incubation of 2,3-difluoro-sialic 
acid (23) showed a decrease in the IC50 values over time in the range of 
1 µM across the panel of influenza neuraminidases tested, indicating 
slow-binding characteristics (Graph 9a). 
 
 
 
Graph 9 Values for IC50 kinetic evaluation of 2,3-difluoro-sialic acid (23) on wild type (wt.) 
and mutant influenza neuraminidases. a) Without pre-incubation; b) with pre-incubation 
(unpublished results). 
a) 
b) 
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However, on Fukui H3N2 wt., G70C H1N9 wt., Cal. Swine H1N1, 
Shepp. Swine H1N1, Viet. Avian H1N5 and Bangli. Avian H1N5 increasing 
IC50 values over time were seen, correlating to slow inactivator dissociation 
(Graph 9a). 
In general, the inactivator IC50 kinetic assay with pre-incubation of the 
2,3-difluoro-sialic acid (23) showed lower IC50 values than the kinetic assay 
without pre-incubation (Graph9b). However, the inactivator IC50 kinetic assay 
with pre-incubation showed an increase in fluorescence intensity on the 
influenza neuraminidase strains tested, which could correlate to higher 
substrate turnover and might indicate a slow dissociation of the inactivator 
(Graph 9b). Remarkably, the influenza strains Miss H1N1 H274Y and 
G70C H1N9 E119G showed a constant IC50 value over the time measured, 
indicating no inactivator dissociation (Graph 9b). 
The inactivator IC50 kinetic assay without pre-incubation of 4-deoxy-
2,3-difluoro-sialic acid (24) gave better absolute IC50 values on B/Perth wt., 
B/Perth D197E, Miss H1N1 wt. and Miss H1N1 H274Y than the parent 
compound 2,3-difluoro-sialic acid (23) (Graph 10a). 
 
 
 
          24 
However, all other influenza strains tested showed increasing IC50 values 
over time correlating to slow inactivator dissociation (Graph 10a). The IC50 
values obtained for G70C H1N9 wt. is in compliance with the results 
previously obtained in time-dependent inactivation experiments of 4-deoxy-
2,3-difluoro-sialic acid (24) (Chapter 6.2.1) with a measured IC50 value of 
92+71 nM and reactivation after 50 minutes. An increase in absolute IC50 
values could correlate to higher substrate turnover and indicates a slow 
dissociation of the inactivator. 
The inactivator IC50 kinetic assay with pre-incubation of 4-deoxy-2,3-difluoro-
sialic acid (24) showed increasing IC50 values over time correlating to slow 
inactivator dissociation, across the panel of influenza neuraminidases tested 
(Graph 10a). 
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However, the inactivator IC50 kinetic assay with pre-incubation on G70C 
H1N9 R292K showed a decrease in IC50 values, correlating to slow-binding 
characteristics. 
 
 
 
 
Graph 10 Values for IC50 kinetic evaluation of 4-deoxy-2,3-difluoro-sialic acid (24) on wild 
type (wt.) and mutant influenza neuraminidases. a) Without pre-incubation; b) with 
pre-incubation (unpublished results). 
 
The inactivator IC50 kinetic assay without pre-incubation of 7-deoxy-
2,3-difluoro-sialic acid (25) was performed on a reduced panel of influenza 
strains (Graph 11a). 
a) 
b) 
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           25 
 
 
Graph 11 Values for IC50 kinetic evaluation of 7-deoxy-2,3-difluoro-sialic acid (25) on wild 
type (wt.) and mutant influenza neuraminidases. a) Without pre-incubation; b) with 
pre-incubation (unpublished results). 
 
However, the 7-deoxy-2,3-difluoro-sialic acid (25) in the kinetic assay 
showed a decrease in the IC50 values over time correlating to slow-binding 
characteristics, but not on Fukui H3N2 wt. where an increase in the IC50 
values over time could be seen (Graph 11a). 
The IC50 kinetic assay with pre-incubation of 7-deoxy-2,3-difluoro-sialic acid 
(25) performed on a reduced panel of influenza strains, showed slow 
inactivator dissociation characteristics, but not on Miss H1N1 H274Y where 
slow binding was observed (Graph 11b). 
The inactivator IC50 kinetic assay without pre-incubation of 8-deoxy-
2,3-difluoro-sialic acid (26) gave a consistent decrease in IC50 values in the 
range of 50 µM throughout the extensive panel of influenza neuraminidases 
tested, correlating to slow binding (Graph 12a). 
 
 
a) b) 
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            26 
 
Graph 12 Values for IC50 kinetic evaluation of 8-deoxy-2,3-difluoro-sialic acid (26) on wild 
type (wt.) and mutant influenza neuraminidases. a) Without pre-incubation; b) with 
pre-incubation (unpublished results). 
 
The IC50 kinetic assay with pre-incubation of 8-deoxy-2,3-difluoro-sialic acid 
(26) showed slow-binding characteristics on the influenza strains tested, but 
with the exception of B/Perth wt., Fukui H3N2 E119V and Viet Avian H1N5 
C1 where slow dissociation could be seen (Graph 12b). 
a) 
b) 
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The slow decrease in IC50 values of 8-deoxy-2,3-difluoro-sialic acid (26) 
obtained for G70C H1N9 wt. is in compliance with the results previously 
obtained in time-dependent inactivation experiments (Chapter 6.2.3). 
The inactivator IC50 kinetic assay without pre-incubation of 9-deoxy-
2,3-difluoro-sialic acid (27) showed consistent decrease in IC50 values in the 
range of 10 to 100 µM throughout the extensive panel of influenza 
neuraminidases tested, correlating to slow binding (Graph 13a) 
 
 
 
          27 
 
 
 
Graph 13 Values for IC50 kinetic evaluation of 9-deoxy-2,3-difluoro-sialic acid (27) on wild 
type (wt.) and mutant influenza neuraminidases. a) Without pre-incubation; b) with 
pre-incubation (unpublished results). 
 
The inactivator IC50 kinetic assay with pre-incubation of the 9-deoxy-
2,3-difluoro-sialic acid (27) still showed slow-binding characteristics, which 
could be due to the fact that reactivation might only occur after the time-span 
measured in this assay (Graph 13b). 
 
a) b) 
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In summary, the IC50 values without pre-incubation of monodeoxygenated 
2,3-difluoro-sialic acid inactivators (24) - (27) against a panel of influenza 
neuraminidases after 60 minutes are compared to the IC50 values of 
activated Oseltamivir (6), Zanamivir (15) and the parent compound 
2,3-difluoro-sialic acid (23) (Table 11). 
The 4-deoxy-2,3-difluoro-sialic acid (24) inactivator gave very encouraging 
IC50 values in nM range, but mainly against Flu B (Table 11, entry 1 and 2) 
and H1N1 (Table 11, entry 3 and 4). Above all, 4-deoxy-2,3-difluoro-sialic 
acid (24) displayed better IC50 values than Oseltamivir (6) against Flu B with 
a slow dissociation from all viruses, wild types and mutants. 
The Flu B mutant FluB/Perth/D197E (Table 11, entry 2) is useful for looking 
at interactions around the C-5 N-acetyl group and displayed cross resistance 
to Oseltamivir (6). The mutation gave comparable effects on the front-line 
influenza neuraminidase inhibitor therapeutics Oseltamivir (6), Zanamivir (15) 
and on all 2,3-difluoro-sialic acid inactivators. 
The mutant Miss/H1N1/H274Y (Table 11, entry 4) displayed specific 
resistance towards Oseltamivir (6) with a 300 fold worse binding to 
Oseltamivir (6). However, there was hardly any effect on the 2,3-difluoro-
sialic acid inactivators with the 8-deoxy-2,3-difluoro-sialic acid (26) and 
9-deoxy-2,3-difluoro-sialic acid (27) inactivators giving an improved IC50 
value compared to the wild type (Table 11, entry 3). 
The IC50 value for the 4-deoxy-2,3-difluoro-sialic acid (24) on 
Fukui/H3N2/wt. (Table 11, entry 5) was encouragingly better than the 
parent compound 2,3-difluoro-sialic acid (23). However, as expected on 
Fukui/H3N2/E119V an Oseltamivir resistant mutant (Table 11, entry 6), 
which is used to look at interactions at position C-4 of the inactivator, the 
4-deoxy-2,3-difluoro-sialic acid (24) gave a 10-fold reduction in binding. 
Mutations of the arginine residue in G70C/H1N9/R292K with Arg292 being 
part of the catalytic arginine triade have dramatic effects on Oseltamivir (6) 
with slowing down the binding 10.000-fold (Table 11, entry 8).187 
Comparable effects were also demonstrated on Zanamivir (15) and 4-deoxy-
2,3-difluoro-sialic acid (24) with a 20-fold increase of the IC50 values. 
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Table 11 IC50 values obtained for the monodeoxygenated 2,3-difluoro-sialic acid inactivators 
(24) to (27) on a panel of influenza neuraminidases without pre-incubation given in µM 
(unpublished results). 
 
 
 
 
 
  6        15    23 
    24       25        26   27 
 
 
= better IC50 values than Oseltamivir (6),     = better IC50 values than 
Zanamivir (15), n.a. = not available. 
 
 
 
 
 
Entry Neuraminidase 6 15 23 24 25 26 27
1 FluB/Perth/wt 0.14 0.17 0.41 0.075 0.23 7.60 9.20
2 FluB/Perth/D197E 0.66 0.43 1.26 0.25 1.50 40.1 79.1
3 Miss/H1N1/wt 0.007 0.008 0.12 0.048 0.06 8.30 10.8
4 Miss/H1N1/H274Y 2.35 0.006 0.14 0.024 0.10 1.10 6.40
5 Fukui/H3N2/wt 0.005 0.032 1.67 0.31 0.47 28.7 44.6
6 Fukui/H3N2/E119V 0.21 0.052 0.46 3.70 0.19 25.1 36.3
7 G70C/H1N9/wt 0.004 0.006 1.10 0.12 n.a. 23.1 n.a.
8 G70C/H1N9/E119G 0.005 0.82 1.20 1.28 n.a. 132.6 n.a.
8 G70C/H1N9/R292K 30.1 0.11 n.a. 2.72 n.a. n.a. n.a.
9 Cal Swine/H1N1 0.020 0.012 0.79 0.43 n.a. 25.8 n.a.
10 Shepp/Swine/H1N1 0.007 0.006 0.79 0.47 n.a. 25.8 n.a.
11 Viet Avian/H5N1/C1 0.004 0.012 2.17 0.99 n.a. 21.7 n.a.
12 Bangli Avian/H5N1/C2 0.021 0.011 0.89 0.54 n.a. 28.2 n.a.
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In general the inactivators 8-deoxy-2,3-difluoro-sialic acid (26) and 9-deoxy-
2,3-difluoro-sialic acid (27) displayed poor inactivation against all influenza 
strains tested. The poor inhibition results might point out the important role of 
OH-8 and OH-9 towards transition-state stabilisation. 
In summary, the second set of experiments with a 30 minutes pre-incubation 
prior to the addition of substrate (121) gave the same trends of inhibition, but 
slightly better absolute IC50 values than the experiments without pre-
incubation (Table 12). 
In contrast to the experiment without pre-incubation the 2,3-difluoro-sialic 
acid (23), 4-deoxy-2,3-difluoro-sialic acid (24) and 7-deoxy-2,3-difluoro-sialic 
acid (25) obtained better inhibition than Oseltamivir (6) and Zanamivir (15) 
against Flu B (Table 12, entry 1 and entry 2). 
In addition the 4-deoxy-2,3-difluoro-sialic acid (24) gave a 10-fold better 
IC50 value on G70C/H1N9/wt. compared to the experiment without pre-
incubation and ended up to be 100-fold better than the parent 2,3-difluoro-
sialic acid (23) (Table 12, entry 7). 
In conclusion, although the 4-deoxy-2,3-difluoro-sialic acid (24) and 7-deoxy-
2,3-difluoro-sialic acid (25) achieved promising IC50 values on Flu B 
neuraminidases, the IC50 values of the monodeoxygenated 2,3-difluoro-sialic 
acid inactivators (24) - (27) vary greatly across the panel of influenza 
neuraminidases (Table 12). Together with the inconclusive inactivation 
results of Oseltamivir (6) and Zanamivir (15) (Table 12), the preservation of 
potency of anti-viral drugs against a number of influenza neuraminidases 
could be seen as a major hurdle.188 
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Table 12 IC50 values obtained for the monodeoxygenated 2,3-difluoro-sialic acid inactivators 
(24) to (27) on a panel of influenza neuraminidases with 30 minutes pre-incubation given in 
µM (unpublished results). 
 
 
  6        15    23 
    24       25        26   27 
 
 
= better IC50 values than Oseltamivir (6),     = better IC50 values than 
Zanamivir (15), n.a. = not available. 
 
 
 
 
 
Entry Neuraminidase 6 15 23 24 25 26 27
1 FluB/Perth/wt 0.10 0.090 0.070 0.030 0.040 1.20 4.50
2 FluB/Perth/D197E 0.71 0.26 0.17 0.030 0.21 14.5 32.2
3 Miss/H1N1/wt 0.003 0.002 0.080 0.070 0.037 2.60 4.50
4 Miss/H1N1/H274Y 2.44 0.002 0.12 0.13 0.10 0.30 4.70
5 Fukui/H3N2/wt 0.002 0.004 1.38 0.32 0.34 5.0 29.5
6 Fukui/H3N2/E119V 0.26 0.003 0.24 3.67 0.10 4.40 26.0
7 G70C/H1N9/wt 0.003 0.003 1.19 0.010 n.a. 10.9 n.a.
8 G70C/H1N9/E119G 0.003 0.68 1.15 1.05 n.a. 107.9 n.a.
8 G70C/H1N9/R292K 24.7 0.095 n.a. 3.88 n.a. n.a. n.a.
9 Cal Swine/H1N1 0.005 0.001 0.60 0.49 n.a. 22.4 n.a.
10 Shepp/Swine/H1N1 0.005 0.001 0.47 0.49 n.a. 22.0 n.a.
11 Viet Avian/H5N1/C1 0.001 0.003 1.66 1.40 n.a. 17.0 n.a.
12 Bangli Avian/H5N1/C2 0.020 0.001 0.86 0.58 n.a. 24.5 n.a.
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Our collaborators then investigated the inactivation behaviour of 4-deoxy-
2,3-difluoro-sialic acid (24) and 8-deoxy-2,3-difluoro-sialic acid (26) under 
conditions more closely related to humans by utilising a plaque reduction 
assay and the results obtained will be discussed next. 
 6.3.2 Plaque reduction assay of 4-deoxy-2,3-difluoro-sialic 
acid (24) and 8-deoxy-2,3-difluoro-sialic acid (26) on 
Miss/H1N1 
 
In the plaque assay, each infectious virus particle multiplies under conditions 
that result in a localized area of infected cells or ‘plaque’. The plaques are 
revealed either as areas of dead/destroyed cells detected by general cellular 
stains or as areas of infected cells detected by immuno-staining. As such, 
the plaque reduction assay is the first stage of in vivo assays and can be 
performed to get an IC50 value that is closer related to the IC50 values 
expected in humans.189 The 4-deoxy-2,3-difluoro-sialic acid (24) and the 
8-deoxy-2,3-difluoro-sialic acid (26) were tested by our collaborators 
(Molecular and Health Technologies, CSIRO, Australia) in a plaque reduction 
assay on Miss/H1N1/wt. (Figure 15).190 
 
 
 
 
 
Figure 15 Plaque reduction assay of Miss/H1N1/wt. with the red lines showing the endpoint 
on reduction in plaque size of a) 2,3-difluoro-sialic acid (23), b) 4-deoxy-2,3-difluoro-sialic 
acid (24) and c) 8-deoxy-2,3-difluoro-sialic acid (26) (unpublished results). 
a) 
b) 
c) 
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The 2,3-difluoro-sialic acid (23) with a neuraminidase inhibitor IC50 of 80 nM 
as well as the 4-deoxy-2,3-difluoro-sialic acid (24) with an IC50 of 70 nM 
against Miss/H1N1/wt. (Table 12, entry 3) gave about a 10-fold worse IC50 in 
the plaque reduction assay, reflecting faster turnover. Similar results were 
seen with 8-deoxy-2,3-difluoro-sialic acid (26), which showed a 
neuraminidase inhibitor IC50 of 2.6 µM and in the plaque reduction assay an 
IC50 of about 10 µM. 
We then set out to understand the effects of inactivation on a physical basis. 
Hence, X-ray crystal structures of wild type influenza neuraminidase N9 
G70C in complex with the monodeoxygenated 2,3-difluoro-sialic acid 
inactivators (24) - (27) were performed. 
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on monodeoxygenated 2,3-difluoro-sialic 
acids in complex with influenza 
neuraminidase N9 
 
 
 Preface 7.1
 
Having successfully observed differences between the rate of glycosylation 
(k1) and deglycosylation (k2) during inactivation of influenza neuraminidases 
with our series of monodeoxygenated 2,3-difluoro-sialic acid inactivators 
(24) - (27), we wished to develop a further understanding of their effects upon 
inactivation on a physical basis (Scheme 68). 
24 R1 = H, R2, R3, R4 = OH 
    25 R2 = H, R1, R3, R4 = OH 
    26 R3 = H, R1, R2, R4 = OH 
    27 R4 = H, R1, R2, R3 = OH 
 
Scheme 68 The glycosylation (k1) and deglycosylation (k2) rate constants associated with the 
mechanism-based inactivators (24) - (27). 
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We considered that analysis of the X-ray crystal structures of the trapped 
covalent sialosyl-enzyme reaction intermediates could give further information 
on the mechanism of inactivation of influenza neuraminidases by 
monodeoxygenated 2,3-difluoro-sialic acid inactivators (24) - (27) on influenza 
neuraminidase. This chapter will first discuss ready available X-ray crystal 
structures of the active site of influenza neuraminidase N9 in complex with 
sialic acid (2) considering the position of the hydroxyl group targeted in the 
deoxygenation of 2,3-difluoro-sialic acid (23). Following, the X-ray 
crystallographic structure of the covalent complex of influenza neuraminidase 
N9 with the monodeoxygenated 2,3-difluoro-sialic acid inactivators (24) - (27) 
will be discussed. It was anticipated that comparing structures determined on 
inactivators (24) - (27) with the structures generated from previous studies 
performed on sialic acid (2) and DANA (16) might give further insight into the 
mechanism through which monodeoxygenated 2,3-difluoro-sialic acid 
inactivators (24) - (27) are processed by influenza neuraminidases. 
The X-ray cyrstal structure of the covalent sialosyl-enzyme intermediate has 
previously been shown by Watts et al. on Trypanosoma rangeli in complex 
with 2,3-difluoro-sialic acid (23) and by Resende on influenza neuraminidase 
N9 in complex with 7-N,N-diethylamino-2,3-difluoro-sialic acid (122) 
(unpublished work).12,164  
 
 
 
    23       122 
The X-ray crystal structures of 2,3-difluoro-sialic acid (23) (Figure 16a) and 
7-N,N-diethylamino-2,3-difluoro-sialic acid (122) (Figure 16b) have both 
confirmed the existence of the covalently linked sialosyl-enzyme intermediate 
by observing clear electron density alongside the proposed covalent bond. 
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Figure 16 X-ray crystal structures of influenza neuraminidase N9 displaying electron density 
alongside the covalently linked sialosyl-enzyme intermediate in complex with a) 2,3-difluoro-
sialic acid (23). The structure is shown with population of the DANA-like compound given in 
green; b) 7-N,N-diethylamino-2,3-difluoro-sialic acid (122) (unpublished results). 
a) 
b) 
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The refined model of 2,3-difluoro-sialic acid (23) (Figure 16a) showed in dual 
occupancy a covalently linked sialosyl-enzyme intermediate of the 2,3-difluoro-
sialic acid (23) and a DANA-like compound (shown in green). The covalently 
linked sialosyl-enzyme intermediate was identified through a clear rotation of 
the carboxyl group compared to 2,3-difluoro-sialic acid (23) and the loss of the 
fluorine atom at position C-2 of 2,3-difluoro-sialic acid (23). 
The distance of ~ 1.4 Å between the oxygen of the residue Tyr406 and 
position C-2 of the inactivator with electron density alongside the putative 
covalent bond indicates covalent binding (Figure 16a). 
The second ligand in the active site of influenza neuraminidase N9 with an 
occurrence of 60% could correspond to a flattened ring conformation 
consistent with a DANA-like elimination product (Figure 16a, shown in green). 
In a study performed by Burmeister et al. the natural sialic acid (2) turnover in 
Flu B neuraminidase showed DANA (16).192 This formation of DANA (16) 
proceeds via simple proton elimination. However, on 2,3-difluoro-sialic acid 
(23) the formation of a of a DANA-like derivative would need a redox 
elimination mechanism. At present, no mechanism for the formation of the 
DANA-like elimination product has yet been proposed and it remains unclear if 
influenza neuraminidases processes 2,3-difluoro-sialic acid (23) through an 
alternative metabolic mechanism. Other explanations could also involve the 
formation of the DANA-like elimination product as part of the crystallisation 
conditions used, or the DANA (16) compound might be a side product formed 
in the synthesis and remained an impurity throughout. The uncertainty of the 
DANA-like elimination product formation needs to be addressed and is part of 
future synthetic and protein crystallographic strategies. 
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To clarify: The influenza neuraminidase N9 used for crystallisation 
studies was provided by Dr. Jennifer McKimm-Breschkin (Materials 
Science and Engineering, CSIRO, Australia). All protein crystallisation, 
X-ray crystallographic studies and refinements were performed by Dr. 
Victor Streltsov at the Australian Synchrotron MX-2 (Livestock 
Industries, CSIRO Australia). The PDB coordinates (unpublished work) 
used in this chapter were provided by Dr. Victor Streltsov, but the 
analysis and interpretation of the results obtained are performed by the 
author. 
 The C-4 position 7.2
 
In the active site of influenza neuraminidase N9, the amino acid residues 
Tyr406, Glu119 and Asp151 have been identified as being crucial for catalysis, 
and are all located within a pocket of 4 Å radius around the oxygen of the C-4 
hydroxyl group of sialic acid (2) (Figure 17). 
 
Figure 17 Key amino acid residues and water molecules located within a 4 Å radius of the 
oxygen at position C-4 of sialic acid (2) in the active site of influenza neuraminidase N9. Amino 
acid residues are shown in stick representation and water molecules in spherical 
representation. Generated with PyMOL (PDB 1MWE).191 
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In addition to the three catalytic residues (Tyr406, Glu119 and Asp151) two 
further amino acid residues (Arg156 and Trp178) and three water molecules 
are also found to lie within the 4 Å pocket around the OH-4 group. Since water 
molecules can play a crucial role in transition-state stabilisation through 
hydrogen bond interactions and/or entropic effects, the presence of water 
molecules could have an effect on the overall neuraminidase activity and so 
will be considered as part of our analysis. 
In general, influenza neuraminidases are known to be particularly tolerant 
towards modifications at position C-4 of sialic acid (2). As previously 
demonstrated by Zanamivir (15), interactions at position C-4 with amino acid 
residues in the active site of influenza neuraminidase are of major interest and 
the introduction of a large basic functionality like a guanidino substituent at this 
position did result in better inhibition of influenza neuraminidase.90,91 
However, the 4-deoxy-2,3-difluoro-sialic acid (24) inactivator gave comparable 
or better IC50 values than the parent 2,3-difluoro-sialic acid (23) on the 
influenza neuraminidase strains tested (Chapter 6.3.1). 
Crystals of influenza neuraminidase N9 in complex with 4-deoxy-2,3-difluoro-
sialic acid (24) were obtained by co-crystallisation. Diffraction data were 
collected from a single crystal that diffracted to 1.9 Å and refinement was 
performed with REFMAC 5.5.0110 on 3710 atoms (Figure 18). 
The refined model showed in dual population a covalently linked sialosyl-
enzyme intermediate of the 4-deoxy-2,3-difluoro-sialic acid (24) and a DANA-
like compound (shown in purple). The covalently linked sialosyl-enzyme 
intermediate was identified through a clear rotation of the carboxyl group 
compared to 4-deoxy-2,3-difluoro-sialic acid (24) and the loss of the fluorine 
atom at position C-2 of 4-deoxy-2,3-difluoro-sialic acid (24). Together with the 
distance of ~ 1.4 Å between the oxygen of the residue Tyr406 and position C-2 
of the inactivator with electron density alongside the putative covalent bond 
indicates covalent binding (Figure 19). 
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Figure 18 Key amino acid residues and water molecules located within a 4 Å radius of the 
covalently bound β-4-deoxy-3-fluoro-sialosyl moiety in the active site of influenza 
neuraminidase N9. Amino acid residues are shown in stick representation and water 
molecules in spherical representation. The structure is shown with population of the DANA-like 
compound given in purple. Generated with PyMOL (unpublished work). 
 
The second ligand in the active site of influenza neuraminidase N9 with an 
occurrence of 80% could correspond to a DANA-like elimination product 
(Figure 18, shown in purple and Figure 19, shown in green). The second 
structure shows a flattened ring conformation consistent with DANA.  
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Figure 19 X-ray crystal structure of influenza neuraminidase N9 displaying electron density 
alongside the covalently linked sialosyl-enzyme intermediate of 4-deoxy-2,3-difluoro-sialic 
acid (24). The structure is shown with population of the DANA-like compound given in green 
(unpublished results). 
 
The X-ray crystal structure obtained from influenza neuraminidase N9 in 
complex with 4-deoxy-2,3-difluoro-sialic acid (24) was superimposed with the 
structure of influenza neuraminidase N9 in complex with sialic acid (2) to 
investigate any conformational changes to the inactivator or active site 
residues of influenza neuraminidase (Figure 20). The alignment tool in 
PyMOL was used on 362 atoms of the backbone and gave a root-mean-
square deviation (RMSD) of 0.103. 
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Figure 20 Superimposition of the active site of influenza neuraminidases N9 in complex with 
sialic acid (2) (SIA-1, grey) and β-4-deoxy-3-fluoro-sialosyl moiety (IH4-1, blue), The structure 
is shown with population of the DANA-like compound given in purple. Key amino acid residues 
and water molecules located within a 4 Å radius of the oxygen at position C-4 of sialic acid (2) 
in the active site of influenza neuraminidase N9. Amino acid residues are shown in stick 
representation and water molecules in spherical representation. Generated with PyMOL 
(PDB 1MWE, grey) (unpublished work).191 
 
The superimposition of the two X-ray crystal structure sets on influenza 
neuraminidase N9 demonstrated highly conserved active site amino acid 
residues and a twisted ring distortion of the covalently linked β-4-deoxy-
3-fluoro-sialosyl moiety was observed. The removal of the OH-4 group results 
in reorientation of the C-5 N-acetyl group and the glycerol side chain. 
Furthermore, the three water molecules close to the Glu119 residue appear to 
be congruent in the active site of influenza neuraminidase N9 (Figure 20).  
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However, one additional water molecule could be seen within a 4 Å radius of 
the oxygen at position C-4 of sialic acid (2). The additional water molecule 
could be in the range of hydrogen-bonding interactions with the C-5 N-acetyl 
group, the catalytic amino acid residues Arg156 and other water molecules. 
This additional water molecule could be an explanation for the behaviour of 4-
deoxy-2,3-difluoro-sialic acid (24) in inactivation kinetics with better IC50 values 
than the parent inactivator 2,3-difluoro-sialic acid (23), as previously 
demonstrated (Chapter 6.3.1). To further investigate the role of this water 
molecule for catalysis, computer aided hydration free energy calculations 
could be performed, however this is beyond the scope of this project.193 The 
role of water molecules towards the inactivation mechanism in influenza 
neuraminidase is ambiguous, but has recently been targeted in novel drug 
discovery efforts.194,195 
The X-ray crystal structure obtained from influenza neuraminidase N9 in 
complex with 4-deoxy-2,3-difluoro-sialic acid (24) was superimposed with the 
structure of influenza neuraminidase N9 in complex with DANA (16), which as 
a competitive transition-state analogue inhibitor could be used to elucidate the 
behaviour of the 4-deoxy-2,3-difluoro-sialic acid (24) in the enzymatic catalytic 
cycle of influenza neuraminidase (Figure 21). 
The superimposition of the two X-ray crystal structure sets on influenza 
neuraminidase N9 using the alignment tool in PyMOL on 365 atoms of the 
backbone gave a root-mean-square deviation (RMSD) of 0.107. The alignment 
showed that the position of the DANA-like ligand obtained in the X-ray crystal 
structure on 4-deoxy-2,3-difluoro-sialic acid (24) closely mimics the position of 
DANA (16) in the structure obtained of its complex with influenza 
neuraminidase N9. 
The previously described additional water molecule was seen again within a 
pocket of 4 Å radius of the oxygen at position C-4 of DANA (16) and could be 
in the range of hydrogen-bonding interactions with the C-5 N-acetyl group, the 
catalytic amino acid residues Arg156 and other water molecules and might 
reinforce the role of this water molecule for catalysis. 
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Figure 21 Superimposition of the active site of influenza neuraminidases N9 in complex with 
DANA (16) (DAN-0, grey) and β-4-deoxy-3-fluoro-sialosyl moiety (IH4-1, blue). The structure is 
shown with population of the DANA-like compound given in purple Key amino acid residues 
and water molecules located within a 4 Å radius of the oxygen at position C-4 of DANA (16) in 
the active site of influenza neuraminidase N9. Amino acid residues are shown in stick 
representation and water molecules in spherical representation. Generated with PyMOL 
(PDB 1F8B, grey) (unpublished work).196 
 
 The C-7 position 7.3
 
In the active site of influenza neuraminidase N9, the catalytic amino acid 
residues Asp151 and Arg152 are located in a pocket within a 4 Å radius 
around the oxygen of the C-7 hydroxyl group of sialic acid (2) (Figure 22). 
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Figure 22 Key amino acid residues and water molecules located within a 4 Å radius of the 
oxygen at position C-7 of sialic acid (2) in the active site of influenza neuraminidase N9. Amino 
acid residues are shown in stick representation and water molecules in spherical 
representation. Generated with PyMOL (PDB 1MWE).191 
 
In addition to the two catalytic residues (Asp151 and Arg152) six water 
molecules are also found to lie within the 4 Å pocket around the OH-7 group. 
Of the five hydroxyl groups present in sialic acid (2) the hydroxyl group at 
position C-7 is considered to contribute least towards non-covalent 
interactions, as previously demonstrated in X-ray crystallographic structures of 
influenza neuraminidase N2 in complex with sialic acid (2) (Figure 9) 
(Chapter 1.5). 
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In support of this observation, studies performed by Macdonald et al. it have 
shown that derivatives of Zanamivir (15) functionalised at the position C-7 with 
an aminohexyl carbamate retain good activity against all influenza virus strains 
tested, while dimeric derivatives of Zanamivir (22) (Chapter 1.5.4) exhibit 
increased potencies attributed to bivalent binding to multiple neuraminidase 
enzymes.131,197,198 
As a consequence, position C-7 is interesting in terms of transition-state 
stabilisation as well as on information of the active site of influenza 
neuraminidase during the inactivation mechanism with 7-deoxy-2,3-difluoro-
sialic acid (25). 
Crystals of 7-deoxy-2,3-difluoro-sialic acid (25) in complex with Influenza 
neuraminidase N9 were obtained by co-crystallisation. Diffraction data were 
collected from a single crystal that diffracted to 1.8 Å and refinement was 
performed with REFMAC 5.6.0100 on 3786 atoms (Figure 23). 
 
Figure 23 Key amino acid residues and water molecules located within a 4 Å radius of the 
7-deoxy-2,3-difluoro-sialic acid (25) in the active site of influenza neuraminidase N9. Amino 
acid residues are shown in stick representation and water molecules in spherical 
representation. Generated with PyMOL (unpublished work). 
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Surprisingly, the refined model showed no evidence of covalent binding of the 
7-deoxy-sialic acid derivative, but an axial group at the anomeric position and 
the sialic acid moiety was seen in a twisted orientation in the active site of 
influenza neuraminidase N9 (Figure 23). This result might be explained by 
considering the mechanism of inactivation (Scheme 69). 
     25       123         124 
 
Scheme 69 The glycosylation (k1) and deglycosylation (k2) rate constants associated with the 
mechanism-based inactivator 7-deoxy-2,3-difluoro-sialic acid (25). 
 
The time frame in the co-crystallisation method might not have been 
appropriate to trap the covalently linked sialosyl-enzyme intermediate, but 
resulted in the isolation of the hydrolysed 3-fluoro-sialic acid (124). In an 
attempt to prove our hypothesis about the hydrolysed 3-fluoro-sialic acid (124), 
co-crystallisation of influenza neuraminidase N9 with the synthetically 
prepared 3-fluoro-sialic acid (124) was performed, however no binding could 
be observed. Impurity concerns of the 7-deoxy-2,3-difluoro-sialic acid (25) with 
β-2,3-difluoro-sialic acid derivative (125) were addressed in extensive 
19F NMR analysis. Together with attempted co-crystallisation of influenza 
neuraminidase N9 with synthetically prepared β-2,3-difluoro-sialic acid (125), 
which showed no binding, it was confirmed that the structure in the refined 
model is not the β-2,3-difluoro-sialic acid derivative (125). 
 
 
 
 
         125 
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As a consequence, an alternative crystallisation method in order to shorten the 
time frame for the crystallisation was used, in which the 7-deoxy-2,3-difluoro-
sialic acid (25) was soaked for 15 minutes at 4 °C with a preformed crystal of 
influenza neuraminidase N9. Diffraction data were collected from a single 
crystal that diffracted to 2.0 Å and refinement utilising REFMAC 5.6.0100 on 
3805 atoms (Figure 24). 
 
Figure 24 Key amino acid residues and water molecules located within a 4 Å radius of the 
covalently bound β-7-deoxy-3-fluoro-sialosyl moiety in the active site of influenza 
neuraminidase N9. Amino acid residues are shown in stick representation and water 
molecules in spherical representation. The structure is shown with population of the DANA-like 
compound given in purple. Generated with PyMOL (unpublished work). 
 
The refined model showed in dual population a putative covalently linked 
sialosyl-enzyme intermediate of the 7-deoxy-2,3-difluoro-sialic acid (25) and a 
DANA-like compound (shown in purple). The covalently linked sialosyl-enzyme 
intermediate could be identified through a clear rotation of the carboxyl group 
compared to 7-deoxy-2,3-difluoro-sialic acid (25) and the loss of the fluorine 
atom at position C-2 of 7-deoxy-2,3-difluoro-sialic acid (25) Together with the 
distance of ~ 1.9 Å between the oxygen of the residue Tyr406 and position C-2 
of the inactivator could be assumed. 
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Unfortunately, the final proof of the covalent intermediate was not possible as 
the electron density map has not been provided. 
The second ligand in the active site of influenza neuraminidase N9 with an 
occurrence of 75% could correspond to a DANA-like elimination product 
(Figure 24). The second structure shows a flattened ring conformation 
consistent with DANA and has previously been demonstrated on X-ray 
structures with 4-deoxy-2,3-difluoro-sialic acid (24) (Chapter 7.2). 
To investigate conformational changes on the inactivator and the active site of 
influenza neuraminidase the X-ray, the crystal structure obtained on influenza 
neuraminidase N9 in complex with 7-deoxy-2,3-difluoro-sialic acid (25) was 
superimposed with the structure of influenza neuraminidase N9 in complex 
with sialic acid (2) (Figure 25). 
The alignment tool in PyMOL was used on 356 atoms of the backbone and 
gave a root-mean-square deviation (RMSD) of 0.107. The superimposition 
showed, a twisted ring distortion of the putative covalently linked β-7-deoxy-
3-fluoro-sialosyl moiety, as it was previously demonstrated on 4-deoxy-
2,3-difluoro-sialic acid (24). 
The removal of the OH-7 group did not cause any reorientation of the glycerol 
side chain as the superimposed crystal structures exhibit congruent 
characteristics. 
Out of six water molecules present in the crystal structure of influenza 
neuraminidase N9 in complex with sialic acid (2) three seem to be congruent 
with the water molecules in the crystal structure obtained on 
influenza neuraminidase N9 in complex with 7-deoxy-2,3-difluoro-sialic acid 
(25) (Figure 25). The water molecules might play a role in the mechanism of 
inactivation on influenza neuraminidase, but a clear catalytic function of the 
water molecules within a pocket of 4 Å radius of the oxygen at position C-7 of 
sialic acid (2) in the active site of influenza neuraminidase N9 could not be 
identified. 
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Figure 25 Superimposition of the active site of influenza neuraminidases N9 in complex with 
sialic acid (2) (SIA-1, grey) and β-7-deoxy-3-fluoro-sialosyl moiety (FS7-700, blue). The 
structure is shown with population of the DANA-like compound given in purple. Key amino acid 
residues and water molecules located within a 4 Å radius of the oxygen at position C-7 of sialic 
acid (2) in the active site of influenza neuraminidase N9. Amino acid residues are shown in 
stick representation and water molecules in spherical representation. Generated with PyMOL 
(PDB 1MWE, grey).191 
 
Finally, the X-ray crystal structure obtained from influenza neuraminidase N9 
in complex with 7-deoxy-2,3-difluoro-sialic acid (25) was superimposed with 
the structure of influenza neuraminidase N9 in complex with DANA (16), which 
as a competitive transition-state analogue inhibitor could be used to elucidate 
the behaviour of the 7-deoxy-2,3-difluoro-sialic acid (25) in the enzymatic 
catalytic cycle of influenza neuraminidase (Figure 26). 
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Figure 26 Superimposition of the active site of influenza neuraminidases N9 in complex with 
DANA (16) (DAN-0, grey) and β-7-deoxy-3-fluoro-sialosyl moiety (FS7-700, blue). The 
structure is shown with population of the DANA-like compound given in purple. Key amino acid 
residues and water molecules located within a 4 Å radius of the oxygen at position C-7 of 
DANA (16) in the active site of influenza neuraminidase N9. Amino acid residues are shown in 
stick representation and water molecules in spherical representation. Generated with PyMOL 
(PDB 1F8B, grey) (unpublished work).196 
 
The alignment tool in PyMOL was used on 344 atoms of the backbone to give 
a root-mean-square deviation (RMSD) of 0.112. 
The superimposition showed a ring distortion of the putative covalently linked 
β-7-deoxy-3-fluoro-sialosyl moiety. However, the distortion of the ring is not as 
pronounced and might show a related configuration of the refined model 
obtained with DANA (16). This ambiguity with regards to the inactivation 
mechanism of 7-deoxy-2,3-difluoro-sialic acid (25) needs to be addressed and 
is part of future synthetic and protein crystallographic strategies. 
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 The C-8 position 7.4
 
In the active site of influenza neuraminidase N9, the catalytic amino acid 
residues Arg292, Glu277 and Tyr406 are located in a pocket within a 
4 Å radius around the oxygen of the C-8 hydroxyl group of sialic acid (2) 
(Figure 27). 
 
Figure 27 Key amino acid residues and water molecules located within a 4 Å radius of the 
oxygen at position C-8 of sialic acid (2) in the active site of influenza neuraminidase N9. Amino 
acid residues are shown in stick representation and water molecules in spherical 
representation. Generated with PyMOL (PDB 1MWE).191 
 
In addition to the three catalytic residues three other amino acid residues 
(Arg224, Asn294 and Glu276) and three water molecules are also found to lie 
within the 4 Å pocket around the OH-8 group. 
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The position C-8 has many important non-covalent interactions within the 
active site of influenza neuraminidase which has previously been 
demonstrated on influenza neuraminidase N2 in complex with sialic acid (2) 
(Figure 9). 
Due to its multiple sites of possible non-covalent interactions, the position C-8 
of sialic acid (2) has been heavily targeted in the development of novel 
influenza neuraminidase inhibitors. 
One of the most prominent examples in influenza neuraminidase inhibitor drug 
design was the introduction of a pentenyl ether side chain instead of the 
glycerol side chain which lead to the development of Oseltamivir (6) (Chapter 
1.5.2.2).99 Hence, it was anticipated that X-ray crystal structures of influenza 
neuraminidase N9 in complex with 8-deoxy-2,3-difluoro-sialic acid (26) could 
be useful to develop some understanding of the active site of influenza 
neuraminidase during the mechanism of inactivation on a physical basis. 
Crystals of influenza neuraminidase N9 in complex with 8-deoxy-2,3-difluoro-
sialic acid (26) were obtained by co-crystallisation. Diffraction data were 
collected from a single crystal that diffracted to 1.85 Å and refinement was 
achieved using REFMAC 5.5.0110 on 3797 atoms (Figure 28). 
The refined model showed in dual population a covalently linked sialosyl-
enzyme intermediate of the 8-deoxy-2,3-difluoro-sialic acid (26) and a DANA-
like compound (shown in purple). The covalently linked sialosyl-enzyme 
intermediate was identified through a clear rotation of the carboxyl group 
compared to 8-deoxy-2,3-difluoro-sialic acid (26) and the loss of the fluorine 
atom at position C-2 of 8-deoxy-2,3-difluoro-sialic acid (26) (Figure 28). 
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Figure 28 Key amino acid residues and water molecules located within a 4 Å radius of the 
covalently bound β-8-deoxy-3-fluoro-sialosyl moiety in the active site of influenza 
neuraminidase N9. Amino acid residues are shown in stick representation and water 
molecules in spherical representation. The structure is shown with population of the DANA-like 
compound given in purple. Generated with PyMOL (unpublished work). 
 
Together with the distance of ~ 1.4 Å between the oxygen of the residue 
Tyr406 and position C-2 of the inactivator with electron density alongside the 
putative covalent bond indicates covalent binding (Figure 29). 
The second ligand in the active site of influenza neuraminidase N9 with an 
occurrence of 60% could correspond to a DANA-like elimination product 
(Figure 28, shown in purple and Figure 29, shown in green). The second 
structure shows a flattened ring conformation consistent with DANA. 
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Figure 29 X-ray crystal structure of influenza neuraminidase N9 displaying electron density 
alongside the covalently linked sialosyl-enzyme intermediate of 8-deoxy-2,3-difluoro-sialic acid 
(26). The structure is shown with population of the DANA-like compound given in green 
(unpublished results). 
 
The X-ray crystal structure obtained from influenza neuraminidase N9 in 
complex with 8-deoxy-2,3-difluoro-sialic acid (26) was superimposed with the 
structure of influenza neuraminidase N9 in complex with sialic acid (2) to 
investigate any conformational changes to the inactivator or active site 
residues of influenza neuraminidase (Figure 30). 
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Figure 30 Superimposition of the active site of influenza neuraminidases N9 in complex with 
sialic acid (2) (SIA-1, grey) and β-8-deoxy-3-fluoro-sialosyl moiety (UB-8-1, blue). The 
structure is shown with population of the DANA-like compound given in purple. Key amino acid 
residues and water molecules located within a 4 Å radius of the oxygen at position C-8 of sialic 
acid (2) in the active site of influenza neuraminidase N9. Amino acid residues are shown in 
stick representation and water molecules in spherical representation. Generated with PyMOL 
(PDB 1MWE, grey).191 
 
The alignment tool in PyMOL was used on 369 atoms of the backbone and 
gave a root-mean-square deviation (RMSD) of 0.101. 
The superimposition of the two X-ray crystal structure sets on influenza 
neuraminidase N9 demonstrated highly conserved active site amino acid 
residues and a twisted ring distortion of the covalently linked β-8-deoxy-3-
fluoro-sialosyl moiety, as it was previously shown on 4-deoxy-2,3-difluoro-
sialic acid (24) was observed. However, an upwards displacement of the 
covalently bound β-8-deoxy-3-fluoro-sialosyl moiety could be seen and the 
loss of hydrogen-bonding interaction at position C-8 might correlate with a 
rotation of the residues Glu276 and Glu277. 
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However, one additional water molecule could be seen within a 4 Å radius of 
the oxygen at position C-8 of sialic acid (2). The additional water molecule 
could be in the range of hydrogen-bonding interactions with the C-5 N-acetyl 
group over another water molecule and the catalytic amino acid residues 
Arg224. This additional water molecule could be an explanation for the 
behaviour of 8-deoxy-2,3-difluoro-sialic acid (26) in inactivation kinetics with 
worse IC50 values than the parent inactivator 2,3-difluoro-sialic acid (23), as 
previously demonstrated (Chapter 6.3.1). To further investigate the role of this 
water molecule for catalysis, computer aided hydration free energy 
calculations could be performed, however this is beyond the scope of this 
project.193 
Finally, the X-ray crystal structure obtained from influenza neuraminidase N9 
in complex with 8-deoxy-2,3-difluoro-sialic acid (26) was superimposed with 
the structure of influenza neuraminidase N9 in complex with DANA (16), which 
as a competitive transition-state analogue inhibitor could be used to elucidate 
the behaviour of the 8-deoxy-2,3-difluoro-sialic acid (26) in the enzymatic 
catalytic cycle of influenza neuraminidase (Figure 31). 
The alignment tool in PyMOL was used on 365 atoms of the backbone to give 
a root-mean-square deviation (RMSD) of 0.111. The superimposition showed 
a twisted ring distortion of the covalently linked β-8-deoxy-3-fluoro-sialosyl 
moiety, which has previously been observed on 4-deoxy-2,3-difluoro-sialic 
acid (24). Remarkably, the glycerol side chain in 8-deoxy-2,3-difluoro-sialic 
acid (26) is rotated towards the additional water molecule, which might 
reinforce the role of this water molecule for catalysis 
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Figure 31 Superimposition of the active site of influenza neuraminidases N9 in complex with 
DANA (16) (DAN-0, grey) and β-8-deoxy-3-fluoro-sialosyl moiety (UB8-1, blue). The structure 
is shown with population of the DANA-like compound given in purple. Key amino acid residues 
and water molecules located within a 4 Å radius of the oxygen at position C-8 of DANA (16) in 
the active site of influenza neuraminidase N9. Amino acid residues are shown in stick 
representation and water molecules in spherical representation. Generated with PyMOL 
(PDB 1F8B, grey) (unpublished work).196 
 
 The C-9 position 7.5
 
In the active site of influenza neuraminidase N9, the catalytic amino acid 
residues Arg224, Ala 246, Glu276 and Asn294 are located in a pocket within a 
4 Å radius around the oxygen of the C-9 hydroxyl group of sialic acid (2) 
(Figure 32). 
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Figure 32 Key amino acid residues and water molecules located within a 4 Å radius of the 
oxygen at position C-9 of sialic acid (2) in the active site of influenza neuraminidase N9. Amino 
acid residues are shown in stick representation and water molecules in spherical 
representation. Generated with PyMOL (PDB 1MWE).191 
 
In addition, four water molecules are also found to lie within the 4 Å pocket 
around the OH-9 group. 
Position C-9 in sialic acid plays a crucial role in multiple non-covalent 
interactions in the active site of influenza neuraminidase N2, as it has 
previously been pointed out (Chapter 1.5). 
Targeting this position together with the rest of the glycerol side chain has 
been a key feature in influenza neuraminidase inhibitor drug design.99 
Therefore, it was anticipated that X-ray crystal structures of influenza 
neuraminidase N9 in complex with 9-deoxy-2,3-difluoro-sialic acid (27) would 
be useful to gain further understanding of the active site of influenza 
neuraminidase during the mechanism of inactivation. 
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Crystals of influenza neuraminidase N9 in complex with 9-deoxy-2,3-difluoro-
sialic acid (27) were obtained by co-crystallisation. Diffraction data were 
collected from a single crystal that diffracted to 2.4 Å and refinement was 
performed using REFMAC 5.5.0110 on 3771 atoms (Figure 33). 
 
Figure 33 Key amino Acid residues and water molecules located within a 4 Å radius of the 
covalently bound β-9-deoxy-3-fluoro-sialosyl moiety in the active site of influenza 
neuraminidase N9. Amino acid residues are shown in stick representation and water 
molecules in spherical representation. The structure is shown with population of the DANA-like 
compound given in purple. Generated with PyMOL (unpublished work). 
 
The refined model showed the covalently linked sialosyl-enzyme intermediate 
and in dual occupancy in an occurrence of 70% a DANA-like compound 
(shown in purple). The distortion of the ring moiety, the loss of a fluorine atom 
at position C-2 and the distance of ~ 1.4 Å between the oxygen of the residue 
Tyr406 and position C-2 all indicated covalent binding character (Figure 33). 
Unfortunately, the final proof of the covalent intermediate was not possible as 
the electron density map has not been provided. 
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To investigate conformational changes on the inactivator and the active site of 
Influenza neuraminidase, the X-ray crystal structure of influenza 
neuraminidase N9 in complex with 9-deoxy-2,3-difluoro-sialic acid (27) was 
superimposed with the structure of influenza neuraminidase N9 in complex 
with sialic acid (2) (Figure 34). 
 
Figure 34 Superimposition of the active site of influenza neuraminidases N9 in complex with 
sialic acid (2) (SIA-1, grey) and β-9-deoxy-3-fluoro-sialosyl moiety (UB9-1, blue). The structure 
is shown with population of the DANA-like compound given in purple. Key amino acid residues 
and water molecules located within a 4 Å radius of the oxygen at position C-9 of sialic acid (2) 
in the active site of influenza neuraminidase N9. Amino acid residues are shown in stick 
representation and water molecules in spherical representation. Generated with 
PyMOL (PDB 1MWE, grey).191 
 
The superimposition of the two X-ray crystal structures utilised the alignment 
tool in PyMOL on 367 atoms of the backbone and gave a root-mean-square 
deviation (RMSD) of 0.140. 
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The superimposition showed a twisted ring distortion of the β-9-deoxy-sialic 
acid moiety and is supporting the proposed formation of a covalent bond as 
previously demonstrated on 4-deoxy-2,3-difluoro-sialic acid (24). Furthermore, 
a re-orientation of the glycerol side chain and rotation of the amino acid 
residue Glu276 could be observed, which might correlate with the loss of 
hydrogen-bonding interaction at position C-9. 
Finally, the X-ray crystal structure obtained from influenza neuraminidase N9 
in complex 9-deoxy-2,3-difluoro-sialic acid (27) was superimposed with the 
structure of influenza neuraminidase N9 in complex with DANA (16), which as 
a competitive transition-state analogue inhibitor could be used to elucidate the 
behaviour of the 9-deoxy-2,3-difluoro-sialic acid (27) in the enzymatic catalytic 
cycle of influenza neuraminidase (Figure 35). 
The alignment tool in PyMOL was used on 344 atoms of the backbone to give 
a root-mean-square deviation (RMSD) of 0.112. 
The superimposition of the two structures showed that the second DANA-like 
ligand obtained in the X-ray crystal structure on 9-deoxy-2,3-difluoro-sialic acid 
(27) is congruent with the data obtained on influenza neuraminidase N9 in 
complex with DANA (16). The re-orientation of the glycerol side chain and 
rotation of the amino acid residue Glu276 is in support of the proposed 
correlation with the loss of hydrogen-bonding interaction at position C-9. 
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Figure 35 Superimposition of the active site of influenza neuraminidases N9 in complex with 
DANA (16) (DAN-0, grey) and β-9-deoxy-3-fluoro-sialosyl moiety (UB9-1, blue). The structure 
is shown with population of the DANA-like compound given in purple. Key amino acid residues 
and water molecules located within a 4 Å radius of the oxygen at position C-9 of DANA (16) in 
the active site of influenza neuraminidase N9. Amino acid residues are shown in stick 
representation and water molecules in spherical representation. Generated with PyMOL 
(PDB 1F8B, grey) (unpublished work).196 
 Conclusions 7.6
 
In conclusion, the X-ray crystal structure of influenza neuraminidase N9 in 
complex with monodeoxygenated 2,3-difluoro-sialic acid inactivators 
(24) - (27) allowed interpretation of the inhibition mechanisms on a physical 
basis. In detail, the superimposition of the structures of 4-deoxy-2,3-difluoro-
sialic acid (24) (Figure 36a) and 7-deoxy-2,3-difluoro-sialic acid (25) in 
complex with influenza neuraminidase N9 showed a shift of the 7-deoxy-
sialosyl moiety away from the Tyr406 amino acid residue (Figure 36b). 
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Figure 36 a) Key amino acid residues and water molecules located within a 4 Å radius of the 
covalently bound β-4-deoxy-3-fluoro-sialosyl moiety (IH4-1, green) in the active site of 
influenza neuraminidase N9. b) Superimposition of key amino acid residues and water 
molecules located within a 4 Å radius of the covalently bound β-4-deoxy-3-fluoro-sialosyl 
moiety (IH4-1, green) and β-7-deoxy-3-fluoro-sialosyl moiety (D7N-700, grey) in the active site 
of influenza neuraminidase N9. Amino acid residues are shown in stick representation and 
water molecules in spherical representation. Generated with PyMOL (unpublished work). 
R152 
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Figure 37 a) Superimposition of key amino acid residues and water molecules located within a 
4 Å radius of the covalently bound β-4-deoxy-3-fluoro-sialosyl moiety (IH4-1, green), 
β-7-deoxy-3-fluoro-sialosyl moiety (D7N-700, grey) and β-8-deoxy-3-fluoro-sialosyl moiety 
(UB8-1, cyan) in the active site of influenza neuraminidase N9. b) Superimposition of key 
amino acid residues and water molecules located within a 4 Å radius of the covalently bound 
β-4-deoxy-3-fluoro-sialosyl moiety (IH4-1, green), β-7-deoxy-3-fluoro-sialosyl moiety 
(D7N-700, grey), β-8-deoxy-3-fluoro-sialosyl moiety (UB8-1, cyan) and β-9-deoxy-3-fluoro-
sialosyl moiety (UB9-1, magenta) in the active site of influenza neuraminidase N9. Amino acid 
residues are shown in stick representation and water molecules in spherical representation. 
Generated with PyMOL (unpublished work). 
a) 
b) 
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This downwards shift could indicate that the 7-deoxy-2,3-difluoro-sialic acid 
(25) is not forming a covalent bond with Tyr406. In contrast to the 7-deoxy-
2,3-difluoro-sialic acid (25), the 8-deoxy-2,3-difluoro-sialic acid (26) and 
9-deoxy-2,3-difluoro-sialic acid (27) are congruent with 4-deoxy-2,3-difluoro-
sialic acid (24) (Figure 37b) and are in compliance with the mechanism-based 
inhibitor design strategy, developed on the covalent glycosyl-enzyme 
intermediate mechanism for neuraminidases (Scheme 8, Chapter 1.5.1). 
Nevertheless, the structures of 8-deoxy-2,3-difluoro-sialic acid (26) and 9-
deoxy-2,3-difluoro-sialic acid (27) showed a rotation of the amino acid 
residues Glu276 and Glu277 (Figure 37b). This rotation could be used to 
explain the poor inactivation previously envisaged against all influenza strains 
tested (Chapter 6.2). Furthermore, additional water molecules in 4-deoxy-
2,3-difluoro-sialic acid (24) and in 8-deoxy-2,3-difluoro-sialic acid (26) 
respectively could be seen. To further investigate the role of this water 
molecules for catalysis, computer aided hydration free energy calculations 
could be performed, however this is beyond the scope of this project.193 
However, the complex structure of IC50 values on different strains of influenza 
neuraminidases and the time-dependency thereof lead to the conclusion that 
minor differences in transition-state conformations in different neuraminidase 
strains result in major effects on Gibbs free energy of binding (∆∆G‡). Hence, 
the main focus will now be put on calculating the Gibbs free energy of binding 
(∆∆G‡) for the monodeoxygenated 2,3-difluoro-sialic acid inactivators 
(24) - (27). The systematic removal of each hydroxyl group not only produces 
analogues that differ in their hydrogen-bonding capabilities, but also influences 
electronic properties. In order to address differences in the electronic nature of 
the monodeoxygenated 2,3-difluoro-sialic acid derivatives (24) - (27) 
compared to the parent compound 2,3-difluoro-sialic acid (23) the 
monodeoxygenated natural substrates (126) - (129) with a 
4-methylumbelliferone fluorescent tag are going to be generated. 
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121 R1, R2, R3, R4 = OH 
126 R1 = H, R2, R3, R4 = OH 
    127 R2 = H, R1, R3, R4 = OH 
    128 R3 = H, R1, R2, R4 = OH 
    129 R4 = H, R1, R2, R3 = OH 
 
The difference in Gibbs free energy of binding (∆∆G‡) (Figure 5) for each 
monodeoxygenated natural substrate (126) - (129) compared to the natural 
substrate (121) consequent upon substitution of each hydroxyl by hydrogen 
are readily calculated from the relative values of Vm/Ki (Equation 6). (Vm/Ki)1 
and (Vm/Ki)2 are the kinetic constants for the deoxygenated analogue and the 
parent compound respectively.8 
 
 
 
 
Equation 6 Difference in Gibbs free energy of binding (∆∆G‡) for monodeoxygenated 
compounds compared to parent compound.8 
 
∆∆GA = RT ln
(Vm/Ki) 1
(Vm/Ki)2
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We set out to generate a series of the monodeoxygenated natural substrates 
(126) - (129) with a 4-methylumbelliferone fluorescent tag to enable the 
determination of differences in Gibbs free energies of binding (∆∆G‡) to 
influenza neuraminidase (Figure 5) for each monodeoxygenated natural 
substrate (126) - (129) compared to the natural substrate (121). 
 
 
 
 
 
121 R1, R2, R3, R4 = OH 
126 R1 = H, R2, R3, R4 = OH 
    127 R2 = H, R1, R3, R4 = OH 
    128 R3 = H, R1, R2, R4 = OH 
    129 R4 = H, R1, R2, R3 = OH 
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 Attempted synthesis of 4-deoxy-2’-8.1
(4-methylumbelliferyl) α-D-sialic acid (126) via the 
C-4 Barton-McCombie deoxygenation 
 
For the synthesis of 4-deoxy-2’-(4-methylumbelliferyl) α-D-sialic acid (126) we 
intended to utilise a 8,9-O-isopropylidene protection group on sialic acid (2) as 
an intermediate towards the synthesis of a C-4 xanthate (130). 
  126       130 
 
 8.1.1 Retrosynthetic analysis 
 
The 4-deoxy-2’-(4-methylumbelliferyl) α-D-sialic acid (126) could be yielded in 
a glycosylation step utilising 4-methylumbelliferone on the β-chloro-4-deoxy-
sialic acid methyl ester (131) according to the procedure of Engstler et al. 
(Scheme 70).199 It was anticipated to achieve formation of the β-chloro-
4-deoxy-sialic acid methyl ester (131) by treatment of the 4-deoxy-sialic acid 
methyl ester derivative (132) with hydrochloric acid gaseous. By analogy with 
the previously accomplished synthesis of the 4-deoxy-2,3-difluoro-sialic acid 
(24) we considered to achieve the formation of 4-deoxy-sialic acid methyl ester 
(132) by Barton-McCombie deoxygenation of the C-4 Xanthate (133).150,152 
The synthesis of the C-4 Xanthate (133) was considered possible from the 
8,9-O-isopropylidene-sialic acid methyl ester, which itself can be produced 
from sialic acid (2). 
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126        131 
 
 
 
 
 
132       133 
 
 
 
 
  2 
 
Scheme 70 Retrosynthetic strategy for the synthesis of 4-deoxy-2’-(4-methylumbelliferyl) 
α-D-sialic acid (126) via the C-4 xanthate (133). 
 
 8.1.2 Attempted formation of 4-deoxy-sialic acid methyl ester 
(132) 
 
The synthesis of 4-deoxy-sialic acid methyl ester (132) started according to 
the procedure of Ogura et al. from sialic acid (2), which after esterification 
utilising trifluoroacetic acid in MeOH at room temperature and isopropylidene 
protection with 2,2’-dimethoxypropane and catalytic amounts of 
p-toluenesulfonic acid (p-TSA) in acetone gave the 8,9-O-isopropylidene-sialic 
acid methyl ester (134) (Scheme 71).153 
2    134    135 
Scheme 71 Attempted synthesis of 8,9-O-isopropylidene-7-O-thiocarbamate-sialic acid methyl 
ester (132). a) (i) TFA, MeOH, r.t., O/N; (ii) 2,2’-Dimethoxypropane, p-TSA, acetone, r.t., O/N, 
93% (134); b) 1,1’-Thiocarbonyldiimidazole, CH2Cl2, 40 °C, 2 d. 
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The introduction of a thiocarbamate at position C-4 using 
1,1’-thiocarbonyldiimidazole was performed in accordance to the previously 
deployed method (Chapter 3.2) but resulted in formation of oxazoline (135) 
(Scheme 71). 
However, treatment of 8,9-O-isopropylidene-sialic acid methyl ester (134) with 
phenyl chlorothionoformate according to the previously developed protocol 
(Chapter 2.3.2) gave the desired 4-O-(phenoxy)thiocarbonyl derivative (136) in 
79% yield (Scheme 72). 
 
 
 
 
 
   134    136 
 
Scheme 72 Synthesis of 8,9-O-isopropylidene-4-O-(phenoxy)thiocarbonyl-sialic acid methyl 
ester (136). Phenyl chlorothionoformate, CH2Cl2/pyridine, - 40 ºC → r.t., 5 h, 79%. 
 
In order to probe the optimal conditions for the Barton-McCombie 
deoxygenation, the thionocarbonate (133) was used as the model substrate, 
while radical initiator, radical carriers, solvents and temperatures were varied 
in an effort to generate 4-deoxy-8,9-O-isopropylidene-sialic acid methyl ester 
(137) in the highest possible yield. 
 
 
 
     137 
In the first set of reactions according to Lopez et al., which has previously 
been described (Chapter 2.3.2), bis(tributyltin) oxide was used to generate 
tributyltin hydride in situ and subjected to thionocarbonate (136) with 
azobiscyanocyclohexane in toluene under reflux conditions (Table 13, entry 1 
and 2).151 
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Table 13 Overview of the different conditions used for the attempted synthesis of 4-deoxy-
8,9-O-isopropylidene-sialic acid derivative (134). Condition A: (Bu3Sn)2O (0.037 eq.), PMHS 
(5 eq.), n-BuOH (5.5 eq.), azobiscyanocyclohexane (0.15 eq.), toluene; Condition B: 
(Bu3Sn)2O (0.037 eq.), PMHS (5 eq.), n-BuOH (5.5 eq.), azobiscyanocyclohexane (0.15 eq.), 
toluene, solution was degassed and molecular sieves added; Condition C: (Bu4N)2S2O8 (3 
eq.), NaHCO3 (6 eq.), DMF; Condition D: (Bu4N)2S2O8 (3 eq.), NaHCO3 (6 eq.), DMF, solution 
was degassed and molecular sieves added; Condition E: Bu3SnH (2 eq.), 
azobiscyanocyclohexane (0.3 eq.), toluene; Condition F: Bu3SnH (3.7 eq.), 50% 2,2-bis(tert-
butylperoxy)-butane solution (0.45 eq.), 1,4-dioxane. 
 
136        138          134 
 
 
a Isolated yields after silica chromatography, dec. = decomposition, n.d. = not determined. 
 
 
 
However, this reaction conditions gave O-thiocarbonyl (138) according to the 
rearrangement mechanism described by Powers et al. under Barton-
McCombie conditions and also resulted in the formation of a highly polar side 
product.160 
The method utilising tetrabutylammonium peroxydisulfate and sodium formate 
as described by Park et al. (Table 13, entry 3 - 5) was used in a facile Barton-
McCombie deoxygenation.157 The 4-O-(phenoxy)thiocarbonyl- derivative (136) 
was subjected to tetrabutylammonium peroxydisulfate and sodium formate in 
DMF at 60 °C for two and a half hours as previously described by Park et al. 
(Table 13, entry 3).157 
Entry Condition Time T [°C] Product Yield (%), Ratio
1 A O/N 80 138 n.d.
2 B 3.5 h 90 dec. n.d.
3 C 2.5 h 60 136 67
4 C 1 d 60 138 + 134 8:1
5 D 5 h 70 136 n.d.
6 E 4 h 80 dec. n.d.
7 F 4 h 100 138 n.d.
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An aqueous work up in order to remove the polar reagents was then 
performed. However, starting material (136) was recovered and an undesired 
side reaction gave a highly polar product that under these conditions could not 
be isolated. 
To overcome the side product formation the solution was degassed and 
molecular sieves was added and in addition the reaction time under these 
conditions was extended (Table 13, entry 4). However, the reaction resulted 
in the formation of the sulfur oxygen exchanged derivative (138) and 
hydrolysis to give (134) in a ratio of 8:1. 
The thionocarbonate (136) was next subjected to radical Barton-McCombie 
conditions using either 2,2-bis(tert-butylperoxy)-butane or 
azobiscyanocyclohexane as a radical initiator and the radical carrier tributyltin 
hydride under reflux conditions in either 1,4-dioxane or toluene (Table 13, 
entry 6 - 7).150 However, the reaction conditions applied resulted in the 
formation of the sulfur oxygen exchanged derivative (138) and formation of a 
highly polar side product, which under these conditions could not be isolated. 
As a consequence, it was concluded that acetylation of 8,9-O-isopropylidene-
4-O-(phenoxy)thiocarbonyl-sialic acid methyl ester (136) could minimise the 
side reactions observed in the Barton-McCombie deoxygenation, which might 
be due to the polar character of the starting material. Hence, 
8,9-O-isopropylidene-4-O-(phenoxy)thiocarbonyl-sialic acid methyl ester (136) 
was acetylated using acetic anhydride and subjected to Barton-McCombie 
conditions using tributyltin hydride in 1,4-dioxane (Scheme 73). 
      136        139        140 
 
Scheme 73 Attempted synthesis of 4-deoxy-8,9-O-isopropylidene-sialic acid derivative (137). 
(i) Ac2O, DMAP, pyridine, r.t., O/N; (ii) Bu3SnH, 50% 2,2-bis(tert-butylperoxy)-butane solution, 
1,4-dioxane, 100 °C, 4 h. 
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However, these conditions gave the sulfur oxygen exchanged derivative (139) 
and the hydrolysed derivative (140) in a ratio of 6:1. 
It was proposed that Barton-McCombie conditions are not applicable to this 
substrate. This might be due to the two protons at position C-3, which are next 
to the xanthate and might interfere under Barton-McCombie conditions. We 
investigated an alternative to the Barton-McCombie protocol to achieve 
deoxygenation, which had recently been proposed by Lam et al. and deploys 
toluates instead of xanthates utilising samarium under single electron transfer 
conditions.200 The proposed mechanism proceeds via a toluate radical anion, 
which subsequently eliminates to give the toluate anion and the deoxygenated 
radical (Scheme 74). 
 
 
 
 
 
 
 
 
Scheme 74 Probable decomposition pathway of a toluate radical anion.200 
 
The 8,9-O-isopropylidene-sialic acid methyl ester (134) was subjected to 
p-toluoyl chloride in dichloromethane in accordance to the protocol of 
Lam et al. to give the C-4 toluate, which was then acetylated to yield 
4-O-toluoyl-sialic acid derivative (141) (Scheme 75). 
 134       141         142 
 
Scheme 75 Attempted formation of 2,7-di-O-acetyl-4-deoxy-8,9-O-isopropylidene-sialic acid 
methyl ester (142). (a) (i) p-Toluoyl chloride, CH2Cl2, 0 ºC → r.t., 2 h; (ii) Ac2O, DMAP, 
pyridine, r.t., O/N, 47% (over 2 steps) (141); (b) Sm, diiodoethane, HMPA, THF, 65 ºC. 
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In a flame-dried Schlenk flask samarium, diiodoethane, freshly distilled HMPA 
and anhydrous THF were heated to 65 °C and the C-4 toluate (141) was 
added. However, these conditions gave recovered starting material (141) and 
the formation of a highly polar side product. The protocol of Lam et al. applied 
to the C-4 toluate (141) led to comparable results obtained under Barton-
McCombie conditions on thionocarbonate (136), which might support the 
proposed concept that radical conditions to form the 4-deoxy derivative on 
sialic acid are not applicable. 
After re-evaluating the synthetic strategy and in search of a more vigorous 
method to form 4-deoxy-2’-(4-methylumbelliferyl) α-D-sialic acid (126) it was 
decided to explore previously accomplished studies towards the synthesis of a 
4-deoxy derivative. A study performed by Hagedorn et al. utilised a 4-iodo-
8,9-O-isopropylidene-sialic acid methyl ester methyl glycoside (143), which 
after dehalogen hydrogenation gave the 4-deoxy derivative. It was anticipated 
that this intermediate could provide a viable route towards the synthesis of 
4-deoxy-2’-(4-methylumbelliferyl) α-D-sialic acid (126). 
 
 
 
 
          143 
 
 Attempted synthesis of 4-deoxy-2’-8.2
(4-methylumbelliferyl) α-D-sialic acid (126) via the 
4-iodo-sialic acid methyl glycoside (143) 
 
 8.2.1 Retrosynthetic analysis 
 
For the synthesis of 4-deoxy-2’-(4-methylumbelliferyl) α-D-sialic acid (126) we 
intended to utilise a glycosylation step utilising 4-methylumbelliferone on the 
β-chloro-4-deoxy-sialic acid methyl ester (131) according to the procedure of 
Engstler et al. (Scheme 76).199 
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132       143 
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Scheme 76 Retrosynthetic strategy for the synthesis of 4-deoxy-2’-(4-methylumbelliferyl) 
α-D-sialic acid (126) via the 4-iodo methyl glycoside (143). 
 
The formation of the β-chloro-4-deoxy-sialic acid methyl ester (131) could be 
achieved by treatment of 4-deoxy-sialic acid methyl ester derivative (132) with 
hydrochloric acid gaseous. It was anticipated to accomplish the synthesis of 
4-deoxy-sialic acid methyl ester (132) via the 4-iodo-8,9-O-isopropylidene-
sialic acid methyl ester methyl glycoside (143) which itself could be formed 
after iodination of protected sialic acid (2) in accordance to the procedure by 
Hagedorn et al.137 
 8.2.2 Attempted synthesis of 4-deoxy-sialic acid methyl ester 
(132) 
 
Sialic acid (2) was treated with Dowex (acidic form) in methanol under reflux 
conditions to give the sialic acid methyl ester methyl glycoside according to the 
method by Kuhn et al. (Scheme 77).201 
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        2       144         145 
 
Scheme 77 Synthesis of 8,9-O-isopropylidene-4-methanesulfonyl-sialic acid methyl ester 
methyl glycoside (145). a) (i) Dowex 50x8, MeOH, 70 °C, O/N; (ii) 2,2’-Dimethoxypropane, 
p-TSA, acetone, r.t., O/N, 53% (over 2 steps) (144); b) MsCl, pyridine, 0 °C, O/N, 47% 
(145).137 
 
Due to the high polarity the sialic acid methyl ester methyl glycoside was not 
purified and isolated at this stage. Subsequent isopropylidene protection with 
2,2’-dimethoxypropane in acetone according to Ogura et al. was performed to 
give the 8,9-O-isopropylidene-sialic acid methyl ester methyl glycoside (144) in 
53% over 2 steps.153 Concurring with the procedure of Hagedorn et al. 
8,9-O-isopropylidene-sialic acid methyl ester methyl glycoside (144) was 
subjected to methanesulfonyl chloride in pyridine to give 8,9-O-isopropylidene-
4-methanesulfonyl-sialic acid derivative (145) in 47% yield.137 The low yield is 
due to a side reaction forming a highly polar product which could not be 
isolated. 
Then, the 8,9-O-isopropylidene-4-methanesulfonyl-sialic acid derivative (145) 
was subjected to sodium iodide in acetone at 100 °C in a pressure tube 
according to the procedure of Hagedorn et al. (Scheme 78).137 
    145           143        146 
 
Scheme 78 Attempted formation of 4-deoxy-8,9-O-isopropylidene-sialic acid methyl ester 
methyl glycoside (146). a) NaI, acetone, 100 °C, 3 h; b) Pd/C, THF/AcOH, r.t., O/N.137 
 
The molecular weight of 4-iodo-8,9-O-isopropylidene-sialic acid derivative 
(143) was confirmed by mass spectrometry of the crude mixture, but the 
desired product could not be isolated after silica column chromatography. 
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To overcome the difficulties in the purification of 4-iodo-8,9-O-isopropylidene-
sialic acid derivative (143), subsequent hydrogenation was attempted to give 
the more stable 4-deoxy-8,9-O-isopropylidene-sialic acid methyl ester methyl 
glycoside (146). In conclusion, the formation of 4-deoxy-2’-
(4-methylumbelliferyl) α-D-sialic acid (126) following the procedure of 
Hagedorn et al. could not be accomplished and need to be resolved in future 
studies.137 
 Attempted synthesis of 7-deoxy-2’-8.3
(4-methylumbelliferyl) α-D-sialic acid (127) via the 
C-7 Barton-McCombie deoxygenation 
 
In parallel to the synthesis of 4-deoxy-2’-(4-methylumbelliferyl) α-D-sialic acid 
(126) we concurrently investigated the formation of 7-deoxy-2’-
(4-methylumbelliferyl) α-D-sialic acid (127) and we intended to utilise a C-7 
xanthate (147). 
  127    147 
This strategy was based on a study performed by Miyazaki et al. utilising a C-7 
O-thiocarbamate derivative, which was then subjected to Barton-McCombie 
conditions to give a 7-deoxy-sialic acid derivative.155 
 8.3.1 Retrosynthetic analysis 
 
The 7-deoxy-2’-(4-methylumbelliferyl) α-D-sialic acid (126) could be yielded in 
a glycosylation step utilising 4-methylumbelliferone on the β-chloro-7-deoxy-
sialic acid methyl ester (145) according to the procedure of Engstler et al. 
(Scheme 79).199 
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Scheme 79 Retrosynthetic strategy for the synthesis of 7-deoxy-2’-(4-methylumbelliferyl) 
α-D-sialic acid (127) via the C-7 xanthate methyl glycoside (147). 
 
The formation of β-chloro-7-deoxy-sialic acid methyl ester (148) could be 
accomplished by treatment of 7-deoxy-sialic acid methyl ester derivative (149) 
with hydrochloric acid gaseous. 
It was anticipated that following the approach of Miyazaki et al. the 7-deoxy-
sialic acid methyl ester (149) could be yielded via a Barton-McCombie 
deoxygenation of the C-7 xanthate (145), which itself could be synthesised 
from sialic acid (2).155 
 8.3.2 Synthesis of 7-deoxy-8,9-O-isopropylidene-sialic acid 
derivative (152) 
 
The previously synthesised 8,9-O-isopropylidene-sialic acid methyl ester 
methyl glycoside (144) (Chapter 8.2.2) was subjected to benzoyl chloride in 
pyridine according to the procedure of Miyazaki et al. to give 4-O-benzoyl-
8,9-O-isopropylidene-sialic acid derivative (150) in 71% yield (Scheme 80).155 
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 144        150         151 
 
Scheme 80 Synthesis of 7-O-thiocarbamate-sialic acid derivative (151). a) BzCl, pyridine, 
0 °C, 40 min., 71% (150); b) 1,1’-Thiocarbonyldiimidazole, CH2Cl2, 40 °C, 48 h, 87% (151).
155 
 
Subsequent treatment with 1,1’-thiocarbonyldiimidazole in dichloromethane 
afforded the 7-O-thiocarbamate-sialic acid derivative (151) in 87% yield. 
The 4-O-benzoyl-8,9-O-isopropylidene-7-O-thiocarbamate-sialic acid methyl 
ester methyl glycoside (151) was then subjected to the previously deployed 
Barton-McCombie protocol utilising tributyltin hydride in 1,4-dioxane to form 
7-deoxy-8,9-O-isopropylidene-sialic acid derivative (152) in 54% yield 
(Scheme 81). 
 
 
 
 
 
   151         152 
 
Scheme 81 Formation of 7-deoxy-8,9-O-isopropylidene-sialic acid methyl ester methyl 
glycoside (152). Luperox® 101, Bu3SnH, 1,4-dioxane, 100 °C, 4 h, 54%. 
 
 8.3.3 Attempted synthesis of 7-deoxy-sialic acid methyl ester 
(149) 
 
The 4-O-benzoyl-7-deoxy-8,9-O-isopropylidene-sialic acid methyl ester methyl 
glycoside (152) was then isopropylidene deprotected under acidic hydrolysis 
concurring with the procedure by Miyazaki et al. (Scheme 82).155 
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    152     153   154 
 
Scheme 82 Attempted Synthesis of 7-deoxy-sialic acid methyl ester (149). (i) 80% AcOH/H2O, 
60 °C, 2 h; (ii) 0.3 N NaOH:MeOH = 1:1; 40 °C, 2 h; (iii) 25 mM HCl, Dowex 50x8, H2O, 80 °C, 
2 h. 
 
Subsequent benzoyl deprotection with sodium hydroxide in methanol and 
hydrolysis of the methyl glycoside were attempted to give the 7-deoxy sialic 
acid derivative (149). However, after purification with a C18 reverse phase 
column an inseparable mixture of methyl glycoside (153) and a DANA-like 
derivative (154) was obtained. In conclusion the synthesis of 7-deoxy-2’-
(4-methylumbelliferyl) α-D-sialic acid (127) could not be accomplished and 
need to be resolved in future studies. 
 Future works 8.4
 
The synthesis of the monodeoxygenated natural substrates (126) - (129) has 
previously been attempted (Chapter 8), but could not be accomplished. 
 
 
 
 
 
121 R1, R2, R3, R4 = OH 
126 R1 = H, R2, R3, R4 = OH 
    127 R2 = H, R1, R3, R4 = OH 
    128 R3 = H, R1, R2, R4 = OH 
    129 R4 = H, R1, R2, R3 = OH 
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The measurement of Gibbs free energy of binding (∆∆G‡) for each 
monodeoxygenated natural substrate (126) - (129) needs to be highly 
accurate and the use of chromophoric tags, like 4-methylumbelliferone, to 
monitor enzyme kinetics is an established method. 
However, the greater intrinsic reactivity towards hydrolysis of 
4-methylumbelliferone compared to the natural substrates might mask the 
effects of individual hydroxyl group contribution towards transition-state 
stabilisation.202 The differences in reactivity for spectroscopic useful non-
natural substrates, compared to natural substrates on the example of 
p-nitrophenol has previously been addressed and was named ‘p-nitrophenol 
ester syndrome’.203 
An elegant study utilising Micromonospora viridifaciens mutant Y370G 
highlighted the differences in Michaelis-Menten kinetic parameters by 
comparing the rate of hydrolysis of 4-methylumbelliferyl 
α-D-N-acetylneuraminylgalactopyranoside (155) to MUNANA (121) and was 
performed by Indurugalla et al.202 Remarkably, the galactopyranoside (155) 
showed comparable rates of hydrolysis to the natural substrate 3’-sialyl 
lactose, but the chromophoric tag, 4-methylumbelliferone still could be used to 
monitor enzyme kinetics. 
 
 
 
 
     155 
A possible new strategy based on 4-methylumbelliferyl 
α-D-N-acetylneuraminylgalactopyranoside (155) would involve the syntheses 
of the monodeoxygenated sialoside analogues (156) - (159), which could be 
useful in the measurement of accurate Gibbs free energies of binding (∆∆G‡) 
for individual hydroxyl group contribution towards transition-state stabilisation. 
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156 R1 = H, R2, R3, R4 = OH 
157 R2 = H, R1, R3, R4 = OH 
158 R3 = H, R1, R2, R4 = OH 
159 R4 = H, R1, R2, R3 = OH 
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A number of approaches towards the syntheses of the four novel 
monodeoxygenated 2,3-difluorosialic acid inactivators (24) - (27) were 
investigated. 
For the synthesis of 4-deoxy-2,3-difluorosialic acid (24) a Barton-McCombie 
protocol using Luperox® 101 as a radical initiator and the radical carrier 
tributyltin hydride under reflux conditions in 1,4-dioxane was developed and 
proved to be applicable to the synthesis of the remaining monodeoxygenated 
2,3-difluorosialic acid derivatives (25) – (27). Following the formation of an 
α-/β-mixture of fluoride anomers in the fluorination of the hemiketal and 
ambiguous 19F NMR coupling constants, X-ray crystallographic conformation 
of the β-anomer was accomplished. 
The total synthesis from β-fluoropyruvic acid (41) to 4-deoxy-2,3-difluoro-sialic 
acid (24) was achieved in 11 steps, with an overall yield of 4%. 
Time-dependent inactivation kinetics performed on wild type influenza 
neuraminidase N9 G70C and 4-deoxy-2,3-difluorosialic acid (24) showed no 
time-dependent inactivation with a fast rate of glycosylation (k1) and a slow 
rate of deglycosylation (k2). 
Remarkably, IC50 measurements of 4-deoxy-2,3-difluorosialic acid (24) 
expressed tight-binding on FluB/Perth/wt. and mutant FluB/Perth/D197E with 
better inhibition than Oseltamivir (6), Zanamivir (15) and the parent compound 
2,3-difluorosialic acid (23). The Oseltamivir (6) resistant mutant 
Miss/H1N1/H274Y did not have any effect on the inhibition of 4-deoxy-
2,3-difluorosialic acid (24). 
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The X-ray crystal structure of influenza neuraminidase N9 in complex with 
4-deoxy-2,3-difluorosialic acid (24) confirmed a covalently linked sialosyl-
enzyme intermediate, supporting our proposed mechanism of influenza 
neuraminidase inactivation. An additional water molecule was identified, which 
could be an explanation for the behaviour of 4-deoxy-2,3-difluoro-sialic acid 
(24) in inactivation kinetics with better IC50 values than the parent inactivator 
2,3-difluoro-sialic acid (23). 
The total synthesis from β-fluoropyruvic acid (41) to 7-deoxy-2,3-difluorosialic 
acid (25) deploying the previously developed Barton-McCombie protocol on 
4-deoxy-2,3-difluorosialic acid (24) was achieved in 13 steps, with an overall 
yield of 4.5%. 
Time-dependent inactivation kinetics performed on wild type influenza 
neuraminidase N9 G70C and 7-deoxy-2,3-difluorosialic acid (25) showed no 
time-dependent inactivation with a fast rate of glycosylation (k1) but no 
deglycosylation (k2). IC50 measurements performed on a panel of influenza 
neuraminidases showed tight-binding and encouraging IC50 values across the 
panel, making position C-7 interesting for future drug discovery efforts. A study 
currently performed at Prof Stephen Withers laboratory is based on these 
findings of the 7-deoxy-2,3-difluorosialic acid (25) and investigates effects of 
O-alkylation at position C-7 of 2,3-difluorosialic acid with regards to 
inactivation and possible alternative breakdown mechanisms. 
The X-ray crystal structure of influenza neuraminidase N9 in complex with 
7-deoxy-2,3-difluorosialic acid (25) used soaking and co-crystallisation 
methods and gave an insight into the inactivation mechanism of the novel 
class of mechanism-based inactivators on a physical basis. 
In brief, the total synthesis from β-fluoropyruvic acid (41) to 8-deoxy-
2,3-difluorosialic acid (26) deploying the previously developed Barton-
McCombie protocol on 4-deoxy-2,3-difluorosialic acid (24) was achieved in 
12 steps, with an overall yield of 2%. 
Time-dependent inactivation kinetics performed on wild type influenza 
neuraminidase N9 G70C and 8-deoxy-2,3-difluorosialic acid (26) showed time-
dependent inactivation with a slow rate of glycosylation (k1) and 
deglycosylation (k2). 
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IC50 measurements showed poor inactivation against a panel of influenza 
neuraminidases, indicating a major contribution of the OH-8 group towards 
transition-state stabilisation. 
The X-ray crystal structure of influenza neuraminidase N9 in complex with 
8-deoxy-2,3-difluorosialic acid (26) confirmed a covalently linked sialosyl-
enzyme intermediate and showed a rotation of the residues Glu276 and 
Glu277 with an additional water molecule, which could be an explanation for 
the poor performance of 8-deoxy-2,3-difluorosialic acid (26) in inactivation 
kinetics. 
Finally, the total synthesis from β-fluoropyruvic acid (41) to 9-deoxy-
2,3-difluorosialic acid (27) deploying the previously developed Barton-
McCombie protocol on 4-deoxy-2,3-difluorosialic acid (24) was achieved in 
14 steps, with an overall yield of 9%. 
Time-dependent inactivation kinetics performed on wild type influenza 
neuraminidase N9 G70C and 9-deoxy-2,3-difluorosialic acid (27) showed time-
dependent inactivation with a slow rate of glycosylation (k1) and a calculated Ki 
= 12.1 + 1.96 µM. The poor IC50 values might be an expression of the large 
dependency of inactivation on non-covalent interactions of the OH-9 group in 
the active-site of influenza neuraminidase. 
The X-ray crystal structure of influenza neuraminidase N9 in complex with 
9-deoxy-2,3-difluorosialic acid (27) showed a rotation of the amino acid 
residues Glu276 and Glu277 as previously deployed on the crystal structure of 
influenza neuraminidase N9 in complex with 8-deoxy-2,3-difluorosialic 
acid (26). 
A principle inactivation mechanism of 2,3-difluorosialic acids on influenza 
neuraminidase has been proposed. However, uncertainties about the 
presence or formation of the second DANA like ligand in the active site of 
influenza neuraminidase need to be resolved. 
Quite alarming is that none of the novel monodeoxygenated 2,3-difluorosialic 
acid inactivators (24) - (27) and Oseltamivir (6) and Zanamivir (15) retained 
activity across the panel of influenza strains tested, which could be seen as 
the crux of anti-viral drugs.188 
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 General 10.1
 
Chemical reagents were purchased from Sigma-Aldrich unless otherwise 
stated. Neu5Ac aldolase 9.2 U/mg EC 4.1.3.3 was purchased from 
Codexis®. Anhydrous dichloromethane and tetrahydrofuran were obtained 
by distillation over calcium hydride or sodium/benzophenone, respectively. 
All anhydrous solvents were used where indicated and were purchased from 
Sigma-Aldrich. All other solvents were purchased from Fisher Scientific and 
used without further purification. 
Glassware for dry reactions was dried by heating in an oven at 120 ºC for at 
least 1h and heating with a hot air gun for 5 minutes. The glassware was 
then allowed to cool under a stream of N2. 
Analytical thin layer chromatography (TLC) was carried out on Merck 
aluminium backed TLC plates silica gel 60 F254 (0.25 mm thickness), viewed 
using UV light of wavelength 254 nm and then stained with ethanolic sulfuric 
acid. Reverse phase analytical TLC was performed with RP-18 F254, pre-
coated on aluminium sheets (0.27 mm thickness) purchased from Merck. 
Column chromatography was performed on silica gel 60 (35-70 micron) from 
Fisher Scientific. Compounds were loaded as an oil, appropriate organic 
solvent (mentioned) or dry loaded by adsorption onto silica.
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Standard work up is referring to diluting the reaction residue in appropriate 
organic solvent (mentioned), washing with an aqueous saturated sodium 
bicarbonate solution, followed by washing with brine. The organic phases 
were then combined and dried over anhydrous magnesium sulfate, filtered 
and the filtrate concentrated in vacuo. 
For slow addition a Razel Scientific Instruments INC. syringe pump was 
used. 
Melting points were obtained using a Reichert-Jung heated-stage 
microscope and are uncorrected. Specific rotations were determined on an 
Optical Activity Ltd.: AA-10 automatic polarimeter. 
 1H, 13C and 19F NMR were recorded using a Jeol Delta (270 MHz), Varian 
Mercury VX (400 MHz) or Bruker Avance III (400 and 500 MHz) 
spectrometers, with acquisition frequencies of 270, 400 or 500 for 1H: 100 or 
125 for 13C and 376 or 470 for 19F. The chemical shifts δ are recorded in 
parts per million (ppm) with reference to tetramethylsilane. The multiplicities 
are assigned as a singlet (s), doublet (d), triplet (t), quartet (q), doublet of 
doublets (dd), doublet of doublet of doublets (ddd), doublet of triplets (dt), 
triplet of doublets (td), broad (br) and multiplet (m). 
High resolution mass spectrometry was performed using a Bruker 
MicrOTOFTM electrospray ionisation mass spectrometer. X-ray 
crystallography was performed by Dr. Mary Mahon (Department of 
Chemistry, University of Bath). Single crystals were analysed at 150(2) K 
using graphite monochromated Mo(Kα) radiation and a Nonius Kappa CCD 
diffractometer. The structures were solved using SHELXS-97 and refined 
using SHELXL-97. 
The kinetic measurements were performed on a BMG LABTECH 
FLUORStar Omega, Software Omega 1.30, double injector with a residual 
volume of 500 µL, the filters set to 355 nm excitation and 460 nm emission 
and a gain of 750. Black 96 well plates Greiner Bio-one were used at a 
temperature of 37 °C. The residual activity was measured over 30 minutes 
and the gradient calculated over the range of 8 to 28 minutes using Omega 
MARS BMG LABTECH software 2.10 R3. Fitting the residual activity to a 
single exponential equation with or without offset and the Lineweaver-Burk 
plot was generated using GraFit 5.0.13. 
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2    30 
 
Methyl 7,8,9-tri-O-acetyl-2,3-didehydro-2,3,5-trideoxy-4’,5’-dihydro-
2’-methyloxazolo[5,4d]-D-glycero-D-talo-non-2-ulopyranosonate (30) 
 
a) Trifluoroacetic acid (1.5 mL, 20 mmol) was added drop-wise to a stirred 
solution of sialic acid (2) (1.5 g, 4.9 mmol) in anhydrous methanol (50 mL) at 
room temperature and was stirred at this temperature overnight. The solution 
was then concentrated in vacuo, redissolved in methanol and concentrated 
in vacuo to give a white solid. 
b) Acetic anhydride (6.9 mL, 73 mmol) was added drop-wise to the crude 
mixture in anhydrous pyridine (25 mL) at 4 ºC and the solution was then left 
to warm to room temperature and was stirred for 3 days. The solution was 
then concentrated in vacuo and residual pyridine was removed by azeotropic 
evaporation with toluene to give a yellow oil. The oil was subjected to a 
standard work up (CH2Cl2), filtered over a silica plug (EtOAc) and the filtrate 
concentrated in vacuo. 
c) Trimethylsilyl trifluoromethanesulfonate (1.5 mL, 8 mmol) was added drop-
wise under vigorous stirring to the crude mixture in anhydrous acetonitrile (45 
mL) at room temperature and was then heated to 50 ºC overnight. The 
solution was then cooled to 4 ºC and potassium carbonate (2.2 g, 15.9 
mmol) was added and stirred for 5 minutes. The mixture was filtered over 
Celite® and the filtrate was concentrated in vacuo. The crude mixture was 
then purified by silica column chromatography (EtOAc:Petroleum Ether 
90:10) affording (30) as an off-white solid (1.53 g, 76% over 3 steps). 
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m.p. 90 - 94 °C (lit. m.p. 92.1 °C). Rf (EtOAc:MeOH 90:10, 0.7). 
1H NMR 
(400 MHz, CDCl3) δ 2.01, 2.05, 2.06 (3s, 9H, C(O)CH3); 2.15 (s, 3H, CCH3); 
3.43 (dd, 1H, J5,6 = 9.8, J6,7 = 2.7 Hz, H-6); 3.81 (s, 3H, OCH3); 3.95 (dd, 1H, 
J5,6 = 9.8, J4,5 = 8.5 Hz, H-5); 4.23 (dd, 1H, J9,9’ = 12.5, J8,9 = 6.3 Hz, H-9); 
4.60 (dd, 1H, J9,9’ = 12.5, J8,9’ = 2.7 Hz, H-9’); 4.82 (dd, 1H, J4,5 = 8.5, J3,4 = 
4.0 Hz, H-4); 5.44 (ddd, 1H, J7,8 = J8,9 = 6.3, J8,9’ = 2.7 Hz, H-8); 5.63 (dd, 1H, 
J7,8 = 6.3, J6,7 = 2.7 Hz, H-7); 6.38 (d, 1H, J3,4 = 4.0 Hz, H-3). 
13C NMR (100 
MHz, CDCl3) δ 14.18 (CCH3); 20.65, 20.81, 20.88 (C(O)CH3); 52.57 (OCH3); 
62.02 (C-9); 62.10 (C-5); 68.89 (C-7); 70.32 (C-8); 72.27 (C-4); 76.78 (C-6); 
107.59 (C-3); 147.19 (C-2); 161.90 (C-1); 167.20 (CCH3); 169.60, 169.83, 
170.68 (C(O)CH3). HRMS (ESI +ve) m/z 414.1384 [M+H]
+ (C18H24N1O10 
requires 414.1400). Melting point204 and spectroscopic data are analogous to 
those reported in the literature.145 
 
 
 
 
       40        41  42+43+44 
 
 
 
        45 
 
Methyl 5-N-acetyl-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-fluoro-
D-erythro-α-L-manno-non-2ulopyranosonate (45) 
 
a) A solution of β-fluoropyruvic acid (41) (3 g, 23.4 mmol), 2-N-acetyl-
D-mannosamine (40) (10 g, 45.2 mmol) and Neu5Ac aldolase (200 mg, 
9.2 U/mg) in water (200 mL) was left to stand at room temperature for 
5 days. The reaction was monitored by the disappearing 19F NMR signal 
corresponding to β-fluoropyruvic acid (41) at δ -229.1 ppm and the appearing 
signals corresponding to formation of axial 3-fluorosialic acid (42) at 
δ -208.1 ppm together with its epimer (44) at -217.7 ppm and the equatorial 
3-fluorosialic acid (43) at -199.2 ppm. 
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After 3 days the mixture was filtered through a Sartorius Stedim Minisart® 
1.2 µm to remove degraded enzyme. Further Neu5Ac aldolase (45 mg) was 
added and left to stand at room temperature for 2 days. The reaction mixture 
was then purified by ion-exchange chromatography (Dowex 1x2 200 ion 
exchange resin, conditioned with 6 M formic acid/H2O) eluting with 0 → 1 M 
formic acid/H2O. The eluate was concentrated in vacuo and the residue was 
lyophilised to give the 3-fluorosialic acids (42), (43) and (44) as a white solid 
which were used without further purification. 
b) Trifluoroacetic acid (7 ml, 91.4 mmol) was added to a stirred solution of 
the 3-fluorosialic acids (42), (43) and (44) in anhydrous methanol (350 mL) 
and left at room temperature overnight. The mixture was then concentrated 
in vacuo three times with methanol affording 3-fluorosialic acid methyl ester 
as a white solid which was used without further purification. 
c) Acetic anhydride (6.19 ml, 66 mmol) was added to a stirred solution of the 
crude methyl ester (1.5 g, 4.4 mmol) and catalytic amounts of 
4-(dimethylamino)pyridine in pyridine (50 mL) at 4 °C and the solution was 
left to stir at room temperature for 17 hours. The solution was concentrated 
in vacuo, residual pyridine was removed by azeotropic evaporation with 
toluene and the residue was then subjected to a standard work up (EtOAc) 
and purified by silica chromatography (EtOAc) to give (45) as a white solid 
(1.809 g, 72% starting from β-fluoropyruvic acid (41)). 
m.p. 192 - 194 °C (lit. m.p. 193 °C). Rf (EtOAc, 0.6). 
1H NMR (400 MHz, 
CDCl3) δ 1.91 (s, 3H, NHC(O)CH3); 2.03, 2.10, 2.16, 2.17 (4s, 12H, 
C(O)CCH3); 3.83 (s, 3H, OCH3); 4.08 – 4.25 (m, 3H, H-5, H-6, H-9); 4.55 (dd, 
1H, J9,9’ = 12.4, J8,9’ = 2.5 Hz, H-9’); 4.92 (dd, 1H, J3,F3 = 49.0, J3,4 = 2.5 Hz, 
H-3); 5.09 – 5.13 (m, 1H, H-8); 5.32 – 5.3 (m, 1H, H-7); 5.54 (ddd, 1H, J4,F3 = 
28.1, J4,5 = 11.0, J3,4 = 2.5 Hz, H-4). HRMS (ESI +ve) m/z 552.1714 [M+H]
+ 
(C22H31F1N1O14 requires 552.1729). Melting point and spectroscopic data are 
analogous to those reported in the literature.141 
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         48 
 
Methyl 5-N-acetyl-3,5-dideoxy-3-fluoro-8,9-O-isopropylidene-D-erythro-
α-L-manno-non-2-ulopyranosonate (48) 
 
a) In analogy to method a) for compound (45). 
b) In analogy to method b) for compound (45). 
c) A solution of 3-fluorosialic acid methyl ester, p-toluenesulfonic acid 
(156 mg, 0.82 mmol) and 2,2’-dimethoxypropane (14.4 mL, 117 mmol) in 
acetone (250 mL) was stirred at room temperature overnight. Triethylamine 
(555 µL, 3.99 mmol) was then added and the crude mixture was 
concentrated in vacuo and purified by silica column chromatography 
(EtOAc:MeOH 99:1 → 90:10) to give (48) as a white solid (6.3 g, 71% 
starting from β-fluoropyruvic acid (41)). 
= - 3° (c = 1, MeOH). m.p. 121 - 125 °C. Rf (EtOAc:MeOH 85:15, 0.5). 
1H NMR (400 MHz, CD3OD) δ 1.31 (s, 3H, CCH3); 1.37 (s, 3H, CCH3); 1.99 
(s, 3H, NHC(O)CH3); 3.52 (d, 1H, J7,8 = 7.4 Hz, H-7); 3.82 (s, 3H, OCH3); 
3.97 – 4.25 (m, 6H, H-4, H-5, H-6, H-8, H-9, H-9’); 4.81 (dd, 1H, J3,F3 = 49.3, 
J3,4 = 2.7 Hz, H-3). 
13C NMR (100 MHz, CD3OD) δ 22.69 (NHC(O)CH3); 
25.69 (CCH3); 27.20 (CCH3); 49.28 (d, J5,F3 = 2.3 Hz, C-5); 53.32 (OCH3); 
67.99 (C-6); 68.95 (d, J4,F3 = 18.4 Hz, C-4); 71.14 (C-7); 72.3 (C-8); 76.47 (C-
9); 91.33 (d, J3,F3 =178.7 Hz, C-3); 95.97 (d, J2,F3 = 26.8 Hz, C-2); 110.2 
(CCH3); 161.90 (C-1); 170.41 (C-1); 174.65 (NHC(O)CH3). 
19F NMR (376 
MHz, CD3OD) – 209.4 (dd, JF3,H3 = 50.4, JF3,H4 = 28.9 Hz, F-3). HRMS (ESI 
+ve) m/z 382.1521 [M+H]+ (C15H25F1N1O9 requires 382.1513). 
 
 
 
 
[a] D
24
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49 
 
Methyl 5-N-acetyl-3,5-dideoxy-3-fluoro-8,9-O-isopropylidene-
4-O-(phenoxy)thiocarbonyl-D-erythro-α-L-manno-non-2-
ulopyranosonate (49) 
 
Phenyl chlorothionoformate (0.76 mL, 5.6 mmol) was added drop-wise to a 
stirred solution of 3-fluoro-8,9-O-isopropylidenesialic acid methyl ester (48) 
(1.95 g, 5.1 mmol) in a mixture of anhydrous dichloromethane (70 mL) and 
anhydrous pyridine (23 mL) at – 40 ºC and was brought to room temperature 
over 1 hour. The mixture was left to stir at this temperature for further 3 
hours. Methanol (1 mL) was added and after 10 minutes, the crude mixture 
was concentrated in vacuo, subjected to a standard work up (CH2Cl2) and 
purified by silica column chromatography (EtOAc:MeOH 99:1) to give (49) as 
an off-white solid (2.07 g, 76%). 
= - 8° (c = 1, CH2Cl2). m.p. 155 - 157 °C. Rf (EtOAc:MeOH 85:15, 
0.5). 1H NMR (400 MHz, CDCl3) δ 1.33 (s, 3H, CCH3); 1.38 (s, 3H, CCH3); 
2.02 (s, 3H, NHC(O)CH3); 3.48 (m, 1H, H-7); 3.82 (s, 3H, OCH3); 3.99 (d, 
1H, J5,6 = 10.6 Hz, H-6); 4.06 (m, 2H, H-9, H-9’); 4.24 (m, 2H, H-8, OH); 4.63 
(ddd, 1H, J4,5 = 11.2, J5,6 = 10.6, J5,NH = 8.1 Hz, H-5); 5.02 (dd, 1H, J3,F3 = 
50.3, J3,4 = 2.1 Hz, H-3); 6.04 (dd, 1H, J4,F3 = 25.5, J4,5 = 11.2 Hz, H-4); 6.11 
(d, 1H, J5,NH = 8.1 Hz, NHC(O)CH3); 7.07 (d, 2H, JHb,Hc = 7.6 Hz, Hb-
PhOC(S)O); 7.32 (t, 1H, JHc,Hd = 7.6 Hz, Hd-PhOC(S)O); 7.44 (t, 2H, JHb,Hc = 
JHc,Hd = 7.6 Hz, Hc-PhOC(S)O). 
13C NMR (100 MHz, CDCl3) δ 23.40 
(NHC(O)CH3); 25.52 (CCH3); 27.35 (CCH3); 47.78 (OCH3); 53.80 (C-5); 
67.70 (C-9); 69.88 (C-7); 72.24 (C-6); 74.42 (C-8); 78.74 (d, J4,F3 = 17.0 Hz, 
C-4); 86.20 (d, J3,F3 =189.2 Hz, C-3); 94.38 (d, J2,F3 = 24.4 Hz, C-2); 109.53 
(CCH3); 121.68 (2Cc-PhOC(S)O); 127.30 (Cd-PhOC(S)O); 129.98 (2Cb-
PhOC(S)O); 153.53 (Ca-PhOC(S)O); 168.18 (C-1); 172.58 (NHC(O)CH3); 
196.53 (PhOC(S)O). 
[a] D
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S
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19F NMR (376 MHz, CD3OD) – 208.36 (dd, JF3,H3 = 50.4, JF3,H4 = 27.5 Hz, 
F-3). HRMS (ESI +ve) m/z 540.1327 [M+Na]+ (C22H28F1N1O10S1Na1 requires 
540.1316). 
 
 
 
 
  50 
 
Methyl 5-N-acetyl-3,4,5-trideoxy-3-fluoro-8,9-O-isopropylidene-
D-erythro-α-L-manno-non-2-ulopyranosonate (50) 
 
3-Fluoro-8,9-O-isopropylidene-4-O-(phenoxy)thiocarbonyl sialic acid methyl 
ester (49) (265 mg, 0.51 mmol) was dissolved in anhydrous 1,4-dioxane 
(6 mL) concentrated in vacuo, ventilated under argon atmosphere, 
redissolved in 1,4-dioxane (12 mL) and molecular sieves (pellets, 4 Å) was 
added. The solution was then degassed and heated to 100 °C. A solution of 
1,4-dioxane (6 mL), tributyltin hydride (0.51 mL, 1.89 mmol) and 
50% 2,2-bis(tert-butylperoxy)-butane with molecular sieves was mixed in a 
flame-dried round-bottom flask and the mixture was then added drop-wise to 
the heated solution in 3 aliquots over 2 hours and left to stir at this 
temperature for further 2 hours. The crude mixture was then cooled, filtered, 
the filtrate concentrated in vacuo and purified by silica column 
chromatography (EtOAc:MeOH 90:10) to give (50) as a white solid (152 mg, 
81%). 
= - 4° (c = 1, CH2Cl2). m.p. 165 - 168 °C. Rf (EtOAc:MeOH 90:10, 
0.3). 1H NMR (400 MHz, CDCl3) δ 1.32 (s, 3H, CCH3); 1.37 (s, 3H, CCH3); 
2.02 (s, 3H, NHC(O)CH3); 2.14 (dddd, 1H, J4ax,F3 = 26.1, J4ax,4eq = 14.7, 
J4ax,5 = 9.7, J3,4ax = 2.2 Hz, H-4ax); 2.29 (m, 1H, H-4eq); 3.48 (m, 2H, H-7, 
OH); 3.83 (s, 3H, OCH3); 3.87 (d, 1H, J5,6 = 10.8 Hz, H-6); 4.11 (m, 3H, H-9, 
H-9’, OH); 4.25 (m, 1H, H-8); 4.36 (m, 1H, H-5); 4.76 (ddd, 1H, J3,F3 = 47.3, 
J3,4ax = J3,4eq = 2.2 Hz, H-3); 5.36 (d, 1H, J5,NH = 8.4 Hz, NHC(O)CH3). 
 
 
[a] D
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13C NMR (100 MHz, CDCl3) δ 23.42 (NHC(O)CH3); 25.61 (CCH3); 27.31 
(CCH3); 31.08 (d, J4,F3 = 21.0 Hz, C-4); 40.9 (C-5); 53.55 (OCH3); 66.06 (C-
9); 67.61 (C-7); 70.07 (C-6); 74.54 (C-8); 86.78 (d, J3,F3 =179.3 Hz, C-3); 
93.23 (d, J2,F3 = 26.1 Hz, C-2); 109.29 (CCH3); 169.50 (C-1); 171.86 
(NHC(O)CH3). 
19F NMR (376 MHz, CD3OD) – 193.30 (ddd, JF3,H3 = 44.5, JF3,H4ax = 27.6, 
JF3,H4eq = 10.4 Hz, F-3). HRMS (ESI +ve) m/z 366.1557 [M+H]
+ 
(C15H25F1N1O8 requires 366.1564). 
 
 
 
 
       52 
 
Methyl 5-N-acetyl-2,7,8,9-tetra-O-acetyl-3,4,5-trideoxy-3-fluoro-
D-erythro-α-L-manno-non-2-ulopyranosonate (52) 
 
a) A solution of 4-deoxy-3-fluoro-8,9-O-isopropylidenesialic acid methyl ester 
(50) (0.6 g, 1.7 mmol) in 80% acetic acid/H2O (40 mL) was stirred at 60 °C 
for 2 hours. The crude mixture was then concentrated in vacuo and residual 
acetic acid was removed by azeotropic evaporation with toluene to give a 
white solid. 
b) Acetic anhydride (7 mL, 75 mmol) was added to a solution of the crude 
mixture and catalytic amounts of 4-(dimethylamino)pyridine at 4 °C and the 
solution were left to stir at room temperature overnight. The solution was 
concentrated in vacuo and residual pyridine was removed by azeotropic 
evaporation with toluene. The crude was then subjected to a standard work 
up (EtOAc) and purified by silica chromatography (EtOAc) to give (52) as a 
white solid (643 mg, 76%). 
= - 4° (c = 1, CH2Cl2). m.p. 212 - 215 °C. Rf (EtOAc:MeOH 90:10, 
0.5). 
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1H NMR (400 MHz, CDCl3) δ 1.94 (s, 3H, NHC(O)CH3); 2.03, 2.04, 2.14, 
2.16 (4s, 12H, C(O)CCH3); 2.27 – 2.35 (m, 1H, H-4eq); 2.46 (dddd, 1H, J4ax,F3 
= 25.6, J4ax,4eq = 14.6, J4ax,5 = 10.2, J3,4ax= 2.1 Hz, H-4ax); 3.82 (s, 3H, OCH3); 
3.90 – 4.01 (m, 1H, H-5); 4.19 – 4.23 (m, 1H, H-6, H-9); 4.58 (dd, 1H, J9,9’ = 
12.5, J8,9’ = 2.1 Hz, H-9’); 4.81 (ddd, 1H, J3,F3 = 46.5, J3,4ax = J3,4eq = 2.1 Hz, 
H-3); 5.12 (ddd, 1H, J7,8 = 7.4, J8,9 = 5.1, J8,9’ = 2.1 Hz, H-8); 5.34 (dd, 1H, 
J7,8 = 7.4, J6,7 = 2.3 Hz, H-7); 5.39 (d, 1H, J5,NH = 7.4 Hz, NHC(O)CH3). 
13C 
NMR (100 MHz, CDCl3) δ 20.57, 20.78, 20.85, 20.94 (C(O)CH3); 23.60 
(NHC(O)CH3); 30.44 (d, J4,F3 = 20.7 Hz, C-4); 40.77 (C-5); 53.31 (OCH3); 
66.22 (C-9); 68.39 (C-7); 71.41 (C-8); 72.23 (C-6); 87.31 (d, J3,F3 =177.8 Hz, 
C-3); 94.20 (d, J2,F3 = 30.6 Hz, C-2); 166.12 (C-1); 167.31 (NHC(O)CH3); 
169.98, 170.34, 170.59, 170.87 (C(O)CH3). 
19F NMR (376 MHz, 
CDCl3) - 194.27 (ddd, JF3,H3 = 44.3, JF3,H4ax =26.5, JF3,H4eq = 11.6 Hz, F-3). 
HRMS (ESI +ve) m/z 494.1679 [M+H]+ (C20H29F1N1O12 requires 494.1674). 
 
 
 
 
          53 
 
Methyl 5-N-acetyl-7,8,9-tri-O-acetyl-3,4,5-trideoxy-3-fluoro-D-erythro-α-
L-manno-non-2-ulopyranosonate (53) 
 
A solution of hydrazine acetate (99 mg, 1.1 mmol) in anhydrous methanol (2 
mL) was cooled to 4 °C and added to a stirred solution of per-O-acetyl-
4-deoxy-3-fluorosialic acid methyl ester (52) (132 mg, 0.3 mmol) in 
anhydrous dichloromethane (4 mL) at 4 °C and left at this temperature 
overnight. The mixture was then diluted with dichloromethane (10 mL), 
subjected to a standard work up and purified by silica column 
chromatography (EtOAc → EtOAc:MeOH 90:10) affording (53) as a white 
solid (62 mg, 51%). 
= + 4° (c = 1, CH2Cl2). m.p. 189 - 193 °C. Rf (EtOAc:MeOH 90:10, 
0.5). 
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1H NMR (400 MHz, CDCl3) δ 1.93 (s, 3H, NHC(O)CH3); 2.04, 2.05, 2.14 (3s, 
9H, C(O)CCH3); 2.19 – 2.30 (m, 1H, H-4eq); 2.34 – 2.41 (m, 1H, H-4ax); 3.86 
(s, 3H, OCH3); 4.15 (dd, 1H, J9,9’ = 12.5, J8,9 = 6.3 Hz, H-9); 4.19 – 4.25 (m, 
1H, H-5); 4.25 – 4.29 (m, 2H, H-6, OH-2); 4.52 (dd, 1H, J9,9’ = 12.5, J8,9’ = 2.7 
Hz, H-9’); 4.97 (ddd, 1H, J3,F3 = 45.8, J3,4ax = J3,4eq = 2.3 Hz, H-3); 5.29 – 5.31 
(m, 1H, H-8); 5.34 (dd, 1H, J7,8 = 8.2, J6,7 = 2.1 Hz, H-7); 5.37 (d, 1H, J5,NH = 
9.3 Hz, NHC(O)CH3). 
13C NMR (100 MHz, CDCl3) δ 20.85, 20.87, 21.10 
(C(O)CH3); 23.45 (NHC(O)CH3); 31.25 (d, J4,F3 = 20.6 Hz, C-4); 40.25 (C-5); 
53.31 (OCH3); 63.20 (C-9); 68.35 (C-7); 71.60 (C-6); 71.96 (C-8); 87.02 (d, 
J3,F3 =177.7 Hz, C-3); 93.34 (d, J2,F3 = 26.5 Hz, C-2); 168.58 (C-1); 169.72 
(NHC(O)CH3); 170.64, 171.10, 171.19 (C(O)CH3). 
19F NMR (376 MHz, 
CDCl3) – 194.28 (ddd, JF3,H3 = 43.2, JF3,H4ax = 26.3, JF3,H4eq = 11.7 Hz, F-3). 
HRMS (ESI +ve) m/z 452.1564 [M+H]+ (C18H27F1N1O11 requires 452.1568). 
 
 
 
      56     57 
 
Methyl 5-N-acetyl-7,8,9-tri-O-acetyl-2,3,4,5-tetradeoxy-2,3-difluoro-D-
erythro-β-L-manno-non-2-ulopyranosonate (56) and Methyl 5-N-acetyl-
7,8,9-tri-O-acetyl-2,3,4,5-tetradeoxy-2,3-difluoro-D-erythro-α-L-manno-
non-2-ulopyranosonate (57) 
 
(Diethylamino)sulfur trifluoride (89 µL, 0.68 mmol) was added drop-wise to a 
stirred solution of hemiketal (53) (205 mg, 0.45 mmol) in anhydrous 
dichloromethane (15 mL) at – 40 °C and the temperature was increased 
to -10 °C within 1 hour. The reaction was then quenched by the addition of 
methanol (0.1 mL) and saturated NaHCO3 solution (0.1 mL), subjected to a 
standard work up (CH2Cl2) and purified by silica column chromatography 
(EtOAc:MeOH 99:1 → EtOAc/MeOH 95:5) to give (56) and (57). 
Data for (56): white solid (92 mg, 45%).  
= - 1° (c = 1, CH2Cl2). m.p. 63 - 65 °C. Rf (EtOAc:MeOH 90:10, 0.4). 
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1H NMR (400 MHz, CDCl3) δ 1.96 (s, 3H, NHC(O)CH3); 2.03, 2.09, 2.14 (3s, 
9H, C(O)CCH3); 2.33 – 2.42 (m, 2H, H-4ax, H-4eq); 3.86 (s, 3H, OCH3); 3.93 
(ddd, 1H, J5,NH = J4ax,5 = 8.2, J4eq,5 = 2.5 Hz, H-5); 4.19 (dd, 1H, J9,9’ = 12.9, 
J8,9 = 5.5 Hz, H-9); 4.34 – 4.37 (m, 2H, H-6, H-9’); 5.09 (dddd, 1H, 
J3,F3 = 47.7, J3,4eq = 5.2, J3,4ax = J3,F2 = 2.1 Hz H-3); 5.29 (m, 1H, H-7); 5.41 
(ddd, 1H, J7,8 = 7.4, J8,9 = 5.5, J8,9’ = 2.3 Hz, H-8); 5.69 (d, 1H, J5,NH = 8.2 Hz, 
NHC(O)CH3). 
13C NMR (100 MHz, CDCl3) δ 20.70, 20.72, 20.89 (C(O)CH3); 
23.50 (NHC(O)CH3); 29.83 (dd, J4,F3 = 21.0, J4,F2 = 3.1 Hz, C-4); 41.86 (d, 
J5,F3 = 5.4 Hz, C-5); 53.48 (OCH3); 61.82 (C-9); 67.85 (C-7); 69.29 (C-8); 
74.11 (d, J6,F3 = 2.3 Hz, C-6); 83.61 (dd, J3,F3 =187.1, J3,F2 = 21.5 Hz, C-3); 
104.99 (dd, J2,F2 = 230.1, J2,F3 = 19.2 Hz, C-2); 164.89 (d, J1,F2 = 30.5 Hz, 
C-1); 169.89 (NHC(O)CH3); 170.17, 170.55, 170.63 (C(O)CH3). 
19F NMR 
(376 MHz, CDCl3) – 125.58 (dd, 1F, JF2,F3 = 12.1, JF2,H3 = 2.1 Hz, 
F-2); - 201.72 (dddd, 1F, JF3,H3 = 48.1, JF3,H4ax = 27.5, JF2,F3 = JF3,H4eq = 12.1 
Hz, F-3). HRMS (ESI +ve) m/z 454.1506 [M+H]+ (C18H26F2N1O10 requires 
454.1525). 
Data for (57): white solid (62 mg, 30%). 
= + 2° (c = 1, CH2Cl2). m.p. 143 - 146 °C. Rf (EtOAc:MeOH 90:10, 
0.5). 1H NMR (400 MHz, CDCl3) δ 1.94 (s, 3H, NHC(O)CH3); 2.04, 2.08, 2.15 
(3s, 9H, C(O)CCH3); 2.18 – 2.27 (m, 1H, H-4eq); 2.30 (ddd, 1H, J4ax,F3 = 25.3, 
J4ax,4eq = 14.7, J3,4ax = 2.1 Hz, H-4ax); 3.86 (s, 3H, OCH3); 4.10 (dd, 1H, 
J9,9’ = 12.4, J8,9 = 6.9 Hz, H-9); 4.11 – 4.19 (m, 1H, H-5); 4.28 (dd, 1H, 
J5,6 = 10.6, J6,7 = 2.1 Hz, H-6); 4.75 (dd, 1H, J9,9’ = 12.4, J8,9’ = 2.1 Hz, H-9’); 
4.78 (dddd, 1H, J3,F3 = 47.1, J3,4eq = 5.2, J3,F2 = J3,4ax = 2.1 Hz, H-3); 5.28 
(ddd, 1H, J8,9 = J7,8 = 6.9, J8,9’ = 2.1 Hz, H-8); 5.41 (d, 1H, J7,8 = 6.9, J6,7 = 2.1 
Hz, H-7); 5.49 (d, 1H, J5,NH = 9.0 Hz, NHC(O)CH3). 
13C NMR (100 MHz, 
CDCl3) δ 20.74, 20.75, 20.78 (C(O)CH3); 23.39 (NHC(O)CH3); 30.81 (d, J4,F3 
= 21.5 Hz, C-4); 39.44 (C-5); 53.46 (OCH3); 62.27 (C-9); 67.43 (C-7); 70.35 
(C-8); 73.39 (d, J6,F3 = 3.1 Hz, C-6); 84.87 (dd, J3,F3 =177.1, J3,F2 = 45.2 Hz, 
C-3); 104.01 (dd, J2,F2 = 227.7, J2,F3 = 29.9 Hz, C-2); 163.67 (d, J1,F2 = 26.8 
Hz, C-1); 169.81 (NHC(O)CH3); 169.97, 170.43, 170.58 (C(O)CH3). 
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19F NMR (376 MHz, CDCl3) – 121.54 (dd, 1F, JF2,F3 = 10.7, JF2,H3 = 2.1 Hz, 
F-2); - 193.11 (dddd, 1F, JF3,H3 = 45.8, JF3,H4ax = 26.5, JF3,H4eq = 12.2, 
JF2,F3 =10.7 Hz, F-3). HRMS (ESI +ve) m/z 454.1506 [M+H]
+ (C18H26F2N1O10 
requires 454.1525). 
 
 
 
         24 
 
5-N-Acetyl-2,3,4,5-tetradeoxy-2,3-difluoro-D-erythro-β-L-manno-non-2-
ulopyranosonic acid (24) 
 
a) Sodium (8 mg, 0.35 mmol) was added to a stirred solution of per-O-acetyl-
4-deoxy-2,3-difluorosialic acid methyl ester (56) (80 mg, 0.18 mmol) in 
anhydrous methanol (5 mL) at room temperature and was left to stir for 
3 hours. The solution was then neutralised through addition of Dowex 50 
Wx8 100 ion exchange resin, H+ form, filtered, and the filtrate concentrated in 
vacuo. 
b) A 0.5M aqueous NaOH solution (0.2 mL) was added to a stirred solution 
of the residue redissolved in water (1 mL) at room temperature and left to stir 
for 30 minutes. The solution was then neutralised through addition of Dowex 
50 Wx8 100 ion exchange resin, H+ form, filtered, the filtrate concentrated in 
vacuo and purified by silica column chromatography (EtOAc:MeOH 1:1) 
affording (24) as a white solid (29 mg, 52% over 2 steps). 
= - 2° (c = 1, H2O). m.p. 127 - 131 °C. Rf (EtOAc:MeOH 70:30, 0.12). 
1H NMR (400 MHz, D2O) δ 1.91 (s, 3H, NHC(O)CH3); 1.95 – 2.08 (m, 1H, 
H-4eq); 2.38 (dddd, 1H, J4ax,F3 = 23.8, J4ax,4eq = 15.1, J4ax,5 = 11.2 J3,4ax = 2.5 
Hz, H-4ax); 3.49 (dd, 1H, J7,8 = 8.6, J6,7 = 1.8 Hz, H-7); 3.54 (dd, 1H, J9,9’ = 
12.3, J8,9 = 6.9 Hz, H-9); 3.75 – 3.81 (m, 2H, H-8, H-9’); 3.83 (dd, 1H, J5,6 = 
11.2, J6,7 = 1.8 Hz, H-6); 4.28 (ddd, 1H, J5,6 = J4ax,5 = 11.2, J4eq,5 = 2.5 Hz, H-
5); 5.12 (dddd, 1H, J3,F3 = 48.4, J3,4eq = 5.7, J3,4ax = J3,F2 = 2.5 Hz, H-3).  
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13C NMR (100 MHz, D2O) δ 22.09 (NHC(O)CH3); 31.25 (d, J4,F3 = 19.9 Hz, 
C-4); 40.52 (d, J5,F3 = 3.7 Hz, C-5); 63.03 (C-9); 68.37 (C-7); 70.68 (C-8); 
76.19 (C-6); 86.41 (dd, J3,F3 =180.6, J3,F2 = 22.1 Hz, C-3); 105.23 (dd, J2,F2 = 
224.1, J2,F3 = 19.2 Hz, C-2); 163.73 (d, J1,F2 = 30.5 Hz, C-1); 174.4 
(NHC(O)CH3). 
19F NMR (470 MHz, D2O) – 122.80 (dd, 1F, JF2,F3 = 12.6, 
JF2,H3 = 2.5 Hz, F-2); - 200.82 (dddd, 1F, JF3,H3 = 47.9, JF3,H4ax = 24.5, JF2,F3 = 
JF3,H4eq = 12.6 Hz, F-3). HRMS (ESI -ve) m/z 312.0900 [M-H]¯ (C11H16F2N1O7 
requires 312.0895). Anal. Calcd. for C11H16F2N1Na1O7+1/2 H2O: C, 38.38; 
H, 4.98; N, 4.07. Found: C, 38.20; H, 5.26; N, 3.87. 
 
 
 
 
        63 
 
Methyl 5-N-acetyl-2,4-di-O-benzoyl-3,5-dideoxy-3-fluoro-
8,9-O-isopropylidene-D-erythro-α-L-manno-non-2-ulopyranosonate (63) 
 
Benzoyl chloride (2 mL, 17.3 mmol) was added drop-wise to a stirred 
solution of 3-fluoro-8,9-O-isopropylidenesialic acid methyl ester (48) (3 g, 7.9 
mmol) in a mixture of anhydrous dichloromethane (36 mL) and anhydrous 
pyridine (12 mL) at – 40 ºC for 30 minutes and was then brought to – 20 ºC 
within 45 minutes. Methanol (1 mL) was added, the crude mixture was 
concentrated in vacuo, subjected to a standard work up (EtOAc) and was 
then purified by silica column chromatography (EtOAc:Petroleum Ether 
80:20) to give (63) and (64). 
Data for (63): white solid (2.41 g, 54%). 
= - 5° (c = 1, CH2Cl2). m.p. 124 - 128 °C. Rf (EtOAc:Petroleum Ether 
90:10, 0.4). 
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1H NMR (400 MHz, CDCl3) δ 0.95 (s, 3H, CCH3); 1.21 (s, 3H, CCH3); 1.94 (s, 
3H, NHC(O)CH3); 3.47 (dd, 1H, J7,8 = 8.5, J7,OH = 5.1 Hz, H-7); 3.91 (d, 1H, 
J5,6 = 10.5 Hz, H-6); 3.92 (s, 3H, OCH3); 3.96 (dd, 1H, J9,9’ = 8.8, J8,9 = 5.3 
Hz, H-9); 4.10 (dd, 1H, J9,9’ = 8.8, J8,9’ = 2.1 Hz, H-9’); 4.24 (ddd, 1H, J7,8 = 
8.5, J8,9 = 5.3 Hz, J8,9’ = 2.1 Hz, H-8); 4.31 (d, 1H, J7,OH = 5.1 Hz, OH-7); 4.61 
(ddd, 1H, J4,5 = J5,6 = 10.5, J5,NH = 7.8 Hz, H-5); 5.25 (dd, 1H, J3,F3 = 48.5, J3,4 
= 2.2 Hz, H-3); 5.75 (ddd, 1H, J4,F3 = 27.9, J4,5 = 10.5, J3,4 = 2.2 Hz, H-4); 
6.12 (d, 1H, J5,NH = 7.8 Hz, NHC(O)CH3); 7.51 (t, 4H, JHb,Hc = 7.8 Hz, Hc-
PhC(O)O, Hc’-PhC(O)O); 7.65 (dt, 2H, JHc,Hd = 7.8, Hd-PhC(O)O, Hd’-
PhC(O)O); 8.04 (d, 2H, JHb,Hc = 7.8 Hz, Hb-PhC(O)O); 8.11 (d, 2H, JHb’,Hc’ = 
7.8 Hz, Hb’-PhC(O)O). 
13C NMR (100 MHz, CDCl3) δ 23.10 (NHC(O)CH3); 
24.83 (CCH3); 26.48 (CCH3); 47.40 (C-5); 53.59 (OCH3); 67.34 (C-9); 69.76 
(C-7); 69.81 (d, J4,F3 = 16.9 Hz, C-4); 73.87 (C-6); 74.13 (C-8); 87.48 (d, J3,F3 
= 186.3 Hz, C-3); 95.79 (d, J2,F3 = 29.9 Hz, C-2); 108.58 (CCH3); 128.19 (Ca-
PhC(O)O); 128.22 (Ca’-PhC(O)O); 128.69 (2Cc-PhC(O)O); 128.78 (2Cc’-
PhC(O)O); 129.93 (2Cb-PhC(O)O); 130.17 (2Cb’-PhC(O)O); 134.10 (Cd-
PhC(O)O); 134.35 (Cd’-PhC(O)O); 162.41 (PhC(O)O); 165.73 (C-1); 167.54 
(PhC’(O)O); 172.51 (NHC(O)CH3). 
19F NMR (376 MHz, CDCl3) – 206.60 (dd, 
JF3,H3 = 50.4, JF3,H4 = 28.9 Hz, F-3). HRMS (ESI +ve) m/z 590.2050 [M+H]
+ 
(C29H33F1N1O11 requires 590.2038). 
Data for (64): white solid (0.8 g, 18%); further data shown below. 
 
 
 
 
          64 
 
Methyl 5-N-acetyl-2,4,7-tri-O-benzoyl-3,5-dideoxy-3-fluoro-
8,9-O-isopropylidene-D-erythro-α-L-manno-non-2-ulopyranosonate (64) 
 
The 2,4,7-tri-O-benzoyl-3-fluoro-8,9-O-isopropylidenesialic acid methyl ester 
(64) was isolated as a side product in the formation of the 2,4-di-O-benzoyl-
3-fluoro-8,9-O-isopropylidenesialic acid methyl ester (63) in 18% yield but 
was also prepared independently. 
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Benzoyl chloride (1.1 mL, 9.6 mmol) was added drop-wise to a stirred 
solution of 3-fluoro-8,9-O-isopropylidenesialic acid methyl ester (48) (0.9 g, 
2.4 mmol) in anhydrous pyridine (15 mL) at 0 ºC and was then brought to 
room temperature and left to stir at this temperature for 5 hours. Methanol 
(1 mL) was added, the crude mixture was concentrated in vacuo, subjected 
to a standard work up (EtOAc) and was then purified by silica column 
chromatography (EtOAc:Petroleum Ether 60:40) to give (64) as a white solid 
(1.36 g, 82%). 
= - 1° (c = 1, CH2Cl2). m.p. 123 - 128 °C. Rf (EtOAc:Petroleum Ether 
90:10, 0.8). 1H NMR (400 MHz, CDCl3) δ 1.03 (s, 3H, CCH3); 1.17 (s, 3H, 
CCH3); 1.91 (s, 3H, NHC(O)CH3); 3.92 (s, 3H, OCH3); 3.94 -3.99 (m, 1H, H-
5); 4.09 – 4.21 (m, 2H, H-9, H-9’); 4.34 (ddd, 1H, J7,8 = 8.6, J8,9 = 5.8, J8,9’ = 
2.2 Hz, H-8); 4.81 (d, 1H, J5,6 = 10.6 Hz, H-6); 5.32 (dd, 1H, J3,F3 = 49.3, J3,4 
= 2.5 Hz, H-3); 5.52 (d, 1H, J7,8 = 8.6 Hz, H-7); 5.74 (d, 1H, J5,NH = 7.8 Hz, 
NHC(O)CH3); 6.42 (ddd, 1H, J4,F3 = 25.8, J4,5 = 11.3, J3,4 = 2.5 Hz, H-4); 7.43 
(t, 2H, JHb,Hc = 7.8 Hz, Hc-PhC(O)O); 7.50 (t, 2H, JHb’,Hc’ = 7.8 Hz, Hc’-
PhC(O)O); 7.55 (t, 2H, JHb’’,Hc’’ = 7.8 Hz, Hc’’-PhC(O)O); 7.57 (d, 1H, JHc,Hd = 
8.6, Hd-PhC(O)O); 7.59 (d, 1H, JHc’,Hd’ = 8.6, Hd’-PhC(O)O); 7.66 (t, 1H, 
JHc’’,Hd’’ = 7.4, Hd’’-PhC(O)O); 8.04 (d, 2H, JHb,Hc = 7.8 Hz, Hb-PhC(O)O); 8.15 
(d, 2H, JHb’,Hc’ = 7.8 Hz, Hb’-PhC(O)O); 8.17 (d, 2H, JHb’’,Hc’’ = 7.8 Hz, Hb’’-
PhC(O)O). 13C NMR (100 MHz, CDCl3) δ 23.47 (NHC(O)CH3); 25.04 
(CCH3); 26.27 (CCH3); 47.42 (C-5); 53.42 (OCH3); 65.96 (C-9); 68.04 (d, 
J4,F3 = 16.9 Hz, C-4); 70.26 (C-7); 70.99 (C-6); 75.02 (C-8); 87.31 (d, J3,F3 
=184.8 Hz, C-3); 95.50 (d, J2,F3 = 29.1 Hz, C-2); 108.67 (CCH3); 127.93 (Ca-
PhC(O)O); 128.54 (2Cc-PhC(O)O); 128.61 (2Cc’-PhC(O)O); 128.84 (2Cc’’-
PhC(O)O); 128.89 (Ca’-PhC(O)O); 129.35 (Ca’’-PhC(O)O); 129.95 (2Cb-
PhC(O)O); 130.10 (2Cb’-PhC(O)O); 130.29 (2Cb’’-PhC(O)O); 133.54 (Cd-
PhC(O)O); 133.66 (Cd’-PhC(O)O); 134.28 (Cd’’-PhC(O)O); 162.41 
(PhC(O)O); 165.12 (C-1); 165.74 (PhC’(O)O); 166.60 (PhC’’(O)O); 170.73 
(NHC(O)CH3). 
19F NMR (376 MHz, CDCl3) - 210.08 (dd, JF3,H3 = 48.8, JF3,H4 = 
26.5 Hz, F-3). HRMS (ESI +ve) m/z 694.2293 [M+H]+ (C36H37F1N1O12 
requires 694.2300). 
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          67 
 
Methyl 5-N-acetyl-2,4-di-O-benzoyl-3,5-dideoxy-3-fluoro-7-O-(imidazol-1-
ylthiocarbonyl)-8,9-O-isopropylidene-D-erythro-α-L-manno-non-2-
ulopyranosonate (67) 
 
1,1’-Thiocarbonyldiimidazole (3.8 g, 21.6 mmol) was added to a stirred 
solution of 2,4-di-O-benzoyl-3-fluoro-8,9-O-isopropylidenesialic acid methyl 
ester (63) (2.5 g, 4.3 mmol) in anhydrous dichloromethane (160 mL) and 
heated to 40 °C for 20 hours. The crude mixture was then concentrated in 
vacuo and purified by silica column chromatography (EtOAc:Petroleum Ether 
80:20) affording (67) as a white solid (2.87g, 95%). 
= + 2° (c = 1, CH2Cl2). m.p. 129 - 132 °C. Rf (EtOAc:Petroleum Ether 
80:20, 0.5). 1H NMR (400 MHz, CDCl3) δ 1.05 (s, 3H, CCH3); 1.16 (s, 3H, 
CCH3); 1.88 (s, 3H, NHC(O)CH3); 3.91 (s, 3H, OCH3); 3.95 (m, 1H, H-5); 
4.12 (dd, 1H, J9,9’ = 12.1, J8,9 = 5.4 Hz, H-9); 4.22 (dd, 1H, J9,9’ = 12.1, J8,9’ = 
2.1 Hz, H-9’); 4.40 (ddd, 1H, J7,8 = J8,9 = 5.4, J8,9’ = 2.1, Hz, H-8); 5.01 (d, 1H, 
J5,6 = 10.5 Hz, H-6); 5.32 (dd, 1H, J3,F3 = 49.2, J3,4 = 2.3 Hz, H-3); 6.12 (d, 
1H, J7,8 = 5.4 Hz, H-7); 6.16 (d, 1H, J5,NH = 7.4 Hz, NHC(O)CH3); 6.32 (ddd, 
1H, J4,F3 = 27.7, J4,5 = 10.9, J3,4 = 2.3 Hz, H-4); 7.04 (s, 1H, Hb-ImC(S)O); 
7.44 (t, 2H, JHb,Hc = 7.8 Hz, Hc-PhC(O)O); 7.54 (t, 2H, JHb’,Hc’ = 7.8 Hz, 
Hc’-PhC(O)O); 7.59 (t, 1H, JHc,Hd = 7.4, Hd-PhC(O)O); 7.65 (s, 1H, 
He-ImC(S)O); 7.67 (t, 1H, JHc’,Hd’ = 7.4, Hd’-PhC(O)O); 8.10 (d, 2H, 
JHb,Hc = 7.8 Hz, Hb-PhC(O)O); 8.15 (d, 2H, JHb’,Hc’ = 8.2 Hz, Hb’-PhC(O)O); 
8.43 (s, 1H, Hd-ImC(S)O). 
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13C NMR (100 MHz, CDCl3) δ 23.40 (NHC(O)CH3); 24.83 (CCH3); 26.13 
(CCH3); 47.15 (C-5); 53.54 (OCH3); 65.70 (C-9); 68.02 (d, J4,F3 = 17.7 Hz, C-
4); 70.67 (C-6); 74.83 (C-8); 78.08 (C-7); 87.41 (d, J3,F3 =184.8 Hz, C-3); 
95.41 (d, J2,F3 = 29.1 Hz, C-2); 109.02 (CCH3); 117.61 (He-ImC(S)O); 127.78 
(Ca-PhC(O)O); 128.62 (2Cc-PhC(O)O); 128.74 (Ca’-PhC(O)O); 128.80 (2Cc’-
PhC(O)O); 129.92 (2Cb-PhC(O)O); 130.27 (2Cb’-PhC(O)O); 131.08 (Hb-
ImC(S)O); 133.80 (Cd-PhC(O)O); 134.39 (Cd’-PhC(O)O); 137.97 (Hd-
ImC(S)O); 162.95 (PhC(O)O); 164.91 (C-1); 165.68 (PhC’(O)O); 170.79 
(NHC(O)CH3); 184.45 (ImC(S)O. 
19F NMR (376 MHz, CDCl3) – 206.82 (dd, 
JF3,H3 = 48.8, JF3,H4 = 27.5 Hz, F-3). HRMS (ESI +ve) m/z 700.1947 [M+H]
+ 
(C33H35F1N3O11S1 requires 700.1976). 
 
 
 
 
         68 
 
Methyl 5-N-acetyl-2,4-di-O-benzoyl-3,5,7-trideoxy-3-fluoro-
8,9-O-isopropylidene-D-erythro-α-L-manno-non-2-ulopyranosonate (68) 
 
In a flame-dried 100 mL round-bottom flask, 2,4-di-O-benzoyl-3-fluoro-
8,9-O-isopropylidene-7-O-thiocarbamatesialic acid methyl ester (67) (0.5g 
mg, 0.7 mmol) was dissolved in anhydrous 1,4-dioxane (15 mL), 
concentrated in vacuo, ventilated under argon atmosphere, redissolved in 
anhydrous 1,4-dioxane (35 mL), degassed three times under argon 
atmosphere and then heated under stirring to 100 °C. In a flame-dried 25 mL 
round-bottom flask, tributyltin hydride (0.7 mL, 2.6 mmol) and Luperox® 101 
(0.1 mL, 0.32 mmol) was added to 1,4-dioxane (8 mL) with molecular sieves 
(pellets, 4 Å). The tributyltin hydride solution was then added to the heated 
solution over 2 hours with a syringe pump under vigorous stirring and was 
left to stir at this temperature for further 2 hours. The solution was then 
cooled to room temperature, concentrated in vacuo and purified by silica 
column chromatography (EtOAc:Petroleum Ether 80:20) to give (68) as a 
white solid (365 mg, 89%). 
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= - 3° (c = 1, CH2Cl2). m.p. 111 - 116 °C. Rf (EtOAc:Petroleum Ether 
80:20, 0.4). 1H NMR (400 MHz, CDCl3) δ 1.16 (s, 3H, CCH3); 1.18 (s, 3H, 
CCH3); 1.84 (s, 3H, NHC(O)CH3); 1.86 (ddd, 1H, J7,7’ = 14.2, J7,8 = 5.3, J6,7 = 
2.1 Hz, H-7); 1.98 (ddd, 1H, J7,7’ = 14.2, J6,7’ = 10.5 J7’,8 = 7.8 Hz, H-7’); 3.52 
(dd, 1H, J9,9’ = 12.3, J8,9 = 6.1 Hz, H-9); 3.87 (s, 3H, OCH3); 3.95 (ddd, 1H, 
J5,6 = J6,7’ = 10.5, J6,7 = 2.1 Hz, H-6); 4.06 – 4.10 (m, 1H, H-9’); 4.12 – 4.19 
(m, 1H, H-8); 5.21 (ddd, 1H, J4,5 = 11.2, J5,6 = 10.5, J5,NH = 9.1 Hz, H-5); 5.21 
(dd, 1H, J3,F3 = 49.1, J3,4 = 2.5 Hz, H-3); 5.52 (d, 1H, J5,NH = 9.1 Hz, 
NHC(O)CH3); 5.67 (ddd, 1H, J4,F3 = 27.9, J4,5 = 11.2, J3,4 = 2.5 Hz, H-4); 7.46 
(t, 2H, JHb,Hc = 7.8 Hz, Hc-PhC(O)O); 7.50 (t, 2H, JHb’,Hc’ = 7.8 Hz, Hc’-
PhC(O)O); 7.60 (t, 1H, JHc,Hd = 7.4, Hd-PhC(O)O); 7.65 (t, 1H, JHc’,Hd’ = 7.4, 
Hd’-PhC(O)O); 8.04 (dd, 4H, JHb,Hc = JHb’,Hc’ = 7.8 Hz, Hb-PhC(O)O, 
Hb’-PhC(O)O). 
13C NMR (100 MHz, CDCl3) δ 23.43 (NHC(O)CH3); 25.07 (CCH3); 27.01 
(CCH3); 35.22 (C-7); 49.55 (C-5); 53.73 (OCH3); 67.31 (C-9); 70.06 (d, 
J4,F3 = 17.6 Hz, C-4); 72.56 (C-6); 72.92 (C-8); 87.72 (d, J3,F3 = 185.5 Hz, 
C-3); 95.79 (d, J2,F3 = 29.2 Hz, C-2); 108.46 (CCH3); 128.27 (Ca-PhC(O)O); 
128.81 (Ca’-PhC(O)O); 128.93 (2Cc-PhC(O)O); 129.00 (2Cc’-PhC(O)O); 
130.29 (2Cb-PhC(O)O, 2Cb’-PhC(O)O); 134.22 (Cd-PhC(O)O); 134.46 
(Cd’-PhC(O)O); 162.92 (PhC(O)O); 165.54 (C-1); 166.97 (PhC’(O)O); 170.43 
(NHC(O)CH3). 
19F NMR (470 MHz, CDCl3) – 207.35 (dd, JF3,H3 = 48.9, JF3,H4 
= 27.9 Hz, F-3). HRMS (ESI +ve) m/z 574.2101 [M+H]+ (C29H33F1N1O10 
requires 574.2089). 
 
 
 
 
           70 
 
Methyl 5-N-acetyl-2,4,8,9-tetra-O-acetyl-3,5,7-trideoxy-3-fluoro-
D-erythro-α-L-manno-non-2-ulopyranosonate (70) 
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a) 0.1M NaOMe/MeOH solution (2 mL) was added to a stirred solution of 
2,4-di-O-benzoyl-7-deoxy-3-fluoro-8,9-O-isopropylidene sialic acid methyl 
ester (68) (1.3 g, 2.3 mmol) in anhydrous methanol (50 mL) at 40 °C and left 
to stir at this temperature for 36 hours. The solution was then neutralised 
through addition of Dowex 50 Wx8 100 ion exchange resin, H+ form, filtered 
and the filtrate concentrated in vacuo. 
b) The crude mixture was redissolved in 80% acetic acid/H2O (80 mL) and 
stirred at 60 °C for 2 hours and was then concentrated in vacuo. 
c) The residue was redissolved in anhydrous pyridine (50 mL) and acetic 
anhydride (2.55 mL, 27.2 mmol) and DMAP (11 mg, 0.09 mmol) were then 
added at 0 °C and left to stir at room temperature overnight. The crude 
mixture was then concentrated in vacuo and purified by silica column 
chromatography (EtOAc) affording (70) as a white solid (932 mg, 83% over 
3 steps). 
= - 4° (c = 1, CH2Cl2). m.p. 77 - 79 °C. Rf (EtOAc:MeOH 90:10, 0.4). 
1H NMR (400 MHz, CDCl3) δ 1.84 – 1.99 (m, 2H, H-7, H-7’); 1.94 (s, 3H, 
NHC(O)CH3); 2.01, 2.02, 2.11, 2.13 (4s, 12H, C(O)CCH3); 3.76 (ddd, 1H, 
J5,6 = J6,7 = 10.2, J6,7’ = 1.7 Hz, H-6); 3.81 (s, 3H, OCH3); 4.06 (dd, 1H, 
J9,9’ = 12.1, J8,9 = 6.4 Hz, H-9); 4.24 (dd, 1H, J9,9’ = 12.1, J8,9’ = 3.2 Hz, H-9’); 
4.27 (ddd, 1H, J5,6 = J4,5 = 10.2, J5,NH = 9.2 Hz H-5); 4.87 (dd, 1H, 
J3,F3 = 49.1, J3,4 = 2.5 Hz, H-3); 5.09 (dddd, 1H, J7,8 = J8,9 = 6.4, 
J7’,8 = J8,9’ = 3.2 Hz, H-8); 5.28 (ddd, 1H, J4,F3 = 28.2, J4,5 = 10.2, J3,4 = 2.5 
Hz, H-4); 5.46 (d, 1H, J5,NH = 9.2 Hz, NHC(O)CH3). 
13C NMR (100 MHz, 
CDCl3) δ 20.69, 20.93, 20.97, 21.19 (C(O)CH3); 23.48 (NHC(O)CH3); 33.41 
(C-7); 49.48 (d, J5,F3 = 2.1 Hz, C-5); 53.31 (OCH3); 65.39 (C-9); 69.02 (d, 
J4,F3 = 17.4 Hz, C-4); 69.64 (C-8); 72.02 (C-6); 87.55 (d, J3,F3 = 185.1 Hz, 
C-3); 95.08 (d, J2,F3 = 28.9 Hz, C-2); 165.60 (C-1); 167.27 (NHC(O)CH3); 
170.51, 170.56, 170.84, 171.51 (C(O)CH3). 
19F NMR (470 MHz, 
CDCl3) - 207.28 (dd, JF3,H3 = 49.3, JF3,H4 = 28.5 Hz, F-3). HRMS (ESI +ve) 
m/z 494.1668 [M+H]+ (C20H29F1N1O12 requires 494.1674). 
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           71 
 
Methyl 5-N-acetyl-4,8,9-tri-O-acetyl-3,5,7-trideoxy-3-fluoro-D-erythro-α-
L-manno-non-2-ulopyranosonate (71) 
 
A solution of hydrazine acetate (902 mg, 9.8 mmol) in anhydrous methanol 
(20 mL) was cooled to 4 °C and added to a stirred solution of per-O-acetyl-
7-deoxy-3-fluorosialic acid methyl ester (70) (1.2 g, 2.5 mmol) in anhydrous 
dichloromethane (40 mL) at 4 °C and left at this temperature overnight. The 
mixture was then diluted with dichloromethane (70 mL), subjected to a 
standard work up and purified by silica column chromatography (EtOAc) 
affording (71) as a white solid (933 mg, 84%). 
= - 1° (c = 1, CH2Cl2). m.p. 69 - 73 °C. Rf (EtOAc, 0.5). 
1H NMR (400 
MHz, CDCl3) δ 1.85 – 1.93 (m, 2H, H-7, H-7’); 1.97 (s, 3H, NHC(O)CH3); 
2.05, 2.08, 2.12 (3s, 9H, C(O)CCH3); 3.81 (ddd, 1H, J5,6 = J6,7 = 10.9, J6,7’ = 
2.1 Hz, H-6); 3.87 (s, 3H, OCH3); 4.07 (dd, 1H, J9,9’ = 12.1, J8,9 = 6.8 Hz, H-
9); 4.33 (ddd, 1H, J4,5 = J5,6 = 10.9, J5,NH = 9.6 Hz, H-5); 4.38 (dd, 1H, J9,9’ = 
12.1, J8,9’ = 3.0 Hz, H-9’); 4.64 (s, 1H, OH-2); 4.87 (dd, 1H, J3,F3 = 49.9, J3,4 = 
2.4 Hz, H-3); 5.24 – 5.29 (m, 1H, H-8); 5.28 (ddd, 1H, J4,F3 = 28.2, J4,5 = 
10.9, J3,4 = 2.4 Hz, H-4); 5.83 (d, 1H, J5,NH = 9.6 Hz, NHC(O)CH3). 
13C NMR 
(100 MHz, CDCl3) δ 20.99, 21.00, 21.39, (C(O)CH3); 23.29 (NHC(O)CH3); 
33.29 (C-7); 49.65 (C-5); 53.60 (OCH3); 65.67 (C-9); 69.73 (d, J4,F3 = 17.5 
Hz, C-4); 69.89 (C-6); 69.92 (C-8); 87.39 (d, J3,F3 = 185.2 Hz, C-3); 94.13 (d, 
J2,F3 = 25.4 Hz, C-2); 168.05 (C-1); 170.66 (NHC(O)CH3); 171.12, 171.60, 
171.71, (C(O)CH3). 
19F NMR (470 MHz, CD3Cl3) – 204.71 (dd, JF3,H3 = 50.2, 
JF3,H4 = 29.1 Hz, F-3). HRMS (ESI +ve) m/z 474.1383 [M+Na]
+ 
(C18H26F1N1Na1O11 requires 474.1388). 
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        73    74 
 
Methyl 5-N-acetyl-2,3,5,7-tetradeoxy-2,3-difluoro-D-erythro-β-L-manno-
non-2-ulopyranosonate (73) and Methyl 5-N-acetyl-2,3,5,7-tetradeoxy-
2,3-difluoro-D-erythro-α-L-manno-non-2-ulopyranosonate (74) 
 
a) (Diethylamino)sulfur trifluoride (368 µL, 1.87 mmol) was added drop-wise 
to a stirred solution of hemiketal (71) (846 mg, 2.81 mmol) in anhydrous 
dichloromethane (40 mL) at – 40 °C and the temperature was increased 
to -10 °C during 1 hour. The reaction was then quenched by the addition of 
methanol (0.2 mL) and saturated NaHCO3 solution (0.2 mL) and subjected to 
a standard work up (CH2Cl2). 
b) The crude mixture was redissolved in methanol (40 mL) and sodium 
(20 mg) was then added to the stirred solution at room temperature and left 
to stir at this temperature for 3 hours. 
The solution was then neutralised through addition of Dowex 50 Wx8 100 ion 
exchange resin, H+ form, filtered, the filtrate concentrated in vacuo and 
purified by silica column chromatography (EtOAc:MeOH 99:1 
→ EtOAc:MeOH 70:30) to give (73) and (74). 
Data for (73): white solid (254 mg, 41%). 
= + 2° (c = 1, CH2Cl2). m.p. 162 - 166 °C. Rf (EtOAc:MeOH 70:30, 
0.4). 1H NMR (400 MHz, CD3OD) δ 1.64 (ddd, 1H, J7,7’ = 14.5, J6,7 = 9.8, J7,8 
= 5.2 Hz, H-7); 1.71 (ddd, 1H, J7,7’ = 14.5, J7’,8 = 9.8, J6,7’ = 2.9 Hz, H-7’); 1.95 
(s, 3H, NHC(O)CH3); 3.41 (dd, 1H, J9,9’ = 11.2, J8,9 = 6.2 Hz, H-9); 3.48 (dd, 
1H, J9,9’ = 11.2, J8,9’ = 4.6 Hz, H-9’); 3.75 (ddd, 1H, J5,6 = J6,7 = 9.8, J6,7’ = 2.9 
Hz, H-6); 3.81 -3.86 (m, 1H, H-8); 3.86 (s, 3H, OCH3); 3.91 – 3.97 (m, 2H, H-
4, H-5); 5.04 (ddd, 1H, J3,F3 = 50.4, J3,F2 = J3,4 = 2.2 Hz, H-3). 
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13C NMR (100 MHz, CD3OD) δ 23.02 (NHC(O)CH3); 37.15 (C-7); 52.44 (d, 
J5,F3 = 3.3 Hz, C-5); 53.97 (OCH3); 67.88 (C-9); 69.29 (C-8); 70.06 (dd, J4,F3 
= 18.4, J4,F2 = 5.0 Hz, C-4); 73.84 (d, J6,F2 = 3.9 Hz, C-6); 89.34 (dd, J3,F3 = 
187.3, J3,F2 = 18.4 Hz, C-3); 106.62 (dd, J2,F2 = 220.6, J2,F3 = 16.7 Hz, C-2); 
167.03 (d, J1,F2 = 34.9 Hz, C-1); 174.10 (NHC(O)CH3).
19F NMR (470 MHz, 
CD3OD) - 123.74 (dd, 1F, JF2,F3 = 11.2, JH3,F2 = 2.2 Hz, F-2); – 200.74 (ddd, 
1F, JF3,H3 = 50.2, JF3,H4 = 27.5, JF2,F3 = 11.2 Hz, F-3). HRMS (ESI +ve) m/z 
328.1215 [M+H]+ (C12H20F2N1O7 requires 328.1208). 
Data for (74): white solid (121 mg, 20%). 
= - 3° (c = 1, MeOH). m.p. 86 - 89 °C. Rf (EtOAc:MeOH 70:30, 0.5) 
1H NMR (400 MHz, CD3OD) δ 1.64 (d, 1H, J7,7’ = 11.8 Hz, H-7); 1.65 (d, 1H, 
J7,7’ = 11.8 Hz, H-7’); 1.98 (s, 3H, NHC(O)CH3); 3.42 (dd, 1H, J9,9’ = 11.2, 
J8,9 = 6.4 Hz, H-9); 3.49 (dd, 1H, J9,9’ = 11.2, J8,9’ = 2.3 Hz, H-9’); 3.84 (s, 3H, 
OCH3); 3.87 – 4.11 (m, 4H, H-4, H-5, H-6, H-8); 4.98 (ddd, 1H, J3,F3 = 45.8, 
J3,4 = J3,F2 = 2.2 Hz, H-3). 
13C NMR (100 MHz, CD3OD) δ 23.04 
(NHC(O)CH3); 36.67 (C-7); 52.0 (d, J5,F3 = 2.1 Hz, C-5); 54.04 (OCH3); 67.85 
(C-9); 68.67 (dd, J4,F3 = 18.4, J4,F2 = 5.1 Hz, C-4); 69.17 (C-8); 73.48 (d, J6,F2 
= 2.2 Hz, C-6); 88.85 (dd, J3,F3 =179.4, J3,F2 = 44.5 Hz, C-3); 106.82 (dd, J2,F2 
= 225.9, J2,F3 = 28.5 Hz, C-2); 165.62 (d, J1,F2 = 27.3 Hz, C-1); 174.15 
(NHC(O)CH3). 
19F NMR (470 MHz, CD3OD) – 122.40 (dd, 1F, JF2,F3 15.5, 
JF2,H3 = 2.2 Hz, F-2); – 210.08 (ddd, 1F, JF3,H3 = 45.2, JF3,H4 = 28.2, JF2,F3 = 
15.5 Hz, F-3). HRMS (ESI +ve) m/z 328.1215 [M+H]+ (C12H20F2N1O7 
requires 328.1208). 
 
 
 
            25 
 
5-N-Acetyl-2,3,5,7-tetradeoxy-2,3-difluoro-D-erythro-β-L-manno-non-2-
ulopyranosonic acid (25) 
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A 0.5M aqueous NaOH solution (1 mL) was added to a stirred solution of 
7-deoxy-2,3-difluorosialic acid methyl ester (73) (198 mg) dissolved in water 
(2 mL) at room temperature and was left to stir for 45 minutes. The solution 
was then neutralised through addition of Dowex 50 Wx8 100 ion exchange 
resin, H+ form, filtered, the filtrate concentrated in vacuo and purified by silica 
column chromatography (EtOAc:MeOH 1:1) affording (25) as a white solid 
(93 mg, 49%). 
= - 4° (c = 1, MeOH). m.p. 151 - 155 °C. Rf (EtOAc:MeOH 70:30, 0.1). 
1H NMR (400 MHz, D2O) δ 1.74 (d, 1H, J7,7’ = 12.1 Hz, H-7); 1.75 (d, 1H, J7,7’ 
= 12.1 Hz, H-7’); 2.10 (s, 3H, NHC(O)CH3); 3.52 (dd, 1H, J9,9’ = 11.3, J8,9 = 
7.0 Hz, H-9); 3.64 (dd, 1H, J9,9’ = 11.3, J8,9’ = 3.6 Hz, H-9’); 3.78 – 3.81 (m, 
1H, H-6); 3.97 – 4.04 (m, 2H, H-5, H-8); 4.20 (ddd, 1H, J4,F3 = 28.5, 
J4,5 = 9.6, J3,4 = 1.8 Hz, H-4); 5.25 (ddd, 1H, J3,F3 = 51.1, J3,4 = J3,F2 = 1.8 Hz 
H-3). 13C NMR (100 MHz, D2O) δ 22.19 (NHC(O)CH3); 34.83 (C-7); 50.95 (d, 
J5,F3 = 3.1 Hz, C-5); 65.71 (C-9); 67.66 (C-8); 68.97 (dd, J4,F3 = 17.9, J4,F2 = 
5.9 Hz, C-4); 71.44 (d, J6,F2 = 4.7 Hz, C-6); 89.17 (dd, J3,F3 =183.0, J3,F2 = 
18.9 Hz, C-3); 106.56 (dd, J2,F2 = 219.6, J2,F3 = 14.8 Hz, C-2); 169.46 (d, J1,F2 
= 26.6 Hz, C-1); 174.90 (NHC(O)CH3). 
19F NMR (470 MHz, D2O) – 120.23 
(dd, 1F, JF2,F3 = 11.9, JF2,H3 = 1.8 Hz, F-2); - 217.10 (ddd, 1F, JF3,H3 = 51.2, 
JF3,H4 = 28.5, JF2,F3 = 11.9 Hz, F-3). HRMS (ESI -ve) m/z 312.0891 [M-H]¯ 
(C11H16F2N1O7 requires 312.0895). Anal. Calcd. for C11H16F2N1Na1O7+1/2 
H2O: C, 38.38; H, 4.98; N, 4.07. Found: C, 38.10; H, 5.20; N, 3.94. 
 
 
 
 
        79 
 
Methyl 5-N-acetyl-2,4,7-tri-O-acetyl-3,5-dideoxy-3-fluoro-
8,9-O-isopropylidene-D-erythro-α-L-manno-non-2-ulopyranosonate (79) 
 
 
 
[a] D
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Acetic anhydride (7.4 ml, 79 mmol) was added to a stirred solution of 
3-fluoro-8,9-O-isopropylidenesialic acid methyl ester (48) (2.5 g, 6.6 mmol) in 
pyridine (70 mL) at 4 °C and the solution was left to stir at room temperature 
for 7 days. The solution was concentrated in vacuo and residual pyridine 
removed by azeotropic evaporation with toluene. The residue was then 
subjected to a standard work up (EtOAc) and purified by silica 
chromatography (EtOAc→ EtOAc:MeOH 90:10) to give (79) as a white solid 
(3.03 g, 91%). 
= - 2° (c = 1, CH2Cl2). m.p. 174 - 177 °C. Rf (EtOAc, 0.5). 
1H NMR 
(400 MHz, CDCl3) δ 1.30 (s, 3H, CCH3); 1.34 (s, 3H, CCH3); 1.92 (s, 3H, 
NHC(O)CH3); 2.11, 2.15, 2.16 (3s, 9H, C(O)CCH3); 3.84 (s, 3H, OCH3); 3.95 
(dd, 1H, J9,9’ = 8.9, J8,9 = 6.3 Hz, H-9); 4.04 (dd, 1H, J9,9’ = 8.9, J8,9’ = 6.3 Hz, 
H-9’); 4.12 (ddd, 1H, J5,6 = J4,5 = 10.9, J5,NH = 9.0 Hz, H-5); 4.23 (ddd, 1H, 
J7,8 = J8,9 = J8,9’ = 6.3 Hz, H-8); 4.26 (dd, 1H, J5,6 = 10.9, J6,7 = 1.8 Hz, H-6); 
4.94 (dd, 1H, J3,F3 = 49.0, J3,4 = 2.6 Hz, H-3); 5.23 (dd, 1H, J7,8 = 6.3, 
J6,7 = 1.8 Hz, H-7); 5.45 (d, 1H, J5,NH = 9.0 Hz, NHC(O)CH3); 5.60 (ddd, 1H, 
J4,F3 = 28.0, J4,5 = 10.9, J3,4 = 2.6 Hz, H-4). 
13C NMR (100 MHz, CDCl3) 
δ 20.43, 20.66, 20.99 (C(O)CH3); 23.29 (NHC(O)CH3); 25.29 (CCH3); 26.59 
(CCH3); 45.96 (C-5); 53.40 (OCH3); 66.07 (C-9); 68.38 (d, J4,F3 = 16.9 Hz, 
C-4); 69.11 (C-7); 71.55 (C-6); 74.38 (C-8); 87.08 (d, J3,F3 = 184.8 Hz, C-3); 
95.12 (d, J2,F3 = 29.1 Hz, C-2); 165.15 (C-1); 166.98 (NHC(O)CH3); 170.37, 
170.53, 171.02 (C(O)CH3). 
19F NMR (376 MHz, CDCl3) – 208.90 (dd, JF3,H3 = 
48.8, JF3,H4 = 27.5 Hz, F-3). HRMS (ESI +ve) m/z 508.1817 [M+H]
+ 
(C21H31F1N1O12 requires 508.1830). 
 
 
 
 
 
          81 
 
Methyl 5-N-acetyl-2,4,7-tri-O-acetyl-9-O-benzoyl-3,5-dideoxy-3-fluoro-D-
erythro-α-L-manno-non-2-ulopyranosonate (81) 
 
[a] D
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a) 2,4,7-Tri-O-acetyl-3-fluoro-8,9-O-isopropylidenesialic acid methyl ester 
(79) (3.5 g, 6.9 mmol) was dissolved in 80% acetic acid/H2O (200 mL) and 
was then stirred at 60 °C for 2 hours. The crude mixture was concentrated in 
vacuo and residual acetic acid was removed by azeotropic evaporation with 
toluene to give a white solid. 
b) The crude mixture was evaporated with pyridine (30 mL), redissolved in 
pyridine (75 mL) and cooled to 0 °C. Benzoyl chloride (0.88 mL, 7.6 mmol) 
was added to the cooled solution and was left to stir at this temperature for 
one hour and was then brought to room temperature and stirred for 6 hours. 
The solution was concentrated in vacuo and residual pyridine was removed 
by azeotropic evaporation with toluene. The crude was then purified by silica 
chromatography (EtOAc:MeOH 99:1) to give (81) as a white solid (2.76 g, 
70% (over 2steps)). 
= + 1° (c = 1, CH2Cl2). m.p. 109 - 112 °C. Rf (EtOAc:MeOH 80:20, 
0.5). 1H NMR (400 MHz, CDCl3) δ 1.88 (s, 3H, NHC(O)CH3); 2.05, 2.11, 2.17 
(3s, 9H, C(O)CCH3); 3.87 (s, 3H, OCH3); 4.24 – 4.42 (m, 4H, H-5, H-6, H-8, 
H-9); 4.45 (dd, 1H, J9,9’ = 11.4, J8,9’ = 2.9 Hz, H-9’); 4.95 (dd, 1H, J3,F3 = 49.0, 
J3,4 = 2.5 Hz, H-3); 5.20 (dd, 1H, J7,8 = 8.2, J6,7 = 1.8 Hz, H-7); 5.32 (d, 1H, 
J5,NH = 7.6 Hz, NHC(O)CH3); 5.50 (ddd, 1H, J4,F3 = 27.8, J4,5 = 10.6, J3,4 = 2.5 
Hz, H-4); 7.44 (t, 2H, JHb,Hc = 7.9 Hz, Hc-PhC(O)O); 7.57 (t, 1H, JHc,Hd = 7.9, 
Hd-PhC(O)O); 8.05 (d, 2H, JHb,Hc = 7.8 Hz, Hb-PhC(O)O). 
13C NMR (100 
MHz, CDCl3) δ 20.75, 20.87, 21.34 (C(O)CH3); 23.41 (NHC(O)CH3); 45.57 
(C-5); 53.72 (OCH3); 65.97 (C-9); 68.62 (C-8); 68.79 (C-7); 69.14 (d, J4,F3 = 
17.1 Hz, C-4); 71.76 (C-6); 87.15 (d, J3,F3 = 185.5 Hz, C-3); 95.81 (d, J2,F3 = 
28.9 Hz, C-2); 128.65 (2Cc-PhC(O)O); 129.97 (2Cb-PhC(O)O); 133.28 (Ca-
PhC(O)O); 133.48 (Cd-PhC(O)O); 165.73 (C-1); 167.07 (PhC(O)O); 168.77, 
170.44 (C(O)CH3); 170.93 (NHC(O)CH3); 171.08 (C(O)CH3). 
19F NMR (470 
MHz, CDCl3) – 208.76 (dd, 1F, JF3,H3 = 49.1, JF3,H4 = 28.1 Hz, F-3). HRMS 
(ESI +ve) m/z 594.1558 [M+Na]+ (C25H30F1N1Na1O13 requires 594.1599). 
 
 
 
 
[a] D
21
Experimental                                                                                    Chapter 10 
 
- 213 - 
 
 
 
 
         84 
 
Methyl 5-N-acetyl-2,4,7-tri-O-acetyl-9-O-benzoyl-3,5-dideoxy-3-fluoro-8-
O-(phenoxy)thiocarbonyl-D-erythro-α-L-manno-non-2-ulopyranosonate 
(84) 
 
Phenyl chlorothionoformate (0.8 mL, 6 mmol) was added drop-wise to a 
stirred solution of 2,4,7-tri-O-acetyl-9-O-benzoyl-3-fluorosialic acid methyl 
ester (81) (1.4 g, 2.4 mmol) in anhydrous pyridine (50 mL) at 0 ºC The 
mixture was then left to stir at room temperature for 15 hours. Methanol 
(0.5 mL) was added, the crude mixture was concentrated in vacuo and 
purified by silica column chromatography (EtOAc) to give (84) as an off-white 
solid (1.43 g, 84%). 
m.p. 133 - 136 °C. Rf (EtOAc, 0.5). 
1H NMR (270 MHz, CDCl3) δ 1.91 (s, 3H, 
NHC(O)CH3); 2.11, 2.12, 2.20 (3s, 9H, C(O)CCH3); 3.83 (s, 3H, OCH3); 4.27 
– 4.39 (m, 2H, H-5, H-6); 4.48 (dd, 1H, J9,9’ = 12.7, J8,9 = 5.5 Hz, H-9); 4.98 
(dd, 1H, J3,F3 = 49.0, J3,4 = 2.5 Hz, H-3); 5.15 (dd, 1H, J9,9’ = 12.7, J8,9’ = 2.3 
Hz, H-9’); 5.34 (d, 1H, J5,NH = 8.5 Hz, NHC(O)CH3); 5.55 (ddd, 1H, J4,F3 = 
27.9, J4,5 = 10.8, J3,4 = 2.5 Hz, H-4); 5.69 (ddd, 1H, J8,9 = J7,8 = 5.5, J8,9’ = 2.3 
Hz, H-8); 5.79 (dd, 1H, J7,8 = 5.5, J6,7 = 2.1 Hz, H-7); 7.16 (d, 2H, JHb,Hc = 7.4 
Hz, Hb-PhC(S)O); 7.25 (t, 1H, JHc,Hd = 7.4, Hd-PhC(S)O); 7.39 (t, 2H, JHb,Hc = 
7.9 Hz, Hc-PhC(S)O); 7.44 (t, 2H, JHb,Hc = 7.9 Hz, Hc-PhC(O)O); 7.57 (t, 1H, 
JHc,Hd = 7.9, Hd-PhC(O)O); 8.06 (d, 2H, JHb,Hc = 7.9 Hz, Hb-PhC(O)O). 
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13C NMR (100 MHz, CDCl3) δ 20.50, 20.65, 20.79 (C(O)CH3); 23.25 
(NHC(O)CH3); 45.52 (C-5); 53.50 (OCH3); 61.72 (C-9); 67.39 (C-7); 68.46 (d, 
J4,F3 = 17.6 Hz, C-4); 72.08 (C-6); 80.32 (C-8); 86.93 (d, J3,F3 = 186.3 Hz, 
C-3); 95.09 (d, J2,F3 = 28.4 Hz, C-2); 121.14 (Ca-PhC(S)O); 121.83 
(2Cb-PhC(S)O); 126.71 (Cd-PhC(S)O); 128.35 (2Cc-PhC(O)O); 129.51 
(2Cc-PhC(S)O); 129.80 (2Cb-PhC(O)O); 133.10 (Cd-PhC(O)O); 153.33 
(Ca-PhC(O)O); 165.03 (C-1); 166.00 (PhC(O)O); 167.07, 170.26 (C(O)CH3); 
170.34 (NHC(O)CH3); 170.57 (C(O)CH3); 193.70 (PhC(S)O). 
19F NMR 
(376 MHz, CDCl3) – 208.86 (dd, JF3,H3 = 48.9, JF3,H4 = 27.5 Hz, F-3). HRMS 
(ESI +ve) m/z 730.1562 [M+Na]+ (C32H34F1N1Na1O14S1 requires 730.1582). 
 
 
 
 
          85 
 
Methyl 5-N-acetyl-2,4,7-tri-O-acetyl-9-O-benzoyl-3,5,8-trideoxy-3-fluoro-
D-erythro-α-L-manno-non-2-ulopyranosonate (85) 
 
In a flame-dried 100 mL round-bottom flask 2,4,7-tri-O-acetyl-9-O-benzoyl-
3-fluoro-8-O-phenyl-thionocarbonatesialic acid methyl ester (84) (0.3 g, 
0.42 mmol) was dissolved in anhydrous 1,4-dioxane (25 mL), concentrated in 
vacuo, ventilated under argon atmosphere, redissolved in anhydrous 
1,4-dioxane (35 mL), degassed three times under argon atmosphere and 
then heated under stirring to 100 °C. 
In a flame-dried 25 mL round-bottom flask, tributyltin hydride (0.4 mL, 
1.57 mmol) and Luperox® 101 (0.1 mL, 0.19 mmol) was added to 
1,4-dioxane (10 mL) with molecular sieves. The tributyltin hydride solution 
was then added to the heated solution over 2 hours with a syringe pump 
under vigorous stirring and was left to stir at this temperature for further 2 
hours. The solution was then cooled to room temperature, concentrated in 
vacuo and purified by silica column chromatography (EtOAc) to give (85) as 
a white solid (188 mg, 80%). 
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= - 1° (c = 1, CH2Cl2). m.p. 164 - 166 °C. Rf (EtOAc:MeOH 90:10, 
0.6). 1H NMR (400 MHz, CDCl3) δ 1.82 (s, 3H, NHC(O)CH3); 2.04 – 2.11 (m, 
1H, H-8); 2.11, 2.13, 2.20 (3s, 9H, C(O)CCH3); 2.27 – 2.36 (m, 1H, H-8’); 
3.85 (s, 3H, OCH3); 4.11 – 4.26 (m, 3H, H-5, H-6, H-9); 4.38 – 4.44 (m, 1H, 
H-9’); 4.96 (dd, 1H, J3,F3 = 49.1, J3,4 = 2.3 Hz, H-3); 5.23 (dd, 1H, 
J7,8 = J6,7 = 7.2 Hz, H-7); 5.34 (d, 1H, J5,NH = 8.1 Hz, NHC(O)CH3); 5.60 (ddd, 
1H, J4,F3 = 27.9, J4,5 = 10.7, J3,4 = 2.3 Hz, H-4); 7.44 (t, 2H, JHb,Hc = 7.9 Hz, 
Hc-PhC(O)O); 7.56 (t, 1H, JHc,Hd = 7.8, Hd-PhC(O)O); 8.03 (d, 2H, 
JHb,Hc = 7.8 Hz, Hb-PhC(O)O). 
13C NMR (100 MHz, CDCl3) δ 20.51, 20.63, 
21.02, (C(O)CH3); 23.07 (NHC(O)CH3); 29.69 (C-8); 45.96 (C-5); 53.44 
(OCH3); 60.83 (C-9); 66.87 (C-7); 68.42 (d, J4,F3 = 17.0 Hz, C-4); 72.66 (C-6); 
86.93 (d, J3,F3 = 185.0 Hz, C-3); 95.29 (d, J2,F3 = 28.7 Hz, C-2); 128.38 
(2Cc-PhC(O)O); 129.56 (2Cb-PhC(O)O); 129.56 (Ca-PhC(O)O); 133.10 
(Cd-PhC(O)O); 165.09 (C-1); 166.65 (PhC(O)O); 167.47 (NHC(O)CH3); 
170.30, 170.52, 171.12 (C(O)CH3). 
19F NMR (376 MHz, CDCl3) – 209.35 
(dd, JF3,H3 = 47.9, JF3,H4 = 27.7 Hz, F-3). HRMS (ESI +ve) m/z 556.1803 
[M+H]+ (C25H31F1N1O12 requires 556.1830). 
 
 
 
          86 
 
Methyl 5-N-acetyl-4,7-di-O-acetyl-9-O-benzoyl-3,5,8-trideoxy-3-fluoro-D-
erythro-α-L-manno-non-2-ulopyranosonate (86) 
 
A solution of hydrazine acetate (483 mg, 5.25 mmol) in anhydrous methanol 
(10 mL) was cooled to 4 °C and added to a stirred solution of 2,4,7-tri-
O-acetyl-9-O-benzoyl-8-deoxy-3-fluorosialic acid methyl ester (85) (728 mg, 
1.31 mmol) in anhydrous dichloromethane (20 mL) at 4 °C and left at this 
temperature overnight. The mixture was then diluted with dichloromethane 
(60 mL), subjected to a standard work up and purified by silica column 
chromatography (EtOAc:Petroleum ether, 90:10) affording (86) as a white 
solid (560 mg, 83%). 
= + 3° (c = 1, CH2Cl2). m.p. 107 - 111 °C. Rf (EtOAc, 0.4). 
[a] D
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1H NMR (400 MHz, CDCl3) δ 1.87 (s, 3H, NHC(O)CH3); 2.09, 2.13 (2s, 6H, 
C(O)CCH3); 2.18 – 2.30 (m, 2H, H-8, H-8’); 3.84 (s, 3H, OCH3); 4.20 (dd, 1H, 
J5,6 = 10.4, J6,7 = 2.0 Hz, H-6); 4.28 – 4.34 (m, 1H, H-9); 4.41 – 4.50 (m, 2H, 
H-5, H-9’); 4.90 (dd, 1H, J3,F3 = 50.5, J3,4 = 2.4 Hz, H-3); 5.17 (s, 1H, OH-2); 
5.21 (dd, 1H, J7,8 = 6.6, J6,7 = 2.0 Hz, H-7); 5.45 (ddd, 1H, J4,F3 = 27.8, J4,5 = 
11.0, J3,4 = 2.4 Hz, H-4); 5.70 (d, 1H, J5,NH = 9.4 Hz, NHC(O)CH3); 7.42 (t, 
2H, JHb,Hc = 7.8 Hz, Hc-PhC(O)O); 7.55 (t, 1H, JHc,Hd = 7.8, Hd-PhC(O)O); 
7.99 (d, 2H, JHb,Hc = 7.8 Hz, Hb-PhC(O)O). 
13C NMR (100 MHz, CDCl3) δ 
20.75, 21.12 (C(O)CH3); 23.12 (NHC(O)CH3); 29.62 (C-8); 45.73 (C-5); 
53.54 (OCH3); 61.50 (C-9); 76.64 (C-7); 69.56 (d, J4,F3 = 16.9 Hz, C-4); 71.70 
(C-6); 86.76 (d, J3,F3 = 187.1 Hz, C-3); 94.06 (d, J2,F3 = 24.5 Hz, C-2); 128.46 
(2Cc-PhC(O)O); 129.58 (2Cb-PhC(O)O); 129.80 (Ca-PhC(O)O); 133.26 (Cd-
PhC(O)O); 167.05 (C-1); 167.91 (PhC(O)O); 170.22 (NHC(O)CH3); 171.012, 
171.22 (C(O)CH3). 
19F NMR (376 MHz, CDCl3) – 205.06 (dd, JF3,H3 = 50.4, 
JF3,H4 = 27.5 Hz, F-3). HRMS (ESI +ve) m/z 514.1694 [M+H]
+ (C23H29F1N1O11 
requires 514.1725). 
 
 
 
         88      89 
 
Methyl 5-N-acetyl-2,3,5,8-tetradeoxy-2,3-difluoro-D-erythro-β-L-manno-
non-2-ulopyranosonate (88) and Methyl 5-N-acetyl-2,3,5,8-tetradeoxy-
2,3-difluoro-D-erythro-α-L-manno-non-2-ulopyranosonate (89) 
a) (Diethylamino)sulfur trifluoride (0.2 ml, 1.52 mmol) was added drop-wise 
to a stirred solution of hemiketal (86) (0.52 g, 1.01 mmol) in anhydrous 
dichloromethane (20 mL) at – 40 °C and the temperature was increased 
to -10 °C within 1 hour. The reaction was then quenched by the addition of 
methanol (0.2 mL) and saturated NaHCO3 solution (0.2 mL) and subjected to 
a standard work up (CH2Cl2). 
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b) The crude mixture was redissolved in methanol (15 mL) and sodium 
(6 mg) was then added to the stirred solution at room temperature and left to 
stir at this temperature overnight. The solution was then neutralised through 
addition of Dowex 50 Wx8 100 ion exchange resin, H+ form, filtered, the 
filtrate concentrated in vacuo. The crude mixture was redissolved in 
anhydrous methanol (15 mL) and trifluoroacetic acid (0.3 mL, 3.9 mmol) was 
added drop-wise to the stirred solution at room temperature and was stirred 
at this temperature overnight. The solution was then concentrated in vacuo, 
redissolved in methanol, concentrated in vacuo and purified by silica column 
chromatography (EtOAc:MeOH 99:1 → EtOAc:MeOH 90:10) to give (88) and 
(89). 
Data for (88): white solid (82 mg, 25% (over 3 steps)). 
= - 1° (c = 1, MeOH). m.p. 113 - 117 °C. Rf (EtOAc:MeOH 80:20, 0.4). 
1H NMR (400 MHz, CD3OD) δ 1.69 – 1.76 (m, 1H, H-8); 1.92 – 1.99 (m, 1H, 
H-8’); 2.01 (s, 3H, NHC(O)CH3); 3.39 (d, 1H, J5,6 = 10.2 Hz, H-6); 3.68 – 3.71 
(m, 2H, H-9, H-9’); 3.82 – 3.87 (m, 1H, H-7); 3.89 (s, 3H, OCH3); 4.01 (ddd, 
1H, J4,F3 = 27.8, J4,5 = 10.2, J3,4 = 1.8 Hz, H-4); 4.20 (dd, 1H, 
J4,5 = J5,6 = 10.2 Hz, H-5); 5.08 (ddd, 1H, J3,F3 = 51.2, J3,F2 = J3,4 = 1.8 Hz, 
H-3). 13C NMR (100 MHz, CD3OD) δ 22.69 (NHC(O)CH3); 36.32 (C-8); 49.11 
(d, J5,F3 = 3.8 Hz, C-5); 49.64 (OCH3); 59.54 (C-9); 66.40 (C-7); 69.55 (dd, 
J4,F3 = 18.4, J4,F2 = 6.2 Hz, C-4); 78.15 (d, J6,F2 = 3.8 Hz, C-6); 89.25 (dd, 
J3,F3 = 187.8, J3,F2 = 17.6 Hz, C-3); 105.78 (dd, J2,F2 = 219.3, J2,F3 = 16.9 Hz, 
C-2); 166.62 (d, J1,F2 = 25.3 Hz, C-1); 175.23 (NHC(O)CH3).
19F NMR 
(470 MHz, CD3OD) – 123.66 (dd, 1F, JF2,F3 = 11.3, JF2,H3 = 1.8 Hz, F-2); – 
221.14 (ddd, 1F, JF3,H3 = 50.8, JF3,H4 = 27.8, JF2,F3 = 11.3 Hz, F-3). HRMS 
(ESI +ve) m/z 328.1208 [M+H]+ (C12H20F2N1O7 requires 328.1208). 
Data for (89): colourless oil (35 mg, 11% (over 3 steps)). 
= - 2° (c = 1, MeOH). Rf (EtOAc:MeOH 80:20, 0.5) 
1H NMR (500 MHz, 
CD3OD) δ 1.61 – 1.64 (m, 1H, H-8); 1.83 – 1.87 (m, 1H, H-8’); 1.93 (s, 3H, 
NHC(O)CH3); 3.29 (dd, 1H, J5,6 = 10.8, J6,7 = 1.3 Hz, H-6); 3.58 – 3.60 (m, 
2H, H-9, H-9’); 3.73 – 3.77 (m, 1H, H-7); 3.89 (s, 3H, OCH3); 4.01 (ddd, 1H, 
J4,F3 = 27.8, J4,5 = 10.8, J3,4 = 2.1 Hz, H-4); 4.11 (dd, 1H, J4,5 = J5,6 = 10.8 Hz, 
H-5); 4.98 (ddd, 1H, J3,F3 = 45.5, J3,4 = J3,F2 = 2.1 Hz, H-3). 
[a] D
25
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13C NMR (125 MHz, CD3OD) δ 22.69 (NHC(O)CH3); 36.34 (C-8); 49.13 
(C-5); 53.90 (OCH3); 59.64 (C-9); 66.41 (C-7); 69.57 (dd, J4,F3 = 18.2, 
J4,F2 = 5.5 Hz, C-4); 78.17 (d, J6,F2 = 3.4 Hz, C-6); 89.27 (dd, J3,F3 = 188.0, 
J3,F2 = 17.6 Hz, C-3); 106.89 (dd, J2,F2 = 219.5, J2,F3 = 16.8 Hz, C-2); 166.66 
(d, J1,F2 = 31.4 Hz, C-1); 175.25 (NHC(O)CH3). 
19F NMR (470 MHz, CD3OD) 
– 122.74 (dd, 1F, JF2,F3 = 15.5, JF2,H3 = 2.1 Hz, F-2); – 210.26 (ddd, 1F, JF3,H3 
= 45.2, JF3,H4 = 27.8, JF2,F3 = 15.5 Hz, F-3). HRMS (ESI +ve) m/z 328.1199 
[M+H]+ (C12H20F2N1O7 requires 328.1208). 
 
 
 
 
            26 
 
5-N-Acetyl-2,3,5,8-tetradeoxy-2,3-difluoro-D-erythro-β-L-manno-non-2-
ulopyranosonic acid (26) 
 
A 0.5M aqueous NaOH solution (0.6 mL) was added to a stirred solution of 
8-deoxy-2,3-difluorosialic acid methyl ester (88) (82 mg) dissolved in water 
(1.5 mL) at room temperature and left to stir for 45 minutes. The solution was 
then neutralised through addition of Dowex 50 Wx8 100 ion exchange resin, 
H+ form, filtered, the filtrate concentrated in vacuo and purified by silica 
column chromatography (EtOAc:MeOH 1:1) affording (26) as a white solid 
(17 mg, 22%). 
= - 3° (c = 1, H2O). m.p. 76 - 79 °C. Rf (EtOAc:MeOH 70:30, 0.1). 
1H NMR (400 MHz, D2O) δ 1.68 – 1.71 (m, 1H, H-8); 1.86 – 1.91 (m, 1H, 
H-8’); 1.96 (s, 3H, NHC(O)CH3); 3.38 (d, 1H, J5,6 = 8.6 Hz, H-6); 3.59 – 3.69 
(m, 2H, H-9, H-9’); 3.73 – 3.81 (m, 1H, H-7); 4.02 – 4.19 (m, 2H, H-4, H-5); 
5.09 (ddd, 1H, J3,F3 = 51.6, J3,F2 = J3,4 = 1.8 H-3). 
13C NMR (125 MHz, D2O) δ 
22.06 (NHC(O)CH3); 35.02 (C-8); 47.42 (d, J5,F3 = 3.4 Hz, C-5); 58.44 (C-9); 
65.26 (C-7); 69.03 (dd, J4,F3 = 18.0, J4,F2 = 5.8 Hz, C-4); 75.65 (d, J6,F2 = 4.2 
Hz, C-6); 89.01 (dd, J3,F3 =183.4, J3,F2 = 18.7 Hz, C-3); 106.77 (dd, J2,F2 = 
219.6, J2,F3 = 14.7 Hz, C-2); 169.48 (d, J1,F2 = 23.5 Hz, C-1); 175.10 
(NHC(O)CH3).  
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19F NMR (470 MHz, D2O) – 121.23 (dd, 1F, JF2,F3 = 11.8, JF2,H3 = 1.8 Hz, F-
2); – 217.69 (ddd, 1F, JF3,H3 = 51.3, JF3,H4 = 28.2, JF2,F3 = 11.8 Hz, F-3). 
HRMS (ESI -ve) m/z 312.0895 [M-H]¯ (C11H16F2N1O7 requires 312.0895). 
Anal. Calcd. for C11H16F2N1Na2O7+H2O: C, 35.12; H, 4.82; N, 3.72. Found: 
C, 35.50; H, 4.87; N, 3.54. 
 
 
 
 
          95 
 
2-N-acetyl-1,3,4-tri-O-acetyl-2-deoxy-6-O-p-tolylsulfonyl-
D-mannopyranose (95) 
 
2-N-acetyl-D-mannosamine (40) (8 g, 36.2 mmol) was dissolved in 
anhydrous pyridine (20 mL) concentrated in vacuo, redissolved in anhydrous 
pyridine (100 mL), cooled to 0 °C and 4-toluenesulfonyl chloride (15.2 g, 79.6 
mmol) dissolved in anhydrous pyridine (15 mL) was added over one hour 
and left to stir at this temperature for 7 hours. Acetic anhydride (11.2 mL, 
119.3 mmol) was then added and the mixture was left to stir at room 
temperature overnight. The solution was concentrated in vacuo and residual 
pyridine removed by azeotropic evaporation with toluene. The crude was 
then subjected to a standard work up (EtOAc) and purified by silica 
chromatography (EtOAc:Petroleum Ether 90:10) to give (95) as a white solid 
(8.38 g, 48%). 
m.p. 168 - 170 °C (lit. m.p. 170 -171 °C). Rf (EtOAc, 0.5). 
1H NMR (270 
MHz, CDCl3) δ 1.95, 1.96, 2.02 (3s, 9H, C(O)CCH3); 2.10 (s, 3H, 
NHC(O)CH3); 2.41 (s, 3H, CH3Ph(SO2)O); 4.05 – 4.09 (m, 2H, H-5, H-6); 
4.22 (dd, 1H, J6,6’ = 11.3, J5,6’ = 2.0 Hz, H-6’); 4.59 (ddd, 1H, J2,NH = 9.3, 
J2,3 = 4.1, J1,2 = 1.8 Hz, H-2); 5.18 – 5.30 (m, 2H, H-3, H-4); 5.95 (d, 1H, 
J1,2 = 1.8 Hz, H-1); 6.26 (d, 1H, J2,NH = 9.3 Hz, NHC(O)CH3); 7.31 (d, 2H, 
JHb,Hc = 8.5 Hz, Hc-CH3Ph(SO2)O); 7.74 (d, 2H, JHb,Hc = 8.5 Hz, 
Hb-CH3Ph(SO2)O). Melting point and spectroscopic data were analogous to 
those reported in the literature.205 
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         96 
 
2-N-acetyl-1,3,4-tri-O-acetyl-2,6-dideoxy-6-iodo-D-mannopyranose (96) 
 
Potassium iodide (0.34 g, 2.05 mmol) was added to a vigorously stirred 
solution of per-O-acetyl-2-N-acetyl-6-tosyl-D-mannosamine (95) (0.5 g, 1.03 
mmol) in butanone (15 mL) and heated to 90 °C for 18 hours. The crude 
mixture was filtered over Celite® and the filtrate was then concentrated 
in vacuo, subjected to a standard work up (EtOAc) and purified by silica 
chromatography (EtOAc:Toluene 75:25) to give (96) as a white solid 
(235 mg, 50%). 
= + 7° (c = 1, CH2Cl2). m.p. 78 - 80 °C. Rf (EtOAc:Toluene 90:10, 
0.3). 1H NMR (400 MHz, CDCl3) δ 2.00 (s, 3H, C(O)CCH3); 2.06 (s, 3H, 
NHC(O)CH3); 2.08, 2.17 (2s, 6H, C(O)CCH3); 3.18 (dd, 1H, J6,6’ = 11.2, 
J5,6 = 5.3 Hz, H-6); 3.37 (dd, 1H, J6,6’ = 11.2, J5,6’ = 3.1 Hz, H-6’); 3.60 – 3.64 
(m, 1H, H-5); 4.59 (ddd, 1H, J2,NH = 9.1, J2,3 = 4.2, J1,2 = 1.9 Hz, H-2); 5.10 
(dd, 1H, J4,5 = J3,4 = 9.8 Hz, H-4); 5.33 (dd, 1H, J3,4 = 9.8, J2,3 = 4.2 Hz, H-3); 
5.78 (d, 1H, J2,NH = 9.1 Hz, NHC(O)CH3); 6.03 (d, 1H, J1,2 = 1.9 Hz, H-1). 
13C NMR (100 MHz, CDCl3) δ 5.74 (C-6); 20.70, 20.72, 20.81 (C(O)CH3); 
23.30 (NHC(O)CH3); 49.12 (C-2); 68.52 (C-3); 69.77 (C-4); 70.50 (C-5); 
91.50 (C-1); 168.09 (NHC(O)CH3); 169.59, 170.01, 170.08 (C(O)CH3). 
HRMS (ESI +ve) m/z 480.0120 [M+H]+ (C14H20I1N1Na1O8 requires 
480.0131). 
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          98 
 
2-N-acetyl-1,3,4-tri-O-acetyl-2,6-dideoxy-D-mannopyranose (98) 
 
Per-O-acetyl-2-N-acetyl-6-iodo-D-mannosamine (96) (0.2 g, 0.42 mmol) was 
dissolved in anhydrous 1,4-dioxane (15 mL) concentrated in vacuo, 
ventilated under argon atmosphere and redissolved in 1,4-dioxane (10 mL). 
The solution was then degassed and heated to 100 °C. A solution of 
1,4-dioxane (5 mL), tributyltin hydride (0.42 mL, 1.56 mmol) and Luperox® 
101 (0.1 mL, 0.19 mmol) with molecular sieves was mixed in a flame-dried 
round-bottom flask. The tributyltin hydride solution was then added to the 
heated solution over 2 hours with a syringe pump under vigorous stirring and 
was left to stir at this temperature for further 2 hours. The solution was then 
cooled to room temperature, concentrated in vacuo and purified by silica 
column chromatography (EtOAc:Petroleum Ether 65:35) to give (98) as a 
white solid (98 mg, 70%). 
= + 9° (c = 1, CH2Cl2). m.p. 71 - 73 °C. Rf (EtOAc, 0.3). 
1H NMR (400 
MHz, CDCl3) δ 1.22 (d, 3H, J5,6 = 6.3 Hz, H-6); 2.00, 2.06, 2.07 (3s, 9H, 
C(O)CCH3); 2.16 (s, 3H, NHC(O)CH3); 3.91 – 3.95 (m, 1H, H-5); 4.61 (ddd, 
1H, J2,NH = 9.1, J2,3 = 4.3, J1,2 = 1.7 Hz, H-2); 4.91 (dd, 1H, 
J4,5 = J3,4 = 10.1 Hz, H-4); 5.29 (dd, 1H, J3,4 = 10.1, J2,3 = 4.3 Hz, H-3); 5.71 
(d, 1H, J2,NH = 9.1 Hz, NHC(O)CH3); 5.96 (d, 1H, J1,2 = 1.7 Hz, H-1). 
13C NMR (100 MHz, CDCl3) δ 17.53 (C-6); 20.72, 20.74, 20.87 (C(O)CH3); 
23.29 (NHC(O)CH3); 49.56 (C-2); 68.27 (C-5); 68.78 (C-3); 70.67 (C-4); 
91.77 (C-1); 168.40 (NHC(O)CH3); 169.98, 170.0, 170.07 (C(O)CH3). HRMS 
(ESI +ve) m/z 354.1159 [M+Na]+ (C14H21N1Na1O8 requires 354.1165). 
Melting point and spectroscopic data were analogous to those reported in the 
literature.206 
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        102 
 
Allyl 2-N-acetyl-3,4,6-tri-O-acetyl-2-deoxy-α-D-mannopyranoside (102) 
 
a) 2-N-acetyl-D-mannosamine (40) (0.11 g, 0.52 mmol) was dissolved in 
anhydrous pyridine (2 mL) concentrated in vacuo, redissolved in anhydrous 
pyridine (4 mL), cooled to 0 °C. Acetic anhydride (0.3 mL, 3.1 mmol) was 
then added and the mixture was left to stir at room temperature overnight. 
The solution was concentrated in vacuo and residual pyridine removed by 
azeotropic evaporation with toluene. 
b) The crude was then redissolved in anhydrous nitromethane (15 mL) and 
allyl alcohol (0.35 mL, 5.1 mmol) and BF3•OEt2 (130 µL, 1.0 mmol) were 
added and the solution was heated to 40 °C for 3 hours. The mixture was 
then cooled, concentrated in vacuo and purified by silica chromatography 
(EtOAc) to give (102) as a white solid (71 mg, 36% (over 2 steps)). 
Rf (EtOAc, 0.5). 
1H NMR (270 MHz, CDCl3) δ 1.96 (s, 3H, C(O)CCH3); 2.02 
(s, 6H, 2C(O)CCH3); 2.04 (s, 3H, NHC(O)CH3); 3.98 – 4.09 (m, 3H, H-5, 
OCH2CHCH2); 4.12 (dd, 1H, J6,6’ = 11.7, J5,6 = 2.3 Hz, H-6); 4.28 (dd, 1H, 
J6,6’ = 11.7, J5,6’ = 5.1 Hz, H-6’); 4.61 (ddd, 1H, J2,NH = 9.1, J2,3 = 4.4, 
J1,2 = 1.6 Hz, H-2); 4.79 (d, 1H, J1,2 = 1.6 Hz, H-1); 5.04 (dd, 1H, 
J4,5 = J3,4 = 9.8 Hz, H-4); 5.18 -5.27 (m, 3H, H-3, OCH2CHCH2 ); 5.76 (d, 1H, 
J2,NH = 9.1 Hz, NHC(O)CH3); 5.85 (m, 1H, OCH2CHCH2). Spectroscopic data 
were analogous to those reported in the literature.173 
 
 
 
         103 
 
Allyl 2-N-acetyl-3,4-di-O-acetyl-2-deoxy-6-O-p-tolylsulfonyl-
α-D-mannopyranoside (103) 
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a) Allyl-per-O-acetyl-2-N-acetyl-α-D-mannopyranoside (102) (55 mg, 
0.14 mmol) was dissolved in methanol (3 mL) and sodium (1 mg) was then 
added to the stirred solution at room temperature and left to stir at this 
temperature for 3 hours. The solution was then neutralised through addition 
of Dowex 50 Wx8 100 ion exchange resin, H+ form, filtered and the filtrate 
concentrated in vacuo. 
b) The residue was dissolved in anhydrous pyridine (4 mL) concentrated 
in vacuo, redissolved in anhydrous pyridine (5 mL), cooled to 0 °C and 
4-toluenesulfonyl chloride (60 mg, 0.32 mmol) dissolved in anhydrous 
pyridine (1 mL) was added over one hour and left to stir at this temperature 
for 7 hours. Acetic anhydride (80 µL, 0.85 mmol) was then added and the 
mixture was left to stir at room temperature overnight. The solution was 
concentrated in vacuo and residual pyridine removed by azeotropic 
evaporation with toluene. The crude was then subjected to a standard work 
up (EtOAc) and purified by silica chromatography (EtOAc) to give (103) as a 
white solid (71 mg, 36% (over 3 steps)). 
Rf (EtOAc, 0.6). 
1H NMR (270 MHz, CDCl3) δ 1.96 (s, 6H, 2C(O)CCH3); 2.06 
(s, 3H, NHC(O)CH3); 2.44 (s, 3H, CH3Ph(SO2)O); 3.98 – 4.01 (m, 4H, H-5, 
H-6, OCH2CHCH2); 4.27 (dd, 1H, J6,6’ = 11.7, J5,6’ = 5.1 Hz, H-6’); 4.61 (ddd, 
1H, J2,NH = 9.4, J2,3 = 4.2, J1,2 = 1.7 Hz, H-2); 4.77 (d, 1H, J1,2 = 1.7 Hz, H-1); 
5.12 (dd, 1H, J4,5 = J3,4 = 9.5 Hz, H-4); 5.21 -5.38 (m, 3H, H-3, OCH2CHCH2); 
5.85 (m, 1H, OCH2CHCH2); 6.08 (d, 1H, J2,NH = 9.4 Hz, NHC(O)CH3); 7.34 
(d, 2H, JHb,Hc = 8.4 Hz, Hc-CH3Ph(SO2)O); 7.79 (d, 2H, JHb,Hc = 8.4 Hz, Hb-
CH3Ph(SO2)O). HRMS (ESI +ve) m/z 500.1571 [M+H]
+ (C22H30N1O10S1 
requires 500.1590). Spectroscopic data were analogous to those reported in 
the literature.173 
 
 
 
         104 
 
Benzyl 2-N-acetyl-2-deoxy-α-D-mannopyranoside (104) 
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a) 2-N-Acetyl-D-mannosamine (40) (0.28 g, 1.26 mmol) was dissolved in 
anhydrous pyridine (4 mL) concentrated in vacuo, redissolved in anhydrous 
pyridine (6 mL), cooled to 0 °C. Acetic anhydride (1.42 mL, 15.1 mmol) was 
then added and the mixture was left to stir at room temperature overnight. 
The solution was concentrated in vacuo and residual pyridine removed by 
azeotropic evaporation with toluene. 
b) The residue was then redissolved in anhydrous nitromethane (5 mL) and 
benzyl alcohol (0.4 mL, 3.9 mmol) and BF3•OEt2 (20 µL, 0.15 mmol) were 
added and the solution was heated to 80 °C for 3 hours. The mixture was 
then cooled, concentrated in vacuo and residual BF3•OEt2 removed by 
azeotropic evaporation with toluene. 
(c) The crude mixture was redissolved in methanol (2 mL) and sodium (2 mg) 
was then added to the stirred solution at room temperature and left to stir at 
this temperature for 1.5 hours. The solution was then neutralised through 
addition of Dowex 50 Wx8 100 ion exchange resin, H+ form, filtered, the 
filtrate concentrated in vacuo and purified by silica column chromatography 
(EtOAc:MeOH 80:20 → EtOAc:MeOH 70:30) to give (104) as a white solid 
(188 mg, 48% (over 3 steps)). 
Rf (EtOAc:MeOH, 70:30, 0.3). 
1H NMR (270 MHz, CDCl3) δ 2.01 (s, 3H, 
NHC(O)CH3); 3.35 (br s, 1H, OH); 3.61 – 3.66 (m, 2H, H-6, H-6’); 3.90 – 3.95 
(m, 1H, H-2); 4.07 (br s, 1H, OH); 4.08 – 4.12 (m, 1H, H-5); 4.30 (br s, 1H, 
OH); 4.32 – 4.46 (m, 1H, H-4); 4.60 (m, 2H, OCH2Ph); 4.77 (m, 1H, H-1); 
4.81 (m, 1H, NHC(O)CH3); 7.25 – 7.40 (m, 5H, OCH2Ph). HRMS (ESI +ve) 
m/z 312.1446 [M+H]+ (C15H22N1O6 requires 312.1447). Spectroscopic data 
were analogous to those reported in the literature.207 
 
 
 
 
 
          105 
 
Benzyl 2-N-acetyl-2,6-dideoxy-6-iodo-α-D-mannopyranoside (105) 
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a) Benzyl 2-N-acetyl-α-D-mannopyranoside (104) (185 mg, 0.59 mmol) was 
dissolved in anhydrous pyridine (2 mL) concentrated in vacuo, redissolved in 
anhydrous pyridine (3 mL), cooled to 0 °C and 4-toluenesulfonyl chloride 
(0.19 g, 1.0 mmol) dissolved in anhydrous pyridine (1 mL) was added over 
30 minutes and left to stir at this temperature for 3 hours. The mixture was 
then put to room temperature and left to stir at this temperature for 3 hours. 
The solution was then concentrated in vacuo and residual pyridine removed 
by azeotropic evaporation with toluene and was subjected to a standard work 
up (EtOAc) 
b) The crude mixture was redissolved in acetone (10 mL) and under vigorous 
stirring sodium iodide (250 mg, 1.67 mmol) was added. The solution was 
heated to 50 °C and stirred at this temperature for 32 hours. The reaction 
mixture was cooled, concentrated in vacuo, redissolved in EtOAc, washed 
with an aqueous saturated sodium thiosulfate solution and followed by 
washing with brine. The organic phases were then combined and dried over 
anhydrous magnesium sulfate, filtered and the filtrate concentrated in vacuo 
and purified by silica column chromatography (EtOAc:MeOH 90:10) to give 
(105) as a white solid (168 mg, 52% (over 2 steps)). 
= + 10° (c = 1, CH2Cl2). m.p. 168 - 171 °C. Rf (EtOAc:MeOH, 90:10, 
0.4). 1H NMR (400 MHz, CD3OD) δ 1.98 (s, 3H, NHC(O)CH3); 3.26 (dd, 1H, 
J6,6’ = 10.4, J5,6 = 9.2 Hz, H-6); 3.41 (dd, 1H, J4,5 = J3,4 = 9.2 Hz, H-4); 3.61 
(ddd, 1H, J4,5 = J5,6 = 9.2, J5,6’ = 2.0 Hz, H-5); 3.67 (dd, 1H, J6,6’ = 10.4, 
J5,6’ = 2.0 Hz, H-6’); 3.92 (dd, 1H, J3,4 = 9.2, J2,3 = 4.9 Hz, H-3); 4.28 (dd, 1H, 
J2,3 = 4.9, J1,2 = 1.3 Hz, H-2); 4.52 (d, 1H, J = 11.5 Hz, OCH2Ph); 4.76 (d, 1H, 
J1,2 = 1.3 Hz, H-1); 4.82 (d, 1H, J = 11.5 Hz, OCH2Ph). 
13C NMR (100 MHz, 
CD3OD) δ 6.33 (C-6); 22.70 (NHC(O)CH3); 54.80 (C-2); 70.19 (OCH2Ph); 
70.45 (C-3); 72.89 (C-4); 74.62 (C-5); 99.61 (C-1); 129.07 168.09 
(Cd-OCH2Ph); 129.48 (2Cb-OCH2Ph); 129.59 (2Cc-OCH2Ph); 138.72 
(Ca-OCH2Ph); 174.23 (NHC(O)CH3). HRMS (ESI +ve) m/z 422.0453 [M+H]
+ 
(C15H21I1N1O5 requires 422.0464). 
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          106 
 
Benzyl 2-N-acetyl-2,6-dideoxy-6-iodo-α-D-mannopyranoside (106) 
 
Benzyl 2-N-acetyl-6-iodo-α-D-mannopyranoside (105) (0.16 g, 0.38 mmol) 
was dissolved in methanol (3 mL) and water (1.5 mL). The solution was 
degassed before and after 20% Pd(OH)2/C (65 mg) was added. A balloon 
filled with hydrogen gas was put on top of the stirred solution and left to stir 
for 4 days. The mixture was filtered over Celite® and the filtrate was 
concentrated in vacuo. The crude mixture was then purified by silica column 
chromatography (EtOAc:MeOH 80:20) affording (106) as a colourless oil (73 
mg, 65%). 
Rf (EtOAc:MeOH, 70:30, 0.8). 
1H NMR (270 MHz, CD3OD) δ 1.29 (d, 3H, J5,6 
= 6.3 Hz, H-6); 2.01 (s, 3H, NHC(O)CH3); 3.30 – 3.41 (m, 1H, H-4); 3.58 - 
3.63 (m, 1H, H-5); 3.92 (dd, 1H, J3,4 = 9.9, J2,3 = 4.7 Hz, H-3); 4.32 (d, 1H, 
J1,2 = 1.3 Hz, H-1); 4.28 (d, 1H, J2,3 = 4.7 Hz, H-2); 4.55 (d, 1H, J = 11.8 Hz, 
OCH2Ph); 4.72 (d, 1H, J = 11.8 Hz, OCH2Ph); 7.28 – 7.34 (m, 5H, OCH2Ph). 
HRMS (ESI +ve) m/z 318.1309 [M+H]+ (C15H21N1Na1O5 requires 318.1317). 
 
 
 
 
 
      114 
 
Methyl 5-N-acetyl-2,4,7-tri-O-benzoyl-3,5-dideoxy-3-fluoro-
8,9-O-carbonothoate-D-erythro-α-L-manno-non-2-ulopyranosonate 
(114) 
 
a) A solution of 2,4,7-tri-O-benzoyl-3-fluoro-8,9-O-isopropylidenesialic acid 
methyl ester (64) (3.2 g, 4.55 mmol) in 80% acetic acid/H2O (275 mL) was 
stirred at 60 °C for 2 hours. 
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The crude mixture was then concentrated in vacuo and residual acetic acid 
was removed by azeotropic evaporation with toluene and the residue was 
then subjected to a standard work up (EtOAc) to give a white solid. 
b) The crude was redissolved in anhydrous dichloromethane (250 mL) and 
1,1’-thiocarbonyldiimidazole (0.8 g, 4.55 mmol) was added to the stirred 
solution and heated to 40 °C for 20 hours. The crude mixture was 
concentrated in vacuo, and the procedure was repeated again. The reaction 
mixture was then concentrated in vacuo and purified by silica column 
chromatography (EtOAc:Petroleum Ether 70:30) affording (114) as a white 
solid (2.58 g, 81%). 
= + 6° (c = 1, CH2Cl2). m.p. 146 - 150 °C. Rf (EtOAc:Petroleum Ether 
80:20, 0.8). 1H NMR (400 MHz, CDCl3) δ 1.90 (s, 3H, NHC(O)CH3); 3.90 (s, 
3H, OCH3); 4.08 – 4.18 (m, 1H, H-5); 4.77 (d, 1H, J5,6 = 10.6 Hz, H-6); 4.93 
(dd, 1H, J9,9’ = J8,9 = 9.2 Hz, H-9); 4.99 (dd, 1H, J8,9 = J8,9’ = 9.2 Hz, H-8); 
5.23 – 5.37 (m, 2H, H-3, H-9’); 5.95 – 5.97 (m, 2H, H-7, NHC(O)CH3); 6.30 
(dd, 1H, J4,F3 = 25.8, J4,5 = 11.3, H-4); 7.43 (t, 2H, JHb,Hc = 7.8 Hz, 
Hc-PhC(O)O); 7.51 (t, 2H, JHb’,Hc’ = 7.8 Hz, Hc’-PhC(O)O); 7.56 (t, 2H, 
JHb’’,Hc’ = 7.8 Hz, Hc’’-PhC(O)O); 7.58 (t, 1H, JHc’’,Hd’’ = 7.4, Hd-PhC(O)O); 7.64 
(t, 1H, JHc’’,Hd’’ = 7.4, Hd’-PhC(O)O); 7.68 (t, 1H, JHc’’,Hd’’ = 7.4, Hd’’-PhC(O)O); 
8.04 (d, 2H, JHb,Hc = 7.8 Hz, Hb-PhC(O)O); 8.07 (d, 2H, JHb’,Hc’ = 7.8 Hz, 
Hb’-PhC(O)O); 8.14 (d, 2H, JHb’’,Hc’’ = 7.8 Hz, Hb’’-PhC(O)O). 
13C NMR 
(100 MHz, CDCl3) δ 23.40 (NHC(O)CH3); 46.43 (C-5); 53.68 (OCH3); 67.83 
(d, J4,F3 = 17.6 Hz, C-4); 68.47 (C-7); 70.63 (C-9); 71.45 (C-6); 81.98 (C-8); 
86.98 (d, J3,F3 = 185.6 Hz, C-3); 95.42 (d, J2,F3 = 29.1 Hz, C-2); 127.18 
(Ca-PhC(O)O); 128.39 (Ca’-PhC(O)O); 128.54 (Ca’’-PhC(O)O); 128.61 
(2Cc-PhC(O)O); 128.83 (2Cc’-PhC(O)O); 129.05 (2Cc’’-PhC(O)O); 129.97 
(2Cb-PhC(O)O); 130.05 (2Cb’-PhC(O)O); 130.39 (2Cb’’-PhC(O)O); 133.82 
(Cd-PhC(O)O); 134.07 (Cd’-PhC(O)O); 134.84 (Cd’’-PhC(O)O); 163.41 
(PhC(O)O); 164.32 (C-1); 165.72 (PhC’(O)O); 165.84 (PhC’’(O)O); 171.16 
(NHC(O)CH3); 190.81 (OC(S)O). 
19F NMR (376 MHz, CDCl3) – 210.43 (dd, 
JF3,H3 = 48.6, JF3,H4 = 26.2 Hz, F-3). HRMS (ESI +ve) m/z 696.1482 [M+H]
+ 
(C34H31F1N1O12S1 requires 696.1531). 
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      115 
 
Methyl 5-N-acetyl-2,4,7-tri-O-benzoyl-3,5-dideoxy-3-fluoro-9-iodo-8-O-
methylthiocarbonyl-D-erythro-α-L-manno-non-2-ulopyranosonate (115) 
 
Iodomethane was freshly distilled prior to use at 60 °C in the dark. 
2,4,7-tri-O-benzoyl-8,9-O-carbonothioate-3-fluorosialic acid methyl ester 
(114) (0.43 g, 0.62 mmol) was dissolved in freshly distilled iodomethane 
(12 mL) and heated in the dark to 56 °C for 20 hours. The reaction mixture 
was concentrated in vacuo and purified by silica column chromatography 
(EtOAc:Petroleum Ether 80:20) to give (115) as a white solid (490 mg, 95%). 
= + 1° (c = 1, CH2Cl2). m.p. 112 - 117 °C. Rf (EtOAc:Petroleum Ether 
80:20, 0.8). 1H NMR (400 MHz, CDCl3) δ 1.92 (s, 3H, NHC(O)CH3); 2.02 (s, 
3H, CH3SC(O)O); 3.34 (dd, 1H, J9,9’ = 11.5, J8,9 = 6.1 Hz, H-9); 3.82 (dd, 1H, 
J9,9’ = 11.5, J8,9’ = 3.1 Hz, H-9’); 3.91 (s, 3H, OCH3); 4.06 – 4.12 (m, 1H, H-5); 
4.69 (d, 1H, J5,6 = 11.0 Hz, H-6); 5.16 (ddd, 1H, J7,8 = J8,9 = 6.1, J8,9’ = 3.1 Hz, 
H-8); 5.30 (dd, 1H, J3,F3 = 49.2, J3,4 = 2.1 Hz, H-3); 5.59 (d, 1H, J7,8 = 6.1 Hz, 
H-7); 5.74 (d, J5,NH = 8.2 Hz, NHC(O)CH3); 6.34 (ddd, 1H, J4,F3 = 27.8, 
J4,5 = 11.3, J3,4 = 2.1 Hz H-4); 7.42 (t, 2H, JHb,Hc = 7.8 Hz, Hc-PhC(O)O); 7.51 
(t, 2H, JHb’,Hc’ = 7.8 Hz, Hc’-PhC(O)O); 7.53 (t, 2H, JHb’’,Hc’’ = 7.8 Hz, Hc’’-
PhC(O)O); 7.57 (t, 1H, JHc’’,Hd’’ = 7.4, Hd-PhC(O)O); 7.62 – 7.67 (m, 2H, Hd’-
PhC(O)O, Hd’’-PhC(O)O); 8.03 (d, 2H, JHb,Hc = 7.8 Hz, Hb-PhC(O)O); 8.15 
(dd, 4H, JHb’,Hc’ = JHb’’,Hc’’ = 7.8 Hz, Hb’-PhC(O)O, Hb’’-PhC(O)O). 
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13C NMR (100 MHz, CDCl3) δ 4.11 (C-9); 13.31 (CH3SC(O)O); 23.44 
(NHC(O)CH3); 46.86 (C-5); 53.48 (OCH3); 68.15 (d, J4,F3 = 16.9 Hz, C-4); 
70.43 (C-7); 70.66 (C-6); 73.14 (C-8); 87.24 (d, J3,F3 = 184.8 Hz, C-3); 95.36 
(d, J2,F3 = 29.1 Hz, C-2); 128.03 (Ca-PhC(O)O); 128.55 (2Cc-PhC(O)O); 
128.74 (2Cc’-PhC(O)O, 2Cc’’-PhC(O)O); 128.78 (Ca’-PhC(O)O); 128.83 
(Ca’’-PhC(O)O); 129.96 (2Cb-PhC(O)O); 130.17 (2Cb’-PhC(O)O); 130.33 
(2Cb’’-PhC(O)O); 133.70 (Cd-PhC(O)O); 133.84 (Cd’-PhC(O)O); 134.22 
(Cd’’-PhC(O)O); 162.84 (PhC(O)O); 164.79 (C-1); 165.80 (PhC’(O)O); 165.94 
(PhC’’(O)O); 170.46 (NHC(O)CH3); 170.55 (CH3SC(O)O). 
19F NMR 
(376 MHz, CDCl3) – 209.82 (dd, JF3,H3 = 48.8, JF3,H4 = 27.5 Hz, F-3). HRMS 
(ESI +ve) m/z 838.0765 [M+H]+ (C35H34F1I1N1O12S1 requires 838.0803). 
 
 
 
 
      116 
 
Methyl 5-N-acetyl-2,4,7-tri-O-benzoyl-3,5,9-trideoxy-3-fluoro-
8-O-methylthiocarbonyl-D-erythro-α-L-manno-non-2-ulopyranosonate 
(116) 
 
In a flame-dried 250 mL round-bottom flask, 2,4,7-tri-O-benzoyl-3-fluoro-
9-iodo-8-O-methylthiocarbonylsialic acid methyl ester (115) (3 g, 3.6 mmol) 
was dissolved in anhydrous 1,4-dioxane (100 mL), concentrated in vacuo, 
ventilated under argon atmosphere, redissolved in anhydrous 1,4-dioxane 
(150 mL), degassed three times under argon atmosphere and then heated 
under stirring to 100 °C. In a flame-dried 50 mL round-bottom flask tributyltin 
hydride (3.55 mL, 13.2 mmol) and Luperox® 101 (0.54 mL, 1.6 mmol) was 
added to 1,4-dioxane (30 mL) with molecular sieves. The tributyltin hydride 
solution was then added to the heated solution over 2 hours with a syringe 
pump under vigorous stirring and was left to stir at this temperature for 
further 2 hours. 
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The solution was then cooled to room temperature, concentrated in vacuo 
and purified by silica column chromatography (EtOAc:Petroleum Ether 
60:40) to give (116) as a white solid (2.5 g, 98%). 
= - 2° (c = 1, CH2Cl2). m.p. 112 - 115 °C. Rf (EtOAc:Petroleum Ether 
80:20, 0.8). 1H NMR (400 MHz, CDCl3) δ 1.36 (d, 3H, J8,9 = 6.4 Hz, H-9, 
H-9’, H-9’’); 1.87 (s, 3H, NHC(O)CH3); 2.00 (s, 3H, CH3SC(O)O); 3.89 (s, 3H, 
OCH3); 4.21 (ddd, 1H, J5,6 = J4,5 = 10.8, J5,NH = 9.0 Hz, H-5); 4.59 (d, 1H, 
J5,6 = 10.8 Hz, H-6); 5.26 (dd, 1H, J3,F3 = 49.8, J3,4 = 2.5 Hz, H-3); 5.34 
(dddd, 1H, J8,9 = J8,9’ = J8,9’’ = J7,8 = 6.4 Hz, H-8); 5.47 (dd, 1H, J7,8 = 6.4, 
J6,7 = 1.5 Hz, H-7); 5.58 (d, J5,NH = 9.0 Hz, NHC(O)CH3); 6.19 (ddd, 1H, 
J4,F3 = 27.8, J4,5 = 10.8, J3,4 = 2.5 Hz, H-4); 7.40 (t, 2H, JHb,Hc = 7.8 Hz, 
Hc-PhC(O)O); 7.47 (t, 2H, JHb’,Hc’ = 7.8 Hz, Hc’-PhC(O)O); 7.50 (t, 2H, JHb’’,Hc’’ 
= 7.8 Hz, Hc’’-PhC(O)O); 7.55 (t, 1H, JHc’’,Hd’’ = 7.4, Hd-PhC(O)O); 7.57 – 7.64 
(m, 2H, Hd’-PhC(O)O, Hd’’-PhC(O)O); 7.99 (d, 2H, JHb,Hc = 7.8 Hz, 
Hb-PhC(O)O); 8.11 (dd, 4H, JHb’,Hc’ = JHb’’,Hc’’ = 7.8 Hz, Hb’-PhC(O)O, 
Hb’’-PhC(O)O). 
13C NMR (100 MHz, CDCl3) δ 13.48 (CH3SC(O)O); 23.44 
(NHC(O)CH3); 46.83 (C-5); 53.64 (OCH3); 68.93 (d, J4,F3 = 17.2 Hz, C-4); 
71.17 (C-7); 71.35 (C-6); 72.26 (C-8); 87.58 (d, J3,F3 = 185.2 Hz, C-3); 95.78 
(d, J2,F3 = 28.9 Hz, C-2); 128.39 (Ca-PhC(O)O); 128.79 (2Cc-PhC(O)O); 
128.86 (2Cc’-PhC(O)O); 128.92 (2Cc’’-PhC(O)O); 129.07 (Ca’-PhC(O)O); 
129.56 (Ca’’-PhC(O)O); 130.22 (2Cb-PhC(O)O); 130.37 (2Cb’-PhC(O)O); 
130.53 (2Cb’’-PhC(O)O); 133.77 (Cd-PhC(O)O); 133.92 (Cd’-PhC(O)O); 
134.38 (Cd’’-PhC(O)O); 163.03 (PhC(O)O); 165.22 (C-1); 166.20 (PhC’(O)O); 
166.44 (PhC’’(O)O); 170.43 (NHC(O)CH3), 170.53 (CH3SC(O)O). 
19F NMR (376 MHz, CDCl3) – 209.32 (dd, JF3,H3 = 48.7, JF3,H4 = 27.8 Hz, F-3). 
HRMS (ESI +ve) m/z 712.1828 [M+H]+ (C35H35F1N1O12S1 requires 
712.1864). 
 
 
 
      117 
 
Methyl 5-N-acetyl-2,4,7,8-tetra-O-acetyl-3,5,9-trideoxy-3-fluoro-
D-erythro-α-L-manno-non-2-ulopyranosonate (117) 
[a] D
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a) To a solution of 2,4,7-tri-O-benzoyl-9-deoxy-3-fluoro-8-O-
methylthiocarbonylsialic acid methyl ester (116) (2.5 g, 3.5 mmol) in 
anhydrous methanol (120 mL) sodium (75 mg) was added at room 
temperature and left to stir at this temperature for 3 hours. More sodium 
(75 mg) was then added and left to stir at room temperature overnight. The 
solution was then neutralised through addition of Dowex 50 Wx8 100 ion 
exchange resin, H+ form, filtered and the filtrate concentrated in vacuo. 
b) The residue was redissolved in anhydrous pyridine (150 mL) and acetic 
anhydride (4.9 mL, 51.9 mmol) and DMAP (17 mg, 0.14 mmol) were then 
added at 0 °C and left to stir at room temperature overnight. The solution 
was concentrated in vacuo and residual pyridine removed by azeotropic 
evaporation with toluene. The crude was then subjected to a standard work 
up (EtOAc) and purified by silica column chromatography (EtOAc:MeOH 
98:2) affording (117) as a white solid (1.31 g, 77% over 2 steps). 
= - 2° (c = 1, CH2Cl2). m.p. 192 - 197 °C. Rf (EtOAc, 0.4). 
1H NMR 
(400 MHz, CDCl3) δ 1.27 (d, 3H, J8,9 = 6.4 Hz, H-9, H-9’, H-9’’); 1.89 (s, 3H, 
NHC(O)CH3); 1.98, 2.07, 2.15, 2.16 (4s, 12H, C(O)CCH3); 3.82 (s, 3H, 
OCH3); 4.17 (dd, 1H, J5,6 = 10.6, J6,7 = 1.7 Hz, H-6); 4.24 (ddd, 1H, 
J5,6 = J4,5 = 10.6, J5,NH = 9.0 Hz, H-5); 4.90 (dd, 1H, J3,F3 = 49.4, J3,4 = 1.4 Hz, 
H-3); 4.96 (dddd, 1H, J8,9 = J8,9’ = J8,9’’ = J7,8 = 6.4 Hz, H-8); 5.19 (dd, 1H, 
J7,8 = 6.4, J6,7 = 1.7 Hz, H-7); 5.27 (d, 1H, J5,NH = 9.0 Hz, NHC(O)CH3); 5.47 
(ddd, 1H, J4,F3 = 27.9, J4,5 = 10.6, J3,4 = 1.4 Hz, H-4). 
13C NMR (100 MHz, 
CDCl3) δ 15.82 (C-9); 20.77, 20.89, 21.11, 21.33 (C(O)CH3); 23.51 
(NHC(O)CH3); 45.98 (C-5); 53.66 (OCH3); 68.86 (d, J4,F3 = 17.1 Hz, C-4); 
70.44 (C-8); 70.51 (C-7); 72.51 (C-6); 87.29 (d, J3,F3 = 185.4 Hz, C-3); 95.52 
(d, J2,F3 = 28.8 Hz, C-2); 165.28 (C-1); 167.28 (NHC(O)CH3); 170.37, 170.56, 
170.85, 171.23 (C(O)CH3). 
19F NMR (470 MHz, CDCl3) – 208.54 (dd, JF3,H3 = 
48.9, JF3,H4 = 27.9 Hz, F-3). HRMS (ESI +ve) m/z 494.1668 [M+H]
+ 
(C20H29F1N1O12 requires 494.1674). 
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      118 
 
Methyl 5-N-acetyl-4,7,8-tri-O-acetyl-3,5,9-trideoxy-3-fluoro-D-erythro-α-
L-manno-non-2-ulopyranosonate (118) 
 
A solution of hydrazine acetate (0.97 g, 10.6 mmol) in anhydrous methanol 
(20 mL) was cooled to 4 °C and added to a stirred solution of per-O-acetyl-
9-deoxy-3-fluorosialic acid methyl ester (117) (1.3 g, 2.6 mmol) in anhydrous 
dichloromethane (40 mL) at 4 °C and left at this temperature overnight. The 
mixture was then diluted with dichloromethane (70 mL), subjected to a 
standard work up and purified by silica column chromatography (EtOAc) 
affording (118) as a white solid (806 mg, 68%). 
= + 4.5° (c = 0.67, CH2Cl2). m.p. 205 - 211 °C. Rf (EtOAc, 0.3). 
1H NMR (400 MHz, CDCl3) δ 1.26 (d, 3H, J8,9 = 6.3 Hz, H-9, H-9’, H-9’’); 1.90 
(s, 3H, NHC(O)CH3); 2.04, 2.08, 2.15, (3s, 9H, C(O)CCH3); 3.85 (s, 3H, 
OCH3); 4.24 (dd, 1H, J5,6 = 10.4, J6,7 = 1.7 Hz, H-6); 4.36 (ddd, 1H, 
J5,6 = J4,5 = 10.4, J5,NH = 9.7 Hz, H-5); 4.72 (s, 1H, OH-2); 4.87 (dd, 1H, 
J3,F3 = 50.0, J3,4 = 2.4 Hz, H-3); 5.16 (dd, 1H, J7,8 = 6.3, J6,7 = 1.7 Hz, H-7); 
5.20 (dddd, 1H, J8,9 = J8,9’ = J8,9’’ = J7,8 = 6.3 Hz, H-8); 5.42 (ddd, 1H, 
J4,F3 = 27.8, J4,5 = 10.4, J3,4 = 2.4 Hz, H-4); 5.55 (d, 1H, J5,NH = 9.7 Hz, 
NHC(O)CH3). 
13C NMR (100 MHz, CDCl3) 16.34 (C-9); 20.98, 21.17, 21.58 
(C(O)CH3); 23.44 (NHC(O)CH3); 45.86 (C-5); 53.71 (OCH3); 69.87 (d, 
J4,F3 = 17.4 Hz, C-4); 70.21 (C-8); 70.50 (C-7); 70.81 (C-6); 87.16 (d, 
J3,F3 = 186.0 Hz, C-3); 94.42 (d, J2,F3 = 25.2 Hz, C-2); 168.02 (C-1); 170.47 
(NHC(O)CH3); 171.13 (2C(O)CH3); 171.79 (C(O)CH3). 
19F NMR (470 MHz, 
CD3Cl3) – 207.74 (dd, JF3,H3 = 49.7, JF3,H4 = 27.8 Hz, F-3). HRMS (ESI +ve) 
m/z 474.1384 [M+Na]+ (C18H26F1N1Na1O11 requires 474.1388). 
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          119        120 
 
Methyl 5-N-acetyl-4,7,8-tri-O-acetyl-2,3,5,9-tetradeoxy-2,3-difluoro-D-
erythro-β-L-manno-non-2-ulopyranosonate (119) and Methyl 5-N-acetyl-
4,7,8-tri-O-acetyl-2,3,5,9-tetradeoxy-2,3-difluoro-D-erythro-α-L-manno-
non-2-ulopyranosonate (120) 
 
(Diethylamino)sulfur trifluoride (0.35 mL, 2.7 mmol) was added drop-wise to 
a stirred solution of hemiketal (118) (0.8 g, 1.8 mmol) in anhydrous 
dichloromethane (40 mL) at – 40 °C and the temperature was increased 
to -10 °C during 1 hour. The reaction was then quenched by the addition of 
methanol (0.2 mL) and saturated NaHCO3 solution (0.2 mL), subjected to a 
standard work up (CH2Cl2) and purified by silica column chromatography 
(EtOAc:Petroleum Ether 80:20 → EtOAc) to give (119) and (120). 
Data for (119): white solid (304 mg, 38%). 
= - 4° (c = 1, MeOH). m.p. 161 - 164 °C. Rf (EtOAc, 0.3) 
1H NMR (500 
MHz, CDCl3) δ 1.24 (d, 3H, J8,9 = 6.1 Hz, H-9, H-9’, H-9’’); 1.93 (s, 3H, 
NHC(O)CH3); 2.06, 2.10, 2.18 (3s, 9H, C(O)CCH3); 3.90 (s, 3H, OCH3); 4.21 
– 4.26 (m, 2H, H-5, H-6); 5.16 (ddd, 1H, J3,F3 = 50.7, J3,4 = J3,F2 = 2.1 Hz, 
H-3); 5.24 (d, 1H, J7,8 = 6.3, H-7); 5.22 (dddd, 1H, J8,9 = J8,9’ = J8,9’’ = J7,8 = 
6.3 Hz, H-8); 5.32 (d, 1H, J5,NH = 8.3 Hz, NHC(O)CH3); 5.40 (ddd, 1H, 
J4,F3 = 26.2, J4,5 = 10.2, J3,4 = 2.1 Hz, H-4). 
13C NMR (125 MHz, CDCl3) 16.58 
(C-9); 20.86, 21.06, 21.38 (C(O)CH3); 23.50 (NHC(O)CH3); 45.78 (d, J5,F3 = 
4.1 Hz, C-5); 53.96 (OCH3); 68.42 (C-8); 68.93 (dd, J4,F3 = 17.3, J4,F2 = 6.1 
Hz, C-4); 70.36 (C-7); 72.57 (d, J6,F2 = 4.4 Hz, C-6); 85.80 (dd, J3,F3 = 194.4, 
J3,F2 = 19.4 Hz, C-3); 104.92 (dd, J2,F2 = 225.1, J2,F3 = 17.3 Hz, C-2); 164.67 
(d, J1,F2 = 30.2 Hz, C-1); 170.17 (NHC(O)CH3); 170.41, 170.68, 171.07 
(C(O)CH3).
19F NMR (470 MHz, CDCl3) – 123.27 (dd, 1F, JF2,F3 = 11.3, JF2,H3 
= 2.1 Hz, F-2); – 216.50 (ddd, 1F, JF3,H3 = 50.8, JF3,H4 = 26.1, JF2,F3 = 11.3 Hz, 
F-3). HRMS (ESI +ve) m/z 476.1365 [M+Na]+ (C18H25F2N1Na1O10 requires 
476.1344). 
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Data for (120): white solid (302 mg, 38%). 
= + 1° (c = 1, MeOH). m.p. 194 - 197 °C. Rf (EtOAc, 0.4). 
1H NMR 
(400 MHz, CDCl3) δ 1.27 (d, 3H, J8,9 = 6.2 Hz, H-9, H-9’, H-9’’); 1.89 (s, 3H, 
NHC(O)CH3); 2.00, 2.09, 2.12 (3s, 9H, C(O)CCH3); 3.86 (s, 3H, OCH3); 4.28 
(dd, 1H, J5,6 = 10.8, J6,7 = 1.7 Hz, H-6); 4.46 (ddd, 1H, J5,6 = J4,5 = 10.8, 
J5,NH = 9.9 Hz, H-5); 5.08 (ddd, 1H, J3,F3 = 46.6, J3,4 = J3,F2 = 2.4 Hz, H-3); 
5.12 (dddd, 1H, J8,9 = J8,9’ = J8,9’’ = J7,8 = 6.2 Hz, H-8); 5.24 (dd, 1H, J7,8 = 6.2, 
J6,7 = 1.7 Hz, H-7); 5.32 (ddd, 1H, J4,F3 = 27.9, J4,5 = 10.8, J3,4  = 2.4 Hz, H-4); 
5.46 (d, 1H, J5,NH = 9.9 Hz, NHC(O)CH3). 
13C NMR (100 MHz, CDCl3) 16.39 
(C-9); 20.79, 21.05, 21.21 (C(O)CH3); 23.36 (NHC(O)CH3); 44.92 (d, 
J5,F3 = 2.2 Hz, C-5); 53.85 (OCH3); 68.93 (d, J4,F3 = 17.2 Hz, C-4); 69.45 
(C-8); 70.02 (C-7); 73.22 (d, J6,F2 = 3.0 Hz, C-6); 85.07 (dd, J3,F3 = 185.0, 
J3,F2 = 43.9 Hz, C-3); 105.37 (dd, J2,F2 = 228.5, J2,F3 = 28.0 Hz, C-2); 162.98 
(d, J1,F2 = 26.7 Hz, C-1); 170.31 (NHC(O)CH3, C(O)CH3); 170.84, 170.87 
(C(O)CH3). 
19F NMR (470 MHz, CDCl3) – 122.15 (dd, 1F, JF2,F3 = 16.6, JF2,H3 
= 2.4 Hz, F-2); – 206.51 (ddd, 1F, JF3,H3 = 46.2, JF3,H4 = 27.4, JF2,F3 = 16.6 Hz, 
F-3). HRMS (ESI +ve) m/z 476.1379 [M+Na]+ (C18H25F2N1Na1O10 requires 
476.1344). 
 
 
 
         27 
 
5-N-acetyl-2,3,5,9-tetradeoxy-2,3-difluoro-D-erythro-β-L-manno-non-2-
ulopyranosonic acid (27) 
 
a) Sodium (45 mg, 2 mmol) was added to a stirred solution of per-O-acetyl-9-
deoxy-2,3-difluorosialic acid methyl ester (119) (0.3 g, 0.6 mmol) in 
anhydrous methanol (15 mL) at room temperature and was left to stir for 7 
hours. The solution was then neutralised through addition of Dowex 50 Wx8 
100 ion exchange resin, H+ form, filtered and the filtrate concentrated in 
vacuo. 
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b) A 0.5M aqueous NaOH solution (1.2 mL) was added to a stirred solution 
of the residue redissolved in water (3 mL) at room temperature and left to stir 
for 3 hours. The solution was then neutralised through addition of Dowex 
50 Wx8 100 ion exchange resin, H+ form, filtered, the filtrate concentrated in 
vacuo and purified by silica column chromatography (EtOAc:MeOH 1:1) 
affording (27) as a white solid (196 mg, 99% over 2 steps). 
= - 2° (c = 1, H2O). m.p. 175 - 179 °C. Rf (EtOAc:MeOH 50:50, 0.4). 
1H NMR (400 MHz, D2O) δ 1.32 (d, 3H, J8,9 = 6.4 Hz, H-9, H-9’, H-9’’); 2.10 
(s, 3H, NHC(O)CH3); 3.39 -3.43 (m, 1H, H-7); 3.85 (d, 1H, J5,6 = 10.4 Hz, H-
6); 4.01 (dddd, 1H, J8,9 = J8,9’ = J8,9’’ = J7,8 = 6.4 Hz, H-8); 4.32 (ddd, 1H, 
J4,F3 = 28.4, J4,5 = 10.4, J3,4 = 2.1Hz, H-4); 4.46 (dd, 1H, J5,6 = J4,5 = 10.4 Hz, 
H-5); 5.27 (ddd, 1H, J3,F3 = 51.4, J3,4 = J3,F2 = 2.1 Hz, H-3). 
13C NMR (100 
MHz, D2O) δ 18.88 (C-9); 22.12 (NHC(O)CH3); 47.10 (d, J5,F3 = 3.3 Hz, C-5); 
66.75 (C-8); 69.28 (dd, J4,F3 = 17.9, J4,F2 = 6.1 Hz, C-4); 72.43 (C-7); 72.67 
(d, J6,F2 = 4.3 Hz, C-6); 89.07 (dd, J3,F3 =183.8, J3,F2 = 18.6 Hz, C-3); 106.36 
(dd, J2,F2 = 219.5, J2,F3 = 14.8 Hz, C-2); 169.60 (dd, J1,F2 = 26.5, J1,F3 = 3.6 
Hz, C-1); 175.0 (NHC(O)CH3). 
19F NMR (470 MHz, D2O) – 121.34 (dd, 1F, 
JF2,F3 = 11.5, J3,F2 = 2.1 Hz, F-2); – 217.92 (dddd, 1F, JF3,H3 = 51.3, JF3,H4 = 
28.7, JF2,F3 = 11.5 Hz, F-3). HRMS (ESI -ve) m/z 312.0881 [M-H]¯ 
(C11H16F2N1O7 requires 312.0895). Anal. Calcd. for C11H16F2N1Na1O7+1/2 
H2O: C, 38.38; H, 4.98; N, 4.07. Found: C, 37.9; H, 5.28; N, 3.78. 
 
 
 
         134 
 
Methyl 5-N-acetyl-3,5-dideoxy-8,9-O-isopropylidene-D-erythro-
α-L-manno-non-2-ulopyranosonate (134) 
 
a) Trifluoroacetic acid (8 ml, 104.5 mmol) was added to a stirred solution of 
sialic acid (2) (ordered from Carbosynth®) in anhydrous methanol (300 mL) 
and left at room temperature overnight. The mixture was then concentrated 
in vacuo three times with methanol affording sialic acid methyl ester as a 
white solid which was used without further purification. 
[a] D
25
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b) A solution of sialic acid methyl ester, p-toluenesulfonic acid (0.2 g, 1.1 
mmol) and 2,2’-dimethoxypropane (19 mL, 155 mmol) in acetone (300 mL) 
was stirred at room temperature overnight. Triethylamine (0.7 mL, 5.3 mmol) 
was then added and the crude mixture was concentrated in vacuo and 
purified by silica column chromatography (EtOAc:MeOH 99:1 → 85:15) to 
give (134) as a white solid (10.46 g, 93%). 
m.p. 113 - 116 °C. Rf (EtOAc:MeOH 80:20, 0.5). 
1H NMR (270 MHz, 
CD3OD) δ 1.31 (s, 3H, CCH3); 1.36 (s, 3H, CCH3); 1.84 (dd, 1H, J3ax,3eq = 
J3ax,4 = 11.8 Hz, H-3ax); 2.00 (s, 3H, NHC(O)CH3); 2.21 (dd, 1H, J3ax,3eq = 
11.8, J3,4 = 4.7 Hz, H-3eq); 3.52 (m, 1H, H-7); 3.77 (s, 3H, OCH3); 3.75 – 4.05 
(m, 6H, H-4, H-5, H-6, H-8, H-9, H-9’). HRMS (ESI +ve) m/z 364.1606 
[M+H]+ (C15H26N1O9 requires 364.1608). Melting point and spectroscopic 
data are analogous to those reported in the literature.153 
 
 
 
 
136 
 
Methyl 5-N-acetyl-3,5-dideoxy-8,9-O-isopropylidene-4-O-
(phenoxy)thiocarbonyl-D-erythro-α-L-manno-non-2-ulopyranosonate 
(136) 
 
Phenyl chlorothionoformate (1.2 mL, 9.1 mmol) was added drop-wise to a 
stirred solution of 8,9-O-isopropylidenesialic acid methyl ester (134) (3 g, 
8.3 mmol) in a mixture of anhydrous dichloromethane (60 mL) and 
anhydrous pyridine (30 mL) at – 40 ºC and brought to room temperature over 
1 hour. The mixture was left to stir at this temperature for further 4 hours. 
Methanol (1 mL) was added and after 10 minutes the crude mixture was 
concentrated in vacuo, subjected to a standard work up (CH2Cl2) and purified 
by silica column chromatography (EtOAc:MeOH 99:1) to give (136) as an off-
white solid (3.27 g, 79%). 
m.p. 131 – 135 °C. Rf (EtOAc:MeOH 90:10, 0.5). 
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1H NMR (400 MHz, CD3OD) δ 1.33 (s, 3H, CCH3); 1.38 (s, 3H, CCH3); 1.99 
(s, 3H, NHC(O)CH3); 2.04 (dd, 1H, J3ax,3eq = J3ax,4 = 11.8 Hz, H-3ax); 2.60 (dd, 
1H, J3ax,3eq = 11.8, J3eq,4 = 5.5 Hz, H-3eq); 3.60 (d, 1H, J5,6 = 9.8 Hz, H-6); 
3.80 (s, 3H, OCH3); 4.00 (dd, 1H, J9,9’ = 8.6, J8,9 = 5.5 Hz, H-9); 4.07 (dd, 1H, 
J9,9’ = J8,9’ = 8.6 Hz, H-9’); 4.14 – 4.19 (m, 2H, H-7, H-8); 4.33 (dd, 1H, 
J4,5 = J5,6 = 9.8 Hz, H-5); 5.86 (ddd, 1H, J3ax,4 = 11.8, J4,5 = 9.8, J3eq,4 = 5.5 
Hz, H-4); 7.07 (d, 2H, JHb,Hc = 7.6 Hz, Hb-PhOC(S)O); 7.29 (t, 1H, JHc,Hd = 7.6 
Hz, Hd-PhOC(S)O); 7.42 (t, 2H, JHb,Hc = JHc,Hd = 7.6 Hz, Hc-PhOC(S)O). 
13C NMR (100 MHz, CDCl3) δ 22.76 (NHC(O)CH3); 25.70 (CCH3); 27.15 
(CCH3); 36.87 (OCH3); 50.94 (C-3); 53.27 (C-5); 67.69 (C-9); 70.63 (C-7); 
72.24 (C-6); 76.71 (C-8); 81.15 (C-4); 96.46 (C-2); 110.22 (CCH3); 122.93 
(2Cc-PhOC(S)O); 127.60 (Cd-PhOC(S)O); 130.60 (2Cb-PhOC(S)O); 154.87 
(Ca-PhOC(S)O); 171.15 (C-1); 173.97 (NHC(O)CH3); 195.89 (PhOC(S)O). 
HRMS (ESI +ve) m/z 500.1581 [M+H]+ (C22H30N1O10S1 requires 500.1590). 
 
 
 
 
 
      141 
 
Methyl 5-N-acetyl-2,7-di-O-acetyl-3,5-dideoxy-8,9-O-isopropylidene-4-O-
toluoyl-D-erythro-α-L-manno-non-2-ulopyranosonate (141) 
 
a) p-Toluoyl chloride (44 µL, 0.33 mmol) and tetramethylethylenediamine 
(TMEDA) (50 µL, 0.33 mmol) were added to a stirred solution of 
8,9-O-isopropylidenesialic acid methyl ester (134) (100 mg, 0.3 mmol) in 
anhydrous dichloromethane (3 mL) at 0 ºC and brought to room temperature 
over 45 minutes. 
After 2 hours the solution was diluted with dichloromethane (3 mL) and 
subjected to a standard work up (CH2Cl2). 
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b) The residue was redissolved in anhydrous pyridine (2 mL) and acetic 
anhydride (83 µL, 0.9 mmol) and DMAP (1 mg, 0.01 mmol) were then added 
at 0 °C and left to stir at room temperature overnight. The crude mixture was 
then concentrated in vacuo and purified by silica column chromatography 
(EtOAc:Petroleum Ether 8:2) affording (141) as a white solid (73 mg, 47% 
over 2 steps). 
m.p. 151 – 154 °C. Rf (EtOAc:MeOH 90:10, 0.7). 
1H NMR (270 MHz, CDCl3) 
δ 1.30 (s, 3H, CCH3); 1.34 (s, 3H, CCH3); 1.79 (s, 3H, NHC(O)CH3); 2.03 -
2.07 (m, 1H, H-3ax); 2.14, 2.15 (2s, 6H, C(O)CCH3); 2.38 (s, 3H, PhCH3); 
2.63 (dd, 1H, J3ax,3eq = 11.8, J3eq,4 = 5.5 Hz, H-3eq); 3.79 (s, 3H, OCH3); 3.89 
– 4.19 (m, 5 H, H-6, H-7, H-8, H-9, H-9’); 5.26 – 5.28 (m, 2H, H-5, 
NHC(O)CH3); 5.52 (ddd, 1H, J3ax,4 = 11.8, J4,5 = 9.8, J3eq,4 = 5.5 Hz, H-4); 
7.22 (d, 2H, JHb,Hc = 8.7 Hz, Hb-PhCH3); 7.85 (d, 2H, JHc,Hd = 8.7 Hz, Hc-
PhCH3). HRMS (ESI +ve) m/z 566.2247 [M+H]
+ (C27H36N1O12 requires 
566.2238). 
 
 
 
 
          144 
 
Methyl (methyl-5-N-acetyl-3,5-dideoxy-8,9-O-isopropylidene-D-erythro-
α-L-manno-non-2-ulopyranos)onate (144) 
 
a) To a stirred solution of sialic acid (2) (8 g, 26 mmol) in anhydrous 
methanol (300 mL) Dowex 50x8 (24 g) was added, heated to 70 °C and left 
at this temperature overnight. The solution was then filtered, washed with 
methanol and concentrated in vacuo affording sialic acid methyl ester methyl 
glycoside as an off-white solid which was used without further purification. 
b) A solution of sialic acid methyl ester methyl glycoside, p-toluenesulfonic 
acid (172 mg, 0.01 mmol) and 2,2’-dimethoxypropane (16 mL, 155 mmol) in 
acetone (200 mL) was stirred at room temperature overnight. 
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Triethylamine (0.6 mL, 5.3 mmol) was then added and the crude mixture was 
concentrated in vacuo and purified by silica column chromatography 
(EtOAc:MeOH 95:5 → 90:10) to give (144) as a white solid (5.2 g, 53% over 
2 steps). 
m.p. 178 - 182 °C. Rf (EtOAc:MeOH 80:20, 0.5). 
1H NMR (400 MHz, CDCl3) 
δ 1.31 (s, 3H, CCH3); 1.36 (s, 3H, CCH3); 1.74 (dd, 1H, J3ax,3eq = J3ax,4 = 12.9 
Hz, H-3ax); 2.04 (s, 3H, NHC(O)CH3); 2.21 (dd, 1H, J3ax,3eq = 12.9, J3eq,4 = 4.9 
Hz, H-3eq); 3.24 (s, 3H, OCH3); 3.44 – 3.49 (m, 1H, H-7); 3.56 (d, 1H, J4,OH = 
10.4 Hz, OH-4); 3.79 (s, 3H, C(O)OCH3); 3.75 – 3.81 (m, 2H, H-5, H-9); 3.92 
- 4.01(m, 2H, H-6, H-9’); 4.10 (m, 1H, H-4); 4.24 - 4.29 (m, 1H, H-8); 4.60 (d, 
1H, J7,OH = 6.1 Hz, OH-7); 6.39 (d, 1H, J5,NH = 8.1 Hz, NHC(O)CH3). 
Spectroscopic data are analogous to those reported in the literature.137 
 
 
 
     145 
 
Methyl (methyl-5-N-acetyl-3,5-dideoxy-8,9-O-isopropylidene-
4-O-methanesulfonyl-D-erythro-α-L-manno-non-2-ulopyranos)onate 
(145) 
 
Methanesulfonyl chloride (68 µL, 0.87 mmol) was added drop-wise over 
40 minutes to a stirred solution of 8,9-O-isopropylidenesialic acid methyl 
ester methyl glycoside (144) (0.3 g, 0.8 mmol) in anhydrous pyridine (4 mL) 
at 0 ºC. The mixture was left to stand at this temperature overnight. The 
crude mixture was then poured on ice-water, extracted with dichloromethane, 
concentrated in vacuo and purified by silica column chromatography 
(Toluene:EtOAc:EtOH 5:1:1) to give (145) as a white solid (171 mg, 47%). 
m.p. 128 – 130°C (lit. m.p. 129 °C). Rf (EtOAc:MeOH 80:20, 0.5). 
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1H NMR (400 MHz, CDCl3) δ 1.31 (s, 3H, CCH3); 1.36 (s, 3H, CCH3); 2.01 – 
2.07 (m, 1H, H-3ax); 2.04 (s, 3H, NHC(O)CH3); 2.59 (dd, 1H, J3ax,3eq = 12.1, 
J3eq,4 = 4.8 Hz, H-3eq); 3.05 (s, 3H, OCH3); 3.30 (s, 3H, SOCH3); 3.44 – 3.49 
(m, 2H, H-7, OH-7); 3.64 (d, 1H, J6,7 = 7.8 Hz, H-6); 3.79 (s, 3H, C(O)OCH3); 
3.98 – 4.08 (m, 2H, H-5, H-9’); 4.10 - 4.15 (m, 1H, H-9’); 4.28 - 4.33 (m, 1H, 
H-8); 5.07 (ddd, 1H, J3ax,4 = 7.8, J4,5 = 6.3, J3eq,4 = 4.8 Hz, H-4); 6.13 (d, 1H, 
J5,NH = 8.3 Hz, NHC(O)CH3). HRMS (ESI +ve) m/z 456.1524 [M+H]
+ 
(C17H30N1O11S1 requires 456.1540). Melting point and spectroscopic data are 
analogous to those reported in the literature.137 
 
 
 
         150 
 
Methyl (methyl-5-N-acetyl-4-O-benzoyl-3,5-dideoxy-
8,9-O-isopropylidene-D-erythro-α-L-manno-non-2-ulopyranos)onate 
(150) 
 
Benzoyl chloride (0.6 mL, 5.4 mmol) was added drop-wise to a stirred 
solution of 8,9-O-isopropylidenesialic acid methyl ester methyl glycoside 
(144) (1.9 g, 4.9 mmol) in anhydrous pyridine (45 mL) at 0 ºC for 5 minutes 
and was then left to stir at this temperature for 35 minutes. Methanol (0.5 
mL) was then added, the crude mixture was concentrated in vacuo, 
subjected to a standard work up (CH2Cl2) and purified by silica column 
chromatography (EtOAc:Petroleum Ether 80:20) to give (150) as a white 
solid (1.69 g, 71%). 
m.p. 146 – 149 °C. Rf (EtOAc:Petroleum Ether 90:10, 0.5). 
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1H NMR (400 MHz, CDCl3) δ 1.27 (s, 3H, CCH3); 1.40 (s, 3H, CCH3); 1.94 (s, 
3H, NHC(O)CH3); 2.12 (dd, 1H, J3ax,3eq = 12.8, J3ax,4 = 11.5 Hz, H-3ax); 2.54 
(dd, 1H, J3ax,3eq = 12.8, J3eq,4 = 5.1 Hz, H-3eq); 3.34 (s, 3H, OCH3); 3.47 – 
3.51 (m, 1H, H-7); 3.72 (dd, 1H, J5,6 = 10.5, J6,7 = 1.4 Hz, H-6); 3.81 (s, 3H, 
C(O)OCH3); 4.03 (dd, 1H, J9,9’ = 10.5, J8,9 = 5.3 Hz, H-9); 4.07 - 4.18 (m, 2H, 
H-5, H-9’); 4.35 - 4.40 (m, 1H, H-8); 4.66 (d, 1H, J7,OH = 4.9 Hz, OH-7); 5.61 
(ddd, 1H, J3ax,4 = 11.5, J4,5 = 6.8, J3eq,4 = 5.1 Hz, H-4); 6.21 (d, 1H, J5,NH = 7.8 
Hz, NHC(O)CH3); 7.44 (t, 2H, JHb,Hc = 7.4 Hz, Hc-PhC(O)O); 7.59 (t, 1H, 
JHc,Hd = 7.4, Hd-PhC(O)O); 7.99 (d, 2H, JHb,Hc = 7.4 Hz, Hb-PhC(O)O). 
Spectroscopic data are analogous to those reported in the literature.155 
 
 
 
 
          151 
 
Methyl (methyl-5-N-acetyl-4-O-benzoyl-3,5-dideoxy-
8,9-O-isopropylidene-7-O-(imidazol-1-ylthiocarbonyl)-D-erythro-
α-L-manno-non-2-ulopyranos)onate (151) 
 
1,1’-Thiocarbonyldiimidazole (0.9 g, 5.1 mmol) was added to a stirred 
solution of 4-O-benzoyl-8,9-O-isopropylidenesialic acid methyl ester methyl 
glycoside (150) (0.8 mg, 1.7 mmol) in anhydrous dichloromethane (40 mL) 
and heated to 40 °C for 48 hours. The crude mixture was then concentrated 
in vacuo and purified by silica column chromatography (EtOAc:Petroleum 
Ether 90:10) affording (151) as a white solid (880 mg, 87%). 
m.p. 117 – 121 °C. Rf (EtOAc:Petroleum Ether 80:20, 0.6). 
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1H NMR (400 MHz, CDCl3) δ 1.35 (s, 3H, CCH3); 1.38 (s, 3H, CCH3); 1.79 (s, 
3H, NHC(O)CH3); 2.02 (dd, 1H, J3ax,3eq = 12.8, J3ax,4 = 11.5 Hz, H-3ax); 2.61 
(dd, 1H, J3ax,3eq = 12.8, J3eq,4 = 5.1 Hz, H-3eq); 3.36 (s, 3H, OCH3); 3.84 (s, 
3H, C(O)OCH3); 4.07 - 4.11 (m, 2H, H-5, H-9); 4.23 (dd, 1H, J9,9’ = 9.2, 
J8,9’ = 5.6 Hz, H-9’); 4.29 (dd, 1H, J5,6 = 10.9, J6,7 = 1.5 Hz, H-6); 4.56 - 4.60 
(m, 1H, H-8); 5.33 (d, 1H, J5,NH = 9.7 Hz, NHC(O)CH3); 5.57 (ddd, 1H, 
J3ax,4 = 11.5, J4,5 = 6.5, J3eq,4 = 5.1 Hz, H-4); 6.05 (dd, 1H, J7,8 = 7.1, J6,7 = 1.5 
Hz, H-7); 7.07 (s, 1H, Hb-ImC(S)O); 7.38 (t, 2H, JHb,Hc = 7.4 Hz, Hc-
PhC(O)O); 7.52 (t, 1H, JHc,Hd = 7.4, Hd-PhC(O)O); 7.70 (s, 1H, He-ImC(S)O); 
7.94 (d, 2H, JHb,Hc = 7.4 Hz, Hb-PhC(O)O); 8.41 (s, 1H, Hd-ImC(S)O). HRMS 
(ESI +ve) m/z 592.1963 [M+H]+ (C27H34N3O10S1 requires 592.1965). 
Spectroscopic data are analogous to those reported in the literature.155 
 
 
 
 
        152 
 
Methyl (methyl-5-N-acetyl-4-O-benzoyl-3,5,7-trideoxy-
8,9-O-isopropylidene-D-erythro-α-L-manno-non-2-ulopyranos)onate 
(152) 
 
In a flame-dried 250 mL round-bottom flask, 4-O-benzoyl-
8,9-O-isopropylidene-7-O-thiocarbamate methyl ester methyl glycoside (151) 
(0.9 g, 1.5 mmol) was dissolved in anhydrous 1,4-dioxane (30 mL), 
concentrated in vacuo, ventilated under argon atmosphere, redissolved in 
anhydrous 1,4-dioxane (70 mL), degassed three times under argon 
atmosphere and then heated under stirring to 100 °C. In a flame-dried 25 mL 
round-bottom flask, tributyltin hydride (1.5 mL, 5.4 mmol) and Luperox® 101 
(220 µL, 0.66 mmol) was added to 1,4-dioxane (16 mL) with molecular 
sieves. The tributyltin hydride solution was then added to the heated solution 
over 2 hours with a syringe pump under vigorous stirring and was left to stir 
at this temperature for further 2 hours. 
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The solution was then cooled to room temperature, concentrated in vacuo 
and purified by silica column chromatography (EtOAc:Petroleum Ether 
90:10) to give (152) as a white solid (369 mg, 54%). 
m.p. 103 – 107 °C. Rf (EtOAc, 0.4). 
1H NMR (400 MHz, CDCl3) δ 1.33 (s, 
3H, CCH3); 1.39 (s, 3H, CCH3); 1.86 (s, 3H, NHC(O)CH3); 1.84 - 2.12 (m, 
2H, H-7, H-7’); 2.02 (dd, 1H, J3ax,3eq = 12.8, J3ax,4 = 11.5 Hz, H-3ax); 2.54 (dd, 
1H, J3ax,3eq = 12.8, J3eq,4 = 5.1 Hz, H-3eq); 3.31 (s, 3H, OCH3); 3.06 (dd, 1H, 
J9,9’ = J8,9 = 7.6 Hz, H-9); 3.77 – 3.86 (m, 4H, H-6, C(O)OCH3); 4.07 - 4.15 
(m, 2H, H-5, H-9’); 4.31 - 4.36 (m, 1H, H-8); 5.40 (ddd, 1H, J3ax,4 = 11.5, J4,5 
= 6.6, J3eq,4 = 5.1 Hz, H-4); 5.53 (d, 1H, J5,NH = 9.4 Hz, NHC(O)CH3); 7.42 (t, 
2H, JHb,Hc = 7.4 Hz, Hc-PhC(O)O); 7.56 (t, 1H, JHc,Hd = 7.4, Hd-PhC(O)O); 
7.98 (d, 2H, JHb,Hc = 7.4 Hz, Hb-PhC(O)O). HRMS (ESI +ve) m/z 466.2063 
[M+H]+ (C23H32N1O9 requires 466.2077). Spectroscopic data are analogous 
to those reported in the literature.155 
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 Biology 10.3
 
Sodium acetate trihydrate (6.8 g, 50 mmol) was dissolved in minimal 
amounts of milli-q water, adjusted to pH 5.5 with 50 % acetic acid and filled 
up to 50 mL with milli-q water to give 1 mM NaOAc buffer pH 5.5. Calcium 
chloride (147 mg, 1 mmol) was dissolved in milli-q water (10 mL) to give 
0.1 mM CaCl2. 2′-(4-Methylumbelliferyl) α-D-N-acetylneuraminic acid (121) 
(MUNANA) (1 mg, 2 mmol) was dissolved in milli-q water (1 mL) to give 
2 mM MUNANA. The G70C H1N9 egg derived neuraminidase 28/01/11 
provided by Dr. Jennifer McKimm-Breschkin (Materials Science and 
Engineering, CSIRO, Australia) 1.4 mg/mL was diluted 1:6000 with BSA 1 
mg/mL. 
 10.3.1 Protocol for the inactivation kinetics of 4-deoxy-
2,3-difluorosialic acid (24) 
 
The incubation solutions in a black 96 Greiner Bio-one well plate in duplicate 
were prepared in the layout shown below (Figure 38) following the assay 
(Table 14) with final concentrations of 4-deoxy-2,3-difluorosialic acid (24) 
inactivator in X1 = 200, X2 = 100, X3 = 50, X4 = 25, X5 = 10 nM and control 
(C). 
 
 
 
 
 
 
 
 
 
Figure 38 Layout of the 96 Greiner Bio-one well plates for inactivation kinetics. 
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Table 14 Assay of 4-deoxy-2,3-difluorosialic acid (24). (A) 1 mM NaOAc pH 5.5, (B) 0.1 mM 
CaCl2. 
 
 
 
 
 
         24 
 
 
 
 
 
 
 
 
 
 
 
 
 
G70C H1N9 egg-derived neuraminidase diluted with BSA 1mg/mL 1:6000 
gave high activity, but BSA had to be added in order to minimise activity loss 
due to neuraminidase being stuck to the plastic tubing of the injector. 
At each of the time points 5 µL of diluted G70C H1N9 neuraminidase was 
injected using pump 1 with an injection speed of 100 µL/sec. Finally, 2 mM 
MUNANA (10 µL) was injected in all wells using pump 2 with an injection 
speed of 100 µL/sec and subsequently the plate was shaken with 500 rpm 
for 15 seconds. 
The fluorescence intensity was measured for 30 minutes for each 
concentration and each time point. The gradients in an interval of 8 to 
28 minutes of all concentrations and all time points measured were divided 
by the gradients of the control and gave the residual activity. 
 
 
200 nM (X1) 100 nM (X2) 50 nM (X3)
10 µL (A) 10 µL (A) 10 µL (A)
10 µL (B) 10 µL (B) 10 µL (B)
10 µL 2 µM (24) 10 µL 1 µM (24) 10 µL 0.5 µM (24)
55 µL H2O 55 µL H2O 55 µL H2O
25 nM (X4) 10 nM (X5) Control (C)
10 µL (A) 10 µL (A) 10 µL (A)
10 µL (B) 10 µL (B) 10 µL (B)
10 µL 0.25 µM (24) 10 µL 0.1 µM (24)
55 µL H2O 55 µL H2O 60 µL H2O
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 10.3.2 Protocol for the inactivation kinetics of 7-deoxy-
2,3-difluorosialic acid (25) 
 
The incubation solutions were made in accordance to the previously 
developed protocol and the same plate layout was used (Figure 38, 
Chapter 10.3.1) following the assay (Table 15) with final concentrations of 
7-deoxy-2,3-difluorosialic acid (25) inactivator in X1 = 50, X2 = 25, X3 = 10, 
X4 = 5, X5 = 1 µM and control (C). 
 
Table 15 Assay of 7-deoxy-2,3-difluorosialic acid (25). (A) 1 mM NaOAc pH 5.5, (B) 0.1 mM 
CaCl2. 
 
 
 
 
 
           25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 µM (X1) 25 µM (X2) 10 µM (X3)
10 µL (A) 10 µL (A) 10 µL (A)
10 µL (B) 10 µL (B) 10 µL (B)
10 µL 500 µM (25) 10 µL 250 µM (25) 10 µL 100 µM (25)
55 µL H2O 55 µL H2O 55 µL H2O
5 µM (X4) 1 µM (X5) Control (C)
10 µL (A) 10 µL (A) 10 µL (A)
10 µL (B) 10 µL (B) 10 µL (B)
10 µL 50 µM (25) 10 µL 10 µM (25)
55 µL H2O 55 µL H2O 60 µL H2O
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 10.3.3 Protocol for the inactivation kinetics of 8-deoxy-
2,3-difluorosialic acid (26) 
 
The incubation solutions were made in accordance to the previously 
developed protocol and the same plate layout was used (Figure 38, 
Chapter 10.3.1) following the assay (Table 16) with final concentrations of 
8-deoxy-2,3-difluorosialic acid (26) inactivator in X1 = 50, X2 = 25, X3 = 10, 
X4 = 5, X5 = 1 µM and control (C). 
 
Table 16 Assay of 8-deoxy-2,3-difluorosialic acid (26). (A) 1 mM NaOAc pH 5.5, (B) 0.1 mM 
CaCl2. 
 
 
 
 
 
           26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 µM (X1) 25 µM (X2) 10 µM (X3)
10 µL (A) 10 µL (A) 10 µL (A)
10 µL (B) 10 µL (B) 10 µL (B)
10 µL 500 µM (26) 10 µL 250 µM (26) 10 µL 100 µM (26)
55 µL H2O 55 µL H2O 55 µL H2O
5 µM (X4) 1 µM (X5) Control (C)
10 µL (A) 10 µL (A) 10 µL (A)
10 µL (B) 10 µL (B) 10 µL (B)
10 µL 50 µM (26) 10 µL 10 µM (26)
55 µL H2O 55 µL H2O 60 µL H2O
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 10.3.4 Protocol for the inactivation kinetics of 9-deoxy-
2,3-difluorosialic acid (27) 
 
The incubation solutions with final concentrations of 9-deoxy-
2,3-difluorosialic acid (27) inactivator in X1 = 25, X2 = 10, X3 = 5, X4 = 2, X5 
= 1 µM and control (C) were made in compliance to the previously developed 
protocol and the same plate layout was used (Figure 38, Chapter 10.3.1) 
following the assay (Table 17). 
 
Table 17 Assay of 9-deoxy-2,3-difluorosialic acid (27). (A) 1 mM NaOAc pH 5.5, (B) 0.1 mM 
CaCl2. 
 
 
 
 
 
           27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 µM (X1) 10 µM (X2) 5 µM (X3)
10 µL (A) 10 µL (A) 10 µL (A)
10 µL (B) 10 µL (B) 10 µL (B)
10 µL 250 µM (27) 10 µL 100 µM (27) 10 µL 50 µM (27)
55 µL H2O 55 µL H2O 55 µL H2O
2 µM (X4) 1 µM (X5) Control (C)
10 µL (A) 10 µL (A) 10 µL (A)
10 µL (B) 10 µL (B) 10 µL (B)
10 µL 20 µM (27) 10 µL 10 µM (27)
55 µL H2O 55 µL H2O 60 µL H2O
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 Crystallographic data for per-O-acetyl-4-deoxy-12.1
β-2,3-difluorosialic acid methyl ester (57) 
 
Table 18 Crystal data and structure refinement for per-O-acetyl-4-deoxy-β-2,3-difluorosialic 
acid methyl ester (57). 
 
 
 
 Identification code k08farm4 
 Empirical formula C18 H25 F2 N O10 
 Formula weight 453.39 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21 
 Unit cell dimensions a = 8.9500(2)Å α = 90o 
       b = 9.2930(2)Å β = 106.533(1)o 
       c = 14.1660(3)Å γ = 90o 
 Volume 1129.51(4) Å3 
 Z 2 
 Density (calculated) 1.333 Mg/m3 
 Absorption coefficient 0.119 mm-1 
 F(000) 476 
 Crystal size 0.45 x 0.20 x 0.08 mm 
 Theta range for data collection 3.92 to 27.49o 
 Index ranges -11<=h<=11; -12<=k<=11; -18<=l<=18 
 Reflections collected 16738 
 Independent reflections 5040 [R(int) = 0.0415] 
 Reflections observed (>2σ) 4363 
 Data Completeness 0.991 
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 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 0.99 and 0.91 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 5040 / 49 / 333 
 Goodness-of-fit on F2 1.039 
 Final R indices [I>2σ(I)] R1 = 0.0366   wR2 = 0.0869 
 R indices (all data) R1 = 0.0469  wR2 = 0.0928 
 Absolute structure parameter 0.2(6) 
 Largest diff. peak and hole 0.209 and -0.146 eÅ-3 
 
Notes: 55:45 disorders modeled for O2, C3, C7, O10 and C18. The ADPs of partial 
occupancy atoms were refined subject to some restraints. Lattice consists of 
hydrogen-bonded chains. 
 
Hydrogen bonds with H..A < r(A) + 2.000 Ångstroms  and  <DHA > 110 deg. 
 
 D-H             d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 N1-H1          0.880    2.011   150.78    2.812    O4 [ -x+1, y-1/2, -z ] 
 
 
 
Table 19 Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 
103) for 1. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
 
 
 
 
  Atom   x   y   z  U(eq) 
F(1) 8663(1) 6892(1) 3024(1) 45(1) 
F(2) 8787(2) 10529(2) 2344(1) 55(1) 
O(1) 6697(1) 8486(1) 2849(1) 32(1) 
O(2) 10461(9) 8636(8) 4404(6) 84(2) 
O(2A) 10472(11) 9346(9) 4261(7) 72(2) 
O(3) 8156(14) 9069(9) 4601(8) 61(2) 
O(3A) 8235(15) 9557(11) 4455(9) 63(3) 
O(4) 3931(2) 10343(1) -358(1) 33(1) 
O(5) 3530(1) 9423(1) 1796(1) 29(1) 
O(6) 1361(2) 8746(2) 629(1) 43(1) 
O(7) 2283(1) 6580(1) 2549(1) 30(1) 
O(8) 3210(2) 4814(2) 1789(1) 42(1) 
O(9) 3846(2) 7516(2) 4481(1) 47(1) 
O(10) 4525(17) 9515(13) 5361(9) 83(3) 
O(10A) 4900(30) 9300(20) 5420(11) 143(8) 
N(1) 5261(2) 8273(2) 135(1) 26(1) 
C(1) 8280(2) 8354(2) 3016(1) 37(1) 
C(2) 8880(2) 9042(2) 2220(2) 41(1) 
C(3) 7915(2) 8626(2) 1199(1) 35(1) 
C(4) 6171(2) 8786(2) 1090(1) 27(1) 
C(5) 5786(2) 7925(2) 1911(1) 25(1) 
C(6) 9119(2) 8924(3) 4045(2) 53(1) 
C(7) 8804(12) 9516(11) 5618(7) 82(3) 
C(7A) 9003(14) 10169(12) 5427(8) 77(3) 
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C(8) 4229(2) 9089(2) -522(1) 26(1) 
C(9) 3431(2) 8363(2) -1476(1) 37(1) 
C(10) 2132(2) 9668(2) 1127(1) 34(1) 
C(11) 1709(3) 11227(2) 1131(2) 45(1) 
C(12) 4090(2) 7947(2) 1894(1) 26(1) 
C(13) 3816(2) 7242(2) 2811(1) 28(1) 
C(14) 2146(2) 5343(2) 2031(1) 32(1) 
C(15) 534(2) 4748(2) 1793(2) 44(1) 
C(16) 3844(2) 8317(2) 3621(1) 35(1) 
C(17) 4316(4) 8217(3) 5332(2) 70(1) 
C(18) 3969(9) 7295(13) 6143(7) 71(2) 
C(18A) 4698(12) 7246(12) 6222(8) 67(2) 
 
 
 
Table 20 Bond lengths [Å] and angles [°] for per-O-acetyl-4-deoxy-β-2,3-difluorosialic acid 
methyl ester (57). 
 
 
 
F(1)-C(1) 1.400(2) F(2)-C(2) 1.398(2) 
O(1)-C(1) 1.375(2) O(1)-C(5) 1.4449(19) 
O(2)-C(6) 1.193(8) O(2A)-C(6) 1.226(9) 
O(3)-C(6) 1.329(12) O(3)-C(7) 1.452(14) 
O(3A)-C(6) 1.252(13) O(3A)-C(7A) 1.468(17) 
O(4)-C(8) 1.232(2) O(5)-C(10) 1.357(2) 
O(5)-C(12) 1.4527(19) O(6)-C(10) 1.196(2) 
O(7)-C(14) 1.351(2) O(7)-C(13) 1.452(2) 
O(8)-C(14) 1.205(2) O(9)-C(17) 1.329(3) 
O(9)-C(16) 1.428(2) O(10)-C(17) 1.219(13) 
O(10A)-C(17) 1.119(17) N(1)-C(8) 1.344(2) 
N(1)-C(4) 1.447(2) N(1)-H(1) 0.8800 
C(1)-C(2) 1.520(3) C(1)-C(6) 1.532(3) 
C(2)-C(3) 1.509(3) C(2)-H(2) 1.0000 
C(3)-C(4) 1.532(2) C(3)-H(3A) 0.9900 
C(3)-H(3B) 0.9900 C(4)-C(5) 1.529(2) 
C(4)-H(4) 1.0000 C(5)-C(12) 1.512(2) 
C(5)-H(5) 1.0000 C(7)-H(7A1) 0.9800 
C(7)-H(7A2) 0.9800 C(7)-H(7A3) 0.9800 
C(7A)-H(7A) 0.9800 C(7A)-H(7B) 0.9800 
C(7A)-H(7C) 0.9800 C(8)-C(9) 1.498(2) 
C(9)-H(9A) 0.9800 C(9)-H(9B) 0.9800 
C(9)-H(9C) 0.9800 C(10)-C(11) 1.497(3) 
C(11)-H(11A) 0.9800 C(11)-H(11B) 0.9800 
C(11)-H(11C) 0.9800 C(12)-C(13) 1.536(2) 
C(12)-H(12) 1.0000 C(13)-C(16) 1.515(2) 
C(13)-H(13) 1.0000 C(14)-C(15) 1.492(3) 
C(15)-H(15A) 0.9800 C(15)-H(15B) 0.9800 
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C(15)-H(15C) 0.9800 C(16)-H(16A) 0.9900 
C(16)-H(16B) 0.9900 C(17)-C(18A) 1.508(12) 
C(17)-C(18) 1.534(10) C(18)-H(18A) 0.9800 
C(18)-H(18B) 0.9800 C(18)-H(18C) 0.9800 
C(18A)-H(18D) 0.9800 C(18A)-H(18E) 0.9800 
C(18A)-H(18F) 0.9800   
C(1)-O(1)-C(5) 114.21(12) C(6)-O(3)-C(7) 118.2(9) 
C(6)-O(3A)-C(7A) 115.3(11) C(10)-O(5)-C(12) 116.74(13) 
C(14)-O(7)-C(13) 115.62(13) C(17)-O(9)-C(16) 116.23(19) 
C(8)-N(1)-C(4) 123.71(14) C(8)-N(1)-H(1) 118.1 
C(4)-N(1)-H(1) 118.1 O(1)-C(1)-F(1) 109.01(16) 
O(1)-C(1)-C(2) 113.54(15) F(1)-C(1)-C(2) 106.07(14) 
O(1)-C(1)-C(6) 109.56(15) F(1)-C(1)-C(6) 105.97(16) 
C(2)-C(1)-C(6) 112.30(18) F(2)-C(2)-C(3) 109.55(17) 
F(2)-C(2)-C(1) 106.03(16) C(3)-C(2)-C(1) 112.13(16) 
F(2)-C(2)-H(2) 109.7 C(3)-C(2)-H(2) 109.7 
C(1)-C(2)-H(2) 109.7 C(2)-C(3)-C(4) 111.11(15) 
C(2)-C(3)-H(3A) 109.4 C(4)-C(3)-H(3A) 109.4 
C(2)-C(3)-H(3B) 109.4 C(4)-C(3)-H(3B) 109.4 
H(3A)-C(3)-H(3B) 108.0 N(1)-C(4)-C(5) 110.48(13) 
N(1)-C(4)-C(3) 110.37(14) C(5)-C(4)-C(3) 108.48(14) 
N(1)-C(4)-H(4) 109.2 C(5)-C(4)-H(4) 109.2 
C(3)-C(4)-H(4) 109.2 O(1)-C(5)-C(12) 108.10(12) 
O(1)-C(5)-C(4) 108.69(13) C(12)-C(5)-C(4) 115.08(13) 
O(1)-C(5)-H(5) 108.3 C(12)-C(5)-H(5) 108.3 
C(4)-C(5)-H(5) 108.3 O(2)-C(6)-O(2A) 33.2(5) 
O(2)-C(6)-O(3A) 126.9(7) O(2A)-C(6)-O(3A) 116.3(7) 
O(2)-C(6)-O(3) 121.0(7) O(2A)-C(6)-O(3) 125.5(7) 
O(3A)-C(6)-O(3) 22.6(7) O(2)-C(6)-C(1) 119.2(4) 
O(2A)-C(6)-C(1) 122.0(5) O(3A)-C(6)-C(1) 113.6(6) 
O(3)-C(6)-C(1) 111.9(5) O(3A)-C(7A)-H(7A) 109.5 
O(3A)-C(7A)-H(7B) 109.5 H(7A)-C(7A)-H(7B) 109.5 
O(3A)-C(7A)-H(7C) 109.5 H(7A)-C(7A)-H(7C) 109.5 
H(7B)-C(7A)-H(7C) 109.5 O(4)-C(8)-N(1) 123.06(16) 
O(4)-C(8)-C(9) 121.58(16) N(1)-C(8)-C(9) 115.36(15) 
C(8)-C(9)-H(9A) 109.5 C(8)-C(9)-H(9B) 109.5 
H(9A)-C(9)-H(9B) 109.5 C(8)-C(9)-H(9C) 109.5 
H(9A)-C(9)-H(9C) 109.5 H(9B)-C(9)-H(9C) 109.5 
O(6)-C(10)-O(5) 123.64(17) O(6)-C(10)-C(11) 126.22(18) 
O(5)-C(10)-C(11) 110.13(17) C(10)-C(11)-H(11A) 109.5 
C(10)-C(11)-H(11B) 109.5 H(11A)-C(11)-H(11B) 109.5 
C(10)-C(11)-H(11C) 109.5 H(11A)-C(11)-H(11C) 109.5 
H(11B)-C(11)-H(11C) 109.5 O(5)-C(12)-C(5) 109.34(12) 
O(5)-C(12)-C(13) 110.50(13) C(5)-C(12)-C(13) 112.48(13) 
O(5)-C(12)-H(12) 108.1 C(5)-C(12)-H(12) 108.1 
C(13)-C(12)-H(12) 108.1 O(7)-C(13)-C(16) 106.50(13) 
O(7)-C(13)-C(12) 109.34(13) C(16)-C(13)-C(12) 112.75(14) 
O(7)-C(13)-H(13) 109.4 C(16)-C(13)-H(13) 109.4 
C(12)-C(13)-H(13) 109.4 O(8)-C(14)-O(7) 123.04(16) 
O(8)-C(14)-C(15) 125.24(17) O(7)-C(14)-C(15) 111.71(15) 
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C(14)-C(15)-H(15A) 109.5 C(14)-C(15)-H(15B) 109.5 
H(15A)-C(15)-H(15B) 109.5 C(14)-C(15)-H(15C) 109.5 
H(15A)-C(15)-H(15C) 109.5 H(15B)-C(15)-H(15C) 109.5 
O(9)-C(16)-C(13) 107.35(15) O(9)-C(16)-H(16A) 110.2 
C(13)-C(16)-H(16A) 110.2 O(9)-C(16)-H(16B) 110.2 
C(13)-C(16)-H(16B) 110.2 H(16A)-C(16)-H(16B) 108.5 
O(10A)-C(17)-O(10) 17.9(18) O(10A)-C(17)-O(9) 123.8(8) 
O(10)-C(17)-O(9) 121.4(6) O(10A)-C(17)-C(18A) 117.1(10) 
O(10)-C(17)-C(18A) 124.6(7) O(9)-C(17)-C(18A) 113.7(4) 
O(10A)-C(17)-C(18) 127.1(9) O(10)-C(17)-C(18) 126.2(7) 
O(9)-C(17)-C(18) 109.0(5) C(18A)-C(17)-C(18) 24.0(4) 
C(17)-C(18)-H(18A) 109.5 C(17)-C(18)-H(18B) 109.5 
C(17)-C(18)-H(18C) 109.5 C(17)-C(18A)-H(18D) 109.5 
C(17)-C(18A)-H(18E) 109.5 H(18D)-C(18A)-H(18E) 109.5 
C(17)-C(18A)-H(18F) 109.5 H(18D)-C(18A)-H(18F) 109.5 
H(18E)-C(18A)-H(18F) 109.5   
 
Symmetry transformations used to generate equivalent atoms. 
 
 
 
Table 21 Anisotropic displacement parameters (Å2 x 103) for per-O-acetyl-4-deoxy-β-2,3-
difluorosialic acid methyl ester (57). The anisotropic displacement factor exponent takes the 
form: -2 gpi2 [ h2 a*2 U11 + ... + 2 h k a* b* U. 
 
 
 
  Atom  U11  U22  U33  U23  U13  U12 
F(1) 45(1) 50(1) 36(1) 1(1) 6(1) 23(1) 
F(2) 47(1) 45(1) 69(1) -12(1) 9(1) -12(1) 
O(1) 26(1) 39(1) 27(1) -9(1) 4(1) 5(1) 
O(2) 44(2) 131(5) 61(3) -40(4) -11(2) 17(4) 
O(2A) 32(2) 113(6) 60(3) -26(4) -2(2) -6(4) 
O(3) 52(3) 89(5) 38(3) -27(3) 4(2) -3(4) 
O(3A) 49(4) 86(6) 44(4) -38(4) -3(3) 26(4) 
O(4) 40(1) 22(1) 37(1) 3(1) 10(1) 2(1) 
O(5) 29(1) 24(1) 33(1) 1(1) 10(1) 5(1) 
O(6) 31(1) 45(1) 48(1) 9(1) 2(1) -2(1) 
O(7) 33(1) 25(1) 33(1) -3(1) 14(1) -2(1) 
O(8) 42(1) 33(1) 56(1) -10(1) 22(1) 0(1) 
O(9) 68(1) 44(1) 30(1) -1(1) 18(1) -2(1) 
O(10) 157(6) 52(4) 55(5) -16(2) 53(4) -21(3) 
O(10A) 280(19) 91(10) 38(4) -29(5) 15(7) -73(11) 
N(1) 32(1) 20(1) 28(1) 0(1) 10(1) 1(1) 
C(1) 29(1) 44(1) 34(1) -9(1) 2(1) 10(1) 
C(2) 26(1) 45(1) 50(1) -6(1) 9(1) 2(1) 
C(3) 28(1) 40(1) 38(1) 0(1) 12(1) 1(1) 
C(4) 28(1) 24(1) 30(1) -2(1) 9(1) 0(1) 
C(5) 28(1) 23(1) 24(1) -3(1) 6(1) 4(1) 
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C(6) 34(1) 76(2) 43(1) -17(1) -1(1) 9(1) 
C(7) 79(4) 113(6) 45(4) -39(4) 4(3) -8(5) 
C(7A) 74(5) 91(6) 52(5) -40(5) -2(4) 16(5) 
C(8) 30(1) 22(1) 27(1) 2(1) 11(1) -1(1) 
C(9) 42(1) 32(1) 32(1) -3(1) 4(1) 2(1) 
C(10) 29(1) 38(1) 37(1) 10(1) 14(1) 5(1) 
C(11) 44(1) 40(1) 55(1) 12(1) 19(1) 15(1) 
C(12) 29(1) 22(1) 26(1) -2(1) 8(1) 1(1) 
C(13) 29(1) 28(1) 27(1) -1(1) 8(1) 0(1) 
C(14) 40(1) 25(1) 33(1) -1(1) 12(1) -2(1) 
C(15) 44(1) 36(1) 54(1) -12(1) 19(1) -9(1) 
C(16) 42(1) 34(1) 30(1) -4(1) 14(1) -3(1) 
C(17) 114(2) 64(2) 36(1) -10(1) 28(1) -12(2) 
C(18) 87(5) 94(5) 37(3) 7(3) 25(4) 4(5) 
C(18A) 113(7) 58(4) 34(3) -7(3) 28(5) -14(5) 
 
 
 
Table 22 Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2 x 103) for 
per-O-acetyl-4-deoxy-β-2,3-difluorosialic acid methyl ester (57). 
 
 
 
  Atom   x   y   z  U(eq) 
H(1) 5391 7376 -24 32 
H(2) 9991 8757 2315 49 
H(3A) 8143 7616 1066 42 
H(3B) 8200 9245 708 42 
H(4) 5927 9824 1159 32 
H(5) 6100 6902 1859 30 
H(7A1) 9470 8748 5988 122 
H(7A2) 7955 9709 5911 122 
H(7A3) 9425 10391 5642 122 
H(7A) 9636 9427 5848 115 
H(7B) 8211 10518 5728 115 
H(7C) 9673 10971 5355 115 
H(9A) 2440 7953 -1440 56 
H(9B) 4099 7593 -1601 56 
H(9C) 3232 9067 -2013 56 
H(11A) 840 11440 547 68 
H(11B) 2610 11819 1121 68 
H(11C) 1399 11441 1726 68 
H(12) 3481 7397 1303 31 
H(13) 4628 6489 3068 33 
H(15A) 128 4607 1080 66 
H(15B) -138 5423 2013 66 
H(15C) 553 3824 2129 66 
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H(16A) 4789 8925 3750 41 
H(16B) 2916 8949 3424 41 
H(18A) 4759 7479 6770 107 
H(18B) 3989 6275 5972 107 
H(18C) 2936 7542 6205 107 
H(18D) 5432 6501 6149 100 
H(18E) 3741 6791 6281 100 
H(18F) 5170 7814 6815 100 
 
 
 
Table 23 Dihedral angles [°] for per-O-acetyl-4-deoxy-β-2,3-difluorosialic acid methyl ester 
(57). 
 
 
 
  Atom1  -  Atom2  -  Atom3  -  Atom4  Dihedral 
C(5) - O(1) - C(1) - F(1) -62.09(18) 
C(5) - O(1) - C(1) - C(2) 55.9(2) 
C(5) - O(1) - C(1) - C(6) -177.64(17) 
O(1) - C(1) - C(2) - F(2) 71.98(19) 
F(1) - C(1) - C(2) - F(2) -168.33(14) 
C(6) - C(1) - C(2) - F(2) -53.0(2) 
O(1) - C(1) - C(2) - C(3) -47.5(2) 
F(1) - C(1) - C(2) - C(3) 72.14(18) 
C(6) - C(1) - C(2) - C(3) -172.54(17) 
F(2) - C(2) - C(3) - C(4) -70.1(2) 
C(1) - C(2) - C(3) - C(4) 47.4(2) 
C(8) - N(1) - C(4) - C(5) 118.22(16) 
C(8) - N(1) - C(4) - C(3) -121.81(16) 
C(2) - C(3) - C(4) - N(1) -175.36(16) 
C(2) - C(3) - C(4) - C(5) -54.19(19) 
C(1) - O(1) - C(5) - C(12) 171.93(14) 
C(1) - O(1) - C(5) - C(4) -62.52(17) 
N(1) - C(4) - C(5) - O(1) -179.03(12) 
C(3) - C(4) - C(5) - O(1) 59.87(16) 
N(1) - C(4) - C(5) - C(12) -57.66(17) 
C(3) - C(4) - C(5) - C(12) -178.76(14) 
C(7A) - O(3A) - C(6) - O(2) 8.9(13) 
C(7A) - O(3A) - C(6) - O(2A) -28.4(12) 
C(7A) - O(3A) - C(6) - O(3) 91(3) 
C(7A) - O(3A) - C(6) - C(1) -177.7(7) 
C(7) - O(3) - C(6) - O(2) 27.4(10) 
C(7) - O(3) - C(6) - O(2A) -12.1(11) 
C(7) - O(3) - C(6) - O(3A) -85(3) 
C(7) - O(3) - C(6) - C(1) 176.3(7) 
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O(1) - C(1) - C(6) - O(2) 164.7(5) 
F(1) - C(1) - C(6) - O(2) 47.2(5) 
C(2) - C(1) - C(6) - O(2) -68.1(5) 
O(1) - C(1) - C(6) - O(2A) -156.7(5) 
F(1) - C(1) - C(6) - O(2A) 85.8(5) 
C(2) - C(1) - C(6) - O(2A) -29.5(5) 
O(1) - C(1) - C(6) - O(3A) -9.2(6) 
F(1) - C(1) - C(6) - O(3A) -126.7(6) 
C(2) - C(1) - C(6) - O(3A) 117.9(6) 
O(1) - C(1) - C(6) - O(3) 15.3(5) 
F(1) - C(1) - C(6) - O(3) -102.2(4) 
C(2) - C(1) - C(6) - O(3) 142.4(4) 
C(4) - N(1) - C(8) - O(4) -2.2(2) 
C(4) - N(1) - C(8) - C(9) 178.79(15) 
C(12) - O(5) - C(10) - O(6) 0.0(2) 
C(12) - O(5) - C(10) - C(11) 178.80(14) 
C(10) - O(5) - C(12) - C(5) 134.17(14) 
C(10) - O(5) - C(12) - C(13) -101.51(15) 
O(1) - C(5) - C(12) - O(5) 72.72(15) 
C(4) - C(5) - C(12) - O(5) -48.96(17) 
O(1) - C(5) - C(12) - C(13) -50.44(17) 
C(4) - C(5) - C(12) - C(13) -172.12(13) 
C(14) - O(7) - C(13) - C(16) -163.54(14) 
C(14) - O(7) - C(13) - C(12) 74.36(17) 
O(5) - C(12) - C(13) - O(7) 89.03(15) 
C(5) - C(12) - C(13) - O(7) -148.46(13) 
O(5) - C(12) - C(13) - C(16) -29.23(19) 
C(5) - C(12) - C(13) - C(16) 93.27(17) 
C(13) - O(7) - C(14) - O(8) -0.5(2) 
C(13) - O(7) - C(14) - C(15) -179.74(15) 
C(17) - O(9) - C(16) - C(13) 161.2(2) 
O(7) - C(13) - C(16) - O(9) 69.79(17) 
C(12) - C(13) - C(16) - O(9) -170.29(14) 
C(16) - O(9) - C(17) - O(10A) -11.4(15) 
C(16) - O(9) - C(17) - O(10) 9.7(8) 
C(16) - O(9) - C(17) - C(18A) -164.8(5) 
C(16) - O(9) - C(17) - C(18) 170.0(4) 
 
Symmetry transformations used to generate equivalent atoms. 
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